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6OUTLINE
outline of this thesis
Amyotrophic Lateral Sclerosis (ALS) is an adult-onset disorder of the motor neurons. 
It is the 3rd cause of death inferred by neurodegenerative diseases after Alzheimer’s and 
Parkinson’s disease. The degeneration of motor neurons causes progressive paralysis 
of voluntary muscles ultimately leading to death because of paralysis of respiratory 
muscles. There is no treatment for this devastating disorder and the pathogenesis is still 
not understood. ALS is a complex, multi-factorial disease that in 90% of the cases has 
no familial aggregation. However, genetic studies in the past years have uncovered the 
genetic defects of several familial ALS forms, and these ALS genes provide footholds 
for systematically investigating the molecular and cellular mechanisms underlying ALS 
pathogenesis. The work presented in this thesis investigates the pathogenesis of ALS in 
cellular and mouse models focusing on three ALS genes: SOD1, dynactin and VAPB. 
In the first chapter of this thesis (the introduction), the neuropathology and genetics 
of ALS and clinically related motor neuron disorders are described, highlighting that 
similar intracellular pathways are affected in these diseases. In chapter two, molecular 
and pathological changes in the SOD1-G93A mouse model, a widely used mouse model 
for ALS that expresses human mutant SOD1-protein, are described in detail. Appearance 
of ubiquitinated aggregates in dendrites of motor neurons is a very early pathological 
phenomenon, possibly contributing to a disruption of intracellular transport in neurons. 
As glial pathology is only observed at a later stage of disease, it is questioned what the 
role of glial cells is in motor neuron degeneration. In chapter three, the role of glia and 
neurons in the pathogenesis of ALS is studied by using the Thy1-SOD1-G93A mouse, 
that expresses mutant SOD1-protein selectively in neurons. These mice develop a late-
onset ALS-like disorder with pathology resembling that of other SOD1-ALS-mice. We 
conclude that expressing mutant SOD1 in motor neurons is sufficient to cause motor 
neuron degeneration. In chapter four, the role of intracellular transport is studied by the 
generation of a mouse with chronic disruption of dynein by overexpression of dominant-
negative BICD2, that mediates active retrograde microtubule-dependent transport. These 
mice develop multiple pathological abnormalities also observed in ALS-patients, but 
they do not develop motor neuron disease. In contrast disruption of dynein in SOD1-ALS 
mice prolongs survival, suggesting that disrupted dynein is beneficial in SOD1-ALS. In 
chapter five, a recent mutation in VAPB in ALS-patients is characterized in a cellular 
model. The mutation results in cytoplasmic aggregates of mutant VAPB, that disrupt the 
normal function of the protein and are toxic to neurons. As VAPB is involved in lipid 
transport, we hypothesize that the disruption of intracellular lipid homeostasis can lead 
to neuronal death. The last chapter discusses the results of the studies described in this 
thesis.
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General introduction
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1.1 AmyoTroPhiC LATerAL SCLeroSiS (ALS), A LATe-onSeT moTor  
 neuron DiSeASe
1.1.1  Clinical aspects of ALS
In 1865 the French neurologist Jean-Martin Charcot described a patient with progressive weakness 
of all extremities without mental retardation, and detected degeneration of the spinal cord at 
autopsy. After seeing more cases, in 1874, he gave the term “amyotrophic lateral sclerosis” to 
this disorder. The term “amyotrophic” refers to the muscle atrophy, whereas “lateral sclerosis” 
refers to the dominant macroscopic abnormality of the spinal cord, i.e. the hardening (sclerosis) 
and atrophy of the lateral white matter. Charcot’s original clinical and anatomical observations of 
ALS are still a good description of the disease (1). ALS therefore sometimes is called Charcot’s 
disease. ALS is also known as Lou Gehrig’s Disease after the American baseball-player who 
died of the disease in 1941, or Motor Neuron Disease (MND) after the cell-type that is primarily 
affected.
Muscle weakness and atrophy in ALS results from the degeneration of the nerve cells 
that innervate the muscles. These are the α-motor neurons that have their cell bodies in the spinal 
cord (figure 1.1) or, in case of the motor neurons innervating the muscles that control facial 
expression and mastication, in motor nuclei in the brainstem. In the clinic, α-motor neurons are 
referred to as lower motor neurons. The hardening of the lateral white matter of the spinal cord 
in ALS results from the degeneration of the pyramidal tract. This tract contains the corticospinal 
axons arising from large neurons located in lamina V of the cerebral cortex, the motor cortex 
Figure 1.1: Upper and lower motor neurons 
(figure 1.1). These cortical motor neurons, also 
named Betz cells or upper motor neurons, project 
to α-motor neurons as well as other neurons in the 
spinal cord (figure 1.1), and directly or indirectly 
control the firing of α-motor neurons (2, 3). The 
organization and connectivity of the pyramidal 
tract neurons in rodents like mice and rat, which 
are frequently used as animal models for ALS, 
differs in some aspects from the pyramidal 
tract in higher primates including humans. By 
definition, ALS is a disease of both lower and 
upper motor neurons, degeneration of either type 
of motor neurons results in different symptoms. 
Lower motor neuron symptoms include muscle 
fasciculations (twitching), cramps that can be 
painful, and muscle weakness and atrophy. Upper 
motor neuron symptoms consist of spasticity, 
muscle weakness, exaggerated tendon reflexes, 
and an extensor plantar response known as the 
Babinski sign.
Upper motor neuron
Lower motor neuron
Motor unit
Muscle
Corticospinal tract
Spinal cord
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ALS-patients are grouped according to the part of the body first affected; in most cases 
symptoms start in one of the limbs. These patients first experience awkwardness when walking or 
running in case of leg onset, or problems with simple manual tasks in case of arm onset. Part of the 
patients (approx. 25%) show ‘bulbar onset’, symptoms starting with functional loss of muscles of 
the head and neck area; (‘bulbar’ refers to the brainstem where α-motor neurons innervating head 
and neck muscles are located). These patients first experience difficulty speaking, characterized 
by nasality and loss of volume, followed by difficulty of swallowing and loss of tongue mobility. 
Regardless of the onset site of symptoms, muscle weakness spreads to other body parts as the 
disease progresses. 
The progression of the disease can be very rapid with patients dying within a year 
after diagnosis, the mean survival is 3 years after diagnosis. Death mainly is due to paralysis of 
respiratory muscles and swallowing problems. ALS-patients usually do not experience major       
sensory deficits and cognitive abnormalities. �owever, a small subset of patients, usually with H         
a familial form of ALS, develop fronto-temporal dementia characterized by personality changes 
(4, 5). The mean age of onset of ALS is above the age of 50; only 5% of cases presents before 
the age of 30 (6), and the disease occurs slightly more frequently in man than in women. In most 
western countries the incidence and the prevalence of ALS are 1-2 and 4-6 per 100.000 persons 
respectively. This means that in The Netherlands about 300-450 people are newly diagnosed 
with ALS each year. Currently, ALS is the third cause of death by neurodegenerative diseases 
after Alzheimer’s and Parkinson’s disease. Because of an increasingly elderly population, the 
incidence of ALS is gradually increasing (6, 7). So far, there is no effective treatment to slow 
disease progression of ALS. The only drug approved in the USA and in most European countries 
is riluzole, which has a very modest effect on survival. Other treatments for ALS are designed to 
relieve symptoms and improve the quality of life for patients. 
Figure 1.2 Spectrum of human neurological disorders that affect upper and lower motor neurons. 
Indicated are upper or lower motor neurons and the primary site of pathology (axon, soma or  both).
CHAPTER 1
10
1.1.2  other motor neuron diseases
In addition to ALS there are a number of other disorders of upper and lower motor neurons 
with partially overlapping spectra of symptoms. As summarized in figure 1.2 and table 1.1 these 
disorders can be distinguished by the age of onset, the rate of disease progression, the involvement 
of upper or lower motor neurons, the part of the neuron that is primarily affected (axon or cell 
body), and the genetic cause of disease. 
 A number of disorders afflict the axons of α-motor neurons. These include a group of 
genetically heterogeneous primary axonal neuropathies called Charcot-Marie Tooth disease type 
2 (CMT-2 or Hereditary Motor and Sensory Neuropathy type 2, HMSN2) that are clinically 
characterized by both motor and sensory deficits, indicating motor and sensory axon involvement 
Table 1.1 
Clinical signs of human upper and lower motor neuron diseases
Disease Clinical signs Incidence /100.000 Onset
ALS-like disorders (upper and lower motor neuron involvement)
Typical ALS Progressive total muscle weakness 1-2 (late) adult
ALS-FTD Progressive muscle weakness and dementia low
(late) 
adult
Upper motor neuron neuronopathies
Juvenile ALS Muscle weakness, spasticity low juvenile
Primary Lateral 
Sclerosis (PLS) Slowly progressing paralysis low adult
Upper motor neuron axonopathies
Hereditary Spastic   
Paraplegia (HSP)
Slow progressive muscle weakness and 
spasticity 2-10 variable
Lower motor neuronopathies
Spinal Muscular 
Atrophy (SMA) type I Proximal muscle weakness 10 infancy
  SMA type II Proximal muscle weakness juvenile
  SMA type III Proximal muscle weakness juvenile
  SMA type IV Proximal muscle weakness adult
SMARD Distal muscle weakness with respiratory distress low infancy
Kennedy’s disease Weakness, muscle atrophy and testicular atrophy low adult
Lower motor axonopathies
Distal SMA Distal muscle weakness 4 juvenile
Charcot-Marie Tooth 
Type 2 (CMT2) Distal weakness and muscle atrophy
30-40 
(CMT1-4)
juvenile/ 
adult
Hereditary Motor 
Neuropathy (HMN) Distal weakness and muscle atrophy low
juvenile/ 
adult
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(Charcot-Marie Tooth disease type 1 and 4 present with similar symptoms as CMT-2, but these 
are demyelinating disorders rather than axonopathies). Other axonopathies include Hereditary 
Motor Neuropathy (HMN) which is associated with distal weakness without sensory loss (8). 
 Spinal Muscular Atrophy (SMA) is a pure lower motor neuron disease affecting 1-1.5 
in every 10.000 births, and is subgrouped in different forms on the basis of the age of onset. 
Adult onset SMA strongly resembles ALS. Spinal and Bulbar Muscular Atrophy (SMBA), also 
known as Kennedy’s disease, represents another lower motor neuron disorder. It is an X-linked 
recessive disorder caused by polyglutamine expansions of the androgen receptor mainly affecting 
males (9). Diseases afflicting upper motor neurons include Primary Lateral Sclerosis (PLS) and 
Hereditary Spastic Paraplegia (HSP), a heterogeneous group of familial disorders characterized 
by progressive lower limb paralysis and spasticity (10). 
1.1.3  neuropathology of ALS
Pathologically, ALS is characterized by a marked loss of α-motor neurons in the spinal cord and 
brainstem, loss of Betz cells in the motor cortex, atrophy of the ventral roots and degeneration 
of the pyramidal tract. Degenerative changes have also been reported for other populations of 
neurons, primarily in the cortex, brain stem and spinal cord, like for instance spinal interneurons 
(11). In addition, glial changes occur in areas with neuronal pathology. Skeletal muscles 
show atrophy and signs of denervation and reinnervation. Pathological studies have revealed 
different types of abnormalities in surviving ALS motor neurons, including fragmentation of 
the Golgi apparatus (12), accumulations of neurofilament in the proximal axon called “axonal 
spheroids”, and the appearance of diverse types of inclusions in the cell bodies. These inclusions 
predominantly consist of abnormal accumulations of proteinaceous material. Bunina bodies are 
small eosinophilic (stained by the acidic dye eosin) structures that consist of amorphous electron-
dense material surrounded by tubular and vesicular structures. Protein constituents identified 
so far in Bunina bodies are cystatin C and transferrin (13). The role of Bunina bodies in ALS 
pathogenesis is not completely understood. Other inclusions are Lewy-body-like inclusions, 
which are relatively large spherical structures (figure 1.3D) (14), and skeins, which consist of 
loosely arranged filamentous material (figure 1.3C) (15). 
 Both Lewy-body-like inclusions and skeins are strongly immunoreactive for ubiquitin, 
a small protein that is attached to proteins targeted for degradation, and plays an important role 
in the degradation of misfolded and damaged proteins (see box 1.2). The presence of ubiquitin 
Figure 1.3. Immunoperoxidase-stainings of motor neurons (MNs) in spinal cord sections of sporadic ALS-
patients with antibodies against TDP-43 reveal different inclusions: A) TDP-43 protein in healthy MN, TDP-43 
aggregate in glial cell (arrow) B) Redistribution of TDP-43 to cytoplasm C) skein D) Lewy-body-like inclusion
A B C D
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in these inclusions indirectly suggests that their formation is linked to increased production or 
impaired degradation of misfolded and damaged proteins. Recently, the protein TDP-43 has been 
identified as a major constituent of Lewy-body-like inclusions and skeins in motor neurons in ALS 
patients (16). Furthermore, it was shown that TDP-43, that normally is present in the nucleus, in 
many ALS motor neurons including those without inclusions was redistributed to the cytoplasm 
(figure 1.3B). �ence, TDP-43 may represent a new major ALS protein (see also 1.3.2).
1.2 PAThoGeneSiS of ALS
1.2.1.  hypotheses on sporadic ALS etio-pathogenesis
The etio-pathogenesis of ALS is still poorly understood. In the large majority of the patients 
(90%) there is no clear inheritance pattern, and hence the disease is sporadic, whereas about 10% 
of the patients show a familial history compatible with Mendelian inheritance (17). In most cases 
the clinical and pathological features of familial ALS patients resemble sporadic ALS, although 
atypical features may occur in some familial forms. The main risk factors for ALS are age and 
sex, ALS occurs a little more frequently in males (approximately 60:40). In the 1950s, a very 
high incidence of ALS with Parkinsonism has occurred in the western Pacific island Guam. The 
increased risk for ALS on this island has been linked to factors in the diet of the indigenous 
Chamorro population, although it is not yet clear which factor (18). Epidemiological studies did 
not reveal other geographic hotspots. Other environmental factors, like previous polio infections, 
exposure to heavy metals or pesticides and smoking have been postulated to contribute to ALS, 
but are still under debate (19). Also the associations of ALS with high physical exercise in for 
example soccer players is being studied (20). In addition, there might be a link between body-
mass-index (BMI), dietary fat-intake and ALS (21, 22). 
 Genetic studies have revealed a number of potential susceptibility or modifying 
factors for sporadic ALS (23, 24). In many instances associations found in one study, were not 
confirmed, or contradicted by others, which could indicate that genetic factors are heterogeneous  
among different populations of patients. For instance, promoter polymorphisms that reduce         
the expression of vascular endothelial growth factor (VEGF) have been associated with an 
increased risk of ALS in some studies, but not by others. These studies were initiated after the 
demonstration that mice with a deletion of the hypoxia response element in the promoter region 
of VEGF, resulting in reduced VEGF levels, displayed progressive motor neuron degeneration 
(25). Furthermore, increasing VEGF-levels was found to be neuroprotective in the SOD1-ALS 
mouse model although the mechanism is not yet understood. VEGF in addition to its angiogenic 
properties has neurotrophic effects (26, 27). Subsequent to VEGF, the functionally related protein       
angiogenin was selected as a candidate gene for sporadic ALS partly because the gene is located 
near a susceptibility locus on chromosome 14q11.2. To date, 10 missense mutations in the gene 
for angiogenin in a small number of ALS patients have been reported (28-30). Angiogenin is a 
ribonuclease of the RNaseA ribonucleases family, the exact functions of its enzymatic activity, its 
substrate, and its mechanism of angiogenesis are not yet understood. 
In addition to angiogenic factors, candidate-gene driven studies have reported associations 
of ALS with variants of several other genes including neurofilament subunits, progranulin 
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polymorphisms, and copy number for the genes that encode survival of motor neuron proteins 1 
and 2 (SMN1 and SMN2, see also table 1.2 and box 1.1) (23, 24). Furthermore, more recently, 
genome-wide association studies have started to yield novel potential susceptibility factors, 
including inositol phosphate receptor 2 gene (ITPR2) and a yet uncharacterized gene, dipeptidyl-
peptidase 6 (DPP6) (31, 32). Again the significance of these genetic associations remains to be 
determined. The uncovering of TDP-43 as a major constituent of the inclusions in ALS motor 
neurons indicate that mislocalization, misprocessing, misfolding and aggregation of this protein 
is an important pathological mechanism in sporadic ALS (see paragraph 1.3.2). In addition to 
aggregate formation multiple mechanisms have been proposed to contribute to motor neuron 
Table 1.2 Genes and loci for ALS and other motor neuron disorders
Disease Gene Function Mouse Ref.
ALS genes
ALS1 (AD) (typical) SOD1 Conversion of superoxide radicals tg (39, 43)
ALS2 (AR) (juvenile) Alsin Rho-GEF GTPase ko (44, 45)
ALS4 (AD)(juvenile) Senataxin DNA/RNA helicase  (46)
ALS8 (AD) VAPB ER protein  (47, 48)
ALS (AD) p150/Dynactin1 Dynein/dynactin subunit tg (49, 50)
ALS loci
ALS5 (AR) 15q15-21   (51)
ALS6 (AD) 16q12   (52)
ALS7 (AD) 20p13   (53)
ALS-X (XD) Xcen   (24)
ALS with Frontotemporal Lobar Degeneration
FTD3 (AD) CHMP2B Endosomal trafficking (ESCRT) (54)
ALS-FTD (AD) 9q21   (55)
ALS-FTD (AD) 9p   (56)
ALS-Parkinson DJ-1 Dopaminergic signaling (57)
Spinal (Bulbar) Muscular Atrophy
SMA (AR) SMN1 Pre-mRNA splicing tg, ko (58)
SMARD (AD/AR) IGHMBP2 DNA/RNA helicase (59)
SBMA (Kennedy) AR Androgen receptor tg (60, 61)
Charcot-Marie-Tooth disease
CMT2A (AD) KIF1B Microtubule transport ko (62)
CMT2B (AD) Rab7 Intracellular membrane trafficking  (63)
CMT2E (AD) NF-L Structural neuronal protein tg (64)
CMT2F (AD) HSP27 Molecular chaperone  (65)
DI-CMTB (AD) Dynamin PtdIns-P-phosphatase  (66)
CMT4B1 (AR) MTMR2B Myotubularin, phosphatase ko (67)
CMT4B2 (AR) MTMR13 interacts with MTMR2B ko (68) 
CMT4J (AR) FIG4 PI(3,5)P2-phosphatase sp (69)
Hereditary Spastic Paraplegia
SPG3A (AD) Atlastin Endosomal dynamin-like GTPase  (70)
SPG4 (AD) Spastin Microtubule interacting ATPase  (71)
SPG10 (AD) KIF5A Microtubule transport  (72)
SPG20 (AR) Spartin Endosomal trafficking  (73)
Legend: (AD) Autosomal dominant, (AR) Autosomal Recessive, (XD) X-linked dominant, (tg) transgenic 
(ko) knockout (sp) spontaneous. For a complete overview: : (66, 74, 75).
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degeneration. These mechanisms include excitotoxicity, mitochondrial dysfunction, abnormal 
calcium homeostasis, oxidative stress, misfolded protein stress (see also box 1.2), intracellular 
transport abnormalities, lack of trophic factors, activation of cell death pathways, and deleterious 
inflammatory processes. Many of these mechanisms are linked to each other and also have been 
proposed to play a role in mouse models of main familial form of ALS (i.e. SOD1-ALS, see 1.3.2) 
(24, 33). 
The theory of excitotoxicity poses that degenerative pathways in neurons are triggered via 
ionotropic glutamate receptors, AMPA and NMDA receptors, usually via increased intracellular 
calcium levels (34). It has been proposed that in ALS, excitotoxic injury may follow from impaired 
clearance of synaptically released glutamate due to glial glutamate transporter problems, although 
evidence supporting such a mechanism is yet inconclusive (34). Alternatively, AMPA receptor 
abnormalities that result in increased calcium permeability or prolonged opening kinetics could 
contribute to motor neuron degeneration (34). It has been shown that metabolically compromised 
and weakened neurons may profit from inhibition of normal synaptic glutamatergic transmission 
levels, putatively by lowering metabolic demands of the neuron. Thus even in the absence of 
primary deficits in glutamatergic transmission, anti-glutamate drugs may be neuroprotective to 
ALS patients. This may explain the therapeutic effect of riluzole, which has anti-glutamatergic 
properties, and which is the only approved drug for ALS having a small beneficial effect on 
survival of ALS patients (34).
In the same way other potentially pathogenic processes, including oxidative stress, 
calcium abnormalities and apoptotic pathways, may contribute secondarily to motor neuron 
degeneration and represent a target for therapeutic approaches (35-38). Furthermore, neuronal 
degeneration triggers changes in surrounding neurons and glia, and these ‘environmental’ 
changes in turn may be deleterious to motor neurons (24, 33). For example, microglia which 
function as the macrophages of the CNS, are activated after neuronal injury, to recognize and 
remove neuronal debris and dead neurons. By doing so, activated microglia may in turn trigger 
inflammatory cascades that have deleterious effects to other (motor) neurons (34). Thus multiple 
pathogenic pathways may contribute to disease progression providing multiple potential targets 
for therapeutic approaches.
1.2.2 mendelian mutations afflicting motor neurons in man and mice
A major breakthrough in ALS genetics came in 1993 with the discovery of superoxide dismutase 
1 (SOD1) mutations in a familial from of ALS (ALS1) (39). SOD1 is a cytosolic 32kDa dimeric 
enzyme that catalyses the conversion of superoxide into oxygen and hydrogen peroxide. SOD1-
ALS mostly shows autosomal dominant inheritance, is similar to lower motor neuron onset 
sporadic ALS, but the mean age of onset may be lower, and male to female ratio is slightly 
different (50:50 as compared to 60:40) (40, 41). To date more than 130 different SOD1 mutations 
have been identified, accounting for 20% of the familial ALS patients in some populations (40, 
42). Most mutations cause single amino acid substitutions, while some mutations result in amino 
acid insertions, deletions and C-terminal truncations (40, 42). Mutations cover all five exons 
of the gene and cause SOD1 mutants with a large variability of biophysical and biochemical 
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Table 1.3 Genetic mutations in mouse models with motor abnormalities
Mouse Clinical signs Gene Function Ref
Wobbler Progressive motor weakness, predominantly forelimbs VPS53
Intracellular membrane 
trafficking (82)
Loa/Cra1 Progressive motor weakness DHC Microtubule transport (83)
Pmn Progressive motor weakness TbcE Tubulin chaperone (84)
nmd Progressive motor weakness IGHMBP2 DNA/RNA helicase (85)
Pale tremor Tremor and abnormal gait FIG4 PIP-phosphatase (69)
Vibrator Tremor PITPα PtdIns transfer (86)
Paralysé Progressive motor weakness unknown Unknown (87)
Dystonia 
musculorum
Abnormal limb coordination and 
ataxia BPAG1 Dystonin (88)
VEGF δ/ δ Late-onset motor neuron disease VEGF Angiogenesis (25)
properties, many mutants maintaining considerable or total enzymatic activity (40, 42). It is firmly 
established that the disease results from a gained toxic activity, as the unifying common feature 
for the diverse SOD1 mutants is an increased propensity to form aggregate-prone monomers. The 
potential mechanism by which SOD1 aggregation may cause ALS is discussed in paragraph 1.3 
(40, 42).  
 More recently mutations in other genes have been identified in familial ALS patients 
(table 1.2), including Alsin (ALS2) (76), Senataxin (ALS4) (46), p150/dynactin1 (49, 77) and        
VAPB (ALS8) (48). Not all subtypes of familial ALS present with the clinical signs of ty               pical 
ALS. For example juvenile-onset ALS2 has mainly upper motor neuron involvement and can be             
considered to be part of a different group of diseases together with primary lateral sclerosis (PLS) 
and some forms of hereditary spastic paraplegia (HSP) (table 1.1) (78). ALS4 is a juvenile-onset 
lower motor neuron disorder with slow progression and clinically resembles distal SMA; ALS 
caused by p150/dynactin1 mutations is a slowly progressive disorder that mainly affects lower 
motor neurons. Also the clinical presentation of ALS8 can vary from an ALS-like to a pure lower 
motor neuron disorder.
The ALS mutations identified so far account for a subset of ALS-cases. The chromosomal 
positions of a number of additional familial ALS mutations have been identified (table 1.2) (24, 
79-81), and additional familial ALS loci and genes remain to be identified. Together the data from 
sporadic and familial ALS genetics indicate that ALS is a genetically highly diverse disorder, and 
demonstrate that multiple molecular pathways may underlie ALS pathogenesis. Adding to this 
complexity is a variability of genes causing non-ALS upper or lower motor neuron disorders in 
humans (table 1.2) or motor neuron disease in mice (table 1.3). 
 However, despite this genetic heterogeneity, the genes involved in motor neuron 
disorders seem to converge on a limited number of cellular/molecular pathways. Many genetic 
defects interfere with intracellular maintenance and logistics affecting metabolism and trafficking 
of RNA (see box 1), cytoskeletal metabolism and factors that control intracellular trafficking (see 
paragraph 1.4). In addition, as discussed below protein aggregates may be a major pathogenic 
event in ALS pathogenesis (paragraph 1.3).
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1.3 ALS: A ProTein AGGreGATion DiSorDer
1.3.1 SoD1- ALS: a protein aggegation disorder of neurons and glia
A hallmark of many neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s 
disease, Huntington’s disease, several cerebellar ataxias and ALS is the presence of insoluble 
aggregates of proteins that are deposited in intracellular inclusions or extracellular plaques, which 
generally are pathognomonic for the disease. This and other findings have led to the notion that 
neurodegenerative diseases in general are protein misfolding disorders, where the accumulation 
of misfolded aggregation-prone proteins over time is a central feature (102-104). The presence   
of ubiquitinated inclusions in ALS motor neurons is well recognized (see 1.1.3), but their role in 
box 1.1 motor neurons are vulnerable to defects in rnA-processing
The genetics of five different neurological disorders (ALS, spinocerebellar ataxia, SMA, FTLD-U and 
fragile-X associated tremor and ataxia syndrome (FXTAS) suggests that motor neurons might be especially 
vulnerable to small alterations in RNA-processing. In ALS4, a juvenile lower motor variant of ALS with 
early onset of symptoms, and in ataxia oculomotor apraxia type 2 (AOA2), an autosomal recessive form of 
spinocerebellar ataxia, mutations in the gene for senataxin were found (46, 89, 90). Senataxin is homologous 
to Immunoglobulin Mu-Binding Protein 2 (IGHMBP2), a protein defective in a form of Spinal Muscular 
Atrophy with Respiratory Distress (SMARD) (table 1.2). This protein is also mutated in the nmd-mouse, 
a spontaneous mouse model for neuromuscular degeneration with spinal motor neuron degeneration and 
axonal pathology (table 1.3). In SMARD and the nmd-mouse, primarily lower motor neurons are affected 
(85). Due to similar clinical presentations and similar genetic etiology, these diseases may be different 
presentations of the same disorder (91). The function of senataxin is not totally clarified, its homologue 
IGHMBP2 is involved in the processing of RNA. Most likely, mutations in senataxin cause defects in RNA 
processing and/or DNA repair.
Spinal Muscular Atrophy (SMA) is caused by mutations in SMN1. The highly homologous proteins Survival 
Motor Neuron (SMN) 1 and 2 are involved in mRNA splicing as part of an “assemblysome” and localize to 
gems, dot-like structures in nuclei. SMN1 and 2 can bind to nuclear ribonucleoproteins (hnRNPs), and are 
involved in the generation of small nuclear riboproteins (snRNPs) (92). The SMN2-gene has resulted from 
a genomic duplication of the SMN1-region, however the SMN2-protein is only partly functional due to 
alternative splicing. All SMA-patients have deletions or missense mutations in the gene for SMN1, leading 
to a functionally impaired protein (93, 94). Consequently, total SMN-levels are too low for the survival of 
motor neurons, which leads to the disease phenotype (95). SMN1/2-mutations have also been identified 
as susceptibility factors for sporadic ALS, indicating a general role of these proteins in maintaining motor 
neuron health (96).
In ubiquitinated inclusions in ALS and FTLD-U-patients, the protein TDP-43 was detected (figure 1.3 and 
paragraph 1.3.2). TDP-43 is normally present in the nucleus and is involved in mRNA splicing as has been 
demonstrated for CFTR (cystic fibrosis protein) and neurofilament (NF-L) mRNA (97-99). In cultured cells, 
TDP-43 localizes to nuclear bodies that co-localize with gems. These gems also contain SMN1, that can 
directly interact with TDP-43, suggesting a common function in mRNA splicing (100). TDP-43 is also 
present in a protein complex responsible for mRNA degradation, as is IGHMBP2. TDP-43 is highly similar 
throughout many organisms, that might indicate a conserved function for the protein (101).
The proteins described above, functioning in RNA-processing, are expressed in many cell-types; how 
mutations in this pathway cause the specific death of motor neurons remains to be established. This selectivity 
has been attributed to the high metabolic capacity of motor neurons that would request a high level of gene 
transcription, however so far this pathway in relation to ALS has not been extensively studied and awaits 
further biological clarification.
INTRODUCTION
17
motor neuron degeneration remains elusive. The role of protein aggregation in ALS pathogenesis 
has most thoroughly been examined in SOD1-linked familial ALS (ALS1).
SOD1 is a small stable copper and zinc-containing homodimeric enzyme of 153 residues. 
Although SOD1 is among the most abundant cytosolic proteins, SOD1 knockout-mice have a 
remarkable mild phenotype showing reduced muscle mass, and abnormalities in distal motor 
axons (105). The mutations associated with ALS occur in all of the functional elements of the 
protein structure, including the active site, the dimer interface, and the β-barrel. Many mutations 
weaken the stability of SOD1, but some mutants (e.g. D90A) show near wild-type like stability and 
enzymatic activity (40, 42). Several lines of evidence indicate that the unifying common feature 
of the diverse SOD1 mutants is the accumulation of misfolded, hydrophobic, and aggregate-prone 
species; SOD1-containing inclusions are a consistent feature in ALS patients and transgenic mice 
carrying ALS-SOD1 mutations (106). Furthermore, it has been shown that mouse lines carrying 
highly diverse mutations all develop similar amounts of soluble hydrophobic, aggregation prone 
sub-fractions, that usually lack disulfide bonds and metal ions, as well as soluble oligomeric              
species. Data from transgenic mice that express unstable SOD1 mutants (G85R, G127X), which 
nearly exclusively express these abnormal species, indicate that this fraction is sufficient to induce 
disease in mice (107, 108).
 How hydrophobic and oligomeric mutant SOD1 species cause the degeneration of motor 
neurons is not understood. These abnormal species are more abundant in spinal cord as compared 
to other areas, which is consistent with the selective vulnerability of motor neurons. Misfolded 
hydrophobic proteins may interfere with components of the protein quality control machinery (see 
box 1.2), or engage in abnormal interactions with specific proteins and intracellular membranous 
organelles. Also oligomeric species may have deleterious interactions with other proteins and 
membranous structures, and furthermore accumulate in micrometer scale aggregates, that have 
been hypothesized to be either toxic or protective (42). To further examine the role of these 
micrometer scale aggregates in the degeneration of motor neurons, in chapter 2 we have precisely 
examined the time of appearance of ubiquitinated SOD1 aggregates as compared to other 
neurodegenerative changes in a line of SOD1-ALS mice that express G93A-mutant SOD1. We 
show that these aggregates appear early in dendrites and may contribute to further degeneration 
of motor neurons by interfering with dendritic trafficking. In chapter 3 we have compared the 
clinical and pathological features of transgenic mice that express G93A-SOD1 specifically in 
neurons or ubiquitously. Ubiquitous G93A-SOD1 mice develop ubiquitinated SOD1 aggregates 
both in neurons and glia. Data from our neuron-specific G93A-SOD1 mice indicate that the 
presence of mutant SOD1 selectively in neurons in principle is sufficient to cause disease, but that 
the presence of mutant SOD1 in glia may contribute to the rapid spreading of disease.
1.3.2 Sporadic ALS: a protein aggregation disorder of TDP-43?
Motor neurons in sporadic ALS-patients also show ubiquitinated inclusions (see 1.1.3). Recently, 
it has been demonstrated that the protein TDP-43 is the main constituent in these inclusions 
(116). Furthermore, TDP-43, normally present in the nucleus, redistributes to the cytoplasm in 
ALS motor neurons. These recent data indicate that TDP-43 plays an important role in ALS 
pathogenesis. TDP-43 abnormalities were originally identified in inclusions in a form of fronto-
CHAPTER 1
18
temporal dementia (Frontotemporal Lobar Degeneration with ubiquitinated inclusions, FTLD-
U), which is a genetically heterogeneous disorder sometimes associated with motor neuron 
disease (16, 116). Furthermore, TDP-43 pathology has been described in Guam ALS, as well as 
occasionally in other neurodegenerative disorders, but does not occur in acute conditions such as 
anoxic, ischemic or neoplastic lesions (16). Thus TDP-43 pathology represents a common disease 
pathway for a heterogeneous group of neurodegenerative diseases, similar to tauopathies and 
synucleopathies representing heterogeneous sets of neurodegenerative conditions characterized 
by tau- and synuclein pathology. 
TDP-43 pathology does not usually occur in SOD1-ALS, but has been found in other 
familial ALS forms (117-119). No TDP-43 mutations have been identified in ALS and FTLD-
U patients (120); mutations in familial disorders with TDP-43 pathology have been found in 
the genes for progranulin (PGRN) and valosin-containing protein (VCP). TDP-43 is a 414 
amino acid nuclear protein encoded by the TARDBP gene on chromosome 1 (121). The protein 
is ubiquitously expressed in multiple tissue types including heart, lung, liver, spleen, kidney, 
muscle and brain. It is speculated to play a functional role in multiple diverse pathways which 
involve its binding to single stranded DNA, RNA and nuclear proteins. Pathological TDP-43 that 
redistributes to the cytosol and aggregates has undergone some posttranslational modifications, 
including N-terminal proteolytic cleavage (generating low-molecular-weight 25 and 35 kDa 
species), phosphorylation, and ubiquitination. Full-length TDP-43 can be cleaved at DXXD-
box 1.2 Protein quality control machinery
Intracellular inclusions, sometimes containing ubiquitin, appear in spinal cord motor neurons of ALS-patients 
and SOD1-ALS mice. In SOD1-ALS mice these aggregates appear in early stages of the disease, suggesting a 
contribution to disease initiation. The main cellular defence pathways for clearance of aggregated misfolded 
proteins in cells are the molecular chaperones, the ubiquitin-proteasome system (UPS), the aggresome and 
the autophagosome-lysosome pathway (103).
Molecular chaperones as heat-shock proteins (Hsp) can prevent aggregation and mediate refolding 
of misfolded proteins. ALS-patients and SOD1-ALS mice express altered levels of Hsp’s, and in many 
cellular models, Hsp’s are able to prevent SOD1-induced cell death. Increasing endogenous Hsp70-levels 
in SOD1-mice did not have a beneficial effect on survival (109), however injection of recombinant �sp70 
delayed disease onset in SOD1-ALS mice (110). So although heat-shock proteins can possibly delay SOD1-
aggregation, their activity most likely reflects a late phase in motor neuron death. 
For degradation via the UPS, misfolded proteins are labelled with poly-ubiquitin for recognition by and 
transportation to the proteasome, this also happens with misfolded and aggregated mutant SOD1-oligomers. 
Overloading the UPS-system by an excess of undegradable aggregates can result in proteasomal dysfunction, 
that in turn might lead to motor neuron death in ALS. However, measurements of proteasome activity in 
SOD1-ALS mice are inconsistent (111): reducing proteasomal activity in SOD1-ALS mice does not induce 
any neurological deficits by itself, and does not change disease onset or survival (112). Also, mutant SOD1-
expressing motor neurons are not more vulnerable to proteasome inhibition than wild-type motor neurons 
(113), indicating that proteasomal dysfunction is not a primary cause of motor neuron death. 
Subsequently, via microtubule-based transport, misfolded protein species are transported to the aggresome, 
where degradation could take place (102). Through autophagy, misfolded proteins or entire organelles are 
invaginated by a double-membrane structure, the autophagosome. After transportation to the cell center, also 
via active transport, the autophagosome fuses with lysosomes and subsequently its contents are degraded. 
Mutant SOD1 can be degraded via the proteasome as well as via the autophagosome (114), however the 
latter is less efficient to clear SOD1-protein aggregates (103). Although increased autophagy-levels are 
observed in SOD1-ALS mice (115), the exact contribution to SOD1-linked ALS has to be further clarified. 
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sites by caspase-3 into C-terminal fragments that redistributes from its nuclear localization to 
cytoplasm (122). The mechanism by which TDP-43 redistributes from the nucleus to the cytosol 
and aggregates is not understood. Recently a role for progranulin in TDP-43 cleavage has been 
suggested. The sequestration of TDP-43 in the cytosol and inclusions could cause loss of function 
of TDP-43 in mRNA splicing (box 1.1), whereas the aggregated and mislocalized protein may be 
toxic to motor neurons, or interfere with various cell functions (123). 
As described, aggregates are a common pathological hallmark of sporadic and familial ALS. 
Also in other neurodegenerative diseases, heat shock proteins, ubiquitin and autophagy markers 
accumulate in aggregates induced by aggregate-prone proteins, suggesting a common disease 
pathway (102-104). The appearance of aggregates is replicated by mouse models for ALS based on 
mutations in SOD1, and these mouse models have taught researchers a lot about other underlying 
pathogenic mechanisms in ALS. Also mutations in p150glued and VAPB (see paragraphs 1.4 and 
1.5), which function in very different intracellular pathways as SOD1, cause aberrant aggregation 
of the mutant protein, suggesting that aggregates might be a common mechanism in ALS. The 
aggregates caused by mutant VAPB as described in chapter 5 do not recruite UPS or autophagy-
related proteins and are structurally distinct from most disease-related aggregates described, and 
therefore might represent a novel type of aggregates. 
1.4 DiSruPTion of inTrACeLLuLAr TrAnSPorT in ALS
1.4.1 Dynein/dynactin mediates retrograde transport in motor neurons
In neurons, newly synthesized proteins and organelles are transported from the cell body to the 
end of the axon (anterograde transport) and endocytic factors, signaling molecules and misfolded 
proteins are transported from the synapse back towards the cell body (retrograde transport). 
Active motor proteins that move along the microtubules mediate this bidirectional transport. 
The kinesin superfamily proteins (KIFs) mediate anterograde transport, retrograde transport is 
facilitated by the cytoplasmic dynein motor and its accessory protein complex dynactin (124). 
The dynactin complex consists of multiple subunits (figure 1.4); the largest subunit of dynactin, 
p150glued, mediates the interaction with the microtubules, while p50/dynamitin links p150glued to 
the dynactin-subunits involved in cargo-binding (125). Interestingly, overexpression of p50/
dynamitin disrupts the dynactin complex and inhibits dynein-dependent organelle transport 
(126). Both the dynein and dynactin-complex are essential for normal development, as knockouts 
in subunits of these motors are lethal in the blastocyst stage of embryogenesis in mice (127).
 The dynein/dynactin motor complex is primarily responsible for microtubule dependent 
minus-end directed cargo transport but is also involved in many other  intracellular motile events   
such as neurotrophic signaling (128) and neuronal migration (129). Furthermore, dynein/dynactin 
is important for proteasomal degradation (130) and autophagy (131). An excessive amount of 
aggregates in neurons can not only impair the proteasomal and autophagic machineries (see 
box 1.2), but might also lead to traffic-jam-like structures in dendrites and axons, thereby 
slowing intracellular transport. As aggregated proteins are transported to the aggresomes and 
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autophagosome via microtubule-dependent transport, disrupted transport by itself could also lead 
to decreased clearance of aggregated proteins by these cellular defence systems (102, 131). In this   
paragraph, studies suggesting the involvement of disrupted intracellular transport and trafficking 
in the etiology of motor neuron diseases are described.
1.4.2 Axonal transport defects can cause motor neuron diseases
The accumulation of neurofilaments (NFs) in axons, resulting in axonal swellings (spheroids), is 
a common pathological hallmark in motor neurons of ALS-patients and SOD1-ALS mice (132, 
133). Based on these observations, NF-mutations were suggested as susceptibility-factors in ALS-
patients, but none of them are clearly associated with the disease (134). In the vicinity of these NF 
swellings, other cellular organelles accumulate, structurally resembling a “traffic jam” that might 
slow axonal transport in general. In line with this, several studies have indeed demonstrated 
decreased anterograde and retrograde axonal transport in SOD1-ALS mice (135, 136). 
 To study whether axonal transport defects can contribute to or even cause motor neuron 
death, mice with a targeted disruption of dynein function, by overexpression of the dynactin 
subunit p50/dynamitin in neurons, were generated. These mice developed a late-onset slowly 
progressive muscle weakness, and motor neuron degeneration accompanied by neurofilament 
inclusions and disrupted retrograde transport (137). In two other mouse models, generated via 
random ENU-induced mutagenesis (Loa/Cra1), that developed late-onset progressive motor 
weakness and a decreases number of α-motor neurons, mutations were mapped to the gene for 
dynein heavy chain (DHC) (see table 1.3). Neurons of these mice also showed a mild delay in fast 
retrograde transport (83). These studies suggested that a disruption of dynein/dynactin function 
affects retrograde trafficking and could lead to motor neuron death. 
This suggestion was enforced by the discovery of so far six mutations in the gene for the 
p150glued subunit of dynactin (DCTN1) in families with slowly progressive lower motor neuron 
Figure 1.4. Retrograde axonal transport in motor neurons. Minus-end directed microtubule transport is mediated 
by the dynein/dynactin motor, that via adaptor proteins can bind to a specific type of cargo (table 1.4). In the 
axon, microtubules are polarized whereas in dendrites microtubules have mixed polarity.  
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disease, with distal SBMA and with ALS-FTD, (49, 50, 77, 138) (table 1.2). One mutation (G59S) 
in p150glued is located in the microtubule-binding domain and disrupts the interaction of dynactin 
with microtubules (50). Motor neurons of affected patients showed somatic inclusions containing 
dynein and dynactin. In cultured neuron-like cells (MN1-cells), overexpression of p150-G59S 
results in neurotoxic aggregates; �sp70, known to inhibit protein aggregation, decreases this 
toxicity (139). Some p150glued mutations (M571T, R785W, C957T, R1101K, T1249I) are located 
in a region critical for the integrity of the dynactin complex (138), the functional consequences of 
other mutations have not been clarified. It is so far not clear whether disrupted dynein/dynactin 
function or aggregation of mutant p150 causes motor neuron death in these affected individuals. 
In disorders caused by mutations in retrograde-transport motors, as described above, 
neuronal cell bodies are affected before axonal degeneration processes start. Mutations in 
anterograde motor proteins in general result in axonopathies with both sensory and motor 
involvement. For example, mutations in kinesin-3 (KIF1B) cause Charcot-Marie-Tooth (CMT) 
disease type 2A (62, 64), mutations in kinesin-1 (KIF5A) cause hereditary spastic paraplegia 
(HSP) (72), and mutations in kinesin-4 (KIF21A) cause an ocular muscle disease, that are all 
characterized by axonal degeneration. So, anterograde transport seems to be primarily essential 
for the maintenance of axonal health.
Defects in proteins that maintain the neuronal cytoskeleton also underlie some motor 
neuron diseases. Neurofilaments are disturbed in CMT2E, that is caused by mutations in the gene 
for NF-L; also mutations in �sp27 lead to a disruption of NF assembly and cause another type 
of CMT (CMT2F) (65). Microtubules are affected by mutations in tubulin chaperone E (Tbce) 
that disrupt microtubule routing, in the mouse model pmn (progressive motor neuropathy) (84), 
and by mutations in microtubule-binding protein spastin, that cause a subtype of HSP (71) (table 
1.3, 1.4). Furthermore, also in Alzheimer’s disease and the polyglutamine diseases, abnormalities 
in axonal transport and (abnormal) interaction of the disease proteins with microtubule motor 
proteins have been observed (reviewed in (140)). These studies show that defects in proteins 
important for microtubule-based transport or the neuronal cytoskeleton can be detrimental for the 
survival of (motor) neurons in many diseases.  
1.4.3 endosomal trafficking and motor neuron diseases
Accumulating evidence from genetic studies suggested that dysfunction of proteins essential for the 
secretory pathway and endosomal trafficking could be specifically deleterious to motor neurons, 
leading to a wide variety of neurological disorders. In a juvenile-onset and slow progressing upper 
motor neuron disorder, the second genetic linkage in familial ALS was found in the gene for Alsin 
(ALS2) (45, 51). To date, over a dozen mutations have been found which are small deletions, 
non- or missense mutations resulting in a loss-of-function of Alsin. Mutations in Alsin have also 
been found in Infantile-Onset Ascending Hereditary Spastic Paraplegia (IOAHSP) a juvenile-
onset upper motor neuron disorder. The clinical signs of juvenile Primary Lateral Sclerosis (PLS) 
are also very similar to ALS2 and IOAHSP. Because of these clinical and genetic similarities, it 
was suggested that these disorders represent a subgroup of motor neuron diseases, the ALS2-like 
disorders (141). 
Alsin is a highly conserved protein that is expressed in several neuronal types in 
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the CNS but not in glial cells. It is mainly cytosolic but also localizes to Rab5-positive early 
endosomal vesicles (142) (figure 1.5). Alsin contains three Rho-GEF GTPase-like domains that 
can specifically bind to and activate Rab5 (143). In cultured cells and neurons, Alsin localizes 
to early endosomes and functions in their fusion to late endosomes (143-146). Alsin-knockout 
mice are viable and have a normal life span, however, show progressive abnormalities in motor 
coordination and motor learning and a decrease in the size of cortical neurons. Their spinal cord and 
corticospinal tract display axonal degeneration, suggesting that these mice develop an axonopathy 
box 1.3.  membrane trafficking: the secretory and endocytic pathway
Microtubule-dependent motor proteins are primarily responsible for intracellular membrane trafficking 
of newly synthesized proteins from the endoplasmic reticulum (ER) via the Golgi apparatus towards 
the plasma membrane (the secretory pathway), and the re-uptake, recycling and degradation of proteins 
via endosomal/lysosomal route (endocytic pathway). For the proper interaction of motor proteins with 
particular membrane cargos, specific adaptor proteins are required that determine transport specificity 
and selectivity for these organelles (150). For example, dynein interacts via adaptor protein RILP with 
Rab7-coated late endosomes (151), via adaptor protein BICD2 with Rab6-positive vesicles in the 
secretory pathway (152, 153) and via �DAC-6 with ubiquitinated cargo (154). In figure 1.5, the secretory 
and endosomal pathway is indicated and in table 1.4 the dynein cargo-adaptor proteins crucial for the 
specificity of dynein-cargo interactions are listed. Dynein/dynactin is crucial for the maintenance of the 
organization and positioning of the Golgi apparatus (155). Disruption of the dynein/dynactin motor in 
cultured cells leads to disturbed intracellular traffic and fragmentation of the Golgi apparatus, the latter 
being a pathological hallmark of ALS motor neurons preceding their death (see 1.1.3) (12, 126). This 
suggests that either disrupted dynein might lead to disturbed membrane trafficking, or that disturbed 
membrane trafficking itself might lead to motor neuron diseases. 
Figure 1.5. Secretory and endosomal trafficking. Shown are the Golgi 
apparatus, the plasma membrane and endosomal pathways: secretory (top), 
endocytosis, recycling endosomes, the MVB-pathway and the localization of 
the Golgi-Associated Retrograde Protein (GARP)-complex. Proteins found 
mutated in motor neuron disorders are indicated with arrowheads. 
Table 1.4  Dynein cargo 
and adaptor proteins
Dynein 
cargo
Adaptor 
(ref)
Rab7-vesicles 
(LE/lys) RILP (151)
Rab6-vesicles 
(late Golgi)
BICD2 
(156)
Rab5-vesicles 
(EE)
Htt/HAP-1 
(157)
Spectrin 
vesicles
Binding via 
Arp1 (158)
COPII vesicles Cdc42 (46)
syntaxin-18 
vesicles
RINT1 
(159)
Retrolinkin-
vesicles
BPAG1n4 
(160)
Neurotrophic 
factors 
Binding to 
TrkR (161)
Misfolded ubiq. 
proteins
HDAC-6 
(154)
SNX4 vesicles Kibra (162)
Retrograde 
injury factors
Via vimen-
tin (163)
Neuro-
filaments
Binding to 
DYN (164)
Nucleus 
(migration) Lis1 (165)
Spindle 
(C.Elegans) Lin-5 (166)
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(147). In some mice astrocytosis and microglial activation was demonstrated, and neurons from 
Alsin knockout mice are more vulnerable to oxidative stress. In line with the putative function 
of Alsin, neurons from Alsin-knockout mice show an accumulation of endocytosed components 
like trophic factors, caused by a defect in early endosomal fusion (44, 145, 148, 149). I n vitro, a 
delayed endosomal fusion is observed in brain cytosol from Alsin mice (149). It is possible that 
a recently identified Alsin-homologue, ALS2-C-terminal like (ALS2CL) has redundant functions 
with Alsin (167). 
Alsin-mutations demonstrate that disturbances in the early endosomal compartment could 
be deleterious to motor neurons. Also alterations in late endosomal compartments can induce motor 
neuron disease, at least in a spontaneous mouse model for lower motor weakness, the Wobbler 
mouse (table 1.3) (168). This mouse has been discovered more than 50 years ago and has been 
used as a model for ALS. Wobbler mice develop an autosomal recessive disease characterized by 
perinuclear vacuolar swellings and degeneration of motor neurons, pathologically accompanied 
by astrogliosis, microglial activation, ubiquitinated inclusions and neurofilament abnormalities 
(169). The mutation causing this phenotype was recently localized to the gene for Vacuolar-
vesicular Protein Sorting 54 (Vps54) (82), which forms a complex together with Vps52 and -53. 
This Golgi-Associated Retrograde Protein (GARP) complex is involved in retrograde transport of 
late endosomes to the trans-Golgi (figure 1.5). The genes are highly conserved from yeast to men; 
in yeast, GARP is the main effector of Ypt6p, the yeast homologue of the small GTPase Rab6, 
and also in human cells, the GARP-complex interacts with Rab6 (170). So far, there have been 
no studies investigating the pathogenesis of mutant Vps54 that is expressed in many tissues; it is 
possible that disturbed endosomal trafficking leads to motor neuron degeneration in this mouse 
model for motor neuron disease.
Also in other motor neuron disorders, mutations in proteins involved in the secretory and 
endosomal pathways have been identified (table 1.2) (see also (75)), for example mutations in late 
endosomal GTPase Rab7 lead to CMT2B (63). HSP can be caused by mutations in Atlastin that 
lead to disruptions of vesicle budding from the ER or fusion with the Golgi apparatus (70, 171). 
Spartin and Spastin, mutated in other forms of HSP, function in the formation of Multivesicular 
Bodies (MVBs) (71, 73), that are specialized endosomes mediating the sorting of ubiquitinated 
cargo targeted for degradation to the lysosome. This pathway is regulated by proteins in the 
Endosomal Sorting Complex for Retrograde Transport (ESCRT) (172, 173) (figure 1.5). One 
protein functioning in this complex, CHMP2B, is mutated in FTLD-U and ALS-patients. The 
mutations lead to a disruption of ESCRT-mediated protein degradation via the autophagosome-
lysosome pathway and also result in TDP-43 accumulation (see also 1.3.2) (123). In sum, many 
proteins involved in the secretory and endosomal pathways are found to be mutated in different 
neurodegenerative disorders. �ow mutations in membrane trafficking proteins cause selectively 
death of motor neurons remains to be solved.
As indicated in this paragraph microtubule transport and intracellular membrane trafficking are 
closely linked cellular pathways and alterations in either one of these pathways are likely to 
affect neuronal survival (150). In chapter 4 of this thesis, we have developed a mouse model with 
chronic disruption of dynein in neurons by overexpressing a truncated form of adaptor-protein 
BICD2, that shows disruption of retrograde axonal transport and endosomal trafficking. 
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1.5 VAPb-LinkeD ALS: ProTein AGGreGATion or SomeThinG eLSe?
A mutation in the gene for Vesicle Associated Membrane Protein (VAMP)-Associated Protein-
B (VAPB) was found in different families with autosomal dominant, slowly progressive, lower 
motor neuron disease with phenotypes varying from typical ALS (ALS8) to late-onset SMA. This 
mutation is supposed to have one common founder, and could represent a new category of motor 
neuron disease, the ALS8-like disorders. The mutation is a single nucleotide alteration, changing 
amino acid 56 from serine into proline (47, 48, 174). VAPB and the highly homologous family 
member VAPA are small type II integral membrane proteins, that are present in the endoplasmic 
reticulum (ER) and pre-Golgi-intermediates (175, 176). VAP-proteins are highly conserved from 
yeast to men; the yeast homologue of VAPB (Scs2p) is involved in inositol-metabolism (177). 
VAP-proteins were originally identified as binding partners of VAMP1 and -2 
(synaptobrevin) in the slug Aplysia Californica (178, 179). VAMPs are involved in the fusion of 
synaptic vesicles with the plasma membrane and therefore the exocytosis of neurotransmitters 
(178). In Drosophila, DVAP regulates the size and number of synapses at the neuromuscular 
junction (180). In mammalian cells, VAPB was found to be involved in protein transport 
between the ER and Golgi apparatus via COPI-vesicles (175) and in vesicle targeting to the 
plasma membrane via SNAREs (181). In addition, VAPB was suggested to have functions in 
the maintenance of the neuromuscular junction as in Drosophila (182). Despite these many 
suggestive functions, the exact role of VAPB in mammalian cells is not clear. Both yeast and 
mammalian VAP-proteins can bind to a number of lipid-binding proteins that links the function 
of VAPB to lipid homeostasis  (183). 
ALS-mutant VAPB (P56S) forms cytosolic aggregates when expressed in cultured cells 
(48), a phenomenon that is further studied in chapter 5. These aggregates impair the function of 
VAPB, that could lead to lipid abnormalities, this hypothesis will be discussed in chapter 6.3. 
We have closely examined the pathways described in paragraph 1.3, 1.4 and 1.5 and their relation 
to ALS in the rest of this thesis,. The timing of the appearance of protein aggregates and other 
cellular and molecular alterations in motor neurons in the SOD1-ALS mouse, are studied in 
chapter 2. The roles of motor neurons and supporting glial cells in disease are investigated by a 
neuron-specific SOD1-mouse in chapter 3. In chapter 4, the role of dynein disruption is studied in 
relation to aggregates, retrograde transport and endosomal trafficking. In chapter 5, aggregates in 
VAPB-linked motor neuron disease are characterized. In sum, this thesis presents an overview of 
the current knowledge on the role of aggregates and intracellular trafficking in ALS.
INTRODUCTION
25
referenCeS
1. Goetz, C. G. (2000) Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot. Muscle Nerve  
 23, 336-343
2. Purves, D. (2001) Lower Motor Neuron Circuits and Motor Control. In Neuroscience (Hall, N., ed), Sinauer  
 Associates Inc., Sunderland (MA)
3. Purves, D. (2001) Upper Motor Neuron Control of the Brainstem and Spinal Cord. In Neuroscience (Hall, N.,  
 ed), Sinauer Associates Inc., Sunderland (MA)
4. Ringholz, G. M., Appel, S. H., et al. (2005) Prevalence and patterns of cognitive impairment in sporadic ALS.  
 Neurology 65, 586-590
5. Talbot, K., and Ansorge, O. (2006) Recent advances in the genetics of amyotrophic lateral sclerosis and   
 frontotemporal dementia: common pathways in neurodegenerative disease. Hum Mol Genet 15 Spec No 2,  
 R182-187
6. ALS-association (2004) About ALS. www.alsa.org 
7. Hirtz, D., Thurman, D. J., et al. (2007) How common are the “common” neurologic disorders? Neurology 68,  
 326-337
8. Bird, T. D. (1998-2007) Charcot-Marie Tooth Hereditary Neuropathy Overview. Gene reviews, http://www. 
 ncbi.nlm.nih.gov/books/bv.fcgi?rid=gene.chapter.cmt2a
9. La Spada, A. R. (1999-2006) Spinal and Bulbar Muscular Atrophy. Gene reviews, http://www.ncbi.nlm.nih. 
 gov/books/bv.fcgi?rid=gene.chapter.kennedy
10. Reid, E. (2003) Science in motion: common molecular pathological themes emerge in the hereditary spastic  
 paraplegias. J Med Genet 40, 81-86
11. Matsumoto, S., Kusaka, H., et al. (1996) Golgi apparatus and intraneuronal inclusions of anterior horn cells in  
 amyotrophic lateral sclerosis: an immunohistochemical study. Acta Neuropathol 91, 603-607
12. Gonatas, N. K., Stieber, A., et al. (2006) Fragmentation of the Golgi apparatus in neurodegenerative diseases          
 and cell death. J Neurol Sci 246, 21-30
13. Okamoto, K., Hirai, S., et al. (1993) Bunina bodies in amyotrophic lateral sclerosis immunostained with rabbit  
 anti-cystatin C serum. Neurosci Lett 162, 125-128
14. Kato, S., Saito, M., et al. (1999) Recent advances in research on neuropathological aspects of familial   
 amyotrophic lateral sclerosis with superoxide dismutase 1 gene mutations: neuronal Lewy body-   
 like hyaline inclusions and astrocytic hyaline inclusions. Histol Histopathol 14, 973-989
15. Leigh, P. N., Whitwell, H., et al. (1991) Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic  
 lateral sclerosis. Morphology, distribution, and specificity. Brain 114 ( Pt 2), 775-788
16. Forman, M. S., Trojanowski, J. Q., et al. (2007) TDP-43: a novel neurodegenerative proteinopathy. Curr Opin  
 Neurobiol 
17. Rowland, L. P. (1998) Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 160 Suppl 1, S6-24
18. Duncan, M. W., Steele, J. C., et al. (1990) 2-Amino-3-(methylamino)-propanoic acid (BMAA) in cycad flour���        
 an unlikely cause of amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Neurology 40,   
 767-772
19. Armon, C. (2001) Environmental risk factors for amyotrophic lateral sclerosis. Neuroepidemiology 20, 2-6
20. Chio, A., Benzi, G., et al. (2005) Severely increased risk of amyotrophic lateral sclerosis among Italian   
 professional football players. Brain 128, 472-476
21. Mattson, M. P., Cutler, R. G., et al. (2007) Energy intake and amyotrophic lateral sclerosis. Neuromolecular  
 Med  9, 17-20
22. Scarmeas, N., Shih, T., et al. (2002) Premorbid weight, body mass, and varsity athletics in ALS. Neurology 59,  
 773-775
23. Schymick, J. C., Talbot, K., et al. (2007) Genetics of sporadic amyotrophic lateral sclerosis. Hum Mol Genet 16  
 Spec No. 2, R233-242
24. Pasinelli, P., and Brown, R. H. (2006) Molecular biology of amyotrophic lateral sclerosis: insights from   
 genetics. Nat Rev Neurosci 7, 710-723
25. Oosthuyse, B., Moons, L., et al. (2001) Deletion of the hypoxia-response element in the vascular endothelial  
 growth factor promoter causes motor neuron degeneration. Nat Genet 28, 131-138
26. Azzouz, M., Ralph, G. S., et al. (2004) VEGF delivery with retrogradely transported lentivector prolongs   
 survival  in a mouse ALS model. Nature 429, 413-417
27. Storkebaum, E., Lambrechts, D., et al. (2005) Treatment of motoneuron degeneration by    
 intracerebroventricular  delivery of VEGF in a rat model of ALS. Nat Neurosci 8, 85-92
28. Crabtree, B., Thiyagarajan, N., et al. (2007) Characterization of human angiogenin variants implicated in   
 amyotro phic lateral sclerosis. Biochemistry 46, 11810-11818
29. Subramanian, V., Crabtree, B., et al. (2008) Human angiogenin is a neuroprotective factor and amyotrophic  
 lateral sclerosis associated angiogenin variants affect neurite extension/pathfinding and survival of motor   
 neurons. Hum Mol Genet 17, 130-149
30. Wu, D., Yu, W., et al. (2007) Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann   
 Neurol 62, 609-617
31. van Es, M. A., van Vught, P. W., et al. (2008) Genetic variation in DPP6 is associated with susceptibility to           
 amyotrophic lateral sclerosis. Nat Genet 40, 29-31
32. van Es, M. A., Van Vught, P. W., et al. (2007) ITPR2 as a susceptibility gene in sporadic amyotrophic lateral           
 sclerosis: a genome-wide association study. Lancet Neurol 6, 869-877
33. Boillee, S., Vande Velde, C., et al. (2006) ALS: a disease of motor neurons and their nonneuronal neighbors.  
 Neuron 52, 39-59
34. Van Den Bosch, L., Van Damme, P., et al. (2006) The role of excitotoxicity in the pathogenesis of amyotrophic           
 lateral sclerosis. Biochim Biophys Acta 1762, 1068-1082
35. Dupuis, L., Gonzalez de Aguilar, J. L., et al. (2004) Mitochondria in amyotrophic lateral sclerosis: a trigger and         
 a target. Neurodegener Dis 1, 245-254
CHAPTER 1
26
36. Manfredi, G., and Xu, Z. (2005) Mitochondrial dysfunction and its role in motor neuron degeneration in ALS.  
 Mitochondrion 5, 77-87
37. Barber, S. C., Mead, R. J., et al. (2006) Oxidative stress in ALS: a mechanism of neurodegeneration and a  
 therapeutic target. Biochim Biophys Acta 1762, 1051-1067
38. Sathasivam, S., and Shaw, P. J. (2005) Apoptosis in amyotrophic lateral sclerosis--what is the evidence? Lancet  
 Neurol 4, 500-509
39. Rosen, D. R., Siddique, T., et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with  
 familial amyotrophic lateral sclerosis. Nature 362, 59-62
40. Andersen, P. M. (2006) Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide   
 dismutase gene. Curr Neurol Neurosci Rep 6, 37-46
41. Andersen, P. M., Sims, K. B., et al. (2003) Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in  
 amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler   
 Other Motor Neuron Disord 4, 62-73
42. Shaw, B. F., and Valentine, J. S. (2007) How do ALS-associated mutations in superoxide dismutase 1 promote  
 aggregation of the protein? Trends Biochem Sci 32, 78-85
43. Gurney, M. E., Pu, H., et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide  
 dismutase mutation. Science 264, 1772-1775
44. Cai, �., Lin, X., et al. (2005) Loss of ALS2 function is insufficient to trigger motor neuron degeneration in  
 knock-out mice but predisposes neurons to oxidative stress. J Neurosci 25, 7567-7574
45. Yang, Y., Hentati, A., et al. (2001) The gene encoding alsin, a protein with three guanine-nucleotide exchange  
 factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 29, 160-165
46. Chen, Y. Z., Bennett, C. L., et al. (2004) DNA/RNA helicase gene mutations in a form of juvenile amyotrophic            
 lateral sclerosis (ALS4). Am J Hum Genet 74, 1128-1135
47. Nishimura, A. L., Mitne-Neto, M., et al. (2004) A novel locus for late onset amyotrophic lateral sclerosis/motor           
 neurone disease variant at 20q13. J Med Genet 41, 315-320
48. Nishimura, A. L., Mitne-Neto, M., et al. (2004) A mutation in the vesicle-trafficking protein VAPB causes late-          
 onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 75, 822-831
49. Puls, I., Jonnakuty, C., et al. (2003) Mutant dynactin in motor neuron disease. Nat Genet 33, 455-456
50. Puls, I., Oh, S. J., et al. (2005) Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann  
 Neurol 57, 687-694
51. Hentati, A., Bejaoui, K., et al. (1994) Linkage of recessive familial amyotrophic lateral sclerosis to   
 chromosome  2q33-q35. Nat Genet 7, 425-428
52. Hand, C. K., Khoris, J., et al. (2002) A novel locus for familial amyotrophic lateral sclerosis, on chromosome  
 18q. Am J Hum Genet 70, 251-256
53. Vance, C., Al-Chalabi, A., et al. (2006) Familial amyotrophic lateral sclerosis with frontotemporal dementia is          
 linked to a locus on chromosome 9p13.2-21.3. Brain 129, 868-876
54. Skibinski, G., Parkinson, N. J., et al. (2005) Mutations in the endosomal ESCRTIII-complex subunit CHMP2B  
 in frontotemporal dementia. Nat Genet 37, 806-808
55. Hosler, B. A., Siddique, T., et al. (2000) Linkage of familial amyotrophic lateral sclerosis with frontotemporal  
 dementia to chromosome 9q21-q22. Jama 284, 1664-1669
56. Morita, M., Al-Chalabi, A., et al. (2006) A locus on chromosome 9p confers susceptibility to ALS and   
 frontotemporal dementia. Neurology 66, 839-844
57. Annesi, G., Savettieri, G., et al. (2005) DJ-1 mutations and parkinsonism-dementia-amyotrophic lateral   
 sclerosis complex. Ann Neurol 58, 803-807
58. Hsieh-Li, H. M., Chang, J. G., et al. (2000) A mouse model for spinal muscular atrophy.        Nat Genet 24, 66-70
59. Grohmann, K., Schuelke, M., et al. (2001) Mutations in the gene encoding immunoglobulin mu-binding   
 protein  2 cause spinal muscular atrophy with respiratory distress type 1. Nat Genet 29, 75-77
60. Ferlini, A., Patrosso, M. C., et al. (1995) Androgen receptor gene (CAG)n repeat analysis in the differential  
 diagnosis between Kennedy disease and other motoneuron disorders. Am J Med Genet 55, 105-111
61. Katsuno, M., Adachi, H., et al. (2003) Transgenic mouse models of spinal and bulbar muscular atrophy            
 (SBMA). Cytogenet Genome Res 100, 243-251
62. Zhao, C., Takita, J., et al. (2001) Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule  
 motor KIF1Bbeta. Cell 105, 587-597
63. Verhoeven, K., De Jonghe, P., et al. (2003) Mutations in the small GTP-ase late endosomal protein RAB7  
 cause  Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet 72, 722-727
64. Mersiyanova, I. V., Perepelov, A. V., et al. (2000) A new variant of Charcot-Marie-Tooth disease type 2 is            
 probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 67, 37-46
65. Evgrafov, O. V., Mersiyanova, I., et al. (2004) Mutant small heat-shock protein 27 causes axonal Charcot-          
 Marie-Tooth disease and distal hereditary motor neuropathy. Nat Genet 36, 602-606
66. Barry, D. M., Millecamps, S., et al. (2007) New movements in neurofilament transport, turnover and disease.  
 Exp Cell Res 313, 2110-2120
67. Bolino, A., Bolis, A., et al. (2004) Disruption of Mtmr2 produces CMT4B1-like neuropathy with myelin   
 outfolding and impaired spermatogenesis. J Cell Biol 167, 711-721
68. Bolino, A., Muglia, M., et al. (2000) Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding 
 myotubularin-related protein-2. Nat Genet 25, 17-19
69. Chow, C. Y., Zhang, Y., et al. (2007) Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and  
 patients with CMT4J. Nature 448, 68-72
70. Tessa, A., Casali, C., et al. (2002) SPG3A: An additional family carrying a new atlastin mutation. Neurology  
 59, 2002-2005
71. Hazan, J., Fonknechten, N., et al. (1999) Spastin, a new AAA protein, is altered in the most frequent form of  
 autosomal dominant spastic paraplegia. Nat Genet 23, 296-303
72. Reid, E., Kloos, M., et al. (2002) A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia  
 (SPG10). Am J Hum Genet 71, 1189-1194
73. Patel, H., Cross, H., et al. (2002) SPG20 is mutated in Troyer syndrome, an hereditary spastic paraplegia. Nat  
INTRODUCTION
27
 Genet 31, 347-348
74. Zuchner, S., and Vance, J. M. (2005) Emerging pathways for hereditary axonopathies. J Mol Med 83, 935-943
75. James, P. A., and Talbot, K. (2006) The molecular genetics of non-ALS motor neuron diseases. Biochim   
 Biophys  Acta 1762, 986-1000
76. Hadano, S., Yanagisawa, Y., et al. (2001) Cloning and characterization of three novel genes, ALS2CR1,   
 ALS2CR2, and ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical region at chromosome  
 2q33-q34: candidate genes for ALS2. Genomics 71, 200-213
77. Munch, C., Sedlmeier, R., et al. (2004) Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS.  
 Neurology 63, 724-726
78. Fink, J. K. (2000-2007) Hereditary Spastic Paraplegia Overview. Gene reviews, http://www.ncbi.nlm.nih.gov/ 
 books/bv.fcgi?rid=gene.chapter.hsp
79. Shaw, P. J. (2005) Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol  
 Neurosurg Psychiatry 76, 1046-1057
80. Julien, J. P., and Kriz, J. (2006) Transgenic mouse models of amyotrophic lateral sclerosis. Biochim Biophys  
 Acta 1762, 1013-1024
81. Simpson, C. L., and Al-Chalabi, A. (2006) Amyotrophic lateral sclerosis as a complex genetic disease. Biochim  
 Biophys Acta 1762, 973-985
82. Schmitt-John, T., Drepper, C., et al. (2005) Mutation of Vps54 causes motor neuron disease and defective  
 spermiogenesis in the wobbler mouse. Nat Genet 37, 1213-1215
83. Hafezparast, M., Klocke, R., et al. (2003) Mutations in dynein link motor neuron degeneration to defects in  
 retrograde transport. Science 300, 808-812
84. Bommel, �., Xie, G., et al. (2002) Missense mutation in the tubulin-specific chaperone E (Tbce) gene in the  
 mouse mutant progressive motor neuronopathy, a model of human motoneuron disease. J Cell Biol159,563-569
85. Grohmann, K., Rossoll, W., et al. (2004) Characterization of Ighmbp2 in motor neurons and implications for  
 the  pathomechanism in a mouse model of human spinal muscular atrophy with respiratory distress type 1  
 (SMARD1). Hum Mol Genet 13, 2031-2042
86. Hamilton, B. A., Smith, D. J., et al. (1997) The vibrator mutation causes neurodegeneration via reduced          
 expression of PITP alpha: positional complementation cloning and extragenic suppression. Neuron 18, 711-722
87. Houenou, L. J., Blondet, B., et al. (1996) The paralyse mouse mutant: a new animal model of anterior horn  
 motor  neuron degeneration. J Neuropathol Exp Neurol 55, 698-703
88. Guo, L., Degenstein, L., et al. (1995) Gene targeting of BPAG1: abnormalities in mechanical strength and cell            
 migration in stratified epithelia and neurologic degeneration. Cell 81, 233-243
89. Chance, P. F., Rabin, B. A., et al. (1998) Linkage of the gene for an autosomal dominant form of juvenile   
 amyotrophic lateral sclerosis to chromosome 9q34. Am J Hum Genet 62, 633-640
90. Moreira, M. C., Klur, S., et al. (2004) Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-             
 ocular  apraxia 2. Nat Genet 36, 225-227
91. De Jonghe, P., Auer-Grumbach, M., et al. (2002) Autosomal dominant juvenile amyotrophic lateral sclerosis  
 and distal hereditary motor neuronopathy with pyramidal tract signs: synonyms for the same disorder? Brain  
 125, 1320-1325
92. Gubitz, A. K., Feng, W., et al. (2004) The SMN complex. Exp Cell Res 296, 51-56
93. Lorson, C. L., Strasswimmer, J., et al. (1998) SMN oligomerization defect correlates with spinal muscular         
 atrophy severity. Nat Genet 19, 63-66
94. Liu, Q., Fischer, U., et al. (1997) The spinal muscular atrophy disease gene product, SMN, and its associated  
 protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell 90, 1013-1021
95. Monani, U. R. (2005) Spinal muscular atrophy��� a deficiency in a ubiquitous protein; a motor neuron-specific  
 disease. Neuron 48, 885-896
96. Orrell, R. W., Habgood, J. J., et al. (1997) The relationship of spinal muscular atrophy to motor neuron disease:  
 investigation of SMN and NAIP gene deletions in sporadic and familial ALS. J Neurol Sci 145, 55-61
97. Buratti, E., Dork, T., et al. (2001) Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR  
 exon 9 skipping. Embo J 20, 1774-1784
98. Wang, H. Y., Wang, I. F., et al. (2004) Structural diversity and functional implications of the eukaryotic TDP           
 gene  family. Genomics 83, 130-139
99. Strong, M. J., Volkening, K., et al. (2007) TDP43 is a human low molecular weight neurofilament (hNFL)  
 mRNA-binding protein. Mol Cell Neurosci 35, 320-327
100. Wang, I. F., Reddy, N. M., et al. (2002) Higher order arrangement of the eukaryotic nuclear bodies.         Proc Natl  
 Acad Sci U S A 99, 13583-13588
101. Lehner, B., and Sanderson, C. M. (2004) A protein interaction framework for human mRNA degradation.   
 Genome Res 14, 1315-1323
102. Kopito, R. R. (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10, 524-530
103. Rubinsztein, D. C. (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 
 443, 780-786
104. Taylor, J. P., Hardy, J., et al. (2002) Toxic proteins in neurodegenerative disease. Science 296, 1991-1995
105. Muller, F. L., Song, W., et al. (2006) Absence of CuZn superoxide dismutase leads to elevated oxidative stress  
 and acceleration of age-dependent skeletal muscle atrophy. Free Radic Biol Med 40, 1993-2004
106. Kato, S. (2008) Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences.  
 Acta Neuropathol 115, 97-114
107. Zetterstrom, P., Stewart, H. G., et al. (2007) Soluble misfolded subfractions of mutant superoxide dismutase- 
 1s are enriched in spinal cords throughout life in murine ALS models. Proc Natl Acad Sci U S A 104, 14157- 
 14162
108. Jonsson, P. A., Ernhill, K., et al. (2004) Minute quantities of misfolded mutant superoxide dismutase-1 cause          
 amyotrophic lateral sclerosis. Brain 127, 73-88
109. Liu, J., Shinobu, L. A., et al. (2005) Elevation of the Hsp70 chaperone does not effect toxicity in mouse models  
 of familial amyotrophic lateral sclerosis. J Neurochem 93, 875-882
110. Gifondorwa, D. J., Robinson, M. B., et al. (2007) Exogenous delivery of heat shock protein 70 increases   
CHAPTER 1
28
 lifespan  in a mouse model of amyotrophic lateral sclerosis. J Neurosci 27, 13173-13180
111. Kabashi, E., and Durham, H. D. (2006) Failure of protein quality control in amyotrophic lateral sclerosis.   
 Biochim Biophys Acta 1762, 1038-1050
112. Puttaparthi, K., Van Kaer, L., et al. (2007) Assessing the role of immuno-proteasomes in a mouse model of            
 familial ALS. Exp Neurol 206, 53-58
113. Vlug, A. S., and Jaarsma, D. (2004) Long term proteasome inhibition does not preferentially afflict motor  
 neurons  in organotypical spinal cord cultures. Amyotroph Lateral Scler Other Motor Neuron Disord 5, 16-21
114. Kabuta, T., Suzuki, Y., et al. (2006) Degradation of amyotrophic lateral sclerosis-linked mutant Cu,Zn-  
 superoxide dismutase proteins by macroautophagy and the proteasome. J Biol Chem 281, 30524-30533
115. Morimoto, N., Nagai, M., et al. (2007) Increased autophagy in transgenic mice with a G93A mutant SOD1  
 gene. Brain Res 1167, 112-117
116. Neumann, M., Sampathu, D. M., et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and         
 amyotrophic lateral sclerosis. Science 314, 130-133
117. Mackenzie, I. R., Bigio, E. H., et al. (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral  
 sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61, 427-434
118. Robertson, J., Sanelli, T., et al. (2007) Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows  
 disparity with ALS. Neurosci Lett 420, 128-132
119. Hasegawa, M., Arai, T., et al. (2007) TDP-43 is deposited in the Guam parkinsonism-dementia complex brains.  
 Brain 130, 1386-1394
120. Gijselinck, I., Sleegers, K., et al. (2007) Neuronal inclusion protein TDP-43 has no primary genetic role in  
 FTD and ALS. Neurobiol Aging [Epub ahead of print]
121. Ou, S. H., Wu, F., et al. (1995) Cloning and characterization of a novel cellular protein, TDP-43, that binds to  
 human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 69, 3584-3596
122. Zhang, Y. J., Xu, Y. F., et al. (2007) Progranulin mediates caspase-dependent cleavage of TAR DNA binding          
 protein-43. J Neurosci 27, 10530-10534
123. Filimonenko, M., Stuffers, S., et al. (2007) Functional multivesicular bodies are required for autophagic   
 clearance of protein aggregates associated with neurodegenerative disease. J Cell Biol 179, 485-500
124. Vale, R. D. (2003) The molecular motor toolbox for intracellular transport. Cell 112, 467-480
125. Schroer, T. A. (2004) Dynactin. Annu Rev Cell Dev Biol 20, 759-779
126. Burkhardt, J. K., Echeverri, C. J., et al. (1997) Overexpression of the dynamitin (p50) subunit of the dynactin  
 complex disrupts dynein-dependent maintenance of membrane organelle distribution. J Cell Biol 139, 469-484
127. Harada, A., Takei, Y., et al. (1998) Golgi vesiculation and lysosome dispersion in cells lacking cytoplasmic  
 dynein. J Cell Biol 141, 51-59
128. Ahmad, F. J., Echeverri, C. J., et al. (1998) Cytoplasmic dynein and dynactin are required for the transport of  
 microtubules into the axon. J Cell Biol 140, 391-401
129. Tai, C. Y., Dujardin, D. L., et al. (2002) Role of dynein, dynactin, and CLIP-170 interactions in LIS1   
 kinetochore function. J Cell Biol 156, 959-968
130. Johnston, J. A., Illing, M. E., et al. (2002) Cytoplasmic dynein/dynactin mediates the assembly of aggresomes.  
 Cell Motil Cytoskeleton 53, 26-38
131. Ravikumar, B., Acevedo-Arozena, A., et al. (2005) Dynein mutations impair autophagic clearance of   
 aggregate-prone proteins. Nat Genet 37, 771-776
132. �irano, A., Donnenfeld, �., et al. (1984) Fine structural observations of neurofilamentous changes in   
 amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 43, 461-470
133. Collard, J. F., Cote, F., et al. (1995) Defective axonal transport in a transgenic mouse model of amyotrophic  
 lateral sclerosis. Nature 375, 61-64
134. Xiao, S., McLean, J., et al. (2006) Neuronal intermediate filaments and ALS��� a new look at an old question.  
 Biochim Biophys Acta 1762, 1001-1012
135. Zhang, B., Tu, P., et al. (1997) Neurofilaments and orthograde transport are reduced in ventral root axons of  
 transgenic mice that express human SOD1 with a G93A mutation. J Cell Biol 139, 1307-1315
136. Williamson, T. L., and Cleveland, D. W. (1999) Slowing of axonal transport is a very early event in the toxicity  
 of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci 2, 50-56
137. LaMonte, B. H., Wallace, K. E., et al. (2002) Disruption of dynein/dynactin inhibits axonal transport in motor  
 neurons causing late-onset progressive degeneration. Neuron 34, 715-727
138. Munch, C., Rosenbohm, A., et al. (2005) Heterozygous R1101K mutation of the DCTN1 gene in a family with  
 ALS and FTD. Ann Neurol 58, 777-780
139. Levy, J. R., and Holzbaur, E. L. (2006) Cytoplasmic dynein/dynactin function and dysfunction in motor   
 neurons. Int J Dev Neurosci 24, 103-111
140. Chevalier-Larsen, E., and Holzbaur, E. L. (2006) Axonal transport and neurodegenerative disease. Biochim  
 Biophys Acta 1762, 1094-1108
141. Bertini, E., Eymard-Pierre, E., et al. (2005) ALS2-related disorders. Gene reviews, http://www.ncbi.nlm.nih. 
 gov/books/bv.fcgi?rid=gene.chapter.iahsp
142. Hadano, S., Kunita, R., et al. (2007) Molecular and cellular function of ALS2/alsin: Implication of membrane  
 dynamics in neuronal development and degeneration. Neurochem Int 
143. Otomo, A., Hadano, S., et al. (2003) ALS2, a novel guanine nucleotide exchange factor for the small GTPase  
 Rab5, is implicated in endosomal dynamics. Hum Mol Genet 12, 1671-1687
144. Topp, J. D., Gray, N. W., et al. (2004) Alsin is a Rab5 and Rac1 guanine nucleotide exchange factor.           J Biol  
 Chem 279, 24612-24623
145. �adano, S., Benn, S. C., et al. (2006) Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/           
 alsin exhibit age-dependent neurological deficits and altered endosome trafficking. Hum Mol Genet 15,233-250
146. Jacquier, A., Buhler, E., et al. (2006) Alsin/Rac1 signaling controls survival and growth of spinal motoneurons.  
 Ann Neurol 60, 105-117
147. Deng, �. X., Zhai, �., et al. (2007) Distal axonopathy in an alsin-deficient mouse model. Hum Mol Genet 16,  
 2911-2920
148. Yamanaka, K., Miller, T. M., et al. (2006) Progressive spinal axonal degeneration and slowness in ALS2-          
INTRODUCTION
29
 deficient mice. Ann Neurol 60, 95-104
149. Devon, R. S., Orban, P. C., et al. (2006) Als2-deficient mice exhibit disturbances in endosome trafficking   
 associated with motor behavioral abnormalities. Proc Natl Acad Sci U S A 103, 9595-9600
150. Caviston, J. P., and �olzbaur, E. L. (2006) Microtubule motors at the intersection of trafficking and transport.  
 Trends Cell Biol 16, 530-537
151. Johansson, M., Rocha, N., et al. (2007) Activation of endosomal dynein motors by stepwise assembly of Rab7- 
 RILP-p150Glued, ORP1L, and the receptor betalll spectrin. J Cell Biol 176, 459-471
152. Grigoriev, I., Splinter, D., et al. (2007) Rab6 regulates transport and targeting of exocytotic carriers. Dev Cell  
 13, 305-314
153. Matanis, T., Akhmanova, A., et al. (2002) Bicaudal-D regulates COPI-independent Golgi-ER transport by  
 recruiting the dynein-dynactin motor complex. Nat Cell Biol 4, 986-992
154. Kawaguchi, Y., Kovacs, J. J., et al. (2003) The deacetylase HDAC6 regulates aggresome formation and cell  
 viability in response to misfolded protein stress. Cell 115, 727-738
155. Karki, S., and Holzbaur, E. L. (1999) Cytoplasmic dynein and dynactin in cell division and intracellular   
 transport. Curr Opin Cell Biol 11, 45-53
156. Hoogenraad, C. C., Akhmanova, A., et al. (2001) Mammalian Golgi-associated Bicaudal-D2 functions in the        
 dynein-dynactin pathway by interacting with these complexes. Embo J 20, 4041-4054
157. Pal, A., Severin, F., et al. (2006) Huntingtin-HAP40 complex is a novel Rab5 effector that regulates early   
 endosome motility and is up-regulated in Huntington’s disease. J Cell Biol 172, 605-618
158. Holleran, E. A., Ligon, L. A., et al. (2001) beta III spectrin binds to the Arp1 subunit of dynactin.           J Biol Chem  
 276, 36598-36605
159. Arasaki, K., Taniguchi, M., et al. (2006) RINT-1 regulates the localization and entry of ZW10 to the syntaxin  
 18 complex. Mol Biol Cell 17, 2780-2788
160. Liu, J. J., Ding, J., et al. (2007) Retrolinkin, a membrane protein, plays an important role in retrograde axonal  
 transport. Proc Natl Acad Sci U S A 104, 2223-2228
161. Yano, H., Lee, F. S., et al. (2001) Association of Trk neurotrophin receptors with components of the            
 cytoplasmic dynein motor. J Neurosci 21, RC125
162. Rayala, S. K., den Hollander, P., et al. (2006) Essential role of KIBRA in co-activator function of dynein light  
 chain 1 in mammalian cells. J Biol Chem 281, 19092-19099
163. Perlson, E., Hanz, S., et al. (2005) Vimentin-dependent spatial translocation of an activated MAP kinase in  
 injured nerve. Neuron 45, 715-726
164. Wagner, O. I., Ascano, J., et al. (2004) The interaction of neurofilaments with the microtubule motor   
 cytoplasmic dynein. Mol Biol Cell 15, 5092-5100
165. Tsai, J. W., Bremner, K. H., et al. (2007) Dual subcellular roles for LIS1 and dynein in radial neuronal             
 migration in live brain tissue. Nat Neurosci 10, 970-979
166. Nguyen-Ngoc, T., Afshar, K., et al. (2007) Coupling of cortical dynein and Galpha proteins mediates spindle  
 positioning in Caenorhabditis elegans. Nat Cell Biol 9, 1294-1302
167. Suzuki-Utsunomiya, K., Hadano, S., et al. (2007) ALS2CL, a novel ALS2-interactor, modulates ALS2-  
 mediated endosome dynamics. Biochem Biophys Res Commun 354, 491-497
168. Falconer, D. S. (1956) Wobbler (wr). Mouse news letters 15, 23-29
169. Pernas-Alonso, R., Perrone-Capano, C., et al. (2001) Regionalized neurofilament accumulation and   
 motoneuron degeneration are linked phenotypes in wobbler neuromuscular disease. Neurobiol Dis 8, 581- 589
170. Liewen, H., Meinhold-Heerlein, I., et al. (2005) Characterization of the human GARP (Golgi associated   
 retrograde protein) complex. Exp Cell Res 306, 24-34
171. Namekawa, M., Muriel, M. P., et al. (2007) Mutations in the SPG3A gene encoding the GTPase atlastin   
 interfere with vesicle trafficking in the ER/Golgi interface and Golgi morphogenesis. Mol Cell Neurosci 35,1-3
172. Williams, R. L., and Urbe, S. (2007) The emerging shape of the ESCRT machinery. Nat Rev Mol Cell Biol 8,  
 355-368
173. Saksena, S., Sun, J., et al. (2007) ESCRTing proteins in the endocytic pathway.       Trends Biochem Sci 
174. Marques, V. D., Barreira, A. A., et al. (2006) Expanding the phenotypes of the Pro56Ser VAPB mutation:   
 Proximal SMA with dysautonomia. Muscle Nerve 34, 731-739
175. Soussan, L., Burakov, D., et al. (1999) ERG30, a VAP-33-related protein, functions in protein transport   
 mediated by COPI vesicles. J Cell Biol 146, 301-311
176. Skehel, P. A., Fabian-Fine, R., et al. (2000) Mouse VAP33 is associated with the endoplasmic reticulum and  
 microtubules. Proc Natl Acad Sci U S A 97, 1101-1106
177. Kagiwada, S., Hosaka, K., et al. (1998) The Saccharomyces cerevisiae SCS2 gene product, a homolog of a  
 synaptobrevin-associated protein, is an integral membrane protein of the endoplasmic reticulum and is required  
 for inositol metabolism. J Bacteriol 180, 1700-1708
178. Skehel, P. A., Martin, K. C., et al. (1995) A VAMP-binding protein from Aplysia required for neurotransmitter          
 release. Science 269, 1580-1583
179. Nishimura, Y., Hayashi, M., et al. (1999) Molecular cloning and characterization of mammalian homologues  
 of vesicle-associated membrane protein-associated (VAMP-associated) proteins. Biochem Biophys Res   
 Commun 254, 21-26
180. Pennetta, G., Hiesinger, P. R., et al. (2002) Drosophila VAP-33A directs bouton formation at neuromuscular         
 junctions in a dosage-dependent manner. Neuron 35, 291-306
181. Weir, M. L., Xie, H., et al. (2001) VAP-A binds promiscuously to both v- and tSNAREs. Biochem Biophys Res  
 Commun 286, 616-621
182. Chai, A., Withers, J., et al. (2008) hVAPB, the causative gene of a heterogeneous group of motor   
 neuron  diseases in humans, is functionally interchangeable with its Drosophila homologue DVAP-33A at the  
 Neuromuscular Junction. Hum Mol Genet 17, 266-80
183. Loewen, C. J., and Levine, T. P. (2005) A highly conserved binding site in vesicle-associated membrane   
 protein- associated protein (VAP) for the FFAT motif of lipid-binding proteins. J Biol Chem 280, 14097-14104

ATF-3 AND C-JUN EXPRESSION IN ALS-SOD1 MICE
31
Chapter 2
ATf3 expression precedes death of spinal 
motoneurons in amyotrophic lateral sclerosis 
(ALS)-SoD1 transgenic mice and correlates 
with c-Jun phosphorylation, ChoP 
expression, somato-dendritic ubiquitination 
and Golgi fragmentation 
European Journal of Neuroscience 2005, 22: 1881-94
CHAPTER 2
32
Chapter 2
ATf3 expression precedes death of spinal motoneurons in amyo-
trophic lateral sclerosis (ALS)-SoD1 transgenic mice and corre-
lates with c-Jun phosphorylation, ChoP expression, somato-den-
dritic ubiquitination and Golgi fragmentation 
Angela S Vlug, Eva Teuling, Elize D. Haasdijk, Pim French, Casper C. 
Hoogenraad and Dick Jaarsma
Department of Neuroscience, Erasmus University Rotterdam, The Netherlands.
Abstract
To obtain insight in the morphological and molecular correlates of motoneuron 
degeneration in amyotrophic lateral sclerosis (ALS) mice that express G93A 
mutant SOD1 (G93A mice), we have mapped and characterized ‘sick’ 
motoneurons labeled by the ‘stress transcription factors’ ATF3 and phospho-
c-Jun. Immunocytochemistry and in situ hybridization showed that a subset of 
motoneurons express ATF3 from a relatively early phase of disease before the 
onset of active caspase 3 expression and motoneuron loss. The highest number 
of ATF3 expressing motoneurons occurred at symptom onset. The onset of ATF3 
expression correlated with the appearance of ubiquitinated neurites. Confocal-
double labeling immunofluorescence showed that all ATF3 positive motoneurons 
were immunoreactive for phosphorylated c-Jun. Furthermore, the majority of 
ATF3 and phospho-c-Jun positive motoneurons also was immunoreactive for 
CHOP (GADD153) and showed Golgi fragmentation. A subset of ATF3 and 
phosphorylated c-Jun immunoreactive motoneurons showed a sick appearance 
characterized by a number of distinctive abnormalities, including an eccentric 
flattened nucleus, perikaryal accumulation of ubiquitin immunoreactivity, juxta-
nuclear accumulation of the Golgi apparatus and the ER, and intense Hsp70 
immunoreactivity. These abnormal cells were not immunoreactive for active 
caspase 3. We conclude that motoneurons in SOD1-ALS mice prior to their death 
and disappearance experience a prolonged sick phase, characterized by the gradual 
accumulation of ubiquitinated material first in the neurites and subsequently the 
cell body.  
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inTroDuCTion
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motoneurons causing 
progressive paralysis. In a subset of ALS patients the disease is caused by mutations in the 
cytosolic CuZn superoxide dismutase (SOD1) gene (Andersen et al., 2003), a small homodimeric 
metalloenzyme that catalyses the conversion of superoxide anion to hydrogen peroxide. More than 
100 different SOD1 mutations have been identified that all cause a rather similar disease phenotype 
(Andersen et al., 2003; Valentine et al., 2004). Mutant SOD1s display reduced conformational 
stability (Valentine et al., 2004), susceptibility to disulfide reduction (Tiwari & �ayward, 2003), 
abnormal metal binding (Valentine et al., 2004), toxic oxidative catalytic activities (Valentine et 
al., 2004), and an increased tendency to oligomerise and aggregate (Johnston et al., 2000). Recent 
studies with spinal cord tissue from ALS patients and transgenic mice expressing SOD1 with the 
G127insTGGG mutations have shown that minute quantities of mutant SOD1 (below 0.5% of 
control SOD1 levels) are sufficient to cause the disease (Jonsson et al., 2004), and that the toxicity 
of mutant SOD1 may be represented by a disulfide-reduced hydrophobic fraction (Stewart et al., 
2004). When exposed to the cellular environment these abnormal SOD1 species may interact 
with a wide range of cellular targets to elicit cellular toxicity (Sherman & Goldberg, 2001).
 Transgenic mice expressing ALS mutant SOD1s develop an ALS-like motoneuron 
disease and have provided a powerful tool to examine the cellular mechanism by which mutant 
SOD1 cause the selective degeneration of motoneurons (Bruijn et al., 2004). Biochemical and 
pathological studies in these mice have revealed several abnormalities in motoneurons prior to 
their death, including mitochondrial abnormalities (Dal Canto & Gurney, 1995; Wong et al., 1995; 
Kong & Xu, 1998; Jaarsma et al., 2001; Liu et al., 2004), slowing of axonal transport (Zhang et 
al., 1997; Borchelt et al., 1998; Williamson & Cleveland, 1999; Dupuis et al., 2000), appearance 
of ubiquitinated structures (Bruijn et al., 1998; Stieber et al., 2000; Wang et al., 2002; Jonsson et 
al., 2004), Golgi fragmentation (Mourelatos et al., 1996), loss of neuromuscular synapses (Frey 
et al., 2000; Fischer et al., 2004), and activation of programmed cell death pathways (Guegan & 
Przedborski, 2003). The association of mutant SOD1 with motoneuronal mitochondria is an early           
and progressive phenomenon in SOD1-ALS mice (Jaarsma et al., 2001; Liu et al., 2004) that 
also has been identified in post-mortem spinal cord tissue from SOD1-ALS patients (Liu et al., 
2004), suggesting that mitochondria may be an early and direct target of mutant SOD1. However, 
it is not understood how, if indeed, these mitochondrial abnormalities are linked to the functional 
deterioration and death of motoneurons. Similarly, the precise role of the other abnormalities, 
and the relationship between different types of abnormalities is poorly understood. This lack of 
knowledge in part is due to a poor understanding of the dynamics and the morphological and 
molecular correlates of motoneuron degeneration in SOD1-ALS mice (Guegan & Przedborski, 
2003).
 Many cell types including motoneurons have been shown to respond to injurious stimuli 
by expression of ATF3, a member of the ATF/CREB family of transcription factors (Tsujino et al., 
2000; �ai & �artman, 2001), or increased expression and phosphorylation of the AP-1 transcription 
factor c-Jun (�erdegen & Leah, 1998). Both ATF3 and c-Jun have been implicated in the control of 
survival and repair programs, but under specific conditions also may trigger cell death programs 
(Behrens et al., 1999; �am et al., 2000; �ai & �artman, 2001; �erdegen & Waetzig, 2001; Nakagomi 
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et al., 2003; Raivich et al., 2004). Since ATF3 and phosphorylated c-Jun are selectively associated        
with injured neurons, they might serve as early markers of degenerating motoneurons. Therefore, 
in this study we have used ATF3 and phospho-c-Jun to map and characterize degenerating 
motoneurons in a line of SOD1-ALS mice expressing G93A mutant SOD1. Our data indicate 
that ATF3 and phospho-c-Jun are expressed in motoneurons in these mice from a relatively early 
stage of disease and mark motoneurons throughout a sick phase that precedes their rapid death 
and disappearance. Our data also indicate that the deterioration of motoneurons correlate with 
the accumulation of ubiquitinated material first in the neurites and subsequently throughout the 
perykaryon.
reSuLTS
ATf3 expression is induced first in motoneurons and subsequently in interneurons in spinal 
cord of G93A mice.
Immunocytochemistry and in situ hybridization showed that ATF3 is not expressed in spinal cord 
of control mice and in young adult G93A mice (age 10 weeks; Figs 1A and 2B). �owever, G93A 
mice older than 15 weeks showed an increasing number of ATF3 positive motoneurons (Figs 1B, 
C, �, I and Fig. 2). A subset of ATF3-labeled motoneurons showed a flattened nucleus (Fig. 1E; 
see below). In addition, in a subset of labeled motoneurons, ATF3 immunoreactivity also was 
found in the cytoplasm of the cell (see Fig. 1G-F and Fig. 4A). As discussed below, extra-nuclear 
ATF3-immunoreactivity co-localized with ubiquitin immunoreactivity. 
 From 20 weeks of age ATF3 also occurred in neurons in the intermediate zone (Rexed’s 
laminae V-VIII and X) of the spinal cord (Figs 1C, I and 2). The number of ATF3 labeled 
interneurons varied between G93A mice of the same age, and positively correlated with the 
duration of symptoms (Fig 2). G93A mice with severe paresis or at end stage disease showed 
ATF3 immunoreactive neurons throughout all laminae of the spinal cord including the dorsal 
horn (Fig. 2). ATF3 labeling did not occur in non-neuronal cells in the spinal cord of control and 
G93A mice, with the exception of sporadic clusters of glial cells with moderate ATF3 labeling 
that occurred in areas with severe neuronal pathology (not shown).
All ATf3 immunoreactive motoneurons are immunoreactive for phosphorylated c-Jun 
Non-transgenic mice show constitutive expression of c-Jun in about 50% of spinal motoneurons 
(�erdegen & Leah, 1998). Previously, we have shown that symptomatic G93A mice showed 
increased c-Jun expression in motoneurons and induction of c-Jun in spinal interneurons (Jaarsma 
et al., 1996). Since the transcriptional activity of c-Jun depends on the phosphorylation of its N-
terminal serine residues (ser63 and ser73), we have examined the distribution of phosphorylated 
c-Jun, using three distinct antibodies that detect either phospho(ser63) or phospho(ser73). The 
specificity of the polyclonal phospho(ser63)-c-Jun antibody  (from Cell Signalling) for phospho-
c-Jun has recently been established in c-JunAA knock-in mice with ser63 and ser73 replaced 
by non-phosphorylable alanines (Brecht et al., 2005). With all three antibodies phospho-c-Jun 
antibodies, no labeling was detected in nuclei of motoneurons and others cells in non-transgenic 
and young adult (age 10 weeks) G93A mice (Fig. 1J and 2B). However, G93A mice older than 15 
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Fig. 1: Induction of ATF3 and CHOP expression and c-Jun phosphorylation in spinal cord of G93A mice 
(A-I) Distribution of ATF3 immunoreactivity (A-F) and mRNA (G-I) in the ventral horn (vh) and intermediate 
zone (iz) of L4-spinal cord of G93A mice of 10 weeks (A, G), 20 weeks (B, D, E, H) and 30 weeks (C, F, I). 
Note in high-magnification images of ATF3 immunoreactive motoneurons (D-F) that ATF3-immunoreactivity 
although primarily localised in the nuclei also occurs in the somato-dendritic cytoplasm. Also note the ATF3-
immunoreactive motoneuron with a flattened eccentric nucleus  (arrow in E). Calibration bars: C, 100 µm; 
D (also for E), 10 µm; and F, 20 µm. (J-L) Distribution of phospho-c-Jun-immunoreactivity in the L4-spinal 
cord of G93A mice of 10 weeks (J), 20 weeks (K) and 30 weeks (L) of age. (M-O) Distribution of CHOP-
immunoreactivity in the L4-spinal cord of G93A mice of 10 weeks (M) and 20 weeks (N, O) of age. Small arrows 
in B, K, and N: labeled motoneurons.
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weeks showed an increasing number of intensely phospho c-Jun immunoreactive motoneurons 
(Figs 1K and 2B), and from 20 weeks phospho-c-Jun also occurred in neurons in the intermediate 
zone (Figs 1L and 2B). Comparison of serial section stained for ATF3 and phospho-c-Jun, 
respectively, showed that the spatio-temporal distribution of phospho-c-Jun was similar to that of 
ATF3 (Figs. 1 and 2). Double-labeling confocal immunofluorescence confirmed that ATF3 and 
phospho-c-Jun were expressed in essentially the same population of motoneurons (Fig. 3A), i.e. 
50 of 50 randomly selected ATF3 labeled motoneurons were positive for phospho-c-Jun, and, 
vice versa, 48 of 50 randomly selected phospho-c-Jun immunoreactive motoneurons were also 
immunoreactive for ATF3 (see material and methods). ATF3 also co localized with phospho-c-
Jun and c-Jun in interneurons of G93A mice, but to what extend they co localize in interneurons 
has not been systematically examined.
The majority of ATf3-phospho-c-Jun positive motoneurons is immunoreactive for ChoP/
GADD153
To further examine the transcriptional context of ATF3 and phospho-c-Jun expressing motoneurons, 
we have studied the expression of a number of a number of other transcription factors associated 
with neuronal injury: i.e c-Fos and krox24, which are transiently expressed in different models 
of neuronal degeneration (�erdegen & Leah, 1998), STAT3, which is phosphorylated and 
transported to the nucleus of axotomized motoneurons (Lee et al., 2004), and C/EBP homologous 
protein CHOP, also named GADD153, which is a stress transcription factor linked to cell death 
(Oyadomari & Mori, 2004).  C-Fos and krox24 were not expressed in motoneurons of G93A 
mice of any age (not shown). Also, we did not identify phospho-STAT3 or nuclear translocation 
of STAT3 in our G93A mice at any age (not shown). In contrast, CHOP-immunoreactivity, like 
ATF3 and phospho-c-Jun selectively appeared in spinal motoneurons of G93A mice older than 15 
weeks (Fig. 1M-O). Double-labeling immunofluorescence showed that the majority (42 of 50) of 
CHOP-immunoreactive motoneurons also was stained for ATF3, and that vice-versa the majority 
of ATF3 motoneurons (44 of 50) also was immunoreactive for CHOP (Fig.3F). CHOP-positive 
ATF3 negative motoneurons showed a relatively healthy appearance, whereas ATF3-postive 
CHOP-negative motoneurons showed either a healthy or a ‘sick’ (see below) appearance. 
ATf3 and phospho-c-Jun and expression precedes the onset of active caspase 3 expression 
and loss of motoneurons
To determine the relationship between ATF3 expression and motoneuron degeneration, we have 
counted motoneurons in serial sections immunostained for choline acetyltransferase (ChAT) or 
CGRP, respectively. No or very little loss of ChAT-labeled motoneurons occurred at 20 weeks of 
age, no-to-moderate (0-20%) loss at 25 weeks of age, and a moderate-to-severe loss (10-60%) at 
29-32 weeks of age, depending on the severity of the symptoms as determined by an hind limb 
extension test  (Fig. 2A).  The same dynamics of motoneuron loss was observed with CGRP 
(Fig. 2A), a peptide that is preferentially localized in large motoneurons (Arvidsson et al., 1993). 
In accord with previous studies which showed that large motoneurons are selectively afflicted 
in G93A mice (Mohajeri et al., 1998), we found that a relatively large percentage (50-95%) 
of CGRP immunoreactive motoneurons were lost in symptomatic G93A mice. However, no or 
little loss of CGRP-labeled motoneurons was observed up to 25 weeks of age (Figs. 2A and 6A-
ATF-3 AND C-JUN EXPRESSION IN ALS-SOD1 MICE
37
Fig. 2: Phospho-c-Jun and ATF3 expression precedes motoneuron loss in G93A mice.
(A) Bar graphs showing the number of ChAT, CGRP and ATF3-labeled motoneurons and ATF3-labeled 
interneurons in L4-spinal cord sections of non-transgenic and G93A mice of different age (see materials and 
methods. Dashed lines in ChAT and CGRP graphs represent the mean number of ChAT and CGRP-labeled 
motoneurons, respectively, of 20 and 30 weeks old control mice.* and ** = P <  0.05 and P < 0.001 compared 
to non-transgenic mice of all age groups and G93A mice of 10, 15 or 20 weeks of age (One-way ANOVA with 
Bonferroni’s Multiple Comparison Test). ** = P< 0.001 compared to non-transgenic mice and G93A mice of 
10, 15 or 20 weeks of age(B) Neurolucida plots of representative consecutive L4 spinal cord sections of G93A 
mice of different ages showing motoneurons (filled circles) and non-motoneurons (open circles) stained for 
phospho-c-Jun and ATF3, respectively.
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C). Since ATF3 and phospho-c-Jun could be identified in motoneurons in G93A mice from 15 
weeks of age, it can be concluded that ATF3 and phospho-c-Jun expression precede the onset of 
motoneuron loss. 
 To further analyze the relation between ATF3 and phospho-c-Jun expression and 
motoneuron death we have compared their expression with the expression of caspase 3, a final 
executioner caspase that has been identified in the spinal cord at the onset of motoneuron death in 
various lines of SOD1-ALS mice (Pasinelli et al., 2000). Immunocytochemistry with an antibody 
specific for active caspase 3 showed that active caspase 3 was not present in lumbar L4 sections 
of our G93A mice at 10 and 15 weeks of age, but was present in a minority (2 of 8) of mice at 20 
weeks, a majority (6 of 8) of mice at 25 weeks, and all mice (18 of 18) sacrificed at 29-32 weeks. 
In accord with previous studies (Pasinelli et al., 2000) active caspase 3 immunoreactivity was 
most frequently associated with irregular structures, 1-5 µm in diameter, in the ventral horn and 
intermediate zone (Fig. 4B). These structures putatively reflect debris of died cells. The frequency 
of these structures, which was about 3 per transverse lumbar section in symptomatic G93A mice, 
did not correlate with the severity of symptoms. Less frequently, active caspase 3 was found 
in cells that could be identified either as neurons (less than 0.5 per L4 section, Fig. 4A-C) or 
astrocytes (not shown). In these cells active caspase 3-labelling was concentrated in the nucleus 
(Fig. 4B-D). Active caspase 3 labeled neurons were predominantly found in the intermediate 
zone (Fig. 4A and B) and the dorsal horn (Fig. 3D), and very infrequently (4 cells in over 100 
L4 sections examined) in motor columns (Rexed’s lamina IX, Fig. 4C). This very low number of 
active caspase 3 immunoreactive motoneurons is consistent with our data obtained with a silver 
degeneration method that stains dying neurons and their processes, which revealed a very low 
number of argyrophilic motoneurons in our G93A mice (not shown). In sum, compared to ATF3 
and phospho-c-Jun, active caspase 3 is expressed at a later time point and in a considerably lower 
number of neurons (Fig. 4A).
 Analysis of ATF3 and active caspase 3 co-expression by double-labelling confocal 
immunofluorescence, showed that all ATF3-immunoreactive motoneurons (50 of 50), including 
motoneurons with an abnormal appearance (see below), were immunonegative for active caspase 
3. Further analysis of ATF3 and phospho-c-Jun immunoreactivity in semi-thin (1 µm) plastic 
sections double-stained for ATF3 or phospho-c-Jun and the complement 3 receptor (CR3, a marker 
of microglia (Jaarsma et al., 2000)), showed that although ATF3 and phospho-c-Jun expressing 
motoneurons often were surrounded by microglial processes these cells did not show classical 
apoptotic changes such as cell shrinkage and chromatin condensation (Fig. 3A). On the other 
hand in the same material we have identified cells with an apoptotic morphology and surrounded 
by microglial processes that were negative ATF3 and phosphorylated c-Jun (Fig. 3A). In sum our 
data indicate that ATF3 and phosphorylated c-Jun are not expressed in cells undergoing apoptosis 
the final stages of cell death.
The onset of ATf3 expression in motoneurons coincides with the appearance of ubiquitinated 
neurites
To obtain insight in the events that trigger ATF3 and phospho-c-Jun expression in motoneurons, we 
compared their spatio-temporal distribution with the distribution with pathological abnormalities 
identified in these mice. The earliest neuropathological feature in our G93A mice is mitochondrial 
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Fig. 4: Active caspase 3 shows a different spatio-
temporal distribution as ATF3 in G93A mice.
(A) Neurolucida plots of representative consecutive 
L4 spinal cord sections from a symptomatic 30 
weeks old G93A mouse showing motoneurons 
(filled circles) and non-motoneurons (open circles) 
stained for active caspase 3 (Casp3) and ATF3, 
respectively. Note the relatively low number of 
active caspase 3 stained neurons. (B-D)  Low (B) 
and high-magnification (C and D) photomicrographs 
of active caspase 3 staining in the sppinal cord 
of G93A mice. Note in (B) that staining is more 
abundant in the intermediate zone as compared to 
the motor column (i.e. left part of the grey matter). 
In the motorcolumns labeling is usually associated 
with unidentifiable structures (arrow head). Labeled 
motoneurons as shown in (C) are very infrequent. 
Labeled neurons usually were interneurons (arrows 
in B; D). Calibration bars: B, 50 µm; C, 15 µm; and 
D, 10 µm.
Note: figure 3 can be found on page 49
swelling and vacuolisation. These mitochondrial abnormalities appear as early as 4 weeks post-
natally (Jaarsma et al., 2001), and hence precede the appearance of phospho-c-Jun and ATF3 
immunoreactive motoneurons by multiple weeks.
 The second abnormality in time in our G93A mice, is the appearance of ubiquitinated 
neurites, i.e. neuronal processes that are intensely stained by antibodies raised against 
polyubiquitinated epitopes (Fig. 5C, E). Ubiquitinated neurites were present in 1 of 5 G93A mice 
of 10 weeks, and in all mice of 15 weeks and older (Fig. 5C, E) their frequency increasing with 
aging. Double-labeling confocal immunofluorescence and immuno-electron microscopy showed 
that this ubiquitin immunoreactivity is localized in dendrites (and occasionally the axon) of 
motoneurons and co-distribute with mutant SOD1 (Jaarsma et al., 2001; Maatkamp et al., 2004). 
Ultrastructural analysis showed that dendritic ubiquitination was characterized by a disorganized 
ensemble of filamentous and amorphous material and, in many occasions, small vesicles (Figs 
5F-K). These ubiquitinated ensembles were surrounded by normal appearing mitochondria 
and cytoplasm (Fig. 5F-K), and usually did not occur in proximity of swollen and vacuolated 
mitochondria in the same dendrite. In some instances dendritic ubiquitin-immunoreactivity could 
be ‘traced back’ to the cell body of motoneurons (e.g. Fig. 3D). Neuritic ubiquitination preceded 
the appearance of ubiquitin in the somata of motoneurons (from 20 weeks of age), inspinal 
interneurons (from 25 weeks), and in glia (from 20-25 weeks). 
  The time of appearance and relative density of ubiquitinated structures grossly correlated 
with the time of appearance and density of phospho-c-Jun and ATF3 positive neurons (Fig. 5A 
and B). Since in most instances it was not possible to identify the cell bodies of ubiquitinated 
neurites, the direct analysis of the relation between dendritic ubiquitination and ATF3 or phospho-
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c-Jun expression was not possible. Indirect evidence from systematic analysis of serial L4 lumbar 
sections of 10, 15 and 20 weeks old G93A mice suggested that the appearance of ubiquitinated 
neurites preceded the appearance of ATF3 and phospho-c-Jun immunoreactivity, because i) 
dendritic ubiquitin immunoreactivity occurred in one 10 weeks old G93A mouse in the absence 
of ATF3 and or phosphorylated c-Jun labeled motoneurons; and ii) the number and distribution 
of ubiquitinated dendrites per L4 section in 15 weeks old G93A mice suggested that multiple 
motoneurons per L4 section had ubiquitinated dendrites (Figs 5A and C), whereas the mean 
frequency of ATF3 immunoreactive motoneurons was 0.55 and 1.3 per L4 section at 15 and 
20 weeks, respectively. Further analysis using double-labeling confocal immunofluorescence of 
ubiquitin and ATF3 showed that i) all motoneurons showing focal (Fig. 3G1) or diffuse (Fig. 3G2) 
perikaryal ubiquitin immunoreactivity (20 of 20) also stained for ATF3 (Figs 3G1 and 3G2); ii) 
the majority of ATF3-immunoreactive motoneurons (37 of 50) did not show perikaryal ubiquitin 
immunoreactivity in the cell body; and iii) extranuclear ATF3 immunoreactivity co-distributed 
with ubiquitin in motoneurons with perikaryal ubiquitin immunoreactivity (Figs 3G1 and G2) and 
in a subset of ubiquitinated neurites (Fig. 3F2). These confocal data indicate that ATF3 expression 
precedes perikaryal ubiquitination.
 
ATf3 and phospho-c-Jun expressing motoneurons show Golgi fragmentation
Fragmentation of the Golgi apparatus, i.e. the transformation of the Golgi apparatus from a network 
of linear profiles to dispersed smaller elements (e.g. see Figs 3D and 3�1), has been identified as 
a constant feature in a subset of motoneurons of ALS patients (Stieber et al., 1998) and SOD1-
ALS mice (Mourelatos et al., 1996; Stieber et al., 2000). To study the relationship between Golgi 
fragmentation and ATF3 or phospho-c-Jun expression we have used antibodies against the cis-
Golgi matrix protein GM130 (Nakamura et al., 1995), and antibodies against proteins that are 
associated with the trans-Golgi as well as different post-Golgi compartments, CGRP, a peptide 
selectively expressed in large motoneurons (see above) and that is localized in the trans-Golgi, 
multivesicular bodies, and secretory granules (Caldero et al., 1992); c-Ret, a receptor tyrosine 
kinase for GDNF-like ligands that is constitutively expressed in most motoneurons; and rab6, a 
small GTP binding protein, which is associated with the trans-Golgi cisternae as well as a subsets 
of trafficking vesicles, and which may play a role in Golgi reorganization during specific forms 
of cell stress (Jiang & Storrie, 2005).
 Motoneurons with fragmented Golgi were identified in our G93A mice from 15 weeks. 
Double labeling confocal immunofluorescence of GM130 and CGRP (Fig. 3�1) and GM130 
with c-Ret (not shown) showed that in motoneurons with fragmented Golgi GM130 on the 
one hand and CGRP or c-ret on the other hand maintain their adjoining slightly overlapping 
localization consistent with their distribution in the cis- and trans-Golgi, respectively. In some 
motoneurons we noted the redistribution of the fragmented Golgi to a subregion of the cell, 
usually in close proximity of the nucleus (Figs 3H1-H4, see below). In sections stained for CGRP, 
another abnormality associated with Golgi fragmentation was identified, in that motoneurons with 
fragmented Golgi showed the accumulation of CGRP in dendrites (Figs 6A-F). This dendritic 
CGRP did not co distribute with GM130 indicating that it reflects a non-Golgi fraction of CGRP 
(not shown). The dendrites that showed accumulation of CGRP immunoreactivity always were 
immunoreactive for ubiquitin, but CGRP did not co-distribute with ubiquitin (Fig. 3H4 and H6). 
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Such a dendritic accumulation was not observed with c-Ret although cells with fragmented Golgi 
usually showed perikaryal accumulation of c-Ret immunoreactivity.
 Double labeling of ATF3 with GM130 indicated that nearly all ATF3 labeled motoneurons 
(47 of 50) showed a fragmented Golgi (Figs 3C and 3H2) and that all of the ATF3-negative 
motoneurons identified in the same fields (84 of 84) displayed a normal Golgi. Accordingly, 
most ATF3 motoneurons that were also positive for CGRP (15 of 17) showed an abnormal Golgi, 
and inversely all CGRP immunoreactive motoneurons with an abnormal Golgi (20 of 20) were 
immunoreactive for ATF3 (Fig. 3H3). Also analysis of phospho-c-Jun or CHOP and GM130 
labeled sections also showed that phospho-c-Jun and CHOP expression correlated with phospho-
c-Jun and Golgi fragmentation. Finally, although not studied systematically, we noted that also 
ATF3-labeled intermediate zone neurons showed Golgi fragmentation. 
Fig. 5: The onset of ATF3 expression correlates with dendritic ubiquitination.
(A, B) Neurolucida plots of representative consecutive L4 spinal cord sections from a 20 weeks (A) and 
30 weeks (B) old G93A mouse showing motoneurons (filled circles) and non-motoneurons (open circles) 
stained for ATF3 and ubiquitin-immunoreactive structures, respectively. Note that both the amount of ATF3 
and ubiquitin labeling increases with aging. (C-F)  Low (C, D) and high-magnification (E) light-microscopic 
photomicrographs, and electron photomicrograph (F) of ubiquitin-immunoperoxidase labeling in the L4 spinal 
cord of 15 weeks (C), 20 weeks (E and F) and a 30 weeks (D) old G93A mouse. In 15 and 20 weeks old 
G93A mice ubiquitin labeling is selectively associated with neurites in the motor columns (arrows in C and E). 
Ultrastructurally, this neuritic labeling is associated with core of motoneuron dendrites (area indicated by arrows 
in F). Note that cytoplasm en mitochondria surrounding the ubiquitinated area have a normal appearance (see 
also Figs 8H and I of Maatkamp et al., 2004). In 30 weeks old G93A ubiqitinated structures are associated 
with both neuronal and glial profiles (not shown) and fill the entire ventral and intermediate gray matter (B 
and D). Calibration bars: C (also for D), 50 µm; E, 25 µm; and F, 500 nm. (G) Standard electron microscopy 
of a ubiquitinated dendrite of a 20 weeks old G93A mouse. (H-K) Post-embedding immunogold labelling of 
ubiquitin (H-J) and hSOD1 (K) in a dendrite of non-trangenic mouse (H), and dendrites of a 20 weeks old G93A 
mouse (I, K), calibration bars 500 nm. 
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A subset of phospho-c-Jun and ATf3 positive motoneurons show a sick appearance 
characterized by a flattened nucleus, juxta-nuclear accumulation of the Golgi apparatus, 
rab6 accumulation, diffuse perikaryal ubiquitination and hsp70 expression 
As indicated above a subset of ATF3, phospho-c-Jun and CHOP positive motoneurons showed 
the accumulation of the fragmented Golgi apparatus in a subregion of the cell. These cells 
showed sick appearance in most instances characterized by a flattened eccentric nucleus. The 
juxta-nuclear area ‘left over’ by the flattened nucleus was occupied by the Golgi as identified by 
GM130 and CGRP immunoreactivity (Figs 3G2, 3H2 and 3H4). Further analysis demonstrated 
that these cells showed moderate to intense ubiquitin and ATF3 labeling throughout most of 
the perikaryon. The region occupied by the Golgi apparatus shows no or very little ubiquitin 
and ATF3 immunoreactivity (Figs 3G2, 3H2, 3H3, 3H4, 3H5, 3H7 and 3J). A peculiar feature 
associated with perinuclear redistribution of the Golgi apparatus is the accumulation of rab6 
immunoreactivity (Fig. 3H5, and 6H, I). Control neurons show relatively rab6 immunoreactivity 
as compared to other cells, but the sick cells can be easily recognized in rab6 stained section (Fig. 
6H). Also CGRP and c-Ret show a relative accumulation in the sick motoneurons. This juxta-
nuclear redistribution was not specific for the Golgi and post-Golgic compartments, since also 
calreticulin, an ER protein, was preferentially distributed in the juxtanuclear region of  ‘sick’ cells 
(Fig. 5I).
 Another feature of the ‘sick’-appearing cells is the presence of heat shock protein Hsp70 
(Figs 6J1 and J2). Hsp70 like the Golgi apparatus and ER was preferentially distributed in the 
perinuclear region not occupied by ubiquitin (Figs 5J). The sick-appearing motoneurons in some 
cases showed resemblance with active caspase 3 immunoreactive motoneurons (compare Figs. 
3C and F2), but double-labeling showed that these cells did not stain for active caspase 3. 
DiSCuSSion
The availability of transgenic SOD1-ALS mice that develop an ALS like motoneuron disease 
enables the detailed characterization of the morphological and molecular correlates of motoneuron 
degeneration in ALS. Several studies have uncovered the recruitment of programmed cell death 
pathways in these mice (Guegan & Przedborski, 2003; Inoue et al., 2003; Kang et al., 2003), but 
the precise morphological and molecular events preceding the death of motoneurons were still 
incompletely understood. In this study we have used antibodies against ATF3 and phosphorylated 
c-Jun to label motoneurons of SOD1-ALS mice in an early phase of their degeneration. Our data 
indicate that 1) ATF3 and phospho-c-Jun are expressed in a subset of motoneurons starting from 
several weeks prior to the onset of their death and disappearance. 2) The number of phospho c-
Jun/ATF3-labelled motoneurons increased with aging and was highest at symptom onset. 3) Most 
phospho-c-Jun/ATF3 labeled motoneurons showed CHOP expression and a fragmented Golgi 
apparatus 4) The morphology of ATF3/ phospho-c-Jun labeled motoneurons varied from normal 
appearing cells to cells with a sick morphology, but none of the phospho-c-Jun/ATF3 labeled 
motoneuron showed the expression of active caspase 3, a major neuronal executioner caspase. 
5) The onset of phospho-c-Jun and ATF3 expression in motoneurons did not correlate with the 
onset of mitochondrial swelling and vacuolization which is the earliest pathological feature in 
G93A mice, but correlated with the appearance of ubiquitin immunoreactivity in dendrites and 
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Fig. 6: Subsets of motoneurons in G93A mice show dendritic accumulation of CGRP, accumulation of 
rab6, and Hsp70 expression.  (A-F)  Low (A-C) and high-magnification (D-F) of CGRP immunoperoxidase 
labeling in the L4 spinal cord of 20 weeks old non-transgenic (A, D) and G93A mice (B, E, F) and a 30 weeks old 
G93A mouse (C). In all control and most 20 weeks old G93A motoneurons CGRP was distributed in elongated 
linear profiles (A, B, D). However, a subset of motoneurons in G93A mice showed a granular labeling pattern, 
consistent with Golgi fragmentation, and furthermore showed abnormal dendritic CGRP labeling (arrows in 
B, C, E, F). (G-I) Low (G, H) and high-magnification (I) of rab6-immunoreactive motoneurons in the L4 spinal 
cord of 30 weeks old non-transgenic (G) and G93A mice (H, I). Neurons show a relatively low level of Rab6 
immunoreactivity as compared to glia. However, a small subset of sick-appearing motoneurons show the 
accumulation of rab6 immunoreactivity. (J-L) Low (J, K) and high-magnification (L) of Hsp70-immunoreactive 
motoneurons in the L4 spinal cord of 30 weeks old non-transgenic (J) and G93A mice (K, L). Hsp70-
immunoreactivity is associated with a small number of sick-appearing motoneurons (arrow head in L). Note 
the flattened nucleus in the Hsp70 immunoreactive neuron. Calibration bars: A and C, 100 µm; I, 15 µm.
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perikarya of motoneurons. In sum, our data provide a description of a number of morphological 
and molecular events that precede the death and disappearance of motoneurons in SOD1-ALS 
mice.
 A central question raised by our data is what induces the coincident activation of c-Jun, 
ATF3 and CHOP in motoneurons G93A mice? The transcriptional activity of c-Jun is controlled 
by the c-Jun-N-terminal kinase (JNK) pathways, a subgroup of mitogen activated protein kinases 
(MAPKs) that integrate various intra- and extracellular signals (Davis, 2000; �erdegen & 
Waetzig, 2001). The c-Jun/JNK- pathway also may trigger ATF3 expression since many of the 
insults that activate the c-Jun/JNK pathways also induce ATF3, and the ATF3 promotor contains 
potential AP1 sites for c-Jun (Hai et al., 1999). ATF3 in turn may contribute to the induction of 
the expression of CHOP (Jiang et al., 2004). Hence, it is possible that the activation c-Jun, ATF3 
and CHOP are part of a coordinated response triggered by the same event. The activation of these 
factors may be linked to the same event that causes Golgi fragmentation, as our data show that 
phospho-c-Jun and ATF3 expression correlate with Golgi fragmentation. Golgi fragmentation 
has been previously identidied in a subset of motoneurons and Betz cells of patients with ALS 
and other motoneuron disorders (Stieber et al., 1998) and in motoneurons in SOD1-ALS mice 
(Mourelatos et al., 1996), but also occurs in some neurons in other neurodegenerative diseases 
(Gonatas et al., 1998). The mechanism underlying Golgi fragmentation is not yet understood. It 
differs from Golgi fragmentation as observed after blocking the secretory pathway by brefeldin, 
but shows similarity with Golgi fragmentation induced by microtubule destabilization (Mourelatos 
et al., 1996). One hypothesis is that Golgi fragmentation is caused by abnormalities in trafficking 
between Golgi and other membrane compartments  (Mourelatos et al., 1996; Stieber et al., 2000), 
possibly because of the presence of aggregated protein complexes that impair dynein trafficking 
(Johnston et al., 2000; Gosavi et al., 2002). Such a mechanism is consistent with a number of our 
data. First abnormal trafficking is suggested by our observation that motoneurons with fragmented 
Golgi show show an abnormal dendritic accumulation of CGRP, as well as the accumulation of 
c-Ret in the perykarya. Second, phospho-c-Jun and ATF3 (and Golgi fragmentation) is shortly 
preceded by the appearance of ubiquitin immunoreactivity in the proximal dendrites. This is 
consistent with previous studies showing a correlation between fragmented Golgi apparatus 
and deposits of ubiquitinated protein in motoneurons of ALS patients (Stieber et al., 1998) and 
SOD1-ALS mice (Stieber et al., 2000). Hence, together the data suggest a scenario where Golgi         
fragmentation, ATF3 and c-Jun expression are down-stream of the accumulation of ubiquitinated 
material in the dendrites and the axon of motoneurons.
 What is the identity of the ubiquitinated material that accumulate in the dendrites and 
axon of the motoneurons. The accumulation of ubiquitin immunoreactivity in neurons has been 
linked to the presence of aggregates of misfolded protein that can not be effectively degraded by 
the proteasome system (Kopito, 2000). Accordingly, the ubiquitinated structures in SOD1-ALS 
mice have been shown to be strongly immunoreactive for mutant SOD1 indicating that they 
represent ensembles of aggregated SOD1 (Bruijn et al., 1998; Stieber et al., 2000; Maatkamp et 
al., 2004). However, ubiquitination may not exclusively represent SOD1 aggregates, because a 
study in chimeric SOD-ALS mice that expressed mutant SOD1 in a subset of their motoneurons, 
showed that accumulation of ubiquitin immunoreactivity also occurred in motoneurons that did 
not express mutant SOD1 (Clement et al., 2003). Hence, ubiquitination may represent a feature 
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associated with degeneration of motoneurons, putatively representing a mix of denatured proteins 
derived from the collapsing cytoplasm. This may explain our ultrastructural data showing that 
dendritic ubiquitination is associated with heterogeneous ensembles of filamentous, amorphous 
and vesicular material, rather than with a single type of aggregate. Our data also show that the 
accumulation of ubiquitinated material is a progressive process that gradually fills the entire 
cell and eventually ‘pushes away’ the Golgi and the ER into a small, usually juxtanuclear 
portion of the cell.  This accumulation of ubiquitinated material in the end also seems to lead to 
impaired proteasome function, because the motoneurons that were entirely filled with ubiquitin 
also expressed Hsp70, which in motoneurons has been found to be selectively upregulated after 
proteasome inhibition and not after other injurious stimuli (Batulan et al., 2003). Significantly, 
recently it has been shown that the level of phospho-c-Jun depends on ubiquitination and 
degradation by the proteasome (Nateri et al., 2004). Also, ATF3 has been shown to be strongly 
up regulated after proteasome inhibition (Zimmermann et al., 2000), raising the possibility that 
ATF3 and phospho-c-Jun expression result from impaired proteasome function. However, this 
scenario is not consistent with our observation that Hsp70 is only expressed in a subset of ATF3 
and phospho-c-Jun positive motoneurons, indicating that impaired proteasome function occurs 
after the onset of ATF3 and phospho-c-Jun expression.
 Does ATF3, c-Jun and CHOP activation have an effect on the viability of motoneurons? 
ATF3 and phospho-c-Jun are well known for their activation after injurious stimuli, and both have 
been linked to either survival or death. The effect of their activation is variable and depends on the 
promotor and cellular contexts (�erdegen & Leah, 1998; �ai et al., 1999; �ai & �artman, 2001). 
C-Jun is a component of the heterodimeric AP-1 transcription factor and has been identified as 
an important factor in inducing neuronal degeneration after trophic factor deprivation (Ham et 
al., 2000; Raivich et al., 2004). �owever, its role in adult neurons is equivocal (�erdegen & 
Waetzig, 2001; Brecht et al., 2005). ATF3 homodimer acts as a transcriptional repressor, but ATF3 
heterodimer with c-Jun (or JunD) functions as a transcriptional activator of specific promoters 
containing CRE sites. Other bZip proteins that dimerize with ATF3 include CHOP, ATF2, and 
JunB (Hai et al., 1999; �ai & �artman, 2001). Recently, it has been shown that ATF3 rescues 
PC12 and superior ganglion cells from c-Jun activated cell death by promoting Hsp27 expression, 
and that Hsp27 is a target gene of c-Jun/ATF3 heterodimers (Nakagomi et al., 2003). However, 
there is a poor correlation between phospho-c-Jun/ATF3 and Hsp27 expression in motoneurons 
of G93A mice (Maatkamp et al., 2004).
 
How do motoneurons in G93A mice die? Our data are consistent with previous reports 
suggesting that the motoneurons ultimately die through the activation of programmed cell death 
pathways (Guegan & Przedborski, 2003; Inoue et al., 2003; Kang et al., 2003). However, our 
data suggest that the activation of caspase 3 is delayed until they reach a very sick state. These 
sick motoneurons are large in size, have an eccentric flattened nucleus, and have a perikaryon 
filled with ubiquitinated material, with the exception of a small juxtanuclear area containing the 
Golgi and the ER. This morphology differs from the morphology of motoneurons in acute in vivo 
models of apoptotic and non-apoptotic motoneuron death (Koliatsos et al., 1994; Oppenheim 
et al., 2001; Tarabal et al., 2001). Whether the sick motoneurons are irreversibly damaged or 
still can be rescued is an open question. A feature of the sick motoneurons is their very intense 
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immunoreactivity for rab6, which is present at a low level in control motoneurons. There are two 
rab6 proteins, rab6A and rab6B, which both are expressed in the brain (Opdam et al., 2000). Rab6 
has been linked to trafficking of specific types of post- and intra-Golgi vesicles, including a COPI-
independent Golgi-to-ER and an endosome-to-Golgi pathway (White et al., 1999; Opdam et al., 
2000; Matanis et al., 2002). Rab6 also has been implicated in stress-induced Golgi redistribution 
to the ER (Jiang & Storrie, 2005). In view of the specific association of high levels of rab6 with 
sick appearing motoneurons, rab6 may play a role in organelle redistribution in these cells. 
 In conclusion, the present study provides a description of a series of changes in 
motoneuron death preceding their death and disappearance in a line of SOD1-ALS mice. The 
data provide a framework to further examine the mechanisms underlying the degeneration of 
motoneurons in ALS. Importantly, we show that ATF3 and phospho-c-Jun are effective markers to 
identify motoneurons in an early phase of their degeneration. Our data raise a number of questions 
raised that need to be resolved in future studies: 1) How are early mitochondrial abnormalities in 
motoneurons of SOD1-ALS mice (Dal Canto & Gurney, 1995; Wong et al., 1995; Kong & Xu, 
1998; Jaarsma et al., 2001; Liu et al., 2004) linked to the further degeneration of motoneurons? 
Significantly, our data show that mitochondria surrounding ubiquitinated areas in dendrites are 
normal, whereas swollen and vacuolated mitochondria occur more distally and in the axon. One 
possibility is that ubiquitination follows from collapse of distal dendrites due to mitochondrial 
pathology. 2) What mechanism causes dendritic and somatic ubiquitination (see above)? 3) How 
are the neurodegenerative changes in the somato-dendritic domain, as depicted in the present 
study, related to the functional deterioration and degeneration of the axon?  A number of studies 
have suggested that the axon is the primary target of mutant SOD1 since transport abnormalities 
and degeneration of the axon and its terminals are early phenomena in SOD1-ALS mice (Zhang 
et al., 1997; Borchelt et al., 1998; Williamson & Cleveland, 1999; Dupuis et al., 2000; Frey et al., 
2000; Fischer et al., 2004). Preliminary analysis of muscle denervation in our G93A mice showed 
no signs of denervation at 15 weeks of age, and mild denervation at 20 weeks of age, indicating 
that denervation coincides or occurs after the onset of ubiquitination and ATF3/phospho-c-jun 
expression. Significantly, ‘the axon first’ hypotheses of mutant SOD1-mediated motoneuron 
degeneration have been challenged by the recent demonstration that expression of Wlds, which is 
an axon-protective protein that attenuates the course of disease in axon-first motoneuron diseases 
(Araki et al., 2004), does not influence motoneuron loss in SOD1-ALS mice (Velde et al., 2004). 
4) �ow are changes in c-Jun and ATF3 signaling related to other signaling events identified in 
motoneurons and surrounding glia in SOD1-ALS mice (Bruijn et al., 2004)? 5) To what extend is 
the sequence of events identified in our study reproduced in human ALS motoneurons? In accord 
with our data c-Jun activation has been identified in post-mortem ALS spinal cord specimen 
(Virgo & de Belleroche, 1995). 
ACknowLeDGemenTS
(Funding: Dutch-MRC (project # NWO-NPA 940-33-023), Prinses Beatrix Fonds (project # 
MAR03-0101) and Hersenstichting Nederland (project # 10F02[2].04)
ATF-3 AND C-JUN EXPRESSION IN ALS-SOD1 MICE
47
mATeriALS & meThoDS
Transgenic mice
Experiments were performed in accordance with the “Principles of laboratory animal care” (NIH publication 
No. 86-23) and the guidelines approved by the Erasmus University animal care committee (DEC; protocol No. 
115-97-01 and 115-99-03). G93A mice descendent from the Gurney G1del-line that carry about 8 transgene 
copy numbers per haploid genome (Gurney, 1997) were maintained in a FVB/N background, Our G93A 
mice develop weakness in one or more limbs from age 24-30 weeks, and reach end stage disease 2–10 weeks 
after onset of limb weakness (Jaarsma et al., 2000; Jaarsma et al., 2001). Pathologically the mice develop 
swelling and vacuolization of a subset of mitochondria from early age long before the onset of motoneuron 
loss and gliosis, which starts from 20 weeks of age (Maatkamp et al., 2004). For the immunocytochemical 
characterization of ATF3 and phospho-c-jun expression in G93A mice we analyzed 7 groups: 1) 10 weeks (at 
this age the mice show swelling and mild vacuolization of a subset of mitochondria but no other pathological 
features (Jaarsma et al., 2001)) 2) 15 weeks); 3) 20 weeks (at this age the mice in addition to mitochondrial 
abnormalities show several degenerative features in motoneurons (e.g. ubiquitination, Golgi fragmentation), 
but no or minimal (<10 %) motoneuron loss (Maatkamp et al., 2004); 4) 25 weeks; 5) symptom onset (29-
32 weeks mild muscle weakness in one or more of the hind limbs); 6) 2 weeks post-symptom onset (29-32 
weeks, moderate to severe muscle weakness in one or more of the hind limbs); 7) 5 weeks post-symptom 
onset (32 weeks, severe muscle weakness of the hind limbs). Non-transgenic littermates and transgenic mice 
expressing wild-type hSOD1 (hSOD1 mice) derived from the Gurney N29 line and aged 10-100 weeks 
(Jaarsma et al., 2000) were used as controls.
Antibodies
Primary antibodies (supplier; applications [I�C, Immunohistochemistry; IF, immunofluorescence] and 
dilutions) reported in this study are��� rabbit anti-ATF3 (Santa Cruz; I�C and IF 1���1000); rabbit anti-calreticulin 
(Affinity BioReagents, I�C and IF 1���5000), rabbit anti-cleaved caspase 3 (Asp175, Cell Signalling, I�C 
1���1000); rabbit anti-CGRP (Calbiochem; I�C and IF, 1���10000); goat anti-ChAT (Chemicon; I�C and IF 
1���500); rabbit anti-C�OP/GADD153 (SantaCruz; I�C and IF 1���2000); rabbit anti c-fos (Ab5, Oncogene 
I�C, IF 1���20000); rat anti-CR3 receptor (clone 5C6; Serotec, I�C 1���500); rabbit anti-GFAP (DAKO; 
I�C 1���10000; IF 1���5000); mouse anti-GM130 (Golgi matrix protein of 130 KDa associated with the cis-
compartment, Transduction Laboratories, IF 1���1000); Rabbit anti-GRP78 (IF and I�C, 1���2000); Rabbit anti 
�sp25 (Stessgen, IF 1���2000); mouse anti-�sp70 (SantaCruz; I�C and IF 1���500); rabbit anti-c-Jun (ab1, 
Oncogene; I�C 1���10000 and IF 1���2000); rabbit anti phospho-c-Jun (Ser73, Upstate Biotechnology; I�C 
1���2000 and IF 1���500); rabbit anti phospho-c-Jun (Ser63; Cell Signalling; I�C 1���2000 and IF 1���500); mouse 
anti phospho-c-Jun (Ser63; Santa Cruz; I�C 1���2000 and IF 1���500); rabbit anti-Krox24 (Santa Cruz; I�C 
1���5000); rabbit anti-phospho-STAT3 (Tyr705; Cell Signalling��� I�C 1���2000); mouse anti rab6 (clone 5B10, 
Matanis et al., 2002); I�C and IF 1���100), goat anti-c-Ret (R&DSystems; IF and I�C 1���50); goat anti-human 
SOD1 (Calbiochem; IF 1���10000); rabbit anti-SOD1 (1���5000); rabbit ant-STAT3 (Santa Cruz; I�C 1���2000);; 
rabbit anti-ubiquitin (Dako; I�C and IF 1���2000); mouse anti-ubiquitin (clone FK2, Affiniti; IF 1���2000).
Secondary antibodies: For avidin-biotin-peroxidase immunocytochemistry biotinylated secondary 
antibodies from Vector Laboratories diluted 1:200 were used. FITC-, Cy3-, and Cy5-conjugated secondary 
antibodies raised in donkey (Jackson Immunoresearch, USA) diluted at 1:200 were used for confocal 
immunofluorescence. Cy3-conjugated donkey anti-rabbit Fab fragments (Jackson Immunoresearch, USA) 
were used in double-labeling experiments with two rabbit primary antibodies.
 
immunocytochemical and histochemical analyses
For immunocytochemistry and immunofluorescence mice were anaesthetised with pentobarbital and 
perfused transcardially with 4% paraformaldehyde with or without glutaraldehyde (0.1 or 0.5 %). The lumbar 
and cervical spinal cord were carefully dissected out and post-fixed overnight in 4% paraformaldehyde. 
Routinely, spinal cord tissue was embedded in gelatin blocks (Jaarsma et al., 2000), sectioned at 40μm 
with a freezing microtome and sections were processed, free floating, employing a standard avidin-biotin-
immunoperoxidase complex method (ABC, Vector Laboratories, USA) with diaminobenzidine (0.05%) as 
the chromogen, or single, double and triple-labelling immunofluorescence (Jaarsma et al., 2000; Jaarsma 
et al., 2001; Maatkamp et al., 2004). In addition, a selected number of frozen sections were processed for a 
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silver staining procedure that selectively labels dying neurons and their processes (Jaarsma et al., 2000).
Some spinal cord specimens were sectioned with a Vibratome (50-60 µm thick). These sections were used 
for pre-embedding immunoperoxidase, post-embedding immunogold or standard electron microscopy as 
described (Jaarsma et al., 2001). In addition Vibratome sections were used for light-microscopic double 
labeling experiments, in which sections were sequentially processed for 2 different primary antibodies using 
the ABC method for both. To label the first antibody CoCl2 was included in the diaminobenzidine solution to 
yield a dark-blue precipitate. The second antibody was visualized with diaminobenzidine alone. Following 
the immunostaining procedure these sections were dehydrated, embedded in Durcupan, sectioned at 1 µm 
and counterstained with methylene blue.
For double-labeling immunofluorescence with two rabbit or two mouse antibodies sections, Cy3-conjugated 
donkey anti-rabbit or donkey anti-mouse Fab fragments were used to label and sterically cover the first 
antibody as described by the manufacturer (Jackson Immunoresearch, USA). Then the sections were 
incubated with the second antibody that consecutively was labeled with FITC-conjugated secondaries. 
Single-labeling experiments were always performed in parallel to these double-labeling experiments to 
evaluate the specificity of the staining.
Immunoperoxidase stained sections were analyzed and photographed using a Leica DM-RB microscope and 
a Leica DC300 digital camera. Quantitative analyses were performed with 20 consecutive L4 lumbar spinal 
cord sections/mouse that were serially immunoperoxidase-labeled for ATF3, ChAT, CGRP and cleaved 
caspase 3, respectively (i.e. sections 1, 6, 11, and 16 were labeled for ATF3, sections 2, 7, 12, 17 for ChAT 
etc.). All analyses were done with control and G93A mouse spinal cords of different ages embedded in the 
same gelatin blocks (Maatkamp et al., 2004). A selected number of sections stained for phospho-c-Jun, 
ATF3, cleaved caspase 3 and ubiquitin were plotted using an Olympus microscope fitted with a LucividTM 
miniature monitor and NeurolucidaTM software (MicroBrightField, Colchester, VT, USA). Statistical 
analysis was done with Graphpad Prism software (San Diego, USA).
Sections stained for immunofluorescence were analyzed with a Zeiss LSM 510 confocal laser scanning 
microscope. For quantitative analysis of co-localization of ATF3 with other markers (active caspase 3, CGRP, 
c-Jun, phospho-c-Jun, CHOP, GM130, Hsp70, ubiquitin) 50 ATF3-labelled motoneurons were randomly 
selected in L4 sections of 20, 25 and 30 weeks old G93A mice using 20x or 63x objectives. All motoneurons 
in a field of 150 x 150 µm surrounding the labeled cell were scored for single or double labeling. In the 
same way 25 or 50 phospho-c-Jun, CHOP, Hsp70, CGRP or ubiquitin immunoreactive motoneurons were 
randomly selected and analyzed for co-localization with ATF3.
Ultra thin sections for electron microscopy were contrasted and analyzed in a Phillips CM100 electron 
microscope operated at 80 kV (Jaarsma et al., 2001).
mrnA in situ hybridisation
In situ hybridization was performed on 12 μm thick cryostat sections using standard methods with 
digoxigenin-labeled cRNA probes (Maatkamp et al., 2004). Sense and anti-sense digoxigenin-labelled 
cRNAs were transcribed from liberalized plasmids containing ATF3 (image clone, NCBI acc no BF166234), 
and c-Jun (image clone, NCBI acc no BE283254).
Fig. 3: Phospho-c-Jun and ATF3 expression correlates with Golgi fragmentation and ubiquitination. 
(A) High magnification of semi-thin (0.5 µm thick) section showing a motoneuron with phospho-c-Jun (dark-
brown) labeled nucleus surrounded by CR3-labeled microglial processes (light brown). Note that the phospho-
c-Jun labeled nucleus has a healthy appearance (long arrow). Also note that the cell with the pyknotic nucleus 
(short arrow) is not phospho-c-Jun labeled. (B) Semithin ATF3 stained section showing a motoneuron with 
intense nuclear and cytosolic ATF3 labeling. Note that part of the cell is ATF3-negative. (C-J) Double-labeling 
confocal immunofluorescence of ATF3 with phospho-c-Jun (E), CHOP (F), ubiquitin (G1 and G2), the cis-Golgi 
protein GM130 (C and H2), CGRP (H3), rab6 (H5), c-Ret (H7) and Hsp70 (J1); or of ubiquitin with GM130 (D), 
CGRP (H4, H6), calreticulin (I) or Hsp70 (J2)).Calibration bars: A, E, F, H2, H3, H4, H5 and H7 = 20 µm; B, C, 
D, G1, H1, I, J1and J2 = 10 µm; H6, 4 µm.
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Abstract
Mutations in superoxide dismutase (SOD1) cause amyotrophic lateral sclerosis 
(ALS), an adult onset progressive paralytic disease characterized by loss of 
motor neurons, and cause an ALS-like disease when expressed in mice. Recent 
data have suggested that motor neuron degeneration result from toxic actions 
of mutant SOD1 operating both in motor neurons and their neighboring glia, 
raising the question whether mutant SOD1 expression selectively in neurons 
is sufficient to induce disease. �ere we show that neuronal expression of 
mutant SOD1 is sufficient to cause motor neuron degeneration and paralysis in 
transgenic mice with cytosolic dendritic ubiquitinated SOD1 aggregates as the 
dominant pathological feature. In addition we show, that crossing our neuron-
specific mutant SOD1 mice with ubiquitously wild-type SOD1 expressing mice 
leads to dramatic wild-type SOD1 aggregation in oligodendroglia after the onset 
of neuronal degeneration. Together our findings support a pathogenic scenario 
where mutant SOD1 in neurons triggers neuronal degeneration, which in turn 
may facilitate aggregate formation in surrounding glial cells.
running title: Neuron-specific SOD1 mice
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inTroDuCTion
Amyotrophic lateral sclerosis (ALS) is a clinically and genetically heterogeneous late onset 
neurodegenerative disease of motor neurons causing progressive paralysis. In a subset of patients 
the disease is caused by mutations in the cytosolic CuZn superoxide dismutase (SOD1) gene 
(Rosen et al., 1993; Boillee et al., 2006a; Pasinelli and Brown, 2006). More than 100 different 
SOD1 mutations have been identified that all cause a rather similar disease phenotype (Andersen 
et al., 2003). All mutants show reduced conformational stability and cause the accumulation of 
hydrophobic and aggregation-prone SOD1 subfractions when expressed in cellular and transgenic 
mouse models (Durham et al., 1997; Johnston et al., 2000; Jonsson et al., 2006b; Shaw and              
Valentine, 2007; Zetterstrom et al., 2007). Aggregates as well as other pathological abnormalities        
do not exclusively occur in neurons, but also in glial cells surrounding the motor neurons (Bruijn 
et al., 1997; Dal Canto and Gurney, 1997; Kato et al., 1997). �ence, mutant SOD1 also can cause H       
damage in glial cells, raising the question to what extent these non-motor neuron abnormalities 
contribute to motor neuron degeneration and disease progression in SOD1-ALS (Lobsiger and 
Cleveland, 2007). This question is also relevant for SOD1-unrelated forms of ALS as most of 
these patients have TDP-43 immunoreactive inclusions in both neurons and glial cells (Arai et 
al., 2006; Neumann et al., 2006). 
 The role of glia cells in SOD1-ALS pathogenesis has been examined in chimeric 
mice that were mixtures of normal cells and mutant SOD1–expressing cells (Clement et al., 
2003). This study indicated that degeneration of motor neurons expressing mutant SOD1 was 
delayed or prevented when they were surrounded by wild-type non-neuronal cells, whereas wild-
type motor neurons could develop degenerative changes when surrounded by mutant SOD1 
expressing neuronal cells (Clement et al., 2003). Similar results were obtained in recent studies 
with spinal primary and embryonic mouse stem cell-derived motor neurons co-cultured with 
mutant SOD1-expressing astrocytes, which showed that mutant SOD1 in astrocytes may cause 
degenerative changes in wild-type motor neurons, and exacerbate toxic effects of mutant SOD1 
in motor neurons (Di Giorgio et al., 2007; Nagai et al., 2007). In addition, studies with mutant 
SOD1 transgenic mice constructed to express no (Beers et al., 2006) or reduced levels (Boillee 
et al., 2006b) of mutant SOD1 in microglia, have suggested non-cell autonomous toxic effects 
of mutant SOD1 operating in microglia. As earlier studies had reported the lack of motor neuron 
degeneration in transgenic mice expressing mutant SOD1 selectively in neurons (Pramatarova et 
al., 2001; Lino et al., 2002) or astrocytes (Gong et al., 2000), it has been proposed that mutant 
SOD1 cause the degeneration of motor neurons by a combination of cell-autonomous and non-
cell-autonomous processes, requiring the presence of mutant SOD1 in both neurons and glia, and 
raising the question whether mutant SOD1 expression in neurons is sufficient to induce disease. 
In contrast to this notion, in this study we show that mutant SOD1 expression in neurons is 
sufficient to induce motor neuron degeneration and paralysis in transgenic mice.
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Figure 1. Neuron-specific G93A-SOD1 expression is sufficient to cause motor neuron disease in 
transgenic mice.
(a and b) Pronuclear injections of the Thy1.2 expression cassette with G93A-mutant human(h)SOD1 cDNA 
(a) yielded two mouse lines (T1, T3) with high G93A-SOD1 expression in the spinal cord as determined by 
immunoperoxidase histochemistry with an hSOD1 specific antibody (b). (c) Western blot with human SOD1-
preffering antibody (SOD100) shows that T1 and T3 mice express G93A-SOD1 throughout the CNS, but 
not in other tissues. (d) Confocal immunofluoresence of T1T3 mouse spinal cord section shows that hSOD1 
immunoreactivity does not codistribute with astro- (GFAP) and oligodendroglial (JBcrystallin) staining. (e) 
Representative blot (e1) and bar graph (e2) of quantitative Western blot analysis of mutant SOD1 expression 
in spinal cord of hemi- and homozygote T3 mice as compared to the ubiquitous G93A-SOD1 expressing 
G1del mice. Values represent means ±SE, n=3. (f) Age of disease onset and end stage of T1T3 (f1) and T3T3 
reSuLTS
neuron-specific G93A-mutant SoD1 expression induces motor neuron disease in mice
Neuron-specific transgenic SOD1-ALS mice were generated using a construct of human SOD1 
cDNA with the G93A mutation cloned into the Thy1.2 expression cassette (Fig. 1a) that drives 
transgene expression in neurons throughout the CNS including spinal motor neurons (Feng et 
al., 2000). Two Thy1.2-G93A lines (T1 and T3) showed transgenic expression throughout the 
brain and spinal cord as determined by Western blot analysis (Fig. 1b) and immunoperoxidase 
histochemistry with antibodies specific for human SOD1 (Fig. 1c). No transgenic human SOD1 
occurred in other tissues (Fig. 1b). Double labeling immunofluorescence on spinal cord sections 
showed that mutant SOD1 was expressed in all motor neurons (ChAT and NeuN positive) as well 
as in other populations of spinal neurons (ChAT negative and NeuN positive), but did not co-
distribute with glial markers, i.e. GFAP (astrocytes), αB-crystallin (oligodendrocytes) and CR3    
(microglia) (Figs 1d and 4f, g). Immunocytochemical analysis of skeletal muscle showed that 
mutant SOD1 immunoreactivity in T3 and T1 mice is selectively distributed in axons and nerve 
endings at the neuromuscular junctions consistent with a neuron specific expression (Fig. 1i).
 Quantitative Western blot showed that mutant SOD1 expression in the spinal cord of 
T3 Thy1.2-G93A mice was approximately fifteen fold lower compared to G1del mice, i.e. a line 
of ubiquitously mutant SOD1 expressing mice carrying a genomic hSOD1 construct with the 
G93A mutation that is derived from the G93A Gurney G1 line (Gurney et al., 1994) (Fig. 1e). 
Confocal immunofluorescence and in situ hybridization showed that mutant SOD1 protein and 
mRNA expression in T1 and T3 mice also was lower at the level of individual motor neurons 
(Supplementary Fig. 1). Hemizygote Thy1.2-G93A mice from either lines T1 and T3 did not 
show clinical and pathological signs of motor abnormalities up to 2 years of age. Furthermore, 
the T3 transgene did not significantly influence disease phenotype of G1del mice (Supplementary 
Fig. 2). As the propensity of mutant SOD1 to induce disease is proportional to its expression 
level (Gurney et al., 1994; Wong et al., 1995; Bruijn et al., 1997; Jonsson et al., 2006b), the 
lack of disease phenotype in our T1 and T3 mice can be explained by insufficient mutant SOD1 
expression. We therefore next generated T3T3 homozygotes that expressed twofold mutant SOD1 
as compared to T3 mice (Figs 1e and 2b, c), as well as mice hemizygous for both the T1 and T3 
insertion sites. Most of the T3T3 (8 of 12) and T1T3 (3 of 5) mice developed an ALS-like motor 
neuron disease before the age of 2 years (i.e. the oldest age examined), showing progressive 
muscle weakness and paralysis (Fig. 1f; Table 1). All the 2 years old T3T3 and T1T3 mice that 
did not develop motor abnormalities showed ubiquitinated neurites in the spinal cord (Fig. 6d; 
Table 2), suggestive of an early presymptomatic stage of disease. End stage T1T3 and T3T3 
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(f2) neuron-specific G93A-SOD1 mice. (g) Age of disease onset and end stage of neuron-specific G93A-
SOD1 mice crossed into ubiquitously wild-type hSOD1 expressing mice. (h) End stage T3T3 and G1del 
mice show similar loss of motor neurons, accumulation of argyrophylic neuronal debris (Ag-staining, h1), 
and astroglial expression of Hsp25 in ventral spinal cord. Motor neurons were counted in lumbar L4 sections 
immunoperoxidase stained for choline acetyltransferase (ChAT) which is present in all motor neurons, or 
CGRP which is expressed in a subset of large motor neurons (h2). Values in the bar graphs represent means 
± SE, n=3; **, P < 0.001 compared with non-transgenic mice and presymptomatic transgenic mice, one-way 
anova with Tukey’s multiple comparison test. (i) Analysis of neuromuscular denervation in sections of medial 
gastrocnemius muscle stained with J-bungarotoxin (J-BTX, motor endplates), antivesicular acetyl choline 
transporter (VAChT, motor nerve endings) and J-hSOD1 (axons and nerve ending). Data are shown as % of 
endplates classified as innervated, denervated, or partially denervated. Bars: 10 Mm (d), 250 Mm (h1) 
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mice showed most of the clinical and pathological features of end stage G1del mice, including 
severe weight loss (> 30% of maximal weight), inability to hang in a hanging wire test (Table 
1), loss of grip strength (Supplementary Fig. 3), severe locomotor deficits (Movie 1), loss of 
motor neurons (Fig. 1h), denervation of neuromuscular synapses (Fig. 1i) and accumulation of 
insoluble and multimeric mutant SOD1 species (Fig. 2f). In addition, end stage T1T3 and T3T3 
mice, like end stage G1del mice, showed the accumulation of argyrophylic neuronal debris not 
only in the ventral spinal cord (Figs 1h and 3b) but also throughout the medullary, pontine and 
mesencephalic reticular formation up to the zona incerta (Fig. 3c,d).  Silver staining showed that 
no degenerative changes did occur in cortex, hippocampus, and striatum despite high levels of 
neuronal mutant SOD1 expression in these brain areas. Furthermore, T1T3 and T3T3 similar to 
G1del mice and other lines of SOD1-ALS mice (Wong et al., 1995; Bruijn et al., 1997) developed 
signs of reactive gliosis, including the appearance of activated microglial cells Fig. 4c), as well 
as increased expression of GFAP (Fig. 4g and 5d) and the heat shock protein Hsp25 (Figs 1h and 
5d) in astrocytes, and reduced expression of the astrocytic glutamate transporter GLT1 (Fig. 5d). 
No astrocytic and microglial changes were observed in the cortex, hippocampus and striatum 
consistent with the absence of argyrophillic degeneration in these brain areas and supporting the 
notion that neuronal degeneration was restricted to the brainstem and spinal cord. Together these 
data show that specific neuronal expression of G93A mutant SOD1 is sufficient to trigger an 
ALS-like motor neuron disease strongly resembling disease phenotypes described in ubiquitous 
expressing mutant SOD1 mice. Importantly, consistent with neuron-specific expression of 
Onset of symptoms was determined on the basis of weight, the ability to extend the hind limbs, and the 
ability to hang upside down on a grid for 1 min. In G1del and T3G1del mice disease onset usually is 
asymmetric characterized by the inability to extend one of the hind limbs. Subsequently, symptoms in 
these mice ‘spread’ to the contralateral hind limb and the fore limbs. Typically, ‘hind limb onset’ mice at end 
stage disease (i.e. when they could not right themselves, showed > 30% weight loss, or developed severe 
eye infection) show complete paralysis of the hind limbs. Notable, impaired hind-limb function does not 
necessarily result in impaired performance in the hanging test as mice are able of performing this test for 
one 1 min using solely their forelimbs. A subset of G1del and T3G1del mice was characterized as ‘forelimb-
onset mice’ as a failure to execute the hanging test was the first symptom. These ‘forelimb-onset mice’ 
showed short disease duration, and reached end stage disease while having relatively preserved hind limb 
function. In contrast to G1del mice, T1T3, T3T3 nor T3hSOD1 mice showed asymmetric onset of disease. 
Typically, in these mice disease onset was characterized by the coincident onset of weight loss, failure to 
extend their hind limbs, and failure to perform normally in the hanging test. Furthermore, all Thy1.2- G93A 
mice retained some ability to move their hind limbs at end stage disease. T1T3 and T3T3 differed in some 
aspects from T3hSOD1 mice: T3hSOD1 mice showed earlier disease onset and a reduced variability of 
onset age than T1T3 and T3T3 mice. In addition, disease duration was significantly longer than in T3T3 
and T1T3 mice (*, P < 0.001, unpaired two-tailed students t-test). Interestingly, most end stage disease 
T3hSOD1wt mice (8 of 10) showed a distended urinary bladder, suggestive of micturition problems, a 
feature that we never observed in T3T3, T1T3 nor G1del mice, but that recently has been reported for 
transgenic mice expressing the wild-type like D90A mutation (Jonsson et al., 2006a).
Onset 
(days)range
End stage 
(days)range
Duration 
(days)
mean ± SE
Asymmetric 
hind limb onset 
(% of mice)
Fully immobi-
lized hind limbs 
at end stage (%)
G1del  (n=10)
T3G1del (n=8)
162 to 249
168 to 197
201 to 290
210 to 248
37 ± 7
37 ± 6
60
75
70
88
T3T3 (n=10)
T1T3 (n=5)
378 to >730
539 to >730
432 to >730
591 to > 730
54 ± 4 (n= 8)
51 ± 3 (n=3)
0
0
0
0
T3hSOD1 
(n=10)
273 to 385 434 to 546 155 ± 13 
(n=10)*
0 0
Table 1. Clinical disease in neuron-specific and ubiquitous G93A-SOD1 mice
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mutant SOD1, end stage Thy1.2-G93A mice show considerable loss of transgenic human SOD1 
immunoreactivity in the spinal cord ventral horn (Figs 1e, 2d and 4g).
Differences between neuron-specific and ubiquitous G93A mice
Further analysis revealed a number of differences between Thy1.2-G93A and G1del mice. First, 
T3T3 and T1T3 mice not only showed a late onset of motor symptoms but also a large variability 
of symptom onset age (Fig. 1f). Second, rather than a focal asymmetric onset of motor symptoms 
as occurring in most G1del mice (Table 1, Movie 2) and SOD1-ALS patients (Sato et al., 2005), 
T3T3 and T1T3 mice showed relatively diffuse symptom onset, characterized by the coincident 
onset of weight loss, failure to extend the hind limbs, and failure to perform normally in a hanging 
wire test, i.e. a test that strongly depends on normal function of the fore limbs (Table 1). In 
accord with a non-focal onset and progression of disease, all Thy1.2-G93A mice showed similar 
amounts of argyrophylic neuronal debris between left and right, and lumbar and cervical segments 
(Fig. 3b), whereas G1del mice in many occasions showed significant differences in argyrophylic 
staining between different parts of the spinal cord (Fig. 3a). Third, electron microscopy revealed 
that T3T3 and T1T3 mice did not develop mitochondrial swelling and vacuolization (Table 2), 
which is a dominant pathological feature in G1 and G1del mice (Dal Canto and Gurney, 1995; 
Jaarsma et al., 2001) as well as in G37R and D90A mutant SOD1 mice (Wong et al., 1995; 
Bergemalm et al., 2006). Fourth, electron microscopy and confocal immunofluorescence showed 
that Thy1.2-G93A mice did not develop SOD1 aggregates in glia (Table 2), while G1del mice 
in accord with previous reports (Dal Canto and Gurney, 1997; Stieber et al., 2000) developed 
ubiquitinated  SOD1 aggregates in both astrocytes and oligodendrocytes (Figs 4, 5 and 7; Table 
2). We showed that in G1del mice both astro- and oligodendroglial aggregates mice were strongly 
immunoreactive for αB-crystallin (Figs 4, 5 and7), a small heat shock protein that in control 
spinal cord is selectively associated with oligodendrocytes, but in G1del mice also was expressed 
in some astrocytes (Figs. 4h,i and 5c; Table 2). In addition, G1del mice showed a large increase 
of the level of detergent-insoluble αB-crystallin (Fig. 5d). In contrast, Thy1.2-G93A mice did not 
show astroglial αB-crystallin expression (Fig. 4g), codistribution of αB-crystallin and ubiquitin 
(Fig. 5b; Table 2 and supplementary Table 1), nor increased levels of insoluble αB-crystallin (Fig. 
5d), indicating that changes in αB-crystallin localization in G1del mice depend on glial mutant 
SOD1 expression.
 
Dendritic ubiquitinated SoD1 aggregates represent the dominant pathological structure in 
neuron-specific G93A mice
We have previously shown in G1del mice that the appearance of cytosolic ubiquitinated SOD1 
aggregates in dendrites precedes further degeneration of motor neurons (Vlug et al., 2005). 
As dendritic ubiquitination also has been identified as an early feature in other ubiquitous 
SOD1-ALS mouse and rat models carrying different mutations (Bruijn et al., 1997; Wang et 
al., 2005; Jonsson et al., 2006b), it may represent a dominant pathological feature in SOD1-
ALS. Accordingly, immunohistochemistry with antibodies to polyubiquitinated epitopes showed 
that all symptomatic Thy1.2-G93A and the majority (6 of 8) of presymptomatic Thy1.2-G93A 
mice older than 40 weeks showed ubiquitin immunoreactive neuritic profiles (Fig. 6; Table 2). 
Double labeling confocal immunofluorescence showed that ubiquitin immunoreactivity mostly 
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Figure 2. End stage neuron-specific G93A-SOD1 mice show reduced total mutant SOD1 expression, 
and the accumulation of detergent-insoluble and multimeric SOD1 species
(a-e) hSOD1-immunoperoxidase staining showing distribution and relative intensity of hSOD1 in the C7 spinal 
cord sections from hemi- and homozygote T3 mice as well as G1del mice. Note that, spinal cord specimens 
were embedded in a single gelatin block and sectioned and stained together to avoid variability in staining. 
Antibody concentration (sheep anti-SOD1, 1:10000) and staining conditions were chosen to maximize 
differences between hemiand homozygote T3 mice (Compare b with c) showing a two-fold difference in hSOD1 
expression as determined by Western blot (Fig. 1e). Under these conditions staining of G1del spinal cord is 
saturated (e), consistent with much higher mutant SOD1 expressions levels (Fig.1e). Note that end stage 
T3T3 mice (d) compared to young presymptomatic T3T3 mice show reduced hSOD1 immunoreactivity in the 
ventral horn (VH) and the intermediate zone (IZ), but equal amounts of hSOD1 immunoreactivity in the dorsal 
horn (DH), consistent with the occurrence of neuronal degeneration in the ventral horn and the intermediate 
zone. (f) Western blot analysis of G93A-SOD1 expression in NP-40-insoluble fraction (P2), showing the 
accumulation of insoluble G93A-SOD1 in spinal cord of both neuron-specific and ubiquitous G93A-SOD1 mice 
(f1). Prolonged exposure revealed the presence of multimeric SOD1 species in the insoluble fraction (arrows 
in f2). Note in f2 that the lanes of T3T3 mice were exposed longer than the other lanes to obtain comparable 
signal of multimeric SOD1 species.
codistributed with the somato-dendritic microtubule-associated protein MAP2 (Fig. 6; Table 2), 
infrequently with neurofilament-M which outlines axonal profiles (Table 2), and as stated before 
never with αB-crystallin and glial markers (Fig.  5b). In presymptomatic Thy1.2-G93A mice 
ubiquitin-immunoreactivity was predominantly associated with thin dendritic processes (Fig. 6g), 
whereas in symptomatic mice labeling also occurred in thicker proximal dendritic profiles that 
in many occasions could be traced back to the neuronal cell bodies (Fig. 6h). Significantly, as in 
G1del mice (Vlug et al., 2005), motor neurons with ubiquitin staining in proximal dendrites also 
showed multiple features of ill health including a flattened eccentric nucleus (Fig. 6h), fragmented 
Golgi apparatus (not shown), and ATF3 expression (not shown).
 Post-embedding immunogold electron microscopy showed that the dendritic aggregates 
in Thy1.2-G93A mice as in G1del mice (Vlug et al., 2005) always were strongly immunoreactive 
for both ubiquitin and human SOD1, and consisted of disorganized ensembles of filamentous 
material, frequently contained vesicular structures, and often were surrounded by mitochondria 
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Figure 3. Distribution of argyrophylic degeneration in neuron-specific and ubiquitous G93A-SOD1 mice 
correlate with symptoms Silver degeneration staining visualizing the distribution of neuronal degeneration in 
ubiquitous (G1del) and neuron-specific (T3T3, T1T3, T3hSOD1) G93A-SOD1 mouse models. Presymptomatic 
mice show no or very little argyrophylic staining (a1, b1, b2 and c1), but levels of argyrophylic staining increase 
in parallel with the severity of symptoms. Argyrophylic staining accumulates in the spinal cord ventral horn as 
well in supra-spinal CNS regions including the medullary (MedRF in c2 and c3), pontine and mesencephalic 
reticular formation (MesRF in D1), and the zona incerta (ZI in d1-d3). In mice with focal asymmetric symptoms, 
also argyrophylic staining is distributed focally in the part of the spinal cord corresponding to the affected limb. 
For instance, a G1del mouse sacrificed shortly after the onset of motor problems in its left hind limb selectively 
shows a high level of argyrophylic degeneration in the left lumbar spinal cord, and low staining levels in the 
right lumbar and cervical cord (a2). Animals sacrificed in later phases of disease also show staining in the 
contralateral side and at cervical levels (a3, a4). Mice with forelimb onset may reach end stage disease with 
relatively preserved hind limb function and concomitant low levels of neuronal degeneration at lumbar levels 
(a5). T1T3, T3T3 and T3hSOD1 mice never showed focal symptom onset and progression of disease, and 
accordingly show similar amounts of argyrophylic staining between left and right, and lumbar and cervical 
segments (b2-b5). Section in (c) and (d) correspond to plates 89 (c1, c3), 85 (c2), 54 (d1), 48 (d2), 44 (d3) of 
the mouse brain atlas of Paxinos and Franklin (2001). CA3, CA3 hippocampal subfield; Cb, cerebellum; DG, 
dentate gyrus; Po, posterior thalamic nuclei; Sol, nucleus of the solitary tract; Sp5, spinal trigeminal nucleus; 
VPM, ventral posteromedial thalamic nucleus. Bars = 500 mm (b1, c1)
CHAPTER 3
62
(Fig. 6i-k). Aggregates in distal dendrites in general were loosely packed (Fig. 6i, j), whereas 
larger aggregates in proximal dendrites were more densely packed showing cores with high levels 
of electron dense proteinaceous material as well as high levels of vesicular structures (Fig. 6k). 
Notably, in addition to these heterogeneous dendritic aggregates, in some neurons of symptomatic 
T3T3 mice we also identified homogenous compact filamentous ubiquitinated SOD1 aggregates, 
that were not associated with vesicular structures (Supplementary Fig. 4).
Table 2. Cellular distribution of ubiquitinated and non-ubiquitinated SOD1 aggregates in 
neuron-specific and ubiquitous G93A-mutant and wild-type hSOD1 transgenic mice
Using light- and electron microscopic immunoperoxidase histochemistry, confocal immunofluorescence 
and post embedding immunogold electron microscopy we have characterized several intensely hSOD1 
immunoreactive structures in G1del mouse spinal cord that appear at different time points. Non-ubiquitinated 
hSOD1-immunoreactive structures were also immunoreactive for cytochrome C and corresponded to swollen 
and vacuolated mitochondria (Jaarsma et al., 2001). Ubiquitinated hSOD1-aggregates were either neuronal 
localized to the dendrites, the soma or the axon, or glial localized to astrocytes or oligodendrocytes that 
always are immunoreactive for JB-crystallin. Neuronal aggregates occur before glial aggregates in G1del 
mice. T1T3 and T3T3 mice only develop neuronal ubiquitinated SOD1 aggregates that are ultrastructurally 
similar to those in G1del mice. hSOD1 mice develop mitochondrial pathology as well as axonal and 
oligodendrocytic ubiquitinated SOD1 aggregates, indicating that wild-type hSOD1 may form aggregates in 
specific structures when expressed at high levels. T3hSOD1 mice develop pathology of both hSOD1 and 
T3T3 and T1T3 mice, but oligodendrocyte pathology is dramatically increased. -: absent; +, ++, +++, ++++: 
infrequent, moderate, frequent, very frequent occurrence,respectively.
non-
ubiquitinated
ubiquitinated
neurons glia
swollen and 
vacuolated 
mitochondria
somato-
dendritic
(MAP2)
axon
(NF-M)
astrocytes
(αB-crystallin 
+; GFAP +)
oligodendrocyte
(αB-crystallin +; 
Rip +; GFAP -)
G1del    
  presymptomatic (15-20 w) 
  onset (>25w)   
  end (>30w)
+++
+++
++
++
+++
++
-/+
+
+
-
-/+
++
-
+
+++
Thy1.2-G93A
 -T1 (104 w)
 -T3 (104 w)
 -T1T3   
 presymptomatic (104 w)   
 symptomatic & end (>77w)
 -T3T3   
 presymptomatic (40-70w)  
 presymptomatic (70-104w) 
 onset (>60w)   
 end (>60w)
-
-
-
-
-
-
-
-
-
-
+
++
-/+
+
++
++
-
-
-
+
-
-/+
+
+
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
T3hSOD1   
  20 w   
  presymptomatic (30-40w)  
  onset (>45w)   
  end (62-78)
++
+++
++++
++++
+
++
++
++
+
+
+
+
-
-
-
-
-
+
++++
++++
hSOD1   
  40w   
  70w  
  104w
++
++++
++++
-
-
-
-
-/+
-/+
-
-
-
-
+
+
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wild-type hSoD1 overexpression facilitates the formation of dendritic ubiquitinated SoD1 
aggregates in neuron-specific G93A mice
It has been shown that high level expression of wild-type SOD1 facilitates the development of 
motor neuron degeneration in ubiquitous mutant SOD1 expressing mice (Jaarsma et al., 2000; 
Deng et al., 2006). To examine whether this facilitating effect operates on mutant SOD1 in neurons, 
hemizygote T3 mice were crossed with transgenic mice ubiquitously expressing high levels of 
wild-type human SOD1 (hSOD1 mice). All T3hSOD1 mice developed signs of muscle weakness 
around 1 year of the age, and reached end stage disease, characterized by motor neuron loss 
and muscle denervation before 80 weeks of age (Fig. 1g-i; Table 1). T3hSOD1 mice developed 
ubiquitinated dendritic SOD1 aggregates that were ultrastructurally similar to those in G1del and 
Thy1.2-G93A mice (not shown). These aggregates were present at a remarkably early age: i.e. 15-
20 weeks (Fig. 6f; Table 2), which is around the same age of appearance as dendritic aggregates 
in G1del mice expressing higher levels of G93A-SOD1, and much earlier than in T1T3 and T3T3 
mice. Importantly, hSOD1 mice never show dendritic ubiquitinated SOD1 aggregates (Table 2) 
(Jaarsma et al., 2000), indicating that the formation of dendritic ubiquitinated SOD1 aggregates 
in T3hSOD1 mice depends on the presence of mutant SOD1. In sum, these data indicate that high 
level wild-type hSOD1 overexpression also facilitates motor neuron degeneration when mutated 
SOD1 expression is restricted to neurons.
massive wild-type hSoD1 aggregation in oligodendrocytes of neuron-specific G93A mice 
crossed with hSoD1 overexpressing mice
Surprisingly, T3hSOD1 mice in addition to dendritic aggregates also showed a very high level 
of ubiquitinated SOD1 aggregates in oligodendrocytes, appearing from symptom onset (Fig. 6f; 
Table 2). These aggregates showed the same characteristics as oligodendrocytic aggregates in 
G1del, i.e. they were intensely immunoreactive for αB-crystallin, enclosed by the oligodendroglial     
marker RIP, while immunonegative for astrocyte (GFAP), microglial (CR3) and neuronal (MAP2, 
NFM) markers (Fig. 7c-i; Table 2). The aggregates were localized to the cell body or processes 
of the oligodendrocytes, and ultrastructurally consisted of 11-14 nm thick randomly oriented 
filaments, (Fig. 7j-l). Importantly, these oligodendrocyte aggregates also were present in the 
spinal cord of aged hSOD1 mice (>70w, Table 2) albeit at a considerable lower number (Figs 
6c and 7b). This indicates that high level expression of wild type SOD1 by it self is sufficient to 
induce ubiquitinated SOD1 aggregates in oligodendrocytes, but that this process is facilitated in 
T3 hSOD1 mice. Of note, the presence of oligodendrocyte aggregates in T3hSOD1 mice (as well 
as in hSOD1 and G1del mice) always was accompanied by the occurrence of axonal degeneration, 
Figure 4. Neuron-specific G93A-SOD1 mice like ubiquitous G93A mice show signs of micro and 
astrogliosis, but do not develop glial SOD1 aggregates.
(a-d) Murine CR3 (complement type 3 receptor)-staining of resting and activated microglia (brown) in thionin 
counter-stained (blue) lumbar L4-ventral horn showing the presence of activated microglia (arrows in c and 
d) in spinal cord of end stage neuron-specific (T3T3) and ubiquitous (G1del) G93A-SOD1 mice. (e-h) Triple-
labeling confocal immunofluorescence of GFAP, aB-crystallin and hSOD1 in lumbar spinal cord sections 
showing that end stage T3T3 mice (g) like end stage G1del mice (h) show increased GFAP-immunoreactivity 
indicative of astrogiosis (g1, h1), but unlike G1del mice do not show increased aB-crystallin-immunoreactivity 
(g2, h2). Intensely JBcrystallin labeled structures in G1del mice usually are strongly immunoreactive for 
trangenic human mutant SOD1 (arrows and arrow heads in h), and occasionally codistribute for GFAP (arrows 
in h). aB-crystallin- and hSOD1-positive but GFAP-negative structures (arrow heads in h) represent SOD1 
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aggregates in oligodendrocytes (see also Figs. 5 and 7). Asterisks in c3 indicate a vacuolated mitochondrion 
which is outlined by a halo of intense hSOD1- immunoreactivity (see also Jaarsma et al., 2001). Note in g, that 
end stage T3T3 mice show loss of hSOD1 in parallel with increased GFAP-staining consistent with neuronal 
degeneration and neuron-specific expression of mutant SOD1. Also note that because of higher hSOD1 levels 
in G1del mice, the hSOD1-signal in h3 has been scanned at lower detector sensitivity as compared to e3-
g3, to avoid saturation of the image. (i) aB-crystallin immunoperoxidase electron micrograph of an astroglial 
SOD1 aggregate in end stage G1del mouse. The astrocyte with the aggregate is outlined by color coding the 
surrounding neuropil. Astroglial SOD1 aggregates consist of disorganized filamentous material, that in accord 
with confocal immunofluorescent images (arrow in h) are immunoreactive for aB-crystallin (arrow in i2). Note 
GFAP filaments right from dashed line in i2. Bars: 20 Mm (a), 10 Mm (e4), 3 Mm (i1).
Fig.4 - continued
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Figure 5. Neuron-specific G93A-SOD1 mice do not show increased levels of insoluble ;B-crystallin and 
;B-crystallin-positive ubiquitinated structures
(a-c). Double-labeling confocal immunofluorescence shows that ubiquitin immunoreactivity in end stage 
neuron-specific G93A-SOD1 mice (T3T3) never codistributes with aB-crystallin (arrow heads in b). In contrast, 
ubiquitous G93A-SOD1 (G1del) mice frequently show intense aB-crystallin labeling of ubiquitinated structures 
(arrows in c). These aB-crystallin positive ubiquitinated structures represent glial ubiquitinated SOD1 aggregates 
(see also Figs 4 and 7). (d) Western blot analysis of the small heat shock proteins JB-crystallin and Hsp25, and 
the astroglial proteins GFAP and GLT1 in total spinal cord homogenate (S1) and 0.5% NP-P40 insoluble pellet 
(P2) of non-transgenic, T3, T3T3 and G1del mice. Note that insoluble aBcrystallin levels are strongly increased 
in symptomatic G1del mice. End stage T3T3 sho a small increase of insoluble aB-crystallin levels which was 
similar to increased insoluble aBcrystallin levels in aged non-transgenic and T3 mice. Large increases of total 
and insoluble Hsp25 occurred in both end stage G1del and T3T3 mice consistent with astroglial induction of 
Hsp25 expression as shown in Figure 1h. End stage G1del and T3T3 mice also showed increased GFAP and 
a trend (non-significant; one-way ANOVA) of reduced GLT-1 expression. Values represent means ± SE, n=3. 
*, **, ***: P < 0.05, P < 0.01, P < 0.001 compared to 20 weeks old non-transgenic mice; #: P < 0.05 compared 
to 104 weeks old nontransgenic mice (one-way ANOVA, Tukey’s multiple comparison test).
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indicating a link between axonal degeneration and oligodendrocyte aggregates. As indicated in 
Table 2, neither T3hSOD1 mice nor hSOD1 mice did develop SOD1 aggregates in astrocytes, 
indicating that aggregate formation in these cells can not be mimicked by high wild-type SOD1 
concentrations, and like the dendritic aggregates in motor neurons depend on the presence of 
mutant SOD1 (Table 2).
DiSCuSSion
In this study we show that transgenic mice expressing G93A-mutant SOD1 specifically in neurons 
develop an ALS-like disease characterized by the loss of motor neurons and muscle denervation. 
Our data conclusively show that mutant SOD1 expression in neurons is sufficient to cause motor 
neuron disease in vivo. Previous studies with ubiquitous mutant SOD1 transgenic mice have 
shown that down-regulation of mutant SOD1 specifically in neurons by either RNAi (Ralph et al., 
2005) or Cre/Lox (Boillee et al., 2006b) delays symptom onset and prolongs survival. In accord 
with our data these studies provide in vivo evidence that toxic actions of mutant SOD1 in neurons 
are important in SOD1-ALS pathogenesis, but since the mice in these studies continue to express 
high levels of mutant SOD1 in glia, these studies leave open the question whether the presence of 
mutant SOD1 in neurons is sufficient to develop disease (Ralph et al., 2005; Boillee et al., 2006b). 
Two previous studies reported on transgenic mice expressing mutant SOD1 selectively in neurons 
that did not develop signs of motor neuron degeneration (Pramatarova et al., 2001; Lino et al., 
2002). The absence of a disease phenotype in these mice may be explained by insufficient mutant 
SOD1 expression. For instance, the mice generated by Pramatarova et al. (Pramatarova et al., 
2001) constructed to express G37R-mutant hSOD1 mice under the control of the neurofilament-
L promotor, produce mutant transgenic SOD1 in spinal cord homogenates at a concentration of 
approximately 0.2 ng/µg protein (Pramatarova et al., 2001), which is lower than in our Thy1.2-
G93A mice (0.5 ng/µg and 1 ng/µg for hemi and homozygotes, respectively), and considerably 
lower than ubiquitous G37R mice generated using genomic constructs(Wong et al., 1995) or a 
cDNA construct controlled by the prion protein promotor (Wang et al., 2005). Mutant SOD1 
concentrations have not been reported for the mice of Lino et al. (Lino et al., 2002) which as in 
our study were generated using the Thy1.2 expression construct to drive either G93A or G85R 
mutant hSOD1 expression. However, Lino et al. (Lino et al., 2002) showed that their highest 
expressing G93A-SOD1 line (line 13) did not influence symptom onset and survival of high copy 
Gurney-G1 mice (Lino et al., 2002). These results are consistent with our data demonstrating 
that the T3 transgene had a minimal effect on survival of G1del mice (Supplementary Fig. 2). 
As other studies have shown that altering neuronal mutant SOD1 levels in ubiquitous mutant 
SOD1 expressing mice has a significant impact on symptom onset (Ralph et al., 2005; Boillee et 
al., 2006b), these data indirectly indicate that neuronal mutant SOD1 expression levels in their 
line 13 mice is much lower than in their G1 mice. In sum, the data from previous studies with 
neuron-specific mutant SOD1 mouse models are consistent with our results with hemizygote T1 
and T3 mouse, and indicate that mutant SOD1 has to be expressed at sufficient high levels in 
order to trigger motor neuron disease within the normal life span of a mouse. Accordingly, the 
lack of a disease phenotype of some ubiquitous mutant SOD1 expressing lines has been linked to 
insufficient mutant SOD1 expression (Deng et al., 2006; Jonsson et al., 2006b).
NEURON-SPECIFIC SOD1-MICE
67
Figure 6. Dendritic ubiquitinated SOD1 aggregates are the dominant pathological feature preceding 
motor neuron degeneration in neuron-specific G93A-SOD1 mice
(a-f) Immunoperoxidase labeling of ubiquitin-immunoreactivity in the ventral horn (VH) of L4 spinal cord sections 
of neuron-specific G93A-SOD1 mice (d, T3T3), ubiquitous G93ASOD1 mice (e, G1del), wild-type hSOD1 
overexpressing mice (c), and double transgenic T3hSOD1 mice (f). In T3T3 mice ubiquitin-immunoreactivity is 
associated with neurite-like structures (arrow heads in d) and neuronal somata with a relatively modest increase 
in the number of labeled structures throughout disease progression. In G1del mice ubiquitinimmunoreactivity 
is predominantly associated with neurite-like structures in early stages of disease (arrow heads in e1 and 
e2), but the amount of ubiquitin-immunoreactive structures increases progressively in late phases of disease, 
due to the appearance of glial ubiquitinated SOD1 aggregates (small arrow in e3, see also Figs 4 and 5). 
Also T3hSOD1 mice show neuritic ubiquitin-immunoreactivity in presymptomatic stages, but from symptom 
onset T3hSOD1 mice show dramatic high levels of ubiquitin-immunoreactivity resulting from oligodendrocytic 
SOD1 aggregates which have a dot-like appearance in immunoperoxidase stained sections (small arrows in 
f2 and f3, see also Fig. 7). In old hSOD1 mice ubiquitin labeling was exclusively associated with these dot-like 
oligodendrocyte aggregates (arrows in c) and never occurred in neuronal profiles. Ubiquitinated structures 
were never observed in 2 years old non-transgenic and hemizygote T3 mice. vlfu, ventrolateral funiculus. (g-
h) Double-labeling confocal immunofluorescence shows that neurtitc ubiquitin immunoreactivity in T3T3 mice 
codistributes with MAP2 immunoreactivity consistent with a dendritic localization. Note in h that the motor 
neuron with ubiquitin-immunoreactivity in the proximal dendrite has a flattened eccentric nucleus suggestive 
 Neuropathological analysis of our neuron-specific G93A mice point to a single           
intracellular defect preceding other degenerative changes, which is the formation of dendritic 
SOD1 aggregates. Our ultrastructural data show that these dendritic SOD1 aggregates are 
associated with disorganized filaments and high levels of vesicular structures suggesting that 
aggregates disrupt the cytoskeleton and organelle trafficking within motor neuron dendrites. As we 
did not observe evidence for other previously reported cellular abnormalities (e.g. mitochondrial 
abnormalities, early axonal abnormalities), we hypothesise that disruption of dendritic trafficking 
by SOD1 aggregates may be the major event triggering motor neuron degeneration. Accordingly, 
somato-dendritic ubiquitination has been reported for all SOD1-ALS mouse models in the 
literature (Bruijn et al., 1997; Dal Canto and Gurney, 1997; Stieber et al., 2000; Jonsson et al., 
2004; Wang et al., 2005), and aggregates ultrastructurally resembling  dendritic aggregates have 
been documented  for human ALS material (Arima et al., 1998; Kato et al., 2000). The precise 
mechanisms causing the formation and composition of these aggregates remain to be determined. 
As shown in the present study dendritic aggregate formation is facilitated in the context of high 
wild-type hSOD1 levels, and identifying the mechanism underlying this facilitation may provide 
novel clues about SOD1-ALS pathogenesis (Furukawa et al., 2006).
 Several lines of evidence have indicated a pathogenic role of mutant SOD1 in astrocytes 
(Clement et al., 2003; Di Giorgio et al., 2007; Nagai et al., 2007) and microglia (Beers et al., 
2006; Boillee et al., 2006b). Furthermore, the ability of mutant SOD1 to form micrometer 
scale aggregates in astrocytes, afflict their function, and trigger their degeneration has been 
demonstrated in SOD1-ALS patients (Kato et al., 1997) and SOD1-ALS transgenic mice (Bruijn 
et al., 1997; Dal Canto and Gurney, 1997; Pasinelli et al., 2000; Vlug et al., 2005). �aving an 
intimate metabolic relationship with neurons, the malfunction or degeneration of astroglia is likely 
to facilitate the degeneration of neurons (Faulkner et al., 2004; Maragakis and Rothstein, 2006). 
Our data demonstrating that neuron-specific expression of mutant SOD1 is sufficient to cause 
disease do not exclude a role for mutant SOD1 in glia. We have identified a number of differences 
between our Thy1.2-G93A mice and G1del mice that express G93A-SOD1 ubiquitously. Part of 
these differences, like the absence of mitochondrial vacuolar pathology may follow from low 
level mutant SOD1 expression as this phenomenon is linked to high SOD1 protein concentrations 
(Bergemalm et al., 2006) and occurs at low levels in low-expressing ubiquitous G93A-SOD1 lines 
next page
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of compromised health. (i-k) Post-embedding immunogold electron microscopy of ubiquitin and transgenic 
human SOD1 in aggregates in distal (h, i) and proximal (j) dendrites. Dendritic aggregates predominantly 
consisted of disorganized filaments (arrow heads in i2, j and k3). Note the presence of mitochondria (m) in 
close proximity of the aggregates in i and j. Aggregates in proximal dendrites show a higher level of aggregated 
material in the centre (k1, k2) and often contain high levels of vesicular structures at the periphery (j). Note 
that the post-embedding immunogold procedure is relatively inefficient as compared to immunoperoxidase 
histochemistry and immunofluoresence methods producing labeling only in areas with high hSOD1 and 
ubiquitin concentrations. Also note that synapses (arrows in i1, j and k1) and mitochondria (m) have a normal 
appearance in the dendritic profiles with aggregates. Bars: 50 Mm (c), 10 Mm (g1, h1), 500 nm (i1, j, k1)
Fig.6 - continued
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Figure 7. Neuron-specific expression of G93A-SOD1 in ubiquitous wild-type hSOD1 overexpressing 
transgenic mice triggers massive wild-type hSOD1 aggregation in oligodendrocytes
(a-i) Double-labeling confocal immunofluorescence showing high levels ubiquitinated structures with a 
diameter up to 10 Mm in the spinal cord of symptomatic T3hSOD1 mice. These ubiquitinated structures are 
immunoreactive for JB-crystallin (arrow in c; d) and hSOD1 (arrow in i) and surrounded by the oligodendrocyte 
marker RIP (f), and do not codistribute with astroglial (GFAP), microcroglial (CR3) and somato-dendritic 
neuronal (MAP2, e) markers. In addition to these oligodendrocyte aggregates T3hSOD1 show infrequent 
JB-crystallin negative ubiquitinated structures (arrow head in c) that are immunoreactive for MAP2 (arrow 
head in e) consistent with a somato-dendritic distribution. Also wild-type hSOD1 mice that do not express the 
T3 transgene also develop oligodendrocyte aggregates albeit at advanced age (> 70 weeks) and at much 
lower numbers (arrow in b; see also Fig. 6 c, f). (j-k) Standard (q) and post-embedding immunogold electron 
microscopy of oligodendrocyte aggregates (r, s) showing that oligodendrocyte aggregates consist of 11-14 nm 
thick randomly oriented filaments. Bars: 20 Mm (a1, g1), 10 Mm (d1, f1), 500 nm (j-k).
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(lines G20 and G5/G5) (Dal Canto and Gurney, 1995, 1997). Also the late and highly variable 
age of motor symptom onset can, at least in part, be explained by relatively low G93A-SOD1 
expression levels, as this is also observed in the low-copy ubiquitous G93A-SOD1 lines (Dal 
Canto and Gurney, 1995, 1997). In contrast, the absence of glial ubiquitinated SOD1 aggregates 
and the lack of accumulation of αB-crystallin in the detergent insoluble fraction in our neuron-
specific G93A-SOD1 mice can be readily explained by the absence of mutant SOD1 in glia. Also 
the diffuse rather than focal onset of motor symptoms in our neuron-specific G93A-SOD1 mice 
might follow from the absence of mutant SOD1 in glial, which could imply that mutant SOD1 in 
glia plays a role in the brush fire-like spreading of disease throughout the spinal cord and brain 
stem.
 Analysis of the spatiotemporal distribution of astroglial SOD1-aggregates in our G1del 
mice indicated that these astroglial aggregates appear in a relatively late phase of disease (Table 
2), selectively in regions with high levels of neuronal degeneration and prominent astrogliosis. 
This raises the possibility that astroglial aggregate formation is triggered or facilitated in the 
context of neuronal degeneration, and hence that the disease may spread from neurons to glia. 
According to such a scenario astrocytes are able to cope with the presence of mutant SOD1 in 
normal conditions, but under stressfull conditions such as the context of neuronal degeneration 
that triggers multiple changes in astrocytes, they become vulnerable to mutant SOD1. Such a 
scenario is supported by our findings in neuron-specific G93A mice crossed with wild-type hSOD1 
overexpressing mice, which show massive wild-type hSOD1 aggregation in oligodendrocytes 
after the onset of neuronal degeneration. As shown in the present study these oligodendrocyte 
aggregates also occur at low frequency in old hSOD1 mice (age > 70 weeks; see table 2), and 
at moderate frequency in symptomatic G1del mice. Since the oligodendrocyte aggregates only 
occur after the onset of neuronal or axonal degeneration and a dramatic difference is seen in the 
number of oligodendrocyte aggregates between T3hSOD1 compared to hSOD1 mice despite equal 
hSOD1 expression, we propose that the formation of oligodendrocyte aggregates depend both on 
the presence of high levels of SOD1 protein as well as the context of neuronal degeneration. 
The reduced levels of oligodendrocyte aggregates in G1del mice as compared to T3hSOD1 
double transgenic mice despite the equal occurrence of axonal and neuronal degeneration, can be 
explained by reduced transgenic SOD1 protein levels in G1del mice as compared to hSOD1 mice 
(Jaarsma et al., 2000), and may indicate that the formation of oligodendrocyte aggregates depend 
on high levels of SOD1 protein rather than the presence of mutant SOD1. In sum our data favor 
a scenario where the oligodendrocytes in T3hSOD1 mice in the context of neuronal degeneration 
they show a reduced ability to prevent wild-type hSOD1 from forming aggregates. 
In sum, on the basis of our data we propose a pathogenic model where mutant SOD1 triggers 
neuronal degeneration, which in turn facilitates aggregate formation and functional deficits in 
surrounding glia. Such a pathological interplay between neurons and glia could facilitate further 
degeneration of neurons and underlie the focal onset and brush fire-like spreading of disease in 
SOD1-ALS.
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Supplementary Fig. 2. The T3 transgene has a marginal effect on disease onset and survival in G1del 
mice. Kaplan Meier plots (a) and bar graph (b) showing age of disease onset and end stage of G1del and 
T3G1del mice. Onset of disease in most mice was characterized by the inability of the mice to extend one 
of the hind limbs. Three G1del and one T3G1del mice showed fore limb onset of disease, the first sign of 
weakness being the inability to hang in a hanging wire test. Onset and end stage age was not significantly 
different between G1del and T3G1del mice (unpaired two-tailed Student t-test).
Supplementary Table 1. Astroglial changes in neuron-specific and ubiquitous  G93A-SOD1 
expressing mice
-, absent or no change; +, infrequent occurrence or small change in expression; ++, moderate occurrence or 
moderate change; +++, frequent occurrence or large change; ++++, very large change
increased 
GFAP
HSP25 
expression
α-Bcrystallin
expression
reduced 
GLT1 ex-
pression
Ubiquitinated 
inclusions
active
caspase3
non-tg (104 w) + + - - - -
G1del (end) +++ ++++ ++ + ++ +
T3 (104 w)
T3T3 (end)
T1T3 (end)
+
+++
+++
++
++++
++++
-
-
-
-
-/+
n.d.
-
-
-
-
-
-
T3hSOD1 
(end)
+++ ++++ - n.d. - -
hSOD1 (104 w) ++ ++ - n.d. - -
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Supplementary Fig. 3. Loss of grip strength in end stage neuron-specific and ubiquitous G93A-SOD1 
mice.
Grip strength was determined by placing mice with 4 limbs on a grid attached to a force gauge, and steadily 
pulling the mice by their tail. Grip strength is defined as the maximum strength produced by the mouse before 
releasing the grid. For each value the test is performed in triplicate. Bar graphs represent means ± SE. ** and 
***, P < 0.01 and P < 0.001, respectively compared with non-transgenic mice and presymptomatic transgenic 
mice, (oneway ANOVA with Tukey’s multiple comparison test)
Supplementary Fig. 1. Mutant SOD1 protein and mRNA levels are lower in motor neurons of neuron-
specific G93A-SOD1 mice as compared to G1del ubiquitous G93ASOD1 mice. 
(a) hSOD1-immunofluoresence showing considerable lower signal within individual motor neurons of T3T3 
mice (arrow in a2) as compared to motor neurons in G1del mice (arrow in a3). Note that, spinal cord specimens 
from the different mice were embedded in a single gelatin block and sectioned and stained together to avoid 
variability in staining. Antibody concentration (sheep anti-SOD1, 1:5000) and confocal microscope settings 
were chosen for optimal detection of hSOD1 labeling in T3T3 spinal cord. Note, that under these conditions 
hSOD1-immunofluorescence signal from motor neurons of G1del mice is saturated (a3), whereas motor 
neurons from non-transgenic mice do not produce any signal above back ground (a1). (b) hSOD1 mRNA in 
situ hybridization showing that motor neurons in T3T3 mice (b2) show much lower hSOD1 mRNA levels as 
compared to G1del mice (b3). Bars: 20 μm (a1, b1).
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Supplementary Fig. 4. ‘Compact’ fibrillary ubiquitinated SOD1 aggregates in neuronspecific G93A-
SOD1 mice
(a) Confocal immunofluorescence revealed infrequent (1-2 per 40 μm thick lumbar L4 or cervical C6 section) 
neurons with skein-like SOD1-aggregates in spinal cord of end stage T3T3 or T1T3 mice. These aggregates 
usually were localized in the perinuclear region but did not co-distribute with autofluorescent material. (b, 
c) Post-embedding immunogold electron microscopy revealed ‘compact’ ubiquitinated SOD1 aggregates 
that consist of densely packed 11-14 nm thick filaments and that are distinct from heterogeneous dendritic 
aggregates as shown in Figure 2h-j. Arrow in c points to polyribosomes. mt, microtubule. (d) Occasionally, 
hSOD1 immunogold-labeling also was present in autophagosome-like structures. Bars: 10μm (a1), 500 nm 
(b1, c, d)
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Transgenic mice
Experiments were performed in accordance with the “Principles of laboratory animal care” (NIH 
publication No. 86-23) and the guidelines approved by the Erasmus University animal care committee. 
To generate Thy1.2-G93A mice a cDNA of hSOD1 carrying the G93A mutation was cloned into the 
Thy1.2 expression cassette (Caroni, 1997; Feng et al., 2000), and injected into fertilized oocytes, using 
standard techniques. Embryos for injection were obtained from FVB mice. Transgenic lines (T1-T10) 
were screened immunohistochemically for G93A-SOD1 expression in the spinal cord using human SOD1 
specific antibody.Two lines (T1 and T3) were used for further studies. Transgenic lines were maintained into 
BCBA background by crossing hemizygote males with non-transgenic females. Transgenic offspring was 
genotyped by PCR. Homozygote T3T3 and double transgenic T1T3 were obtained by crossing T3 males 
with T3 and T1 females, respectively. Double transgenic offspring were distinguished from hemizygotes by 
Southern Blot. 
Other mice used in this study were G1del mice, that carry a genomic hSOD1 construct with the G93A 
mutation, and hSOD1 mice, i.e. transgenic mice carrying a genomic construct of wild-type hSOD1. G1del 
mice are descendent from the Gurney G1 mice but show a reduced transgene copy number (8 instead of 
24 transgene copy numbers per haploid genome) and show a delayed onset of disease as compared to the 
original Gurney G1mice (Gurney, 1997). hSOD1 mice are derived from the Gurney N29 line (Gurney et al., 
1994) and have been extensively characterized in our lab in previous studies (Jaarsma et al., 2000). Double 
transgenic T3hSOD1 mice were generated by crossing T3 and hSOD1 hemizygotes. 
Routinely, transgenic mice were weighed and inspected for signs of muscle weakness once (Thy1.2-G93A 
mice) or twice (G1del mice) a week, using a set of simple tests: mice were examined for their ability to 
extend their hind limbs when suspended in the air by their tail, and their ability to hang upside down on a 
grid for 60 s. In addition, at specific ages grip strength was measured using a grid attached to a force gauge 
(Bioseb, France). Mice reached end stage disease when they could not right themselves within 5 s when 
placed on their back, lost more than 30% of their maximal weight, or developed infection of one of the eyes. 
Mice selected for analysis of the clinical course of disease were sacrificed at end stage disease or when 
they reached 2 years of age. After the experiment all mice were analyzed for neuromuscular denervation, 
and pathological abnormalities in the spinal cord (e.g. ubiquitin pathology, motor neuron loss, gliosis, 
argyrophylic neuronal debris). Mice developing tumors before end stage disease or 2 years of age were 
excluded from the study.
Antibodies
Primary antibodies (supplier; applications [I�C, Immunohistochemistry; IF, immunofluorescence; WB, 
Western blot] and dilutions) reported in this study are��� Mouse anti JB-crystallin (Stessgen; I�C and IF 
1���1000, WB 1���2000), rabbit anti-ATF3 (Santa Cruz; I�C and IF 1���1000); anti-cleaved caspase 3 (Asp175, 
Cell Signalling; I�C 1���200), rabbit anti- CGRP (Calbiochem; I�C and IF, 1���10000); goat anti-ChAT 
(Chemicon; I�C and IF 1���50); rat anti-CR3 receptor (clone 5C6; Serotec, I�C 1���500; IF 1���100); rabbit 
anti-GFAP (DAKO; I�C 1���10000; IF 1���5000; WB 1���5000); rabbit anti GLT1 (from Dr. N.J. Maragakis; WB 
1���10000); anti-GM130 (Transduction Laboratories, IF 1���1000); Rabbit anti �sp25 (Stessgen, IF 1���2000); 
mouse anti-MAP2 (Sigma; IF 1���1000); chicken anti-neurofilament-M (Chemicon; IF 1���2000); mouse anti-
RIP (from Dr. B. Friedman; IF 1���200); sheep anti-hSOD1 (Calbiochem; I�C 1���5000-1���20000; IF 1���5000); 
rabbit anti-SOD1 (from Dr. �.W. Verspaget; I�C and IF��� 1���5000); rabbit anti SOD1 (SOD100, StressGen; 
WB 1���5000); rabbit anti-murine SOD1 (SOD101, StressGen; WB 1���8000); rabbit anti-ubiquitin (Dako; 
I�C and IF 1���2000); mouse anti-ubiquitin (clone FK2, Affiniti; IF 1���2000); goat anti-VAChT (Chemicon, 
IF 1:1000). Secondary antibodies: For avidin-biotin-peroxidase immunocytochemistry biotinylated 
secondary antibodies from Vector Laboratories diluted 1:200 were used. FITC-, Cy3-, and Cy5-conjugated 
secondary antibodies raised in donkey (Jackson Immunoresearch, USA) diluted at 1:200 were used for 
immunofluorescence.
western blot
Tissue specimens were homogenized and sonicated in ten volumes of PBS containing 0.5% Nonidet P-40 
(NP-40) and 1x protease inhibitors cocktail (Sigma, St. Louis, MO) and centrifuged at 800 g for 5 min at 
4°C, and protein concentrations of the supernatants (S1) were determined using the BCA method (Pierce, 
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Rockford, IL).. To obtain the detergent
insoluble fraction P2, S1 fractions were centrifuged at 15000 g for 15 min. P2 pellets were thoroughly washed 
five times with PBS-0.5% NP-40 and then resuspended in sample buffer for SDS-page electrophoresis 
and Western-blotting. 2–30 Mg protein of S1 and P2 were electrophoresed on 10% - 15% SDS-page gels 
and blotted on PVDF membranes (Millipore). For quantitative analysis of hSOD1-immunoreactivity 
recombinant hSOD1 protein (0.5–50 ng, from H.W. Verspaget) was electrophoresed and blotted together 
with the tissue samples. The membranes were blocked with 5% non-fat dry milk (Bio-Rad) in PBS with 
0.05% Tween20 (PBST), incubated in primary antibody, diluted in PBST with 1% dry milk followed by an 
incubation in secondary antibody, incubated in chemiluminescence reagent (ECL, Amersham), exposed to 
film or a Kodak Image station, and analysed with Kodak Image analysis and ImageQuant 2.2 software.
immunohistochemical and histopathological procedures
For immunocytochemistry and immunofluorescence mice were anaesthetised with pentobarbital and 
perfused transcardially with 4% paraformaldehyde. The lumbar and cervical spinal cord were carefully 
dissected out and post-fixed overnight in 4% paraformaldehyde. Routinely, spinal cord tissue was embedded 
in gelatin blocks (Jaarsma et al., 2000), sectioned at 40μm with a freezing microtome and sections were 
processed, free floating, employing a standard avidin-biotin-immunoperoxidase complex method (ABC, 
Vector Laboratories, USA) with diaminobenzidine (0.05%) as the chromogen, or single, double and triple-
labelling immunofluorescence (Jaarsma et al., 2000; Jaarsma et al., 2001; Maatkamp et al., 2004). In 
addition, a selected number of frozen sections were processed for a silver staining procedure that selectively 
labels dying neurons and their processes (Jaarsma et al., 2000). 
Immunoperoxidase-stained sections were analyzed and photographed using a Leica DM-RB microscope and 
a Leica DC300 digital camera. Sections stained for immunofluorescence were analysed with a Zeiss LSM 
510 confocal laser scanning microscope using 40x/1.3 and 63x/1.4 oil-immersion objectives. Quantitative 
analyses of motor neurons was performed as described before (Vlug et al., 2005) on serial lumbar 4 (L4) 
sections immunoperoxidase stained for ChAT or CGRP. 
For analysis of neuromuscular denervation medial gastrocnemius muscle from 4% paraformaldehyde fixed 
mice were dissected, embedded into gelatin blocks and sectioned at 80μm with a freezing microtome. 
Sections were immunolabeled, free floating, for goat-anti- VAChT and rabbit anti-hSOD1 or goat-anti-
VAChT and chicken-anti-NFM followed by Cy3 anti-goat and Cy5 anti-chicken or anti-rabbit secondaries, 
and motor endplates were labeled with FITC-bungarotoxin (1:500, Molecular Probes). For quantitative 
analyses, muscle sections were examined under a Leica DM-RB fluorescence microscope, end-plates being 
scored as ‘innervated’ in case of complete overlap between bungarotoxin and VAChT labeling, ‘partially 
denervated’ in case of partial overlap, and ‘denervated’ in case of the absence of VAChT labeling at the 
end-plate. Per muscle all endplates within three sections were analyzed. In addition, muscle sections were 
analyzed with a Zeiss LSM 510 confocal laser scanning to examine neurofilament-M and hSOD1 labeling. 
In Thy1.2-G93A mice the disappearance of VAChT labeling always was associated with loss of hSOD1 
labeling (Figure 1i).
electron microscopy
For electron microscopy mice were perfused transcardially with 4% paraformaldehyde with 0.1% (pre-
embedding immunoperoxidase and post-embedding immunogold electron microscopy) or 1% glutaraldehyde 
(standard post-embedding and immunogold labeling electron microscopy). Specimens were sectioned 
with a Vibratome and further processed using standard methods as described before (Jaarsma et al., 2001; 
Kushner et al., 2005; Vlug et al., 2005). For standard electron microscopy Vibratome section (150 Mm 
thick) were postfixed in 1% osmium, dehydrated and embedded in Durcupan. Ultrathin (50–70 nm) were 
contrasted with uranyl acetate and lead citrate, and analyzed in a Phillips CM100 electron microscope at 
80 kV. Pre-embedding immunoperoxidase electron microscopy was performed to examine the subcellular 
distribution of ubiquitin and JB-crystallin. Vibratome sections (50-60 Mm thick) were immunoperoxidase 
stained as described (Jaarsma et al., 2001), post-fixed in 1% osmium, and further processed as described for 
standard electron microscopy. For postembedding electron microscopy, Vibratome sections (150-300 Mm 
thick) were dehydrated and embedded in Lowicryl HM20 using a freeze substitution procedure (Jaarsma 
et al., 2001), or embedded in Durcupan using an Osmium-free method (Kushner et al., 2005). Ultrathin 
(50–70 nm) were sections of processed for post-embedding immunogold-labeling of ubiquitin and hSOD1 
as described before (Jaarsma et al., 2001).
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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition 
characterized by progressive motor neuron degeneration and muscle paralysis. 
Genetic evidence from man and mouse has indicated that mutations in the 
retrograde dynein/dynactin motor complex are correlated with motor neuron 
degeneration. In this study, we have generated transgenic mice with neuron 
specific expression of the N-terminus of Bicaudal D2 (BICD2-N), an inhibitor of 
dynein/dynactin, to examine the effect of chronically impaired dynein/dynactin 
function. Motor neurons expressing BICD2-N showed accumulation of dynein 
and dynactin in the cell body, endosome and Golgi dispersion, as well as several 
signs of impaired retrograde trafficking, the appearance of giant neurofilament 
swellings in the proximal axon, reduced retrograde labelling by tracer injected in 
the muscle, and delayed expression of the injury transcription factor ATF3 after 
axon transection. Despite these abnormalities, BICD2-N mice did not develop 
signs of motor neuron degeneration and motor abnormalities. Progressive motor 
neuron degeneration and impaired axonal retrograde transport has been reported 
in SOD1-G93A transgenic mice. Surprisingly, crossing the BICD2-N mice with 
SOD1-G93A mice delays disease progression and significantly increases the life 
span of SOD1-ALS mice. Together these data indicate that impaired dynein/
dynactin transport by itself is not sufficient to cause motor neuron disease and 
may even be beneficial in some forms of ALS.
running title: BICD2-N mice
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inTroDuCTion
Amyotrophic lateral sclerosis (ALS) is a clinically and genetically heterogeneous disease 
characterized by late onset progressive degeneration of motor neurons resulting in paralysis of 
limb, facial and respiratory muscles (Boillee et al., 2006; Pasinelli and Brown, 2006). There 
is little knowledge about the cellular and molecular mechanisms underlying sporadic ALS 
pathogenesis, representing the majority of the cases. A minority of ALS patients (10%) show 
Mendelian inheritance, a subset of whom have mutations in the Cu/Zn superoxide dismutase 
(SOD1) gene resulting in SOD1 aggregates in motor neurons and glia (Boillee et al., 2006; Pasinelli 
and Brown, 2006). More recently, mutations in a variety of other genes have been identified in 
patients with ALS and ALS-like diseases (Boillee et al., 2006; Pasinelli and Brown, 2006). In a 
family with a slowly progressive motor neuron disease, a missense (G59S) mutation was found in 
the p150glued subunit of dynactin (DCTN1) (Puls et al., 2003) and subsequently other p150glued 
Figure 1. BICD2-N acts as a dominant-negative linker of the dynein/dynactin complex
A-D) Expression of GFP-p50-mito (A,C) and GFP-BICD2-N-mito (B,D) (green) in HeLa cells causes disruption 
of the Golgi apparatus as seen with Golgi marker GM130 (red) (A,B), accumulation of GFP-BICD2-N (B,D) 
but not GFP-p50-mito (A,C) in the juxta-nuclear region, and recruitment of mitochondria as stained with Mito-
Trackter (MitoT) (red, C2,D2) and p150 (blue, C3,D3) to this region in GFP-BICD2-N expressing cells. Separate 
dual images of triple colour combinations are shown in C,D 4-6, showing colocalization of GFP-p50-mito and 
GFP-BICD2-N-mito with both mitochondria and p150. E) Primary neurons expressing GFP, GFP-BICD2-N and 
GFP-p50 for 2 days, fixed and stained with antibodies against p150 (red), show an increased somatal p150 
signal in GFP-BICD2-N (E2), but not in GFP-p50 transfected neurons (E3). Inset shows enlargement of soma. 
Scale bars: A,C1,E1; 10mm. F) Quantification of p150-immunoreactivity in GFP, GFP-BICD2-N and GFP-p50 
expressing neurons relative to control neurons in the same image. Respectively 10, 10 and 4 images were 
quantified. ***p<0.001
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mutations have been reported in ALS patients (Munch et al., 2004). Dynactin is a multiprotein 
complex that regulates  microtubule based motility of the cytoplasmic dynein motor complex by 
increasing the processivity and efficiency of the motor (Schroer, 2004; Vallee et al., 2004). A link 
between impaired dynactin/dynein function and motor neuron disease was first demonstrated by 
overexpression of the dynactin subunit p50, also named dynamitin, which disrupts the dynactin/
dynein complex and causes a late-onset motor neuron disease in transgenic mice (LaMonte et al., 
2002). In addition, heterozygous missense mutations in the cytoplasmic dynein heavy chain 1 
gene (dync1h1) were found in two mouse models with late onset motor degeneration, Legs at odd 
angles (Loa) and cramping 1 (Cra1) (Hafezparast et al., 2003). Together, these data suggest that 
abnormalities in dynein/dynactin function may play a role in the pathogenesis of familiar ALS 
and possibly sporadic ALS (Levy and Holzbaur, 2006). 
 In neurons, dynein/dynactin mediates transport of multiple axonal cargo’s including 
endosomes, signalling complexes, degradation products and neurofilaments (Pfister, 1999; Roy et 
al., 2005; Levy and �olzbaur, 2006; Ibanez, 2007) and has been shown to be essential for axonal 
outgrowth in Drosophila (Martin et al., 1999; Liu et al., 2000). �owever, the precise relationship 
between dynein/dynactin function, retrograde axonal transport and the pathological features 
observed in ALS-patients is unclear. One potential consequence of disrupted dynein/dynactin 
function in ALS pathology are the reported abnormalities in axonal neurofilament distribution, 
i.e. proximal neurofilament swellings in ALS motor axons (Carpenter, 1968; Delisle and 
Carpenter, 1984; �irano et al., 1984; Motil et al., 2007) and the mild neurofilament abnormalities 
in p50-overexpressing and heterozygous G59S-p150glued mice (LaMonte et al., 2002; Lai et 
al., 2007). �owever, impaired retrograde trafficking is a late phenomenon in symptomatic p50-
expressing mice (LaMonte et al., 2002), and no overt abnormalities in overall retrograde axonal 
transport were found in nerves from heterozygous Loa/+ mice (Hafezparast et al., 2003). Golgi 
fragmentation is also an early pathological hallmark in ALS motor neurons and could be caused 
by inhibition of dynein/dynactin (Burkhardt et al., 1997; Gonatas et al., 2006), however no data 
on Golgi abnormalities have so far been reported for dynein/dynactin mouse models and patients 
with p150glued mutations (LaMonte et al., 2002; �afezparast et al., 2003; Puls et al., 2005; Lai et 
al., 2007). It is currently not clear which pathological features in motor neurons are related to the 
inhibition of dynein/dynactin and whether loss of dynein/dynactin function is the primary cause 
of motor neuron degeneration and motor abnormalities in ALS.
 To determine the effect of dynein/dynactin inhibition in motor neurons, we have 
generated transgenic mice with neuron specific expression of the N-terminus of Bicaudal D2 
(BICD2-N). Previous studies have shown that Bicaudal D is an evolutionarily conserved protein, 
which is involved in dynein-mediated motility both in Drosophila and in mammals by linking the 
dynein motor to cytoplasmic cargo (Bullock and Ish-�orowicz, 2001; �oogenraad et al., 2001; 
Matanis et al., 2002; �oogenraad et al., 2003; Grigoriev et al., 2007). By deleting the C-terminal 
cargo binding region, the N-terminus of BICD binds and recruits the dynein/dynactin complex 
and has been shown to chronically impaired dynein-dynactin function (�oogenraad et al., 2001; 
Hoogenraad et al., 2003). Thus, BICD2-N overexpression is a powerful tool in dissecting the 
roles of dynein and dynactin in motor neurons.
 Here we show that expression of BICD2-N in motor neurons impairs dynein/dynactin 
function in the axon and the cell body, including Golgi fragmentation, axonal neurofilament 
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swellings and reduced retrograde tracing, but most distinctly a severe reduction in endosomal 
staining in the cell body. Despite these changes, we found no evidence of motor neuron degeneration 
up to two years of age. Instead BICD2-N attenuated the disease phenotype of transgenic mice that 
express an ALS-linked SOD1 mutation and develop an ALS-like disease.
reSuLTS
biCD2-n binds and recruits dynein/dynactin
Previous studies showed that the N-terminus of BICD2 (BICD2-N) binds to cytoplasmic dynein 
and dynactin (�oogenraad et al., 2001; �oogenraad et al., 2003), and inhibits dynein-dependent 
organelle distributions, similarly to overexpression of dynamitin/p50 (Burkhardt et al., 1997). To 
directly compare the two dynein/dynactin inhibitory constructs and determine their functional 
differences, we first made use of the dynein/dynactin induced organelle relocalization assay 
(Hoogenraad et al., 2003). We previously showed that tethering of BICD2-N to membrane 
organelles induces their transport by cytoplasmic dynein (Hoogenraad et al., 2003). When GFP-
BICD2-N and GFP-p50 were coupled to a mitochondrial localization signal (mito) and expressed 
at high levels in Hela-cells, both constructs disrupted Golgi morphology but show a very distinct 
cellular distribution (Fig. 1A, B). Hela cells transfected with GFP-p50-mito show a normal 
distribution of mitochondria and dynein/dynactin (Fig 1C, D). However, GFP-BICD2N-mito 
causes a dramatic relocalization of mitochondria to perinuclear clusters around the centrosome 
and a concentration of dynactin/dynein staining (Hoogenraad et al., 2003) (Figure 1D), indicating 
that, in contrast to GFP-p50-mito, GFP-BICD2N-mito is able to induce microtubule minus end-
directed dynein movement. 
 We next have examined the effects of GFP-p50 and GFP-BICD2-N expression in 
cultured hippocampal neurons. Similar to Hela cells, both GFP-BICD2-N and GFP-p50 cause 
Golgi fragmentation and endosome abnormalities (Fig. 2), reflecting disrupted dynein-dependent 
organelle distributions in hippocampal neurons. Interestingly, the endosome abnormalities 
observed in neurons were distinct from those in Hela cells. Rather than a redistribution of the 
endosomes to the cell periphery (Burkhardt et al., 1997; �oogenraad et al., 2001), recycling 
endosomes in hippocampal neurons visualized by staining early endosome antigen 1 (EEA1) 
(Mu et al., 1995), Rab4 binding protein GRASP-1 (Ye et al., 2000; Stinton et al., 2005) and 
Rab11-binding protein Rip11 (Wallace et al., 2002), showed reduced endosomal size, density 
and intensity (Fig. 2B-D, F and G). These data suggest that dynein/dynactin inhibition in neurons 
may cause a reduction rather than redistribution of endosomal compartments (see below). Most 
remarkably, GFP-BICD2-N and GFP-p50 had a distinct effect on the distribution of dynein/
dynactin in hippocampal neurons, in that GFP-BICD2-N caused an increase in dynein and dynactin 
staining in the cell body and proximal dendrites, whereas GFP-p50 showed a normal distribution 
of dynein/dynactin (Fig. 1E). These data together with previously published results, indicate that 
p50 and BICD2-N inhibit dynein/dynactin function via different mechanisms; overexpression 
of p50 disassembles the dynactin complex (Maier et al., 2008) and BICD2-N binds and recruits 
dynein/dynactin and accumulates the dynein motor complex in the neuronal cell body.
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Figure 2 BICD2-N induces Golgi fragmentation and endosome alterations in primary cultured 
neurons
A-D) Expression of GFP-p50 (A3-D3) and GFP-BICD2-N (A2-D2), but not GFP (A1-D1) in primary hippocampal 
neurons leads to fragmentation of the Golgi apparatus as seen with antibodies against cis-Golgi marker 
GM130 (A,E), a decreased number and size of Early Endosomal Autoantigen (EEA1)-postive vesicles (B,F) 
and a decreased intensity of Rab4-binding protein GRASP1 and Rab11-interacting protein Rip11 staining 
(C,D,G). Inset shows an enlargement of the soma. E) Percentage of neurons with dispersed Golgi apparatus, 
35 neurons per experiment were counted. F) Quantification of number and size of EEA1 and GRASP1-vesicles 
in GFP, GFP-BICD2-N and GFP-p50 transfected neurons relative to control neurons in the same image G) 
Quantification of Rip11 and GRASP1-immunoreactivity in GFP, GFP-BICD2-N and GFP-p50 transfected 
neurons relative to control neurons in the same image. *p<0.05, **p<0.01, ***p<0.001
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Somato-dendritic accumulation of dynein/dynactin in motor neurons of biCD2-n transgenic 
mice
To examine the effect of BICD2-N expression in motor neurons in vivo, we generated transgenic 
mice by cloning GFP-BICD2-N into the Thy1.2 expression cassette (Fig. 3A), that drives 
postnatal transgene expression in motor neurons and other populations of neurons throughout 
the brain (Caroni, 1997; Feng et al., 2000). Transgenic lines were screened on the basis of GFP 
signal and BICD2-N immunoreactivity in motor neurons as identified by ChAT-immunostaining. 
Three lines with different transgene expression levels in motor neurons were selected for further 
study, none of which showed transgene expression in all motor neurons. Line BN1 had low-
to-high GFP-BICD2-N expression in about 50% of the lumbar and cervical motor neurons, 
line BN3 had low-to-moderate expression in about 70% of the motor neurons and line BN4 
had low-to-very high expression in 30% of the motor neurons (Fig. 3B). All lines also showed 
transgene expression throughout the brain, predominantly in the deep lamina of the cortex and the 
Figure 3. Generation of Thy1.2-BICD2-N transgenic mice
A) The Thy1.2-GFP-BICD2-N construct was generated by cloning amino acid 1-637 of BICD2 coupled to GFP 
into the Thy1.2 vector as described under methods. B) Confocal immunofluorescence of L4 lumbar spinal 
cord sections of BICD2-N transgenic mice line BN1, BN3 and BN4, with GFP-BICD2-N in green and motor 
neurons as labeled by ChAT in red showing the difference in number of transgenic neurons and expression 
levels between the three lines. C) GFP-immunoperoxidase staining of line BN1 shows transgene expression 
in different brain areas as the hippocampus and cortex, but not in cerebellum. D) Western blot analysis of 
spinal cord and sciatic nerve tissues of control, BN1 and BN3-mice shows differences in transgene expression 
between BN1 and BN3 mice (upper left panels), and an increase in DHC immunoreactivity in the spinal cord of 
BN-mice, but no change in other dynein or dynactin subunits (lower left panels). GFP-BICD2-N is not detected 
in sciatic nerve (right panels). 
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hippocampus (Fig. 3C). Most analyses were performed with multiple lines, but unless otherwise 
stated data presented in the figures are from line BN1. 
 Since BICD2-N altered the distribution of dynein/dynactin components in Hela cells and 
cultured neurons, we have first examined whether the Thy1.2-GFP-BICD2-N mice showed an 
altered distribution of dynein/dynactin. Western blotting showed increased expression of dynein 
in the spinal cord of BN1 and BN3 mice as compared to non-transgenic mice, whereas other 
dynein/dynactin components were unaltered (Fig. 3D). Confocal immunofluorescence showed 
a large increase of p150glued and DYNC1H1 immunoreactivity in BICD2-N expressing motor 
neurons (Fig. 4A, B and D). GFP-negative neurons in Thy1.2-GFP-BICD2-N mice showed the 
same levels of p150glued and DYNC1H1 immunoreactivity as motor neurons of non-transgenic 
mice, indicating that increased labelling resulted specifically from the presence of BICD2-N. 
Increased labelling was specific for dynein-dynactin components, as no increased labelling was 
observed for any other marker examined, including the kinesins Kif5A (Fig. 4C and D) and Kif5C 
(not shown), neurofilament proteins (NF-M, Fig. 7C; SMI32, not shown), neuron-specific class 
III beta-tubulin (TuJ1, not shown), MAP2 (not shown), ChAT (Fig. 3B), and the small heat shock 
protein Hsp25 (not shown).
 Further analysis indicated that GFP-BICD2-N was diffusely expressed over the somato-
dendritic compartment of motor neurons, but was absent in motor axons in the ventral roots, as 
well as in all axons in the sciatic nerve. Also axons of other populations of neurons expressing 
GFP-BICD2-N like layer V cortical neurons were devoid of GFP-BICD2-N. Remarkably, a 
subset of neurons that expressed GFP-BICD2-N at relatively high levels, were surrounded by 
spherical structures with a diameter of 0.5-2 µm in diameter that displayed very high levels 
of GFP signal (Fig. 4). These spheres were also intensely immunoreactive for p150glued and 
DYNC1H1, but not for any other investigated markers, like for instance, Kif5A (Fig. 4C). Confocal 
immunofluorescent analysis with an antibody against the muscarinic M2-receptor which outlines 
the cell membrane of motor neurons, indicated that in most instances these spheres were attached 
to the motor neuron via thin processes (Supplemental Fig. 1A). This was confirmed by electron 
microscopic analysis of serial sections (Supplemental Fig. 1B and C). Electron microscopy also 
showed that these spine-like structures were filled with electron dense material, and in the case of 
motor neurons did not contain synaptic specialisations like post-synaptic densities, and were not 
contacted by presynaptic boutons.
 
high doses of biCD2-n cause giant proximal neurofilament swellings in motor axons 
Impaired dynein/dynactin function in cultured neurons causes axonal neurofilament abnormalities, 
consisting of distal or proximal neurofilament accumulation depending on the level of inhibition 
(Motil et al., 2007). Therefore, in BN-mice we studied the distribution of neurofilament proteins as 
well as peripherin, an intermediate filament protein that is expressed at high levels in motor axons. 
Analysis of sections of the gastrocnemic muscle showed no major changes in neurofilament-M and 
peripherin immunoreactivity in motor nerve endings at the neuromuscular junctions. However, 
analysis of spinal cord sections revealed intense peripherin and neurofilament-M immunoreactive 
structures in the most ventral aspect of the grey matter, where the motor axons enter the white 
matter to course to the ventral roots (Fig. 5A, B). In some instances these structures also were 
BICD2-N MICE
87
identified in motor axons crossing the white matter, as well as in the proximal aspect of the ventral 
roots. The structures also were intensely labelled with antibodies against against the SMI31 and 
SMI32 epitopes representing phosphorylated and non-phosphorylated neurofilament, respectively 
(Sternberger and Sternberger, 1983). Further analysis by electron microscopy showed that these 
structures consisted of swollen myelinated axons with a diameter reaching up to 20 µm that were 
filled with filamentous material (Fig. 5D), and strongly resembled proximal giant filamentous 
axonal swellings reported in ALS patients (Carpenter, 1968; �irano et al., 1984; Corbo and �ays, 
1992). Comparison of spinal cord sections from different transgenic lines showed that the giant 
axonal neurofilament swellings occurred in BN1 and BN4 lines, but not in mice from the BN3 
line. As BN3 mice express the GFP-BICD2-N transgene at lower levels than BN1 and BN4 
mice, the absence of neurofilament swellings in these mice can be explained by insufficient GFP-
BICD2-N expression, suggesting that BICD2-N has to be expressed above a certain threshold in 
order to induce the proximal filamentous axonal swellings. Comparison of BN1 of different ages 
(4, 20 and 104 weeks) showed that axonal swellings did not occur at 4 weeks, and that similar 
amounts of swellings were present at 20 and 104 weeks (Fig 5E). This indicates that the axonal 
swellings are a relatively early phenomenon that does not progress with further aging.
biCD2-n motor neurons show signs of reduced of retrograde axonal transport 
To examine whether motor neurons expressing BICD2-N show reduced retrograde axonal 
transport we performed tracing experiments with the retrograde tracer fluoro-gold (LaMonte et 
al., 2002). In our experiments we have taken advantage of the chimeric expression of the GFP-
BICD2-N transgene in the motor neurons in our transgenic lines, in particular the BN1 line which 
expresses the transgene in about 60% of the motor neurons the remaining motor neurons serving 
as controls. Fluoro-gold was injected in the gastrocnemic muscle of BN1 mice and 48 hours 
post-injection lumbar L4-L5 sections were examined for fluorogold and GFP signals. As shown 
in Fig. 6, the amount of fluoro-gold labelling negatively correlated with the level of GFP-signal, 
indicating that the presence of GFP-BICD2-N diminishes retrograde fluoro-gold transport in a 
dose-dependent manner. 
 Axonal injury activates a number of retrograde signalling pathways to reorganize 
gene expression and initiate repair programs in the injured neuron (Hanz and Fainzilber, 2006). 
To examine whether BICD2-N expression has an effect on retrograde injury signalling, we 
have studied ATF3 expression after sciatic nerve transection in BN1 mice and non-transgenic 
littermates, as ATF-3 is one of the transcription factors that is strongly induced in axotomized 
motor neurons (Tsujino et al., 2000). No nuclear ATF3 labelling is present in lumbar spinal cord 
sections of non-axotomized BN1 and control mice. Twelve hours post-axotomy of the left sciatic 
nerve, weak nuclear ATF3-staining was observed in ipsi-lateral sciatic nerve motor neurons, 
which are localized in the dorso-lateral aspect of the L4-L5 spinal cord (Fig. 7B, C), and more 
intense labelling occurred at later time points. BN1 mice at 12 hours post-axotomy showed a 
reduced number of ATF3-positive motor neurons as compared to controls, but this difference was 
not statistically significant, and no difference was observed at 24 hours post-axotomy. �owever, 
densitometric analysis of ATF3 expression levels in axotomized BN1 mouse spinal cord showed 
that at 12 hours post-axotomy, high level BICD2-N expressing motor neurons showed reduced 
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ATF3 expression as compared to BICD2-N-negative motor neurons (Fig. 7D, E). No differences 
in ATF3 labelling intensities were observed between BICD2-N-positive and negative sciatic 
nerve motor neurons at 24 hours post-axotomy (Fig. 7D, E). These data indicate that at high levels 
BICD2-N attenuates retrograde injury signalling. 
biCD2-n causes Golgi fragmentation and endosome abnormalities
To examine the extent of dynein/dynactin dysfunction in the somato-dendritic domain of BICD2-
N motor neurons, we have studied the distribution of multiple organelle markers in spinal cord 
sections. Using an antibody against the cis-Golgi matrix protein GM130 (Nakamura et al., 1995) 
we found motor neurons with fragmented Golgi apparatus in BN1 and BN4, but not BN3 mice. 
Fragmentation was characterized by the transformation of the Golgi apparatus from a network 
of linear profiles into dispersed smaller elements (Figs 8D). Double labelling with antibodies 
against CGRP, a peptide that is present in the trans-Golgi and secretory granules of most large 
motor neurons (Caldero et al., 1992), indicated that the fragmented Golgi consisted of mini-stacks 
containing both trans- and cis-Golgi elements (Fig. 8D). Golgi fragmentation was selectively 
Figure 4. BICD2-N causes somato-
dendritic accumulation of dynein/dynactin 
in motor neurons  in vivo
A-C) Double labeling confocal 
immunofluorescence images of L4 lumbar 
spinal cord sections of control (A1), BN1 
(A2,A4,B,C) or BN3 (A3) mice showing GFP 
in green and p150 (A), DHC (B) and Kif5A(C) 
in red demonstrates an increase in p150 and 
DHC but not in Kif5A immunoreactivity in 
transgenic motor neurons.D) Quantification 
of p150, DHC and KIF5A immunoreactivity 
in motor neurons of control and GFP-BICD2-
N line 1 shows increase in p150 and DHC 
but not Kif5A intensitty dependent upon 
transgene expression level. The following 
number of neurons were measured (non-tg/
tg); p150: 28/50; DHC: 24/40, KIF5A: 10/12. 
Fluorescent intensity of GFP in different 
groups of neurons; Non-tg: a.u.(arbitrary-
units)<25; low:25<a.u.<100, medium:100<a.
u.<175, high:a.u.>175. *** p<0.001. Scale 
bars: A1=100mm, A4=25mm
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present in the highest GFP-BICD2-N expressing motor neurons. Analysis of Golgi fragmentation 
in BN1 mice of different ages indicated that the frequency of motor neurons with fragmented 
Golgi increased with aging (Fig. 10A). Golgi fragmentation was never observed in GFP-BICD2-
N-negative motor neurons in BN1 mice, nor in motor neurons of non-transgenic mice of any 
age. 
 Endosomal changes were studied using antibodies against EEA1 (Mu et al., 1995), 
GRASP-1 and Rip11 (see above). All antibodies yielded reduced labelling in moderate-to-high 
GFP-BICD2-N expressing motor neurons of BN1 mouse cervical and lumbar spinal cord sections 
(Figs 9 and 10B) and the same results were obtained in BN4 mice (not shown). In non-transgenic 
Figure 5. Motor neurons of BICD2-N mice develop giant proximal axonal neurofilament swellings
A-C) BN1-mice (B,C2-4) but not non-transgenic mice (A,C1) develop large axonal swellings as shown by 
immunoperoxidase staining of peripherin in L4 spinal cord sections (A,B) and confocal immunofluorescence 
of NF-M (arrows in C). A2 and B2 shows enlargement of boxed regions in A1 and B1. Somatal NF-M staining 
is not different in control and transgenic (asterix) neurons (C3). NF-accumulations are already present in 
young BN1 mice (C2,C3) and do not increase in size and number in older mice (C4, E). D) Standard electron 
microscopic-image of swelling (asterisk) in BN1 mice.E) Quantification of the total area of NF swellings per 
section in young (20w) and old (100w) BN1 mice indicates that NF accumulation is not a time-dependent 
process.
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Figure 6. BICD2-N causes reduced retrograde fluorogold labelling
A) Fluoro-gold retrograde tracer was injected in the gastrocnemic muscle of 30 weeks-old BN1 mice, 48 
hours later animals were sacrificed and labelling in the spinal cord was monitored B) Confocal fluorescence 
images of L4 lumbar spinal cord sections, transgenic motor neurons (B1) show no or reduced labelling (B2) as 
compared to non-transgenic motor neurons, (B3) merged image. Scale bar=25mm  C) Scatter plot (C1) and 
bar graph (C2) of FG signal as a function of GFP signal. FG intensity negatively correlates with the amount 
of transgene expression, in B2 only transgenic neurons with an FG-signal >30 were analyzed. Fluorescent 
intensities of GFP labelling in different groups of neurons; Non-tg: a.u.<25; Low: 25<a.u.<100, Medium: 100<a.
u.<175, High: a.u.>175. *p<0.01.
motor neurons EEA1-immunoreactivity was localized in a relatively homogeneous population of 
recycling endosomes that were diffusely distributed over the cell body of the motor neurons (Fig. 
9A, B and E). In GFP-BICD2-N expressing motor neurons both the mean endosomal size and 
densities were reduced, the amount of reduction being proportional to GFP-BICD2-N expression 
levels. GRASP-1-immunoreactive endosomes were more heterogeneous in size and distribution 
as compared to EAA1-immunoreactive organelles and in most instances GRASP-1 and EAA1-
immunoreactivities showed poor colocalisation (Fig. 9J). The variability in GRASP-1 particle 
size in part resulted from a population of relatively large particles that were localised in close 
proximity of the Golgi as identified with GM130 antibody (Fig. 9G). A distinct feature of the 
majority of BICD2-N motor neurons in BN1 mice was the disappearance of this population of 
relatively large GRASP-1 particles, independent of the status of the Golgi apparatus (Figs. 9H, 
10C and D). Invariably, all motor neurons showing Golgi fragmentation showed large reductions 
of EAA1, GRASP-1, and Rip11 immunoreactivities (Fig. 10B). Endosomal abnormalities also 
were examined with an antibody against Vti1b, a Q-SNARE protein that localises predominantly 
to endosomes and the trans-Golgi area and is involved in fusion events between endosomal 
compartments (Antonin et al., 2000). Vti1b-immunoreactivity was predominantly localized in 
proximity of the trans-Golgi as identified with anti-CGRP-antibody (Fig. 8E-G). Consistent with 
the other endosome abnormalities reduced Vti1b-immunoreactivity occurred in BICD2-N motor 
neurons (Figs 8F, G and 10B).
 Inhibition of dynein/dynactin also causes a redistribution of lysosomes in non-neuronal 
cells (Burkhardt et al., 1997). However, no consistent changes in the distribution of lysosomes, 
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as identified with an anti-LAMP1 antibody, were observed in BICD2-N motor neurons 
(Supplemental Fig. 2A). Furthermore, no consistent changes in the densities of mitochondrial 
(SOD2) and endoplasmic reticulum (ER, calreticulin) signals were observed in BICD2-N 
neurons were observed (supplemental Fig. 2B, C). In addition, we have examined the distribution 
of autofluorescent inclusions in motor neurons. Autofluorescent inclusions represent lipofuscin 
bodies, which contain cellular debris and represent a prominent feature of aging motor neurons 
(Szweda et al., 2003). No consistent changes in autofluorescence was observed in BICD2-N 
motor neurons with the exception of a few very high expressing BICD2-N neurons identified 
in aged mice from the BN4 line that showed reduced autofluorescence as compared to controls 
(not shown). Together the data indicate that BICD2-N in motor neurons predominantly affect 
endosomal compartments. 
Figure 7. Reduced retrograde injury signalling in GFP-BICD2-N mice after axotomy of the sciatic 
nerve.
A) The sciatic nerves of 20-weeks old BN1 and non-tg mice were cut with scissors, 24 or 48 hours later animals 
were sacrificed and L4 spinal cord sections were analysed. B) Immunoperoxidase staining of ATF-3 12 and 24 
hours post-axotomy shows induced ATF-3 expressing 24 hours after axotomy in both BN1 and non-tg mice. 
Middle panels show enlargement of motor neurons from non-tg mice. C) Number of ATF-3 positive motor 
neurons in non-tg and BN1 mice 12 and 24 hours after axotomy reveals a small decrease in BN1-mice 12 
hours post-axotomy. D) Confocal fluorescence images of L4 spinal cord section of BN1 mouse 12 hours post-
axotomy shows a higher expression of ATF-3 in one non-transgenic motor neuron compared to a GFP-positive 
motor neuron. E) Measurements of ATF-3 immunoreactivity in BN1 mice shows a dose-dependent decrease 
in ATF-3 expression 12 hours post-axotomy, and slightly reduced staining 24 hours post-axotomy in transgenic 
motor neurons as compared to control neurons in the same image. Fluorescent intensity of GFP labelling 
in different groups of neurons; Non-tg: a.u.<25; low: 25<a.u.<100, medium: 100<a.u.<175, high: a.u.>175. 
**p<0.01 by one-way ANOVA. 
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Fig. 8. High levels of BICD2-N cause Golgi fragmentation in motor neurons.
A-D) Triple labelling immunofluorescence of GFP, cis-golgi marker GM130 and golgi-resident peptide CGRP 
in lumbar spinal cord section of BN1 mouse shows dose-dependent disruption of the Golgi apparatus in 
transgenic motor neurons (D2,3, not in C2,C3) (B4,C4), also when the Golgi is dispersed (D4). 
E-G) Triple labelling immunofluorescence of GFP, late endosomal protein Vti1b and CGRP shows a dose-
dependent reduction of Vti1b-particles by BICD2-N expression, and a close spatial association between Vti1b 
and CGRP (E4-G4). Scale bars: A1=25mm, B1=10mm, B4=2mm
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Fig. 9 BICD2-N causes abnormalities in multiple endosomal compartments
A-E) Double (A-D) and triple (E) labelling confocal immunofluorescence of EEA1 (A,B,E) and Rip11 (C,D) of 
lumbar spinal cord sections of non-tg (A) and BN1 mouse (B-E). Transgenic motor neurons show a reduced 
staining for EEA1 (B2, E2) and Rip11 (C2, D2) as compared to control motor neurons, but no reduction in 
autofluorescence (E3). EEA1-labelling is specific as it does not colocalize with autofluorescence (E4,E5). F-H) 
Triple labelling confocal immunofluorescence of GFP, GRASP1 and GM130 shows a dose-dependent decrease 
in GRASP1 vesicles in transgenic motor neurons (note the difference in red staining between H2 and I2) as 
compared to control motor neurons (G2). This decrease occurs at lower GFP-expression levels than Golgi-
fragmentation (compare blue staining in G2 and H2). J) Triple labelling confocal immunofluorescence of GFP, 
EEA1 and GRASP1 shows that GRASP1- and EEA1-vesicles represent different endosomal compartments, 
that both disappear in transgenic motor neurons. Scale bars: A1=75mm, C1=25mm, D1=5mm, E1=10mm, 
F1=25mm, J1=20mm, G1=2mm. 
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Fig. 10 Age and dose-dependent Golgi and endosomal alterations in BICD2-N mice
Measurements of cellular abnormalities as shown in figure 8 and 9. 
A) The percentage of transgenic motor neurons with a dispersed Golgi apparatus increases in old BICD2-N 
mice.B) A dose-dependent decrease in staining for endosomal markers EEA1, GRASP1, Rip11 and Vti1b 
in transgenic motor neurons as compared to control motor neurons in the same section. C,D) The relative 
diameter (C) and absolute number (D) of EEA1 and GRASP1 immunoreactive particles decreases with higher 
BICD2-N expression.The following number of neurons were measured (non-tg/tg); EEA1: 17/35, GRASP1: 
37/30, Rip11: 15/27, Vti1b: 9/17. Fluorescent intensity of GFP labelling in different groups of neurons; Non-tg: 
a.u.<25; Low: 25<a.u.<100, Medium: 100<a.u.<175, High: a.u.>175. *p<0.05, **p<0.01, ***p<0.001
biCD2-n expression increases survival of SoD1-G93A ALS mice
To determine whether BICD2-N influenced viability of motor neurons, BN1 mice were tested for 
the development of motor abnormalities up to the age of 2 years, and subsequently analyzed for 
degenerative changes in the neuromuscular system. BN1 mice did not show evidence of reduced 
muscle strength, as determined by a hanging wire test (Supplemental Fig. 3C) and grip strength 
measurement (not shown). Furthermore, BN1 mice did not display weight loss (Supplemental 
Fig. 3D). Analysis of the number of motor neurons showed that 2 years old BN1 mice showed 
the same number of L4 spinal cord motor neurons as 2 years old non-transgenic mice and 20 
weeks old BN1 mice (Supplemental Fig. 3F). In addition, the number of BICD2-N motor neurons 
was the same in 20 weeks and 2 years old BN1 mice (Supplemental Fig. 3F). Consistent with 
the absence of neurodegenerative changes, 2 years old mice did not show evidence of increased 
astrocytosis and microgliosis as compared to non-transgenic controls (Supplemental Fig. 3A, 
B). Furthermore, analysis of neuromuscular junctions of the gastrocnemic muscle revealed that 
2 years old BN1 mice did not show increased levels of denervated neuromuscular junctions as 
compared to controls (Supplemental Fig. 3G). In sum, BN1 mice up to the age of two years do 
not show signs of premature motor neuron loss.
 To further examine whether inhibition of dynein/dynactin function by BICD2-N is 
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Figure 11. BICD2-N increases survival of 
SOD1-ALS mice in a dose-dependent way.
A,B) Survival plots of BN1 (A) and BN3 (B) /SOD1-
G93A double transgenic mice demonstrates that 
BICD2-N expression lengthens the life span of 
SOD1-G93A mice. (C) Age of death in BN(3)/
SOD1-G93A mice age of death is slightly later 
than in SOD1-G93A mice, and significantly later 
in the higher expressing BN(1)/SOD1-G93A 
mice. **p<0.01
deleterious to motor neurons and could contribute to motor neuron degeneration in ALS we 
crossed our BICD2-N transgenic mice with G1del mice, a transgenic ALS mouse model that 
express SOD1 with the G93A-ALS mutation and develop a fatal progressive motor neuron disease 
from 24-32 weeks of age (Gurney et al., 1994; Vlug et al., 2005). Unexpectedly double transgenic 
BN1/G1del mice showed a delayed onset of motor symptoms as compared to G1del mice (225 
± 8  versus 189 ± 6 day; Mean ± SE), and increased survival (271 ± 8  versus 237 ± 5 day; Mean 
± SE; P < 0.01, Tukey’s multiple comparison test, see Fig. 11A and C). To examine whether 
the beneficial effect was caused by BICD2-N expression in a second experiment we crossed 
G1del mice with BN3 mice that express BICD2-N at lower levels albeit in a higher percentage 
of motor neurons (see Fig. 3C). Also BN3/G1del mice showed increased survival as compared 
the respective G1del group (256 ± 8  versus 236 ± 5 day; Mean ± SE; non-significant Tukey’s 
multiple comparison test; p < 0.05, Logrank test, Fig. 11B). Together these data indicate that the 
BICD2-N has a beneficial effect on survival of G1del mice and this effect grossly correlates with 
BICD2-N expression levels. 
DiSCuSSion
Neurons are polarized cells with a complex morphology characterized by a dendritic tree that 
consists of a network of processes with a length up to 100 fold the diameter of the cell body, 
and an axon that can have length of up to 104 times the diameter of the cell body. Therefore, the 
maintenance of the functional and structural integrity of neurons throughout life is a complex 
task that requires sophisticated transport machineries. Long distance transport in neurons is 
predominantly mediated by microtubule-dependent motors, and the importance of this trafficking 
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Figure S1. BICD2-N 
induces the formation of 
spine-like protrusions in 
neurons
A) Double labelling confocal 
i m m u n o f l u o r e s c e n c e 
of GFP (green) and 
muscarinic M2 receptor 
(red) of lumbar motor 
neuron of BN1 mouse. 
A2 shows enlargement of 
protrusion in A1 with an 
invagination of the neuronal 
plasma membrane (arrow) 
that surrounds the GFP-
containing protrusion. 
B,C) Standard immunogold 
electron microscopy of 
protrusions shows higher 
magnification of such an 
invagination (arrow in B1 
and C1), the contents of 
the protrusion maintaining 
direct contact with the 
neuronal cytoplasm. 
B2 and C2 are higher 
magnifications of B1 and 
C1. 
Figure S2. BICD2-N-
expression does not 
induce changes in 
lysosomes, mitochondria 
and endoplasmic reticulum 
in motor neurons
A-C) Double labelling 
immunofluorescence of 
GFP and lysosomal protein 
LAMP1 (A), mitochondrial 
protein SOD2 (B) and ER-
protein calreticulin (C) in 
lumbar spinal cord sections 
of BN1 mouse show similar 
staining in transgenic 
(A3,B3,C3) and control (A4, 
B4,C4) motor neurons. 
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Figure S3. BICD2-N mice do not show evidence of motor neurons loss up to two years of age.
A) No reactive astrocytes and increased Hsp25-staining in lumbar spinal cord in BN1 mouse (A2,A4) as 
compared to non-tg mouse (A1,A3) as seen by triple labeling confocal immunofluorescence of GFP, GFAP 
(red) and Hsp25 (blue). B) Immuperoxidase-staining of CR3 reveals no reactive microglia in non-tg (B1) 
and BN1 (B2) mice. C) Performance in hanging wire test is not different in BN1 mice compared to non-tg 
mice up to two years of age.D) Average weight of male BN1 mice and male non-tg mice is not different 
E) Diameter of motor neurons (black bars) and motor neuron nuclei (grey bars) is the same in non-tg and 
BN1 mice  F) No loss of general motor neurons (ChAT, black bars) and transgenic motor neurons (GFP, 
grey bars) in young and old BN1 mice as compared to non-tg mice G) A slight (non-siginificant) increase 
in partially innervated and denervated neuromuscular junctions (NMJs) in 100 weeks-old BN1 mice as 
compared to control mice.
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for the proper functioning of neurons is demonstrated by the occurrence of mutations in 
microtubule-dependent motor proteins in diverse neuronal disorders (Vale, 2003; �irokawa and 
Takemura, 2005; Chevalier-Larsen and �olzbaur, 2006). Furthermore, microtubule-dependent 
trafficking abnormalities have been linked to multiple late onset neurodegenerative diseases like 
Alzheimer’s and �untington’s diseases (Guzik and Goldstein, 2004; �irokawa and Takemura, 
2005; Caviston and �olzbaur, 2006). Genetic studies have provided a strong link between 
mutations in components of the dynein/dynactin microtubule minus-end directed motor complex 
and motor neuron diseases, including ALS, but the mechanisms underlying this selective 
vulnerability remain to be established (�afezparast et al., 2003; Levy et al., 2006; Pfister et al., 
2006; Lai et al., 2007). 
 In the present study we have generated a novel mouse model with impaired dynein/
dynactin function taking advantage of the properties of the N-terminus of BICD2, that binds 
efficiently to dynein and dynactin (�oogenraad et al., 2001; �oogenraad et al., 2003). Our data 
indicate that BICD2-N recruits dynein and dynactin and accumulates the dynein motor complex 
in the neuronal cellbody. In this way, BICD2-N acts in a dominant negative by reducing the 
available pool of dynein/dynactin in the axon and reducing retrograde axonal transport. This 
mode of action is different from dynein/dynactin inhibition caused by overexpression of p50 
which causes the disruption of the dynactin complex (Schroer, 2004; Melkonian et al., 2007). 
We show that when expressed in neurons in culture or in vivo BICD2-N causes the accumulation 
of dynein/dynactin components in the somato-dendritic compartment, putatively by (partially) 
impeding dynein and dynactin components of entering the axon. Accordingly, the BICD2-N mice 
show signs of reduced retrograde transport and develop giant neurofilament swellings in the 
proximal axon, a feature that is consistent with reduced dynein/dynactin function (Julien and 
Kriz, 2006; Levy et al., 2006; Motil et al., 2007). 
 Despite the accumulation of dynein/dynactin components in the perykaryon and proximal 
dendrites, motor neurons expressing BICD2-N also develop abnormalities in this compartment, 
i.e. Golgi fragmentation, and endosomal abnormalities. Fragmentation and dispersion of the Golgi 
apparatus is a well established consequence of dynein/dynactin inhibition (Burkhardt et al., 1997; 
�arada et al., 1998; Allan et al., 2002; King, 2003; Bonifacino and Rojas, 2006), but here we 
show for the first time that it can be achieved in neurons in vivo. Our data indicate that only motor 
neurons expressing relatively high levels of BICD2-N showed Golgi fragmentation, and that 
the frequency of neurons with fragmented Golgi increased with aging. This suggests that Golgi 
fragmentation is an all or none phenomenon that requires a certain threshold of dynein/dynactin 
inhibition to occur. Embryonic fibroblasts from homozygous Loa/Loa mice do not develop Golgi 
fragmentation, but show impaired Golgi restoration after Golgi fragmentation induced by the 
microtubule depolymerizing agent nocodazole (Hafezparast et al., 2003). The same mechanism 
that impairs restoration of the Golgi in Loa/Loa cells may contribute to Golgi fragmentation in 
our BICD2-N mice. Endosome abnormalities in BICD2-N-mice require lower doses of BICD2-
N to occur and show a more dose-dependent behaviour. Our data also show that the effect of 
dynein/dynactin inhibition may be different for different endosomal compartments and that 
endosomal changes in neurons are strikingly different from those observed in cultured cells with 
radially oriented microtubules. The differences between neurons and other cells may follow from 
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differences in microtubule organisation as well as differences in endosomal functional pathways 
(Soldati and Schliwa, 2006; Schmidt and �aucke, 2007). The multiple abnormalities in distinct 
endosomal compartments is consistent with the many functions of dynein/dynactin in endosomal 
trafficking (Soldati and Schliwa, 2006).  In the present study we also show that a subset of BICD2-
N motor neurons develops spine-like protrusions that contain very high levels of BICD2-N as 
well as dynein/dynactin components. Since the population of motor neurons developing these 
spine-like structures grossly corresponded to the population with endosomal abnormalities, it is 
possible that mechanisms that cause these spine-like structures overlap with processes causing 
the endosome abnormalities.   
 The aim of this study was to generate a mouse model to study aspects of ALS and related 
motor neurons diseases. Accordingly, our mice develop well established features of ALS motor 
neurons, i.e. giant proximal neurofilamentous axonal swellings and Golgi fragmentation (Delisle 
and Carpenter, 1984; �irano et al., 1984; Gonatas et al., 2006). Furthermore, a lower number and 
reduced size of EAA1-positive endosomal vesicles as observed in our mice strongly resembles the 
phenotype of cellular models of a familial form of ALS caused by homozygous loss of function of 
alsin, a 184-kDa protein with guanine-nucleotide-exchange factor (GEF) domains that has been 
implicated in endosomal trafficking (Chandran et al., 2007). �owever, unlike other mouse models 
with dynein/dynactin abnormalities (LaMonte et al., 2002; �afezparast et al., 2003; Lai et al., 
2007), our mice up to the age of 2 years do not develop signs of premature motor neuron death. 
These data indicate that axonal neurofilament abnormalities, Golgi fragmentation and endosome 
abnormalities are ALS phenomena that can be explained by impaired dynein/dynactin function, 
but that these abnormalities are not necessarily linked to neuronal degeneration. The motor neuron 
degeneration phenotype in other mouse models may be explained by gained toxic activities of 
mutated dynein and dynactin subunits (�afezparast et al., 2003; Lai et al., 2007) or by more 
efficient dynein/dynactin inhibition of p50 (LaMonte et al., 2002). Alternatively, the disruption 
of dynactin by p50 overexpression may uncover specific toxic activities of dynactin subunits. A 
surprising finding of our study was that the BICD2-N transgene increased survival in transgenic 
mice that carry an ALS-linked SOD1 mutation and develop an ALS-like motor neuron disease. 
These findings are consistent with previous data showing that also SOD1-ALS mice carrying the 
Loa (Kieran et al., 2005; Chen et al., 2007) or the Cra1-mutations in DYNC1�1 (Teuchert et al., 
2006) show prolonged survival. In contrast, the disease phenotype of SOD1-ALS mice that were 
heterozygous for G59S-mutant p150glued or Swl-mutant DYNC1H1 was unaltered (Chen et al., 
2007; Lai et al., 2007). Together the data indicate that motor neurons are vulnerable to specific 
abnormalities in dynein/dynactin function, and that different abnormalities in dynein/dynactin 
function may contribute to motor neuron degeneration via distinct mechanisms.
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mATeriALS AnD meThoDS
GfP-biCD2-n and GfP-p50 expression constructs
GFP-BICD2-N constructs have been described before (Hoogenraad et al., 2001), GFP-p50 was a gift 
from Dr. T. Schroer. GFP-mito was a gift from B. Distel (Voorn-Brouwer et al., 2001). For expression in 
hippocampal neurons, GFP-BICD2 and GFP-p50 were subcloned into pGW1 expression vectors. 
heLa cell transfection and immunocytochemistry
HeLa cells were cultured in DMEM/HAM’s F10 (50/50%) medium containing 10% FCS and 1% penicillin/
streptomycin. One day prior to transfection, cells were plated at 1:25 in Lab-tek chamber slides (Nunc). 
Cells were transfected with SuperFect transfection reagent (Qiagen) according to the manufacturers protocol 
and grown for 16 hours. Two hours before fixation, cells were serum-stimulated with fresh medium. Cells 
were fixed in 4% paraformaldehyde for 10 minutes at room temperature followed by 5 minutes in 0.1% 
Triton-X-100 in PBS. Slides were blocked in 0.5% BSA/0.02% glycine in PBS and labeled with primary 
antibody as described by (Hoogenraad et al., 2000).
Primary neuron cultures and transfection
Primary rat hippocampal neurons were plated at a density of 75.000 on 15 mm glass coverslips and transfected 
at DIV13 with GFP, GFP-BICD2-N or GFP-p50 using Lipofectamine-2000 (Qiagen) as previously described 
(�oogenraad et al., 2005). After 2 days of transfection, neurons were fixed and stained with the antibodies 
indicated. Representative cells were imaged using a confocal microscope. The appearance of the Golgi 
apparatus was investigated; p150, EEA1, GRASP1 and Rip11 fluoresence intensity and vesicle sizes in were 
measured with Metamorph software and differences between control and transfected neurons were analyzed 
using the Student’s t-test. Representative cells were imaged using a confocal microscope.
biCD2-n and SoD1-G93A transgenic mice
Animals were housed and handled in accordance with the “Principles of laboratory animal care” (NIH 
publication No. 86-23) and the guidelines approved by the Erasmus University animal care committee 
(DEC; protocol No. 115-97-01 and 115-99-03).  GFP-BICD2-N cDNA as described before was subcloned 
into the XhoI site of the pThy1.2 expression vector (Caroni, 1997), which was a gift from Dr P.Caroni. The 
EcoRI-PvuI fragment containing the expression cassette was isolated from gel and purified using Elutip 
ion exchange column (Schleicher & Shuell, Keene, N�). The DNA was resuspended in injection buffer at 
a concentration of 0,5µg/µl and injected into fertilized FVB mouse eggs. Offspring was genotyped by PCR 
from isolated tail-DNA using 5’ primer ET18 (CCAGGCACTCACTGAGAAGATC) and 3’ primer ET15 
(CATGGAGGGAGAAGTGGCG). Four positive mice were crossed with wild-type FVB-mice to screen 
for germ-line integration, three mice (line1, 3 and 4) were identified as founder mice and used for further 
breeding and experiments.
G93A-SOD1 mice descendent from the Gurney G1del-line that carry 8 transgene copy numbers per haploid 
genome were purchased from Jackson Laboratories (Bar Harbor, ME),  The mice develop weakness in one 
or more limbs from age 24-30 weeks, and reach end stage disease 2–10 weeks after onset of limb weakness 
(Jaarsma et al., 2001). 
Female or male heterozygous SOD1-G93A and BICD2-N (line BN1 and BN3) mice were bred together to 
obtain BN1 or BN3/SOD1-G93A double transgenic animals. Hemizygous SOD1-G93A, BN1/3 as well as 
non-transgenic littermates were used as controls. 
From 10 weeks of age, all mice were inspected weekly by examining the hind-limb extension, by testing 
the ability to hang upside-down on a wire (hanging-wire test, described in (Jaarsma et al., 2001)) and by 
measuring the body weight. Onset of paresis was determined by the hanging-wire test, end-stage disease was 
characterized when animals were unable to right themselves or when they developed eye-infection.
western blotting
Spinal cords or sciatic nerves of different types of mice were homogenized in respectively 10 or 20 volumes 
of PBS containing 0.5% Nonidet P-40 and 1× protease inhibitor cocktail (Complete, Roche), sonicated and 
centrifuged at 0,9 rcf for 15 min to obtain the S1-fraction. Protein concentrations were determined using 
the BCA method (Pierce, Rockford, IL). For SDS-PAGE electrophoresis and Western-blotting, samples 
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containing 2–10 µg protein were mixed with Leamli sample buffer, separated on different percentages of 
SDS-page gels and blotted on PVDF membranes (Millipore). The membranes were blocked with 5% non-fat 
dry milk (Bio-Rad) in PBS with 0.05% Tween20 (PBST), incubated in primary antibody, diluted in PBST 
with 1% dry milk followed by an incubation in secondary antibody, incubated in chemiluminescence reagent 
(ECL, Amersham), exposed to film or a Kodak Image station, and analysed with Kodak Image analysis and 
ImageQuant 2.2 software.
Antibodies
Primary antibodies {supplier; applications��� (ICC)=immunocytochemistry, (I�C)= immunohistochemistry; 
(IF)=immunofluorescence; (WB)= Western blotting; dilutions} used in this study are��� mouse-anti GM130 
(BD Biosciences, ICC 1:1000, IF 1:1000), mouse-anti-p150 (BD Biosciences, WB 1:1000, ICC, 1:1000 
IF,1:500), human-anti EEA1 (gift from Dr. M.J. Fritzler, IF: 1:500), mouse-anti EEA1 (BD Biosciences, 
ICC 1:500), rabbit-anti-GRASP-1 (Chemicon, ICC, 1:200, IF, 1:500), rabbit-anti Rip11 (a gift from dr. 
R.Prekeris, ICC 1:100, IF 1:500), goat-anti-choline acetyltransferase (ChAT, Chemicon, IF, 1:500), rabbit-
anti-BICD2 ((Hoogenraad et al., 2001), WB 1:1000), rabbit-anti-GFP (Abcam, IHC, 1:10000, WB 1:1000), 
rabbit-anti-DHC (Santa Cruz, IF, 1:500, WB: 1:1000), rabbit-anti dynactin (Santa Cruz, WB: 1:1000), 
mouse-anti DIC74 (Chemicon, WB: 1:1000), mouse-anti-p50 (BD Biosciences, WB, 1:1000), mouse-
anti Arp1 (Sigma, WB: 1:2000), mouse-anti actin (Chemicon, WB, 1:10000), rabbit-anti SOD1(101) 
(Stressgen, WB��� 1���1000), rabbit-anti-Kif5a (Abcam, IF, 1���2000), rabbit anti-ATF3 (Santa Cruz; I�C and 
IF 1:1000), rabbit-anti-peripherin (Chemicon, IHC, 1:1000), chicken-anti NF-M (Chemicon, IF, 1:10000), 
mouse-anti NF-M (sigma, IF, 1:10000), rabbit-anti-CGRP (Calbiochem, IF, 1:10.000), mouse-anti Vti1b 
(Transduction laboratories, IF 1:200), rat-anti muscarinic M2-receptor (Chemicon, IF 1:200), sheep-anti 
SOD2 (Calbiochem, IF 1���1���5000), mouse-anti LAMP1 (DS�B, IF��� 1���10), rabbit anti-calreticulin (Affinity 
BioReagents, IF 1���5000), rabbit anti �sp25 (Stessgen, IF 1���2000), rabbit anti-GFAP (DAKO; IF 1���5000), rat 
anti-CR3 receptor (clone 5C6; Serotec, I�C 1���500).
Secondary antibodies used for IF or ICC were Alexa-488, -568 or -633- conjugated goat-anti mouse or goat-
anti rabbit antibodies from Molecular Probes; or Fitc, Cy3 or Cy5 anti- rabbit, mouse or goat antibodies 
from Jackson Laboratories; all antibodies were used 1���400. For I�C, 
Biotinylated goat-anti-rabbit or anti-mouse IgG (Vector) were used at 1:400. For WB and FT, HRP-
conjugated goat-anti-mouse or anti-rabbit IgG were used at 1:5000. 
immunocytochemical and histochemical analyses
For immunocytochemistry and immunofluorescence mice were anaesthetized with pentobarbital and perfused 
transcardially with 4% paraformaldehyde with or without glutaraldehyde (0.1 or 0.5%). The lumbar and 
cervical spinal cord were carefully dissected out and postfixed overnight in 4% paraformaldehyde. Routinely, 
spinal cord tissue was embedded in gelatin blocks (Jaarsma et al., 2000), sectioned at 40 µm with a freezing 
microtome, and sections were processed, free-fLoating, using a standard avidin–biotin–immunoperoxidase 
complex method (ABC, Vector Laboratories, USA) with diaminobenzidine (0.05%) as the chromogen, or 
single-, double- and triple-labelling immunofluorescence (Vlug et al., 2005). Immunoperoxidase-stained 
sections were analysed and photographed using a Leica DM-RB microscope and a Leica DC300 digital 
camera. Sections stained for immunofluorescence were analyzed with a Zeiss LSM 510 confocal laser 
scanning microscope. 
Densitometric analysis of immunofluorescence images.
Sections were mounted on coverslips, and placed on glass slides with Vectashield. mounting medium. Images 
were taken using a Zeiss LSM 510 confocal laser scanning microscope with 63x Plan apo oil immersion 
objective. 
Optical densities were determined using Metamorph image analysis software. Statistical analyzes were 
performed with MS Excel or  Graphpad Prism software..
fluoro-gold retrograde tracing
30 weeks old BN1 mice were used to determine retrograde tracing using the neurotracer Fluoro-gold 
(FluoroChrome, Denver, CO) as described in (LaMonte et al., 2002). Briefly, mice were anaesthesized, 
immobilized and a 2% solution of Fluoro-gold in 0.9% saline was injected into the gastrocnemic muscle. After 
48 hours, mice were anaesthetized with pentobarbital and perfused transcardially with 4% paraformaldehyde, 
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sectioned, mounted and analyzed with a Zeiss LSM 510 confocal laser scanning microscope with 40x Plan-
apo oil immersion objective. Fluorogold signal was detected using 405 nm laser and a META detector.
Axotomy
20 weeks old BN1 and non-transgenic animals were anaesthetized, the sciatic nerve was exposed, bound with 
suture and cut just above the division of the sciatic nerve into the tibial and common peroneal nerves. A 2 
mm-piece of the nerve was removed. Animals were left to recover for 12 or 24 hours. Following transection, 
animals were perfused transcardially with 4% paraformaldehyde and processed for immunohistochemistry 
as described before with antibodies against ATF-3.
electron microscopy
For electron microscopy mice were perfused transcardially with 4% paraformaldehyde with 0,5% 
glutaraldehyde, specimens were sectioned with a Vibratome and further processed using standard methods 
as described before (chapter 2). For standard electron microscopy Vibratome section (150 Mm thick) were 
postfixed in 1% osmium, dehydrated and embedded in Durcupan. Ultrathin (50–70 nm) were contrasted 
with uranyl acetate and lead citrate, and analyzed in a Phillips CM100 electron microscope at 80 kV. 
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Abstract
The vesicle-associated membrane protein (VAMP)-associated proteins (VAP), 
VAPA and VAPB interact with lipid binding proteins carrying a short motif 
containing two phenylalanines in an acidic tract (FFAT motif) and targets them 
to the cytosolic surface of the endoplasmic reticulum (ER). A genetic mutation 
(P56S) in the conserved major-sperm protein homology (MSP) domain of VAPB 
has been linked to motor neuron degeneration in affected ALS patients. We 
report that in the central nervous system VAPB is abundant in motor neurons 
and that the P56S substitution causes aggregation of mutant VAPB in immobile 
tubular ER clusters, perturb FFAT-motif binding and traps endogenous VAP in 
mutant aggregates. Expression of mutant VAPB or reduction of VAP by shRNA 
in primary neurons causes Golgi dispersion and cell death. VAPA and VAPB are 
reduced in human amyotrophic lateral sclerosis (ALS) patients and SOD1-ALS 
transgenic mice, suggesting that VAP family proteins may be involved in the 
pathogenesis of sporadic and SOD1-linked ALS. Our data support a model in 
which reduced levels of VAP family proteins result in decreased ER anchoring of 
lipid binding proteins and cause motor neuron degeneration.
running title: Mutant VAPB causes motor neuron disease
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inTroDuCTion
Many late-onset neurodegenerative diseases are characterized by aggregate-prone proteins (Taylor 
et al., 2002). The failure of a protein to adopt its proper structure usually confers to its dominant 
toxic properties and threatens normal cell function and viability (Taylor et al., 2002; Ross and 
Poirier, 2005). In both sporadic and familial ALS patients protein inclusions in motor neurons 
are a constant and pathognomic feature. ALS-linked mutations in SOD1, the most common and 
best characterized form of familial ALS, lead to misfolding and aggregate formation resulting in 
dominant toxic functions of mutant SOD1 (Boillee et al., 2006). Recently, a missense mutation 
(P56S) in the gene encoding vesicle associated membrane protein (VAMP)-binding protein B 
(VAPB) has been identified in a familial form of ALS (ALS8, (Nishimura et al., 2004)). Expression 
of VAPB-P56S in cultured cells results in the formation of cytosolic aggregates (Nishimura et al., 
2004), however the cellular mechanism leading to VAPB-linked motor neuron degeneration is 
not known.
 The VAP family of proteins was originally identified in Aplysia californica as a binding 
partner of VAMP/Synaptobrevin (Skehel et al., 1995); it consists of two genes in mammals, VAPA 
(VAP-33) and VAPB (ALS8, VAPC) (Nishimura et al., 1999). VAPs are ubiquitously expressed 
type II integral membrane proteins which localize to the ER and pre-Golgi intermediates (Skehel 
et al., 2000) and have been proposed to regulate transport between the ER and the Golgi (Soussan 
et al., 1999; Amarilio et al., 2005). Moreover, VAPs have been shown to target lipid-binding 
proteins carrying the FFAT motif to the ER (Kaiser et al., 2005; Loewen and Levine, 2005). 
In yeast, the VAP-homologue Scs2 binds the FFAT motif and in absence of Scs2 the FFAT-
containing proteins mislocalize to the cytoplasm (Loewen et al., 2003). The FFAT motif consists 
of the consensus amino acid sequence EFFDAxE; it was identified because of its conservation 
in several lipid binding protein families implicated in the transfer of lipids between the ER and 
other organelles, such as the Golgi, endosomes and plasma membrane (Olkkonen, 2004; �olthuis 
and Levine, 2005; Levine and Loewen, 2006). Since the lipid binding properties and supposed 
physiological roles of FFAT-motif containing proteins are very diverse, VAPs are likely involved 
in multiple metabolic pathways (Lev, 2004; Olkkonen, 2004; Kawano et al., 2006; Levine and 
Loewen, 2006; Perry and Ridgway, 2006). 
 To gain insight into the events leading from VAP alterations to motor neuron disease, 
we investigated the distribution of VAPB in the central nervous system (CNS) and focused on 
the biochemical and cellular effects of the ALS linked P56S mutation in VAPB. Our data suggest 
that VAPB-P56S causes motor neuron degeneration via a dominant negative mechanism whereby 
mutant aggregates trap endogenous wild type VAP, reduce cytosolic VAP levels and impair lipid 
binding protein function. Since VAP expression is also reduced in the spinal cord of human 
ALS patients and SOD1-ALS transgenic mice, we propose that VAP may be an important factor 
involved in the pathogenesis in sporadic and SOD1-linked ALS. The data support a model in 
which reduced levels of VAP family proteins cause neuron degeneration.
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Figure 1. Distribution and localization of VAPB in vivo 
A) Antisera against VAPA and VAPB were made against GST-VAP fusion proteins containing amino acid 
1-225 of VAPB (Ab#1006-00) and amino acid 132-225 of VAPA (#1006-04) and VAPB (#1006-02). MSP: 
major sperm protein homology domain, cc: coiled-coil region, TM: transmembrane domain. B-C) Cells were 
fixed and processed for immunofluorescence using antibodies to VAP (green) and PDI (red). D-F) Lysates of 
COS-1 cells expressing VAP and control proteins (D), cultured cells (E) and mouse CNS (F) were analyzed 
by immunoblotting using VAP antibodies. G-I) Low- (G1, H1, I1) and high-magnification (G2, H2, H3, I2) 
of immunoperoxidase stainings using anti-VAPB antibody #1006-00 in murine dorsal hippocampus (G), 
cerebellum (H), and spinal cord (I). VAPB is expressed at high levels in motor neurons (I2) and large neurons 
in the cerebellar nuclei (H1, H3) as compared to neurons in cerebellar cortex (H1) including cerebellar Purkinje 
cells (H2) and hippocampus (G), including hippocampal pyramidal cells (G2). CN, cerebellar nuclei, DG; 
dentate gyrus, pyr; pyramidal layer, rad; stratum radiatum of  CA1 hippocampal subfield, gl; granule cell layer, 
ml; molecular layer, wm; white matter, PC; Purkinje cell. J-K) Double labeling confocal immunofluorescence of 
VAPB immunoreactivity (green) and ribosomal protein P0 (red) in mouse spinal motor neurons (J) and dorsal 
horn neurons (K). VAPB (J1, K1) colocalizes with P0 (J2, K3) in motor neurons, but show low expression 
levels in most dorsal horn neurons. Merge is shown at right. (L) Immunoperoxidase staining using anti-VAPB 
antibody #1006-00 in human lumbar motor neurons (L1), ventral root motor axons (L2), and CA1 hippocampal 
pyramidal neurons (L3). As in mouse, in man VAPB-immunoreactivity in motor neurons is considerably higher 
than in other neurons, showing a Nissl body-like distribution (L1). Bar: 200 µm (G1, I1); 100 µm (H1); 10 µm 
(G2, H2, H3, I2); 20 µm (J3, K3); 30 µm (L1, L2, L3)
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reSuLTS
VAPA and VAPb localize to the er and are widely distributed
Human VAPA and VAPB show 60% amino acid similarity and are composed of three domains, 
including a highly conserved cytosolic N-terminal MSP domain, a central coiled-coil region and a 
C-terminal transmembrane domain (TMD) (Nishimura et al., 1999) (Figure 1A). We have raised 
antibodies against the variable central domain of VAPA (#1006-04) and VAPB (#1006-02) and 
the whole cytosolic domain of VAPB (#1006-00) (Figure 1A) and tested them using lysates of 
Figure 2: The P56S mutation leads to aberrant aggregation of VAPA and VAPB
A-D) HeLa cells expressing HA-tagged VAPB-wt (A), VAPB-P56S (B, D) and VAPA-P56S (C) were fixed and 
processed for immunofluoresence using antibodies against HA (green) and the ER marker calreticulin (red). 
HeLa cells in (D) were incubated for 2 hours at 20°C prior to fixation. Enlargement of boxed regions indicated 
in the merged pictures is shown at right. E) Lysates (L) of COS-1 cells transfected with HA-VAPB-wt and 
HA-VAPB-P56S were solubilized with Triton-X100, fractionated in supernatant (S) and pellet (P) under non-
reducing (-DTT) or reducing (+DTT) conditions and analyzed by immunoblotting using anti-HA antibodies. 
Cells were either maintained at 37°C or incubated for 2 hours at 20°C before lysis.F) Quantification of the 
number of VAPB-P56S clusters per cell, incubated at 15°C or 20°C for 3 hours or treated with 5µg/µl Brefeldin 
A (BFA) or 10µM Nocodazole (Noco) for 30 minutes, as indicated. Error bars indicate SEM. **<0.005%.
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COS-1 cells expressing HA-tagged VAPA or VAPB. The VAPA antibody strongly reacted with 
wild type VAPA (VAPA-wt) and P56S mutant VAPA (VAPA-P56S) but did not recognize VAPB or 
control proteins, SOD1 and BICD2-N (Figure 1D). Alternatively, both VAPB antibodies showed 
a very strong reaction with wild type VAPB (VAPB-wt) and P56S mutant VAPB (VAPB-P56S) 
but did not detect VAPA or other control proteins (Figure 1D). In mock transfected COS-1 cells, 
both VAPB antibodies detected a major band of ~33 kDa (Figure 1D), which likely represents 
the endogenous VAPB. We conclude that the new VAP antibodies specifically recognize either 
VAPA or VAPB.
 VAPs have been reported to localize to the ER in cultured cells (Soussan et al., 1999; 
Skehel et al., 2000; Amarilio et al., 2005). Accordingly, immunofluorescence microscopy revealed 
that in HeLa cells, VAPA and VAPB antibodies produce a typical reticulate staining pattern, which 
partially coincides with protein disulfide isomerase (PDI), an ER resident protein (Figure 1B,C). 
Western blot analysis showed that VAPB was present in all cell lines examined, and VAPA was 
present in all but COS-1, COS-7 and MDCK cells (Figure 1D,E). Accordingly, analysis of mouse 
tissues including kidney, heart, skeletal muscle, liver, spleen, lung, and different brain areas, 
showed that VAPA and VAPB are expressed in all tissues and throughout the CNS (Figure 1F 
and data not shown). These results are consistent with previous Northern blot analyses showing a 
broad tissue distribution of VAPA and VAPB (Nishimura et al., 1999; Skehel et al., 2000). These 
data indicate that both VAPA and VAPB localize to the ER and are widely expressed in neuronal 
and non-neuronal tissues and cell lines.
VAPb is highly abundant in motor neurons in mouse and human spinal cord
Next, we investigated the distribution of VAPB in the mouse and human CNS. We used the 
two new VAPB antibodies, which produced very similar staining patterns. In all brain areas 
VAPB immunoreactivity was predominantly localized to neuronal cell bodies and their 
proximal dendrites, whereas little or no labeling was found in glial cells. The highest levels of 
immunoreactivity emerged in motor neurons in spinal cord and caudal brain stem (Figure 1I). 
Neurons in the cerebellar nuclei (Figure 1H) and large neurons throughout the reticular formation 
(data not shown) also stained strongly for VAPB, while lower staining intensities occurred in 
cortical and hippocampal neurons (Figure 1G) or cerebellar Purkinje cells (Figure 1H). Within 
the white matter staining was predominantly associated with axonal profiles and light VAPB 
staining also was observed in motor axons in the ventral roots. The distribution of VAPB in 
sections from human hippocampus, cerebellar cortex and spinal cord was consistent with that in 
mouse CNS, in that high levels of labeling occurred in motor neurons (Figure 1L1), whereas low 
to moderate staining occurred in hippocampal (Figure 1L2) and cerebellar neurons. 
 The subcellular distribution of VAPB in human and murine motor neurons strongly 
resembled the distribution of Nissl substance (Figure 1L), i.e. orderly arrays of broad cysternae 
of ER and polyribosomes (Peters, 1991). Accordingly double labeling showed that VAPB 
immunoreactivity grossly colocalized with ribosomal protein P0 in murine and human motor 
neurons (Figure 1J,K), but poorly colocalized with the cis-Golgi marker GM130 (data not 
shown). Since VAP proteins originally were identified as VAMP-associated proteins we also have 
examined whether VAPB co-distributed with presynaptic proteins in the neuromuscular endplates 
and central synapses, however we did not observe any synaptic VAPB labeling in these structures 
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(data not shown). In sum, the data indicate that VAPB is highly expressed in motor neurons in 
mice and human with a dominant localization in the rough ER.
The P56S mutation leads to aberrant aggregation of VAPb
To characterize the properties of VAPB carrying the ALS-linked P56S mutation we established 
a cellular VAP aggregation model in cultured cells. In Hela cells, HA-VAPB-wt predominately 
localized to the ER similar to endogenous VAPB (Figure 2A) and P56S mutant HA-VAPB protein 
formed cytosolic aggregates, which did not colocalize with ER markers, such as calreticulin and 
PDI (Figure 2B) (Nishimura et al., 2004). Aggregate formation was seen in all transfected cells 
independently of expression levels.  18 hours after transfection, 26 ± 4 VAPB-P56S aggregates 
with an average diameter of 1.2 µm2 (range 0.8-2.5 µm) could be found per HeLa cell. Other cell 
types were also susceptible to HA-VAPB-P56S aggregate formation: although the average cluster 
size and number could vary significantly, the P56S-mutated VAPB protein formed cytosolic 
aggregates in all cell types examined (data not shown). These data indicate that the P56S mutation 
leads to abnormal clustering of VAPB independently of cellular context. 
 Since VAPB-P56S clusters do not coincide with the ER, we tested whether they 
colocalize with other organelle or vesicular trafficking markers. Expression of �A-VAPB-
P56S in HeLa cells had no detectable effect on the cis or trans Golgi morphology, endosomes 
and lysosomes as determined by localization of their respective markers, GM130, γ-adaptin, 
EEA1 and LAMP1 (Supplementary Fig 1). Block of vesicular trafficking by 15°C incubation, 
Figure 3. Electron 
microscopy analysis of 
VAPB-P56S aggregates 
in HeLa cells
A-C) Transmission 
electron photomicrographs 
of anti-HA immunogold 
labeled ultra-thin sections 
of HeLa cells transfected 
with HA-VAPB-P56S. 
Immunogold labeling is 
specifically associated 
with clusters of electron 
dense tubular profiles 
(A). Occasionally, labeled 
profiles are continuous 
with unlabeled profiles 
reminiscent of ER tubules 
(B) or with mitochondrial 
outer membranes (C). 
Arrows indicate unlabelled 
ER-tubules; asterisks 
indicate normal appearing 
cytoplasm in VAPB-P56S 
aggregates; 
m: mitochondria, nu: 
nucleus, lys: lysosome, 
RER: rough ER. 
Bars: 200 nm (A1, B1, C1); 
100 nm (A2, B2, C2)
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Brefeldin A (BFA) or nocodazole treatment had no significant influence on the number and size 
of VAPB-P56S aggregates (Figure 2F and Supplementary Fig 1). Next, we investigated transport 
through the secretory pathway by using the temperature sensitive mutant of vesicular stomatitis 
virus-glycoprotein (ts045-VSVG) fused to YFP (VSVG-YFP) in cells containing VAPB-P56S 
aggregates. Using temperature shifts we found that VAPB-P56S aggregates did not substantially 
interfere with the VSVG-YFP transport and never colocalized with VSVG-YFP at any of its 
trafficking steps (data not shown). Together these data indicate that VAPB-P56S aggregates 
constitute no part of the secretory or other vesicular trafficking routes in �eLa cells.   
 The proline at position 56 in VAPB is highly conserved among the VAP family proteins 
from various species (Nishimura et al., 1999). To investigate whether the P56S mutation in VAPA 
(VAPA-P56S) forms cytosolic aggregates as well, we expressed HA-VAPA-P56S in HeLa cells. 
Figure 4. VAPB-P56S 
clusters are immobile porous 
aggregates 
A) Diagram of GFP-tagged 
VAPB constructs. B) Fluorescent 
recovery plots compare the 
rates of recovery of GFP-VAPB-
wt (black triangle), GFP-VAPB-
P56S (black box), as well as a 
non-bleached control region 
(open circles). Fluorescence 
intensity was normalized to 
intensity before bleaching.  C-E) 
Representative confocal images 
of HeLa cells expressing GFP-VAPB-wt and GFP-VAPB-P56S. To visualize the  obility of the GFP-chimeras 
small regions of interest of identical size (outlined square in C) were photobleached and monitored for recovery 
for 300 seconds (D). Half the area of a VAPB-P56S aggregate was bleached in E. F) Projection of confocal 
images of HeLa cell expressing HA-VAPB-P56S and GFP, fixed and stained with anti-HA (red) antibody. 
Enlargement of the boxed region containing a single confocal stack (0.6 µm) is shown at the bottom.
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Transfected cells showed on average 9 ± 2 VAPA-P56S clusters, which did not coincide with 
ER markers and were similar in appearance to VAPB-P56S aggregates (Figure 2C). However in 
contrast to �A-VAPB-P56S expressing cells, significant proportion of �A-VAPA-P56S localized 
to the ER in addition to aggregates (Figure 2C). In all cell lines examined, the average cluster 
size was significantly larger and the number of clusters was smaller in VAPA-P56S compared to 
VAPB-P56S expressing cells (data not shown). 
Figure 5. VAPB-P56S recruits both wild type VAPA and VAPB 
A-B) HeLa cells transfected with HA-VAPB-P56S (A) or HA-VAPA-P56S (B) and stained with anti-HA (green) 
and anti-VAPA (red) (A) or anti-VAPB (red) (B) antibodies. C-D) HeLa cells double transfected with HA-VAPB-
P56S and myc-VAPB-wt (C) or myc-VAPA-wt (D), fixed and stained with anti-HA (green) and anti-Myc antibodies 
(red), to visualize the expressing VAP protein. E) Lysates (L) of COS-1 cells transfected with HA-VAPB-wt and 
HA-VAPB-P56S were solubilized with Triton-X100, fractionated in supernatant (S) and pellet (P) and analyzed 
by immunoblotting using anti-VAPB (#1006-03) antibodies. F) COS-1 cells cotransfected with HA-VAPB-P56S 
and myc-VAPA-wt or myc-VAPB-wt were immunoprecipitated with control IgG or HA antibodies. The cells were 
incubated for 2 hours at 20°C before lysis to solubilize VAPB-P56S. Each IP reaction is shown in three lanes: I: 
input to IP reaction; S: supernatant remaining after IP; P: precipitated pellet. The lysate (L), I, S, and P samples 
were immunoblotted for the indicated proteins. G) COS-1 cells cotransfected with HA-VAPB-P56S and GFP-
VAPB-wt-N or GFP-VAPB-TMD were immunoprecipitated and immunoblotted as in F. H-K) HeLa cells single or 
double transfected with GFP-VAPB-TMD (H,J) or GFP-VAPB-wt-N (I,K) and HA-VAPB-P56S (J,K) and stained 
with anti-calreticulin, to reveal the ER (H,I) or anti-HA (J,K) antibodies, to visualize the expressing VAP protein. 
L-N) HeLa cells single or double transfected with GFP-VAPB-P56S-N and HA-VAPB-wt (M) or HA-VAPB-P56S 
(N) and stained with anti-calreticulin (L) or anti-HA (M,N) antibodies.
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 To gain better understanding of the biochemical properties of the wild type and mutant 
VAPB proteins we tested their solubility in non-ionic detergents. Wild type VAPB was present in 
both the Triton-X100 soluble and insoluble fractions, whereas VAPB-P56S was only present in 
the detergent insoluble fraction (Figure 2E). Similar results were obtained when the samples were 
run under non-reducing conditions (-DTT) (Figure 2E).  Incubation of cells at 20°C has been 
shown to reverse aggregation of proteins like mutant cystic fibrosis transmembrane conductance 
regulator (CFTR) (Denning et al., 1992) and prion protein (Singh et al., 1997). We tested whether 
a similar effect could be observed for the mutant VAPB and found that the average number of 
VAPB-P56S aggregates decreased by ~50% in HeLa cells incubated at 20°C compared to control 
cells at 37°C (Figure 2F and Supplementary Fig 1); moreover, at 20°C some of the VAPB-P56S 
localized to the ER (Figure 2D). In line with these data, Western blots showed that VAPB-P56S 
partly shifted towards the soluble fraction if the transfected COS-1 cells were maintained for 2 
hours at 20°C (Figure 2E). This effect was not observed at other temperatures, such as 15 and 
30°C (Figure 2E and data not shown). We conclude that at 20°C VAPB mutant proteins partially 
solubilize and distribute within the ER similar to the wild type VAPB. 
P56S mutant VAPb forms protein aggregates containing er tubules
To further characterize the structure of the HA-VAPB-P56S aggregates we used anti-HA 
post-embedding immunogold electron microscopy. No anti-HA labeling was observed in non-
transfected HeLa cells. In HA-VAPB-P56S transfected HeLa cells immunogold labeling was 
specifically associated with clusters of electron dense tubular profiles with diameters of 20-40 nm 
that formed irregular branched networks (Figure 3A). Their morphology strongly resembled the 
anastomozing networks of smooth ER observed in cells specialized in steroid synthesis (Fawcett, 
1981). However, the borders of the tubules showed a more diffuse and electron dense appearance, 
strongly suggestive of the presence of high protein levels (Figure 3A). Notably, the tubular profiles 
usually were loosely packed and were intermingled with cytoplasm (asterisks in Figure 3A). 
 In agreement with immunofluorescence analysis of the VAPB-P56S aggregates, the size 
of the tubule clusters was variable. Interestingly, in cells expressing large numbers of clusters, the 
�A-VAPB-P56S positive tubules were often continuous with the normal-appearing ER profiles 
(Figure 3B) or the outer membranes of mitochondria (Figure 3C). In the latter case, parts of the 
mitochondrial outer membranes showed both a diffuse electron dense appearance and immunogold 
labeling, indicating that they contained VAPB aggregates. Immunogold labeling did not occur in 
the rough ER and mitochondrial outer membranes with normal morphology, nor could it be found 
in the Golgi apparatus, lysosomes, aggrosomes and other intracellular structures. We conclude 
that VAPB-P56S aggregates include tubular membrane structures, which most likely originate 
from the ER. Their appearance was clearly distinct from organized smooth ER (OSER) (Snapp et 
al., 2003) induced by the co-expression of VAPs and FFAT-motif proteins (Amarilio et al., 2005; 
Lehto et al., 2005).
 
P56S mutant VAPb forms immobile aggregates
To characterize the dynamics of wild type and mutant VAPB proteins we have generated their GFP-
tagged versions. Since fusion of GFP to either N- or C-terminus of VAPB leads to an abnormal 
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cellular localization and aberrant mobility in SDS-PAGE electrophoresis (data not shown), 
we inserted the GFP tag between the TM-domain and the cytosolic tail of the VAPB protein 
(Figure 4A). These internally GFP-tagged wild type and P56S mutant VAPB behaved similarly to 
untagged-VAPB constructs (Figure 4C and data not shown). We monitored the behavior of GFP-
VAPB-wt and GFP-VAPB-P56S in HeLa cells 24 hours after transfection. While GFP-VAPB-wt 
was very dynamic within the cell, as described for other ER transmembrane proteins (Lippincott-
Schwartz et al., 2001), the overall location of VAP-P56S aggregates did not change significantly 
during a 300 second period (Movies 1 and 2). 
 Next, we used fluorescence recovery after photobleaching (FRAP) to examine the 
motility of VAP molecules. A 4 by 4 µm region of the cell was bleached by high laser power 
and the fluorescence intensity was measured over a period of 300 seconds. Notably, fluorescence 
recovered very rapidly into the bleached area of GFP-VAPB-wt expressing cells (Figure 4B,D; 
Movie 1), consistent with the high motility of ER-resident proteins (Lippincott-Schwartz et al., 
2001). In GFP-VAPB-P56S transfected cells, only 35% of the fluorescent signal associated with 
the aggregates recovered within 300 seconds after photobleaching, indicating that the mutant 
proteins are largely immobilized (Figure 4B,D; Movie 2). Comparable results were obtained 
upon photobleaching half of an area of a typical VAPB-P56S aggregate (Figure 4E, Movie 3). 
The lack of fluorescent recovery for VAPB-P56S aggregates is very similar to that observed for 
other mutant proteins that form immobile aggregates (Chai et al., 2002; Kim et al., 2002) but 
differs from proteins inducing organized ER architectures (Snapp et al., 2003).
 Since EM analysis revealed that VAPB-P56S aggregates are intermingled with normal-
appearing cytosol, we examined whether non-interacting soluble proteins, such as GFP can diffuse 
through mutant VAPB aggregates. GFP displayed a uniform pattern of localization both within 
and outside VAPB-P56S clusters (Figure 4F) in accord with a porous architecture but unlike solid 
mutant huntingtin aggregates (Matsumoto et al., 2005). 
VAPb-P56S aggregates do not overlap with chaperone, proteasome, autophagy and er 
stress markers
Protein aggregate formation is often influenced by molecular chaperones (Sherman and Goldberg, 
2001) and protein degradation routes such as the ubiquitin-proteasome system, aggresome and 
autophagosome pathways (Kopito, 2000; Rubinsztein, 2006). To investigate the role of these 
pathways in the cellular response to VAPB-P56S aggregates, we assessed the distribution of their 
markers, such as Hsp70, ubiquitin, vimentin, Atg8/LC3 and Atg12 in HeLa cells transfected with 
HA-VAPB-P56S. In contrast to the aggregates induced by mutant Htt fragments (GFP-Htt(Q74)) 
(Waelter et al., 2001), used as a positive control in our experiments, VAPB-P56S aggregates 
did not colocalize with any of the above mentioned markers (Supplementary Fig 2 and data 
not shown). Consistent with these data, the treatment of HA-VAPB-P56S expressing cells with 
proteasome inhibitor MG132 for 4 or 24 hours did not significantly influence aggregate formation 
or change the number of VAPB-P56S clusters (Supplementary Fig 2 and data not shown). 
However when we tested the solubility of VAPB-P56S in cells treated with 10 µM MG132 for 
24 hours, the VAPB-P56S levels increased in the soluble fraction while the insoluble fraction 
CHAPTER 5
116
was unaffected (Supplementary Fig 2), suggesting that solely non-aggregated VAPB-P56S is 
significantly degraded by the proteasome.
 Several studies demonstrated that increased expression of chaperones, such Hsp70 
and �sp104, suppresses aggregate formation (Muchowski et al., 2000; Vacher et al., 2005). We 
cotransfected �eLa cells with �A-VAPB-P56S and �sp70 or �sp104; in contrast to mutant �tt 
expressing cells, we found no colocalization of the chaperones with VAPB-P56S and no significant 
Figure 6. VAPB-P56S disturbs 
binding to FFAT-motif containing 
proteins
A-C) HeLa cells double transfected 
with GFP-FFAT plus HA-VAPB 
constructs and stained with anti-
HA (red) antibodies to visualize 
the expressing VAP protein. 
D-F) HeLa cells double 
transfected with ORP3-GFP 
plus HA-VAPB constructs and 
stained with as in A-C. G) COS-
1 cells cotransfected with GFP-
FFAT and VAPB constructs were 
immunoprecipitated with GFP 
antibodies. Each IP reaction is 
shown in three lanes: I: input 
to IP reaction; S: supernatant 
remaining after IP; P: precipitated 
pellet. The I, S, and P samples 
were immunoblotted for the 
indicated proteins. H) COS-
1 cells cotransfected with 
GFP-FFAT and HA-VAPB-
wt were immunoprecipitated 
and immunoblotted as in G. I) 
Coomassie stained gel of purified 
GST-VAPB proteins (top panel). 
The GST-fusion proteins were 
loaded with Hela-cell extracts 
transfected with GFP-FFAT and 
GFP-FFAT-SCR, precipitated 
and immunoblotted (bottom two 
panels). 20% of the input (I) is 
loaded on gel.  J) COS-1 cells 
cotransfected with ORP3-GFP 
and HA-VAPB constructs were 
immunoprecipitated with control 
IgG and GFP antibodies and 
immunoblotted as in G.
H
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Figure 7. VAPB-P56S expression and VAP reduction causes cell death and Golgi fragmentation in 
primary neurons A-B) Primary neurons expressing wild-type and mutant HA-tagged VAPA and VAPB were 
fixed and stained with HA-antibodies (green) and anti-PDI antibodies (red in B). Enlargement of the boxed 
region containing a single confocal stack (0.8 um) is shown at right. C) Primary neurons transfected with wild 
type (C1) and mutant (C2) HA-tagged VAPB and shRNA against VAPA and VAPB (C3) at DIV13 for two (C1,2) 
and six (C3) days and stained with anti-HA (green, C1,2) or anti-ß-galactosidase (green, C3) and anti-PDI 
antibodies (red, inset). D) Representative images of primary neurons expressing wild-type (D1) and mutant 
(D2) HA-tagged VAPB and shRNA against VAPA and VAPB (D3), fixed and stained with HA-antibodies (green, 
D1,2) or ß-galactosidase (D3) and the cis-Golgi marker GM130 (red, inset).E) Quantification of neuronal 
survival by counting the number of wild type VAPB, mutant VAPB and ß-galactosidase expressing neurons 
per coverslip, 2 days (VAPB-WT and mutant) or 6 days (shRNA) after transfection from respectively 6 and 
4 independent experiments. F) Quantification of percentage of neurons with dispersed Golgi apparatus of 
control GFP, wild type or mutant VAPB and shRNA- expressing cells 2 days (VAPB-WT and mutant) or 3 days 
(shRNA) after transfection. *** p<0.0005, **p<0.001, *p<0.10. 
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difference in the size and number of VAPB-P56S clusters (data not shown). Furthermore, we 
observed no upregulation of the ER stress-response markers such as the chaperone Grp78/BiP 
and the phosphorylated form of the alpha-subunit of eukaryotic initiation factor 2 (eIF-2α) in 
VAPB-P56S expressing cells (Supplementary Fig 2). Taken together these data indicate that 
VAPB-P56S aggregates do not seem to recruit protein quality control and degradation machinery 
in contrast to many well characterized aggregation-prone proteins. 
VAPb-P56S recruits wild type VAPA and VAPb via the TmD
In vitro GST-pull down experiments suggested that VAPB-P56S associates with exogenous wild 
type VAPB (Kanekura et al., 2006). We investigated the effect of VAPB-P56S on endogenous 
VAPA and VAPB proteins in our cellular model and examined the specific VAP domains involved 
in the binding. In COS-1 cells transfected with the wild type HA-VAPB, endogenous VAPB 
is present in both the soluble and insoluble fraction as in non-transfected cells (Figure 5E and 
data not shown). Expression of HA-VAPB-P56S, however, reduced the amount of endogenous 
VAPB in the soluble fraction and increased the amount of insoluble endogenous VAPB (Figure 
5E), suggesting that VAPB-P56S traps endogenous VAPB in the aggregates. Indeed, HeLa cells 
expressing VAPB-P56S recruited a considerable amount of endogenous VAPA to mutant VAP 
aggregates, whereas VAPA-P56S clusters accumulated endogenous VAPB (Figure 5A, B). Co-
localization and co-immunoprecipitation experiments confirmed that both wild type VAPA and 
VAPB bind to VAPB-P56S (Figure 5C,D,F). Together these data indicate that mutant VAPB-
P56S is capable of recruiting both wild type VAPA and VAPB, providing a possible explanation 
for the dominant effect of the P56S mutation in VAPB-linked ALS patients.
 Structural studies have suggested that VAPs form dimers via the central coiled-coil 
domain in the cytosolic tail and the GxxxG-motif in the TMD (Russ and Engelman, 2000; Kaiser 
et al., 2005). In contrast to the C. elegans MSP protein itself (�aaf et al., 1996; Smith and Ward, 
1998), the N-terminal MSP homology domain in VAP is monomeric in solution and does not 
dimerize in vitro (Kaiser et al., 2005). To determine which part of wild type VAPB is responsible 
for the observed interaction with VAPB-P56S, we generated GFP-tagged constructs encoding the 
transmembrane portion of VAPB (VAPB-TMD) and the cytosolic part of VAPB (VAPB-wt-N) 
(Figure 4A). As expected, GFP-VAPB-TMD in HeLa cells showed ER localization (Figure 5H), 
whereas GFP-VAPB-wt-N revealed a diffuse cytosolic and nuclear distribution (Figure 5I). Co-
expression experiments demonstrated that VAPB-TMD was recruited to the mutant aggregates 
(Figure 5J,K) and co-precipitated with the full-length VAPB-P56S (Figure 5G), while VAPB-wt-
N showed no interaction with the mutant VAPB (Figure 5K,G), indicating that wild type VAPs 
bind to VAPB-P56S aggregates via the TMD. 
 Next, we examined the effect of the P56S mutation on the formation of the cytosolic 
aggregates. HeLa cells expressing GFP-VAPB-P56S-N form compact cytosolic aggregates 
(Figure 5L), which are larger but less abundant compared to the VAPB-P56S clusters (~4 ± 1 
clusters per cell with a diameter of ~3.2 µm). Co-expression of GFP-VAPB-P56S-N and HA-
VAPB-wt or HA-VAPB-P56S showed that, in contrast to VAPB-wt, VAPB-P56S strongly co-
clusters with mutant cytosolic aggregates (Figure 5M,N). Similar results were obtained using 
GFP-tagged constructs containing mutant and wild type MSP domains (data not shown). We 
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conclude that the P56S mutation dramatically enhances the binding between the cytosolic VAPB 
portions, providing a likely explanation for the observed VAP-P56S aggregation.
 
The P56S mutation in VAPb perturbs the binding to ffAT-motif containing proteins 
To examine whether P56S influences the interaction of VAPB with its binding partners we used 
pull-down assays combined with mass spectrometry. We generated biotinylation-tagged VAPB-
wt (Bio-HA-VAPB-wt) and P56S (Bio-HA-VAPB-P56S) constructs and co-expressed them with 
the protein-biotin-ligase BirA in HeLa cells (Lansbergen et al., 2006). Localization of biotinylated 
wild type and mutant VAPB-proteins was similar to that of wild type and mutant HA-VAPB 
(data not shown). Biotinylated proteins from cells expressing either BirA alone or in combination 
with wild type or mutant Bio-HA-VAPB were isolated using streptavidin-beads and analyzed 
on a Coomassie-stained gel, by Western blotting (data not shown) and by mass-spectrometry. 
After background correction using the BirA-only control data, the mass-spectrometry results 
from VAPB-wt expressing HeLa cells revealed several FFAT-motif containing proteins, i.e. Nir2, 
ORP3, ORP6 and ORP9 (Supplementary Table 1), whereas no FFAT-domain proteins were pulled 
down from Bio-HA-VAPB-P56S expressing cells, indicating that the P56S mutation inhibits the 
interaction with FFAT-motif containing proteins. Similar results were obtained using GST-pull 
down experiments (data not shown).
 To confirm this finding we generated GFP-FFAT reporter constructs containing either 
the FFAT motif of Nir2 (residues: EFFDAHE) or the permutated version of this sequence (GFP-
FFAT-SCR; residues��� EDNFA�E). Structural studies of VAPA have shown that two amino acids, 
K87 and M89 are critical for FFAT-binding (Kaiser et al., 2005). We made the double point 
mutation K87D/M89D in HA-tagged VAPB-construct (VAPB-K87D/M89D) and used it as a 
negative control. Co-expression of wild type VAPB and GFP-FFAT in HeLa cells showed their 
prominent colocalization in cluster-like structures in the ER (Figure 6A), reminiscent of organized 
smooth ER (OSER) (Snapp et al., 2003). In contrast, none of the mutated VAPB constructs 
induced ER-clustering or colocalization with GFP-FFAT (Figure 6B,C). Co-immunoprecipitation 
experiments confirmed that wild type VAPB and not VAPB-K87D/M89D or VAPB-P56S were 
pulled down by GFP-FFAT (Figure 6G,H). Consistently, GST-pull down experiments showed that 
wild type VAPB (full length and cytosolic domain) associated with GFP-FFAT, while the VAPB-
P56S mutant forms were unable to bind to GFP-FFAT (Figure 6I). The VAP-FFAT interaction 
was specific for the FFAT-domain, since GFP-FFAT-SCR did not interact with VAPB-wt or the 
mutated VAPB proteins (Figure 6H,I). 
 Mass spectrometry results were further confirmed by co-expression experiments using 
FFAT-motif containing protein ORP3. While the wild type VAPB and ORP3-GFP prominently 
colocalized in cluster-like structures in the ER (Figure 6D), none of the mutated VAPB constructs 
coincided with ORP3-GFP (Figure 6E,F). Co-immunoprecipitation experiments showed that only 
wild type VAPB and not its mutated versions were pulled down by GFP-ORP3 (Figure 6J). These 
experiments consistently demonstrate that the P56S mutant VAPB is unable to interact with FFAT 
motif-containing proteins. 
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Figure 8. Reduced VAPB expression in ALS 
patients and SOD1-ALS transgenic mice
A-C) Immunoperoxidase (A) and confocal 
immunofluorescence staining (B, C) of VAPB in 
cervical spinal cord of SOD1-G93A transgenic ALS 
mice prior to symptom onset (A2) and at end stage 
disease (A3). VAPB immunoreactivity (green, B2) 
is not present in ubiquitinated inclusions (red, B3) 
in motor neurons of symptomatic SOD1-G93A mice 
(B). Motor neurons displaying Golgi fragmentation 
visualized by anti-GM130 antibody (red, C2) show 
reduced VAPB expression (green, C1). D) Western 
blot analysis of spinal cord homogenates of young 
non-transgenic (20 weeks), aged non-transgenic 
(80 weeks), presymptomatic SOD1-G93A (15 
weeks and 20 weeks), and symptomatic SOD1-
G93A (30 weeks and end-stage) mice. E-F) VAPB-
immunoperoxidase staining in control (E) and human 
ALS (F) lumbar spinal cord. Compared to motor 
neurons (E3) and pyramidal tract (E2) in control 
issue, ALS spinal cord sections show a substantial 
loss of VAPB-immunoreactivity in remaining motor 
neuronal profiles (F3, F4), and reduced staining of 
the pyramidal tract (F2). pyr: pyramidal tract. Bars: 
100 µm (A1, A2, A3; E3, F3); 20 µm (B1, C1); 800 
µm (E1, F1); 50 µm (E2, F2). 
mutant VAPb and VAP knockdown induce cell death and Golgi fragmentation in primary 
neurons
As in non-neuronal cells, VAPB-P56S forms cytosolic aggregates in primary neurons which do 
not colocalize with ER markers (Figure 7A, B). To examine whether mutant VAPB leads to an 
increase in cell death in neuronal cells, we transfected primary cultured rat hippocampal neurons 
at 13 days in vitro (DIV13) with mutant and wild-type VAPB. Two days after transfection, the 
number of neurons expressing VAPB-P56S was decreased by ~60% compared to wild-type 
VAPB and control neurons (Figure 7C,E and data not shown), suggesting that neuronal viability 
is greatly reduced in cultures transfected with mutant VAPB. Furthermore, neurons expressing 
VAPB-P56S show aberrant neuronal morphology (Figure 7A,C). Hence, neuronal cells may be 
uniquely sensitive to mutant VAPB as the expression of VAPB-P56S does not increase cell death 
in HeLa or COS-1 cells (data not shown). 
 Since we showed that VAPB-P56S recruits endogenous VAPA and VAPB into insoluble 
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aggregates and reduces cytosolic VAP levels (Figure 5A,E), we hypothesized that decreased VAP 
family protein levels would phenocopy the mutant VAPB effects. To reduce VAP expression in 
neurons, we used a plasmid (pSuper) based-method for VAP knockdown and designed two rat 
VAP-shRNAs (VAPA-shRNA#4 and VAPB-shRNA#1) based on siRNA-sequences shown to be 
effective to decrease VAP expression in Hela cells (Supplementary Fig 3A). RNAi constructs 
Supplementary Fig 1. VAPB-P56S aggregates do not colocalize with cellular organelles
A-D) Representative images of HeLa cells transfected with HA-VAPB-P56S, fixed and processed for 
mmunofluorescence using antibodies against HA (green) and trans-Golgi marker γ-adaptin (A), cis-Golgi 
marker GM130 (B), lysosomal marker LAMP1 (C) or early endosomal marker EEA1 (D) (red). Enlargement of 
the boxed region in the merged images is shown at right. Note that VAPB-P56S aggregates do not colocalize 
with any of the tested markers. E) Redistribution of VAPB-P56S mutant proteins to the ER. Representative 
images of HeLa cells transfected with HA-VAPB-wt or HA-VAPB-P56S incubated at 37°C (control), 15°C or 
20°C for 3 hours, treated with 5µg/µl Brefeldin A (BFA), which inhibits intracellular transport or 10µM Nocodazole 
(Noco), which disrupts the microtubule network, for 30 minutes, fixed and processed for immunofluorescence 
using antibodies against HA. Note that in contrast to HA-VAPB-P56S expressing cells at 37°C, HA-VAPA-
P56S partially localizes to the ER at  20°C. 
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were cotransfected in hippocampal neurons at DIV13 with a plasmid encoding for β-galactosidase 
(β-gal), to highlight the transfected neurons and immunostained for VAPA and VAPB six days 
later (Supplementary Fig 3). VAPA-shRNA or VAPB-shRNA expressing neurons showed ~70% 
reduction in immunostaining for the respective VAP (Supplementary Fig 3), indicating an effective 
knockdown for both VAP-shRNA constructs.
 We next investigated whether knockdown of VAP influences neuronal viability. Although 
no effect on neuronal survival was observed in VAPB knockdown neurons, absence of VAPA 
decreased the number of transfected neurons by ~80% compared to control neurons (Figure 
7E). A second VAPA-shRNA#2, showing ~60% reduced VAPA immunostaining confirmed 
the observed cell death; ~30% of the transfected neurons survived (data not shown). Similar 
results are obtained after knockdown of both VAPA and VAPB, where only ~20% of the neurons 
survived compared to control cells (Figure 7E), indicating that VAP family proteins are important 
for neuronal viability. Since VAPA is the most abundant VAP in hippocampus (Figure 1F), it is 
likely that VAPA is redundant for VAPB function in hippocampal neurons. However, we can not 
rule out a specific role for VAPA in neuronal survival. 
 As a disrupted Golgi apparatus is an early pathological hallmark of neurodegeneration 
that is generally caused by disturbed intracellular trafficking (Gonatas et al., 2006), we analyzed 
the Golgi morphology in neurons expressing VAPB-P56S or VAP-shRNA. Transfection of 
hippocampal neurons at DIV13, results in significant Golgi fragmentation in ~15% of the VAPB-
P56S expressing neurons and ~15% (ranging from 10-20%) in VAP knockdown neurons as 
compared to ~1% (ranging from 0-3%) in control neurons (Figure 7D,F).  Overall, these data 
show that VAPB-P56S expression in neurons has similar effects as knockdown of endogenous 
VAP-levels, suggesting that the dominant effect of VAPB-P56S is caused by a loss-of-function of 
VAP in these cells. 
motor neurons show reduced VAP immunoreactivity in ALS tissue
To examine whether loss of VAP function might also be involved in the pathogenesis of sporadic 
ALS and SOD1-linked ALS, we analyzed the VAPA and VAPB expression levels in spinal cord 
sections from human ALS patients and in ALS-prone transgenic mice that express G93A-mutated 
SOD1 (Jaarsma et al., 2001). No change in VAP expression was observed in G93A-SOD1 mice 
prior to disease onset (10-25 weeks of age) or in aged controls, but symptomatic and end-stage 
G93A-SOD1 mice (30-40 weeks) showed a reduction of VAPA and VAPB immunoreactivity as 
determined by immunohistochemistry and Western blot analysis (Figure 8A,D). This reduced 
VAP expression could, at least in part, be explained by the loss of motor neurons, because 
the reduction of VAP expression temporally correlated with the onset of motor neuronal loss. 
�owever, calreticulin, a resident ER protein, was significantly less affected in the end-stage 
G93A-SOD1 mice compared to VAP (Figure 8D). Also in spinal cord sections from ALS patients 
(n=4) VAPB immunoreactivity in motor neurons was reduced as compared to controls (n=3) 
and significantly lower VAPB expression was seen in the pyramidal tract (Figure 8E,F). Double 
labeling showed that in the spinal cords of SOD1-ALS mice and ALS patients VAPB was not 
present in ubiquitinated inclusions that are a dominant pathological hallmark of ALS (Figure 8B 
and data not shown). However, a reduced VAPB immunoreactivity was primarily observed in 
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motor neurons displaying Golgi fragmentation (Figure 8C), consistent with the loss-of function 
data in primary neuron cultures (Figure 7). Our observations suggest that the reduced expression 
of VAP is not only coupled to VAPB-linked ALS but more generally associated with the viability 
of motor neurons in both sporadic and familiar ALS.
DiSCuSSion
Characterization of VAPb-P56S aggregates
Our results show that mutant VAPB protein aggregates are different in several aspects from any 
other described aggregate-prone mutants in neurodegenerative diseases (Taylor et al., 2002; 
Forman et al., 2004; Selkoe, 2004). First, the accumulation of VAPB-P56S into micrometer-
scale aggregates is remarkably efficient. This is different from clustering of other aggregate-prone 
proteins, such as mutant SOD1 and Htt, where micrometer-scale aggregates form over days at 
high levels of mutant protein (Waelter et al., 2001; Chai et al., 2002; Kim et al., 2002; Matsumoto             
et al., 2005). This is consistent with the idea that the P56S mutation creates a high affinity for               
self-association (discussed below).
 Second, VAPB-P56S aggregates do not recruit protein quality control and degradation 
machinery components. Most aggregate-prone proteins identified in neurodegenerative diseases 
recruit molecular chaperones or proteasome components (Kopito, 2000; Taylor et al., 2002; 
Rubinsztein, 2006). Furthermore, aggregation of mutant Htt and SOD1 is enhanced in response 
to proteasome inhibition (Waelter et al., 2001; Iwata et al., 2005). We do not observe these 
phenomena in cells expressing VAPB-P56S and could explain the efficient aggregation of the 
mutant VAP protein.
 Third, mutant VAPB clusters are ultrastructurally distinct from other micrometer scale 
aggregates that are usually composed of a network of fibrillar polymers (Taylor et al., 2002; 
Ross and Poirier, 2005). Instead, the VAPB-P56S aggregates consist of tubules, which can be 
continuous with the ER, suggesting that they are derived from it. Still, VAPB aggregates are clearly 
distinct from the ER as they lack ER markers, and tubule borders within the aggregates show an 
electron dense appearance suggestive of the presence of high levels of protein.  Furthermore, 
photobleaching experiments show that the VAPB-P56S proteins are largely immobile, similar 
to the aggregated SOD1 and �tt mutants (Chai et al., 2002; Kim et al., 2002), but different 
from ER clusters that can be obtained by overexpressing ER proteins such as cytochrome b(5) 
(Snapp et al., 2003). Occasionally, the VAPB-P56S tubular aggregates are continuous with the 
outer membranes of mitochondria, which may be explained by the close association of some ER 
compartments with mitochondria (Goetz and Nabi, 2006). 
mutant VAPb induces membrane-protein aggregates
How does mutant VAPB form aggregates? Structural analysis indicates that wild type VAP 
proteins form dimeric complexes where both the coiled-coil and the C-terminal transmembrane 
domains induce VAP dimerization while two FFAT-motifs bind the MSP homology domains in 
a 2���2 complex (Russ and Engelman, 2000; Kaiser et al., 2005). In VAPB-wt the P56 residue lies 
within the loop connecting the d1- and d2-strands within the MSP homology domain (Kaiser et al., 
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Supplementary Fig 2. VAPB-P56S aggregates do not colocalize with chaperone, proteasome, autophagy 
and ER stress markers A-D) Representative images of HeLa cells transfected with HA-VAPB-P56S or GFP-
Htt(Q74), fixed and processed for immunofluorescence using anti-HA (A,C) and proteasome markers anti-
ubiquitin (A,B) or anti-vimentin (C,D) antibodies. While Htt(Q74) colocalizes with proteasomal components 
and leads to intracellular redistribution of vimentin, VAPB-P56S aggregates do not stain for ubiquitin or effect 
the vimentin filament network in the cell.E-F) Representative images of HeLa cells transfected with HA-VAPB-
P56S, fixed and processed for immunofluorescence using anti-HA (E,F) and ER stress markers anti-Grp78/BiP 
(E) and anti-phospho-eIF-2alpha (F) antibodies. Note that the ER-stress markers are not influenced by VAP-
P56S aggregates, in contrast to studies using mutant Htt (Waelter et al., 2001).G) COS-1 cells transfected 
with HA-VAPB-wt and HA-VAPB-P56S were incubated for 24 hours with (+MG132) or without (-MG132) 
proteasome inhibitors, harvested (lysates (L)) and solubilized with Triton-X100, fractionated in supernatant (S) 
and pellet (P) under non-reducing (-DTT) or reducing (+DTT) conditions and analyzed by immunoblotting using 
anti-HA antibodies. Note that treatments with proteasome inhibitors increases the VAPB-P56S levels in the 
soluble fraction  H-I) Representative images of HeLa cells transfected with HA-VAPB-P56S or GFP-Htt(Q74) 
incubated for 24 hours with proteasome inhibitor MG132 (1µM), fixed and processed for immunofluorescence 
using antibodies against HA (H) and vimentin (H,I). J-K) Representative images of HeLa cells transfected 
with HA-VAPB-P56S, fixed and processed for immunofluorescence using antibodies against HA (J,K) and 
autophagy markers Atg8/LC3 (J) and Atg12 (K). Note that VAP-P56S aggregates are not labeled by the 
autophagy markers, in contrast to mutant Htt.
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Supplementary Fig 3. 
shRNA knockdown of 
VAPA and VAPB in primary 
hippocampal neurons
A) Knockdown of endogenous 
VAPA and VAPB-levels by 
different siRNA-oligos. HeLa-
cells were transfected with 
siRNA-oligos for 4 days and 
protein samples were analyzed 
by Western Blot with anti-
VAPA (#04), anti-VAPB (#00) 
and anti-actin antibodies.
B-E) Representative images of 
primary neurons co-expressing 
ß-galactosidase and pSuper 
(B,D) or VAPA-shRNA#4 
(C) or VAPB-shRNA#1 (E) 
for 6 days and stained for ß-
galactosidase and endogenous 
VAPA (B,C) or VAPB (D,E). 
Enlargement shows VAP 
staining in dendrites. 
F) Quantification of VAPA 
and VAPB-levels in dendrites 
of knockdown neurons. 
Per image, VAP-levels of 
two untransfected and two 
transfected dendrite sections 
were measured using 
Metamorph software, ~5 
images per shRNA-construct 
were measured. Differences 
were analysed using the 
Student’s T-test. *** p<0.0005, 
* p<0.05. 
2005) (Supplementary Fig 4A). The characteristic ‘S-shape’ of this loop is maintained by the cis 
peptide bond conformation stabilized by the proline residue. This conformation seems required to 
establish the hydrogen bonding network that maintains the precise register of the d1 strand with 
respect to the e strand. The side chain of P56 and the d1-strand pack against hydrophobic core 
residues of the MSP homology domain (Supplementary Fig 4A). We show that the mutant and not 
wild type MSP homology domains are recruited to the aggregates. The most likely explanation 
for the clustering of mutant VAPB is that the serine substitution breaks the cis conformation 
of the peptide bond to assume the energetically much more favorable trans conformation. This 
structural change together with the placement of a polar side chain in close proximity to a 
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hydrophobic environment is expected to destabilize the hydrogen-bonding interaction network 
established by the d1-d2 loop and d1-strand (Nishimura et al., 2004), consequently exposing 
hydrophobic residues to the solvent (Supplementary Fig 4A). The aberrant VAPB structure may 
induce self-association of dimeric VAPB with neighboring mutant VAPB molecules, whereby 
VAPB complexes are still tethered to the ER membrane by their TMDs (Supplementary Fig 4B). 
Interactions between the TMDs of the mutant and wild type VAPB proteins cause entrapment of 
the latter in the aggregates.
mutant VAPb recruits wild type VAP, disrupts ffAT-binding and causes cell death 
Why does mutant VAPB and reduced VAP expression leads to death of neuronal cells? VAP 
proteins are adaptors for recruiting FFAT-motif containing lipid binding proteins to ER 
membranes, and disruption of VAP induces the mislocalisation of these proteins (Loewen et al., 
2003). Knockdown experiments and analysis of FFAT motif CERT mutants revealed that VAPs 
are implicated in ceramide transport and sphingomyelin synthesis in cultured mammalian cells 
but most likely involved in several other lipid trafficking pathways (Kawano et al., 2006; Perry 
and Ridgway, 2006). In Drosophila, the FFAT-motif containing protein retinal degeneration B 
(rdgB) is implicated in phospholipid transport and metabolism and is essential for photoreceptor 
viability (Lev, 2004). 
 Close examination of the high-resolution crystal structure of the complex formed 
between the MSP domain of VAPA and a FFAT motif-containing peptide originating from 
ORP1 shows that P56, and in particular N57, is positioned next to the FFAT peptide binding site 
(Supplementary Fig 4A). As discussed above, the local conformational change induced by the 
serine substitution is expected to impair the hydrogen-bonding network formed between VAPB 
MSP and the C-terminal moiety of the bound FFAT peptide. Here we show that the interaction 
with the FFAT-motif is disrupted by the P56S mutation. Although the disruption of FFAT binding 
alone can not explain the effects of the dominant VAPB mutation, we believe that repressed FFAT 
binding, in addition to the recruitment of wild type VAP to mutant VAPB aggregates, further 
impairs normal VAP function and accelerates the reduced ER anchoring of FFAT-motif containing 
lipid binding proteins. We hypothesize that reduced levels of VAP similar to its yeast homologue 
Scs2 (Kagiwada et al., 1998) disturbs lipid homeostasis. Evidence supporting this model comes 
from the observed Golgi dispersion in primary neurons expressing VAP-P56S and shRNA-VAP 
constructs. Disruption of intracellular transport and abnormal lipid metabolism has been shown 
to lead to Golgi disassembly (Fukunaga et al., 2000; Gonatas et al., 2006).
model of VAP leading to motor neuron degeneration
Expression analyses show that VAPs are ubiquitously expressed in all tissues and throughout 
the CNS, raising the question why its mutation in vivo preferentially affects motor neurons. We 
show that VAPB is highly abundant in motor neurons as compared to other cells in the CNS. Due 
to their exceptionally large size and complex morphology, motor neurons are likely to require a 
high rate of lipid metabolism and well organized lipid transport mechanisms, that may be linked 
to the high level of VAPB expression and explain the preferential vulnerability of motor neurons 
to VAPB mutations. 
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 Our data point to several potential deleterious effects by which VAPB-P56S can cause 
degeneration and death of neurons. VAPB-P56S forms stable aggregates that are continuous 
with the ER, mitochondria and possibly other membranous organelles, recruits wild type VAPs 
and impairs normal VAP function. This in combination with the disrupted binding to FFAT-
motifs by mutant VAPB may result in abnormal lipid transport and biosynthesis and induce 
slow degeneration of neurons (Supplementary Fig 4C). Loss of DVAP-33 in Drosophila results 
in motor abnormalities, defects at the neuromuscular junctions and death at early larval stage 
(Pennetta et al., 2002), indicating that in flies deleterious consequences of the loss of VAP are 
restricted to motor neurons. We show that VAP expression is reduced in motor neurons from 
sporadic ALS patients and SOD1-ALS mice, suggesting that the decreased expression of VAPB 
might be a common feature associated with motor neuron degeneration. We propose that VAPB 
mutation or deficiency results in an abnormal lipid metabolism in motor neurons. Interestingly, a 
number of observations have linked defects in lipid homeostasis to ALS pathogenesis and motor 
neuron degeneration. Altered levels of sphingomyelin, ceramides, and cholesterol esters and 
altered expression of genes involved in the control of lipid metabolism have been identified in 
the spinal cord of ALS patients and transgenic SOD1-ALS mice (Malaspina et al., 2001; Cutler 
et al., 2002). In addition, mice with a targeted disruption in the Liver X receptor β (LXRβ), an 
ubiquitous sterol-activated nuclear receptor involved in cholesterol and sterol metabolism, exhibit 
degenerative changes in motor neurons and muscle atrophy remniscent of ALS (Andersson et al., 
2005; Xie et al., 2005). Furthermore, plant and bacterial sterol derivatives have been shown to 
be neurotoxic, and have been linked to the pathogenesis of Guam ALS-parkinsonism dementia 
complex (Ly et al., 2007)
 In sum, we hypothesize that the combination of loss of function (disrupted FFAT-motif 
binding), dominant-negative effects (wild type VAP recruitment) and gain of toxic function 
(disrupted membrane trafficking) may lead to VAPB-linked motor neuron disease. The dominant 
negative VAPB-P56S effect correlates well with the VAP knockdown phenotype and reduced 
expression of VAP in sporadic and familial ALS, indicating the reduction of VAP family proteins 
is a likely factor contributing to motor neuron degeneration.  
Animal models will provide further insight into the cellular mechanisms by which a reduction in 
ER-resident membrane VAP proteins can result in specific degeneration of motor neurons in vivo 
and reveal the particular lipid trafficking routes affected by mutant VAP aggregates.
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Supplementary Fig 4. Model of mutant VAPB 
leading to motor neuron degeneration
A) Structure of the complex formed between the 
MSP domain of VAPA (in light gray mixed ribbon/
sticks representation) and the FFAT motif-containing 
peptide originating from ORP1 (in yellow sticks 
representation; PDB ID 1Z9O). The S-shaped d1-
d2 loop and the C-terminal half of the e-strand of 
VAPA MSP are represented as sticks (β-strand 
nomenclature according to (Kaiser et al., 2005)). 
Hydrophobic residue side chains of VAPA MSP 
laying beneath the d1-d2 loop and the d1-strand are 
represented as sticks and colored in green. Oxygen, 
nitrogen, and carbon atoms are colored in red, blue, 
and gray/yellow, respectively. The hydrogen-bonding 
network involving the d1-strand, e-strand, Asn57 of 
VAPA MSP, and the C-terminal moiety of the FFAT 
motif-containing peptide is highlighted by yellow 
dashed lines.
B) Model for the formation of P56S mutant VAPB 
aggregates. Wild type VAPB undergoes dimerization 
mediated by the coiled-coil domain (black) and the 
C-terminal transmembrane domain containing the 
GxxxG motif (grey). The P56S change induces local 
conformation changes in the MSP homology domain 
(red) which results in self-association of mutant MSP domains between neighboring mutant VAPB molecules. 
The recruitment of wild type VAPB to the mutant VAPB complexes is mediated by the transmembrane domain 
(blue dashes) and the interaction with the FFAT-motif is disrupted by the P56S mutation.
C) We propose a mechanistic model in which the P56S mutant VAPB expression leads to motor neuron 
degeneration through two overlapping pathways. The mutation induces a local conformational change of the 
MSP domain, which leads to aberrant self-association and aggregation and disrupts the binding to FFAT-
containing proteins. In addition, the mutation causes recruitment of wild type VAPA and VAPB in aggregates 
thereby lowering the concentrations of wild type VAPs in the ER, leading to a further impairment of normal VAP 
function. This dominant negative effect may further abolish the mistargeting of FFAT-motif containing proteins 
and induce the formation of larger tubular aggregates. In the long term, mutant aggregates may influence 
membrane trafficking and further disrupt the mislocalization of FFAT-motif containing lipid binding proteins, 
which together may cause abnormal transport and lipid biosynthesis leading to motor neuron degeneration.
mATeriALS AnD meThoDS
GST/his-VAP constructs and antibody generation
Nucleotide sequences encoding VAPB amino acids 1-225 and VAPA and VAPB amino acids 132-225 were 
cloned into pGEX-4T (Pharmacia) to create glutathione-S-transferase (GST)-fusion proteins, and into 
pET-32A (Novagen) to create His-tagged fusion proteins. GST-VAP fusion proteins were induced in BL21 
Escherichia coli cells by Isopropyl β-D-1-thiogalactopyranoside (IPTG) and purified using glutathione-
Sepharose 4B beads (Amersham) according to the manufacturer’s instructions. Purified proteins were 
concentrated using Centricon (Biorad) and injected into New Zealand White Rabbits in a suspension of 
TiterMax Gold adjuvant (Sigma). Sera 1006 of rabbits #00 and #01 are against VAPB amino acid 1-225, #02 
and #03 against VAPB 132-225, and #04 and #05 against VAPA amino acid 132-225. His-VAP fusion proteins 
were induced in Rosetta bacteria, and purified using Nickel beads (Qiagen) according to the manufacturer’s 
protocol. His-tagged fusion proteins were coupled to CNBr-activated Sepharose 4B-columns (Amersham) 
and used to purify VAP antibodies.
C
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Supplementary Table 1. FFAT motif containing proteins as binding partners of 
bio-HA-VAPB in HeLa cells identified by mass spectrometry
Identified protein (VAPB)             MW (Da)     % cover      Pept. uniq     Pept. total      NCBI GI number
OSBPL3 / ORP3                          102130           28.3                19                23              17389382
OSBPL6 / ORP6                          107379             7.3                  4                  4              14210532
OSBPL9 / ORP9                            63059             7.9                  3                  3              19684104
PITPNM1 / NIR2                          135844             6.9                  6                  6              12667436
Identified protein (VAPB-P56S)   MW (Da)     % cover      Pept. uniq     Pept. total      NCBI GI number 
No FFAT motif containing proteins were identified
The table shows FFAT motif containing proteins identified with a significant Mascot score in the pull down with 
streptavidin beads from extracts of HeLa cells co-expressing biotin ligase BirA and bio-HA-VAPB or bio-HA-
VAPB-P56S. The list is corrected for background proteins which were identified in a control pull-down from 
HeLa cells expressing BirA only. For each identified protein, the list is filtered for duplicates and shows only the 
hits with most identified peptides. Abbreviations used in the table to indicate the identified proteins: OSBPL, 
oxysterol binding protein-like; ORP, OSBP related protein; PITPNM, phosphatidylinositol transfer protein, 
membrane-associated; NIR, N-terminal domain-interacting receptor
expression constructs
The following mammalian expression plasmids have been described: tsVSVG-YFP (Toomre et al., 1999), 
ORP3-GFP (Lehto et al., 2005), Htt(Q74)-GFP and GFP-Hsp-70 (gift from Dr. H. Kampinga) and Hsp104 
(gift from Dr. S. Lindquist) and BirA (Lansbergen et al., 2006). Full-length human VAPA and VAPB constructs 
were generated by PCR using IMAGE clones 2822547 (BC002992) and 3543354 (BC001712) as templates 
and cloned into HA- and Myc-tagged pGW1-expression vectors. P56S, K87D and M89D mutations were 
generated by site-directed mutagenesis. GFP-VAPB-TMD (amino acid 213-245), GFP-VAPB-N (amino 
acid 1-213) and GFP-VAPB-MSP (amino acid 1-158) were cloned by PCR in a modified pβactin-16-pl 
vector. GFP-VAPB was obtained by cloning VAPB-N into GFP-VAPB-TM. GFP-FFAT was obtained by 
cloning the amino acid sequence of the FFAT-domain of the human Nir2-protein and flanking amino acids 
(NSSEE EFFDAHE GFSDS) into pEGFP-C1 (Clontech). For GFP-SCR, the amino acids were mixed 
(FESSE EDNFAHE GFSDS). Bio-HA-VAPB-constructs were generated by incorporating a biotinylation-tag 
(MSGLNDIFEAQKIEWHE) into the HA-tagged VAP-constructs. VAPA#4 (gcatgcagagtgctgtttc), VAPA#2 
(ggaaactgatggaagagtg) and VAPB#1 (ggtgatggaagagtgcagg) shRNAs were designed against rat VAPA and 
VAPB sequences (NM_031631 and NM_019806 respectively), annealed and inserted into pSuper-vector 
(Hoogenraad et al., 2005). 
Antibodies and reagents
The following primary antibodies were used for immunocytochemistry. Mouse monoclonal antibodies 
against��� PDI (Affinity BioReagents, 1���300), GM130 (BD Biosciences, 1���1000), �A (Roche, 1���500), LAMP1 
(Developmental Studies Hybridoma Bank, 1:50), Ubiquitin FK1 (Biomol, 1:300), vimentin (Sigma, 1:200) 
and Myc (Santa Cruz 1:500), ß-galactosidase (Promega, 1:2000). Polyclonal rabbit antibodies aganist: 
VAPA (#1006-04, 1���500), VAPB (#1006-00, 1���500), calreticulin (Affinity BioReagents, 1���1000), �A (Santa 
Cruz, 1:500), γ-adaptin (BD Biosciences, 1:500), BiP/GRP78 (Stressgen, 1:500), Eif2a (Sigma, 1:500), 
ß-galactosidase (MP Biomedicin, 1:2000) and Atg8/LC3 and Atg12 (gift from Dr. R. Kopito (Iwata et al., 
2005), 1:1000). The following primary antibodies used for Western blot analysis: rabbit anti-VAPA (#1006-
04, 1:500), rabbit anti-VAPB (#1006-02, 1:1000), mouse anti-alpha-tubulin (Sigma, 1:5000), rabbit anti-HA 
(Santa Cruz, 1:500), mouse anti-beta-actin (Chemicon, 1:5000), rabbit anti-SOD101 (Stressgene, 1:1000), 
rabbit anti-GFP (Abcam, 1���1000), rabbit anti-Myc (Cell-signaling, 1���500), rabbit-anti-calreticulin (Affinity 
BioReagents, 1:1000). Nocodazole and Brefeldin A were obtained from Sigma. 
CHAPTER 5
130
heLa cell transfection and immunocytochemistry
HeLa cells were cultured in DMEM/HAMF10 (50/50%) medium containing 10% FCS and 1% penicillin/
streptomycin. One day prior to transfection, cells were plated at 1:25 in Lab-tek chamber slides (Nunc). 
Cells were transfected with SuperFect transfection reagent (Qiagen) according to the manufacturers protocol 
and grown for 16 hours. Two hours before fixation, cells were serum-stimulated with fresh medium. Cells 
were fixed in 4% paraformaldehyde for 10 minutes at room temperature followed by 5 minutes in 0,1% 
Triton-X-100 in PBS. Slides were blocked in 0.5% BSA/0.02% glycine in PBS and labeled with primary 
antibody for 2 hours at room temperature, as described by (Hoogenraad et al., 2000). 
CoS-1 cell transfection and western blot analysis 
COS-1 cells were cultured in DMEM/HAMF10 (50/50%) medium containing 10% FCS and 1% penicillin/
streptomycin. COS-1 cells were transfected by the DEAE-dextran method (Hoogenraad et al., 2000). Cells 
were harvested 24 hours after transfection, by scraping the cells in PBS, and lysating cell pellets in lysis 
buffer (25 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.5% Triton-X-100 and Protease Inhibitors, Roche) followed 
by sonification. Supernatant and pellet fractions were separated by centrifugation at 13.000 rpm for 15 min, 
pellets were dissolved in an equal amount of lysis buffer. Samples were mixed with 4x Sample Buffer (8% 
SDS, 25%Glycerol, 0.05 M Tris pH 6.8, 200 mM DTT, 40 mg/l Bromophenol Blue) and boiled. Equal 
amounts of proteins were loaded onto 10% SDS-PAGE gels and subjected to Western Blotting on PVDF-
membrane. Blots were blocked with 2% Bovine Serum Albumin/ 0.05% Tween-20 in PBS and incubated 
with primary antibodies at 4°C overnight. Blots were washed with 0.05% Tween20 in PBS 3 times for 10 
minutes at room temperature and incubated with either anti-rabbit or anti-mouse IgG antibody conjugated to 
HorseRadish Peroxidase (Dako). Blots were developed with Enhanced Chemiluminescent Western Blotting 
Substrate (Pierce). 
Primary neuron cultures and transfection
Primary rat hippocampal neurons were plated at a density of 75.000 on 15 mm glass coverslips and 
transfected at DIV13 with HA-VAPB-wt, P56S, VAP-shRNA, ß-galactosidase or GFP using Lipofectamine-
200 as previously described (�oogenraad et al., 2005). After two days of transfection, neurons were fixed 
and stained with anti-HA, anti-GM130 and anti-PDI antibodies, and the number of transfected neurons 
per coverslip was counted. The appearance of the Golgi apparatus was investigated and differences were 
analyzed using the Chi-square test. Representative cells were imaged using a confocal microscope. 
immunoprecipitation
COS-1 cells were cultured, transfected and harvested as described above. To increase the solubility of 
VAPB-P56S, transfected cells were incubated for 2 hours prior to lysis. Cells were lysed in lysis buffer 
(25 mM Tris-HCl (pH 8-8.5), 50 mM NaCl and 0.5%Triton-X-100 and Protease Inhibitors, Roche) and 
centrifuged at 13.000 rpm for 15 minutes. Supernatants were mixed with an equal amount of lysis buffer, 
Protein-A-agarose beads (Pharmacia) and 3-5 µg of mouse anti-HA (Covance), mouse anti-GFP, rabbit anti-
HA (Santa Cruz) or control IgG (Sigma). Samples were incubated overnight rotating at 4°C, centrifuged 
at 2000rpm and pellets were washed twice with lysis buffer. Proteins were eluted by boiling in 4x sample 
buffer. Analysis by Western blotting was performed as described above. 
biotin-streptavidin pull-down
For biotin-streptavidin pull-down assays, Hela-cells were transfected with Biotin-tagged VAPB-wt and 
P56S using Lipofect 2000 (Invitrogen) transfection reagent according to the manufacturer’s instructions. 
Cells were lysed 16 hours later in 20 mM Tris-HCl pH 8.0, 150 mM KCl, 1% Triton-X-100 and protease 
inhibitors (Roche). Cell lysates were centrifuged at 13.000 rpm for 15 min and the supernatants were 
incubated with Dynabeads M-280 Streptavidin (Dynal, Invitrogen) for 45 min. Beads were separated by 
using a magnet (Dynal, Invitrogen) and washed 5 times in lysis buffer. For protein elution, the beads were 
boiled in NuPAGE LDS 4x Sample buffer, separated and supernatants were run on a 10% NuPAGE Bis-Tris 
gel (Invitrogen). The gel was stained with the Collodial Blue Staining Kit (Invitrogen), and analyzed by 
Western blotting. Mass spectrometry was performed as described before (Lansbergen et al., 2006). 
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GST-pull down
Full-length VAPB and VAPB-N (amino acid 1-213) with or without the P56S-mutation were obtained by 
PCR and cloned into pGEX-4T (Pharmacia) to create glutathione-S-transferase (GST)-fusion proteins. 
Proteins were induced and purified as described before and analyzed by SDS-PAGE to control for induction 
and quantities. Hela-cells were transfected with GFP-FFAT and GFP-FFAT-SCR by using Lipofectamine-
2000 transfection reagent (Invitrogen) and lysed in 50mM Tris-HCl, 100mM NaCl and 1% Triton-X-100 
containing protease inhibitors (Roche). Lysates were incubated with GST-beads (Amersham) for 2 hours at 
4°C, washed 4 times with lysis buffer and analyzed by SDS-PAGE and Western blotting as described before. 
Blots were incubated with rabbit anti-GFP antibodies (Abcam, 1:1000). 
Photobleaching experiments
For quantitative FRAP experiments, Hela-cells were grown in 6-wells plates on 25mm coverslips (Menzel-
Gläser), transfected with GFP-tagged VAPB as described above and imaged on a 37°C temperature-
controlled stage of a Zeiss 510 laser scanning microscope (LSM) 60-mW Argon laser (488 nm) and a 40x 
1.2 n.a. or 63x Planapochromat 1.4 n.a. oil immersion lens (Zeiss) as described before (modified from the 
method described in (Essers et al., 2006)). The microscopes were equipped with an objective heater. A region 
of interest was bleached with high laser power, followed by imaging a larger part of the cell for 300 sec at 
low laser power to prevent bleaching. The fluorescence intensity of the bleached region was measured every 
second to obtain fluorescence recovery curves. Fluorescence intensity after photobleaching was calculated 
relative to intensity before bleaching. By measuring a non-bleached region in the same cell, we normalized 
for decrease in fluorescence that appears trough bleaching in any case. Average fluorescent intensities were 
calculated for VAPB-wt, VAPB-P56S and control regions. 
immunohistochemistry and confocal immunofluorescence
The brain and spinal cord were sectioned at 40μm with a freezing microtome. Sections were processed 
free floating, employing a standard avidin-biotin-immunoperoxidase complex method (ABC, Vector 
Laboratories) with diaminobenzidine (0.05%) as the chromogen, or double-labeling immunofluorescence 
(Jaarsma et al., 2001). The VAPB-antibodies were diluted at 1:4000 in Tris-Buffered-Saline (TBS, pH7.6) 
containing 1% normal horse serum and 0.2% triton X-100. Biotinylated secondary goat-anti rabbit (Vector 
Laboratories) diluted at 1���200 was used as a secondary antibody.  For double labeling immunofluorescence 
sections were incubated with VAPB-antibodies (diluted 1:1000), combined with mouse anti-ubiquitin (FK2, 
Biomol), mouse anti-synaptophysin (Sigma), mouse anti-GM130 (BD Biosciences), or human anti-P0 (1: 
200; Immunovision). Immunoperoxidase-stained sections were analyzed and photographed using a Leica 
DM-RB microscope and a Leica DC300 digital camera. Sections stained for immunofluorescence were 
analyzed with a Zeiss LSM 510 confocal laser-scanning microscope. 
electron microscopy 
For EM, 24 hours prior to fixation, �eLa cells were transfected with �A-VAPB-P56S with Lipofect-
2000 transfection reagent (Invitrogen) according to the manufacturers instructions. Cells were fixed in 2% 
glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4 for 30 min, scraped, and collected as a pellet, and left 
overnight in fresh fixative. Cells were further fixed with osmium tetroxide and embedded in Durcupan 
(Fluka) by standard procedures. Ultrathin sections (70 µM) were cut, mounted on Formvar-coated nickel 
grids, and processed for immunogold labelling using the procedure described before (Jaarsma et al., 2001). 
Primary and secondary antibodies were mouse anti-�A-11 (1���500; clone 16812; Babco, Richmond, CA) 
and 10 nm gold-conjugated goat anti-mouse (1���30; Aurion, Wageningen, The Netherlands). Gold-labeled 
sections were analyzed in a Phillips CM10 electron microscope at 80 kV.
G93A-SoD1 mice
G93A-SOD1 mice descendent from the Gurney G1del-line that carry about 8 transgene copy numbers per 
haploid genome were housed and handled in accordance with the “Principles of laboratory animal care” 
(NIH publication No. 86-23) and the guidelines approved by the Erasmus University animal care committee 
(DEC; protocol No. 115-97-01 and 115-99-03). Non-transgenic mice were used as controls. The mice 
develop weakness in one or more limbs from age 24-30 weeks, and reach end stage disease 2–10 weeks after 
onset of limb weakness (Jaarsma et al., 2001). For immunocytochemistry mice of different ages and disease 
stages were anaesthetized with pentobarbital and perfused transcardially with 4% paraformaldehyde.
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human tissue
Paraffin sections from L3 lumbar spinal cord from four ALS patients (average age 56 years; range, 42–
68 years), and three controls (average age 57 years; range, 45–65 years) were obtained from files of The 
Netherlands ALS tissue bank. Tissue was obtained and used in a manner compliant with the Declaration of 
Helsinki. Informed consent was obtained for the use of brain tissue. All autopsies were performed within 
8 h after death of patients. The ALS cases were sporadic with either bulbar (n = 2) or spinal onset (n = 2). 
Average duration of disease after diagnosis was 33 months (range 20–72 months). Control cases died from 
myocardial infarct (n = 1) or cancer (n = 2). One control case showed mild Alzheimer’s pathology.
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The studies described in this thesis were aimed to gain a better understanding of the molecular 
factors underlying motor neuron death in Amyotrophic Lateral Sclerosis (ALS). The conclusions 
from these studies and the implications for ALS are discussed in this chapter. These include two 
already ongoing discussions: whether ALS is a cell-autonomous disease or not (paragraph 6.1), 
and whether disrupted retrograde axonal transport is a crucial phenomenon in the development of 
ALS (paragraph 6.2). Next, our studies suggest the involvement of two molecular pathways that 
have not been extensively studied in ALS so far, e.g. the role of endosomes (paragraph 6.2) and 
lipid metabolism (paragraph 6.3). In context with earlier published data, it will be discussed why 
it is reasonable to believe that alterations in these pathways can lead to motor neuron disease. The 
chapter is concluded by a look towards the future of ALS-research.
6.1 SoD1-ALS: A ProTein AGGreGATion DiSorDer of neuronS  
 AnD GLiA
In the spinal cord of ALS-patients and SOD1-ALS-mouse models, not only pathological changes 
appear in motor neurons, also microglia and astrocytes show pathological abnormalities. The 
question if, and how different non-neuronal cell-types contribute to the complex, multi-factorial 
process of motor neuron death is still unresolved. 
6.1.1 Aggregation, a principle pathological feature in SoD1-ALS mice
In chapter 2, we showed that the appearance of ubiquitinated perikaryal and dendritic aggregates 
in motor neurons is one of the first pathological changes observed in a line of SOD1-ALS mice. 
Transgenic mice that express different human mutated SOD1-species develop motor neuron 
disease resembling human ALS, an overview of these mice is given in table 6.1 (1). The enzymatic 
activities of the different SOD1-mutants vary widely, but do not correlate with the time of disease 
onset; also mice lacking endogenous SOD1 or expressing high levels of wild-type SOD1 have a 
normal life span (2, 3). This suggests that mutant SOD1 possesses a toxic gain-of-function rather 
than a loss-of-function. Disease onset and severity also do not correlate with absolute levels of 
mutant SOD1-protein as shown in table 6.1, rather correlate with the stability of the respective 
mutant protein. ALS-patients and SOD1-ALS mice with unstable SOD1-mutants have a low 
mean survival time (4), and small quantities of a very unstable SOD1-mutant (G127x) can induce 
disease in transgenic mice (5).
 The most used mutant SOD1-mouse line expresses high levels of SOD1-G93A, and 
has a life span of 4-5 months (6). From this original line, the G1-line that carries 25 transgene 
copies, several other lines have been derived, that have fewer transgene copies, accompanied by 
lower mutant SOD1-levels and a later disease onset (6, 10, 16). This gene-dosage effect of mutant 
SOD1 is also demonstrated in mice homozygous for SOD1-G93A, -G127x or D90A -transgenes, 
that show an earlier disease onset than their heterozygous littermates (3, 9, 16) (table 6.1). In our 
study in chapter 2, we have used the low-copy SOD1-G93A mouse (G1del or ‘slow’ mouse with 
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Table 6.1 Lines of mutant SOD1 mice
Mouse strain Ratio mut SOD1/ endogenous SOD1
Life 
span(d)
Mitoch.
path. Aggregates Ref
Stable SOD1-mutants
G93A (G1) (25) 17 124 yes MN(s+a), A, O (6)
 - G1del (8) 8 253 yes MN(s+a), A,O (3)
 - G1del homozygous 145 yes MN(s+a), A, O (7)
 - G20 (2) 3 343 few MN(s+a) (8)
 - G5/G5 (10) > 400 few MN(s+a),
D90A line 134 ND > 2 years MN(s+a), A
(9)
D90A 134 homozygous 20 407
G37R line 42 12 154
 - Line 9 6.2 180
 - Line 106 5.2 225
 - Line 20 5 365 yes MN(s+a) (10)
Lox-G37R ND 255 yes MN(s+a), A, O (11)
PrP G37R line 110 ND > 2 years None
(12)
 - line 110 homozygous 1.6x 110 300 MN(s+a), A
L84V (1)
A4V ND > 2 years None (13)
wtSOD1 N29 (7) 24 yes
MN(a) , O (3)
 - Line KT (13) ? >2 years
Unstable SOD1-mutants
G85R 0.9 345 MN(s+a), A (14)
G86R (mouse) 1 120 (15)
G127x line 716 (19) ND 700
(16)
 - line 716 homozygous ND 250
 - line 832 (28) ND 213
 - line 832 homozygous 0.45 126 MN(s+a)
L126x Low 359 MN(s) (17)
Cu-binding site mutants
H46R/H48Q 5 350 MN(s+a), A
H46R/H48Q/H63G/H120G 4-5 250-350 MN(s+a) (18)
Cell-type specific promoters
Thy1-G93A (neurons) 0.5 >2 years no None Chapter 
3 - homozygous 1? 490 yes MN(s+a), A
Thy1-G93A (neurons) Low > 2 years None (19)
Thy1-G85R (neurons) <1 > 2 years None (19)
NF-L G37R (neurons) 3-4? > 2 years None (20)
GFAP-G85R (glia) ND > 2 years A (21)
MN-Luc:G93A ND > 500 d ND MN (22)
If determined, number of transgene copies (in brackets) and protein levels relative to endogenous SOD1 are 
show. Lines in bold have been used for the studies described in chapter 2 and 3. Legend aggregates: MN= 
motor neuron, (s)= soma, (a)= axon, A=astrocytes, O=oligodendrocytes
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8 transgene copies), that develops symptoms from 25-30 weeks of age and reaches end-stage 
disease at 30-35 weeks of age. As ALS is a late-onset disease in humans, we speculate that this 
mouse, because of its low protein levels and therefore slower disease onset and progression, is a 
better model for the human disease than the more widely used G1 mouse. 
In the majority of SOD1-ALS mice and in SOD1-linked human ALS, ubiquitinated aggregates 
containing misfolded SOD1 are observed, suggesting a common disease mechanism (1). These 
aggregates appear in perinuclear and dendritic regions in motor neurons in early stages of the 
disease, and can be found in other cell types in later stages of disease, as seen in chapter 2. 
Mutant SOD1 can cause damage to non-neuronal cells, as seen by the activation of microglia and 
astrocytes, however it is not completely clear if, and how these cell-types contribute to initiation 
and propagation of motor neuron death. To address this question, we generated transgenic mice 
expressing SOD1-G93A specifically in neurons. 
6.1.2 neuron-specific expression of mutant SoD1 causes motor neuron disease in mice
Using the Thy1.2-promoter, we developed neuron-specific SOD1-mice as described in chapter 
3. Hemizygous animals, expressing low levels of mutant SOD1 were healthy up to two years 
of age, homozygous mice developed a very late-onset motor neuron disease, with pathology 
resembling that seen in G1del-mice (see table 6.1). Apparently, mutant SOD1-expression in 
neurons is sufficient to cause motor neuron degeneration and death. In addition, neuron-specific 
mutant SOD1 also induced astrocytosis and microglial activation. Like in ubiquitous SOD1-ALS 
mice, dendritic SOD1-aggregates were observed at a pre-symptomatic stage, strengthening the 
suggestion from chapter 2 that these structures could be the main initiators of disease. 
 Previously developed neuron-specific SOD1-mice, expressing either SOD1-G93A or 
SOD1-G85R in motor neurons with the Thy1.2 promoter (19), or SOD1-G37R in large neurons 
driven by the NF-L promoter (20) (table 6.1), did not develop pathology or motor neuron disease 
up to two years of age. It can be argued that the amount of mutant SOD1-protein in these mice is 
too low to initiate disease, as mutant SOD1-levels are lower than in G1del-mice and our neuron-
specific SOD1-mice. Both G1del-mice and our neuron-specific SOD1-mice show an earlier 
disease onset when mice are bred to homozygosity, accompanied by higher protein levels. It is 
very well possible that the aforementioned mice will develop a late-onset motor neuron disease, 
when bred homozygously. A study with chimaeric mice in which certain cells did, and others 
did not express mutant SOD1 showed that the non-neuronal environment can influence neuronal 
health (23). In these mice, wild-type motor neurons surrounded by mutant SOD1-expressing glial 
cells developed degenerative pathology, and wild-type glial cells surrounding mutant SOD1-
expressing motor neurons could delay the process of motor neuron death. These studies lead to 
the current belief that SOD1-linked ALS is a non-cell autonomous disease, and that multiple cell-
types are needed for the death of motor neurons (as discussed in (24, 25)). 
 However, the study described in chapter 3 demonstrates that motor neuron disease can 
be caused by mutant SOD1 solely expressed in neurons. Our data are supported by a number of 
studies. First, targeted reduction of mutant SOD1 in neuronal cells via RNAi leads to a delayed 
disease onset in two independent studies (26, 27). Second, specific deletion of mutant SOD1 via 
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neuronal-specific Cre-recombinase in Lox-SOD1-G37R mice slowed the early phases of disease 
(11). These studies suggest that mutant SOD1-expressing motor neurons are the main initiators 
of motor neuron death. Recently, transgenic mice expressing SOD1-G93A in neurons only via 
neuron-specific Cre-recombinase were made that develop a mild motor weakness, a lower body 
weight, and a decreased number of motor neurons at 500 days (22). However, neither protein 
levels were investigated, nor was the pathology of these mice examined, in addition it is not 
known whether at a later age, the mice developed motor neuron disease, or whether these mice 
showed earlier disease onset when bred homozygously. �owever, this latter study confirms our 
notion that there is a threshold-level above which mutant SOD1 in neurons specifically can induce 
motor neuron death.
  
6.1.3 expression of wtSoD1 accelerates disease progression in SoD1-ALS mice
Co-expression of high levels of wild-type human SOD1 (wtSOD1) with ubiquitous mutant SOD1-
mice accelerates disease in many studies (see table 6.2) (3, 13, 28). In chapter 3, we crossed 
neuron-specific SOD1-mice with ubiquitous wtSOD1-expressing mice. Double transgenic 
mice developed motor neuron disease from 1 year of age with a very long duration of disease: 
already at an early presymptomatic stage (15 weeks), ubiquitinated SOD1-aggregates appear in 
dendrites. In addition, in oligodendrocytes (a cell-type without mutant SOD1 expression) a high 
level of ubiquitinated SOD1-aggregates is observed. These aggregates are structurally similar to 
oligodendrocytic aggregates that appear at a lower level in wtSOD1-mice (3), indicating that they 
can occur independent of mutant SOD1-expression. In neuron-specific mutant SOD1-mice, but 
not in wtSOD1-mice, axonal degeneration processes take place that could facilitate the formation 
of these aggregates. These observations indicate that pathological changes in motor neurons can 
trigger damage to surrounding cells. 
Table 6.2 Wild-type SOD1 and CCS accelerate disease in SOD1-ALS mice
Combination Life span mSOD1 mouse
Life span double 
transgenic
Increase (-)
decrease (+) Ref.
G85R/ wtSOD1 (line 30) No change (29)
G85R/ SOD1 knockout No change (29)
G1/wtSOD1 (line N29) 127 118 -7% (13)
G1del/wtSOD1 (N29) 236 190 -20% (3)
Thy1-G93A/wtSOD1 (N29) > 2 years 490 ->50% Ch. 3
A4V/ wtSOD1 > 2 years 319 ->50% (13)
L126Z/ wtSOD1 359 201 -44% (13)
G85R/ wtSOD1 (line?) 348 197 -42% (28)
G37R/ CCS knockout
G93A/ CCS knockout
G85R/ CCS knockout
163
142
310
146
134
353
-10% (ns)
-6% (ns)
+14 (ns)
(30)
hSODwt (N29)/CCS tg No disease (31)
G93Adel/ CCS tg 250 50 -80% (31)
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 In an earlier study, neither deleting endogenous mouse SOD1 nor co-expressing human 
wtSOD1 had an effect on disease onset and survival of SOD1-G85R mice (29). This difference 
can be caused by the use of a different wtSOD1-expressing mouse with lower SOD1-levels, or 
by the use of a different SOD1-mutant, as a recent study did show earlier disease onset with 
G85R/wtSOD1 double transgenic mice (table 6.2) (28). It has also been suggested that the large 
variability of disease onset in the SOD1-G85R mouse could mask a change in disease (13).
How can wtSOD1 accelerate disease in SOD1-ALS mice? And, could wtSOD1 induce motor 
neuron disease by itself? It has been suggested that mutant and wtSOD1 could form dimers, 
thereby recruiting wtSOD1 into mutant SOD1-aggregates (‘seeding’) (32). SOD1-L126Z is not 
able to dimerize with wtSOD1, yet wtSOD1 does enhance the phenotype of SOD1-L126x-mice, 
arguing against the formation of such dimers (13). Moreover, in oligodendrocytes in Thy1-SOD1/
wtSOD-mice, ubiquitinated SOD1-containing aggregates appear, indicating that mutant SOD1 is 
not needed for wtSOD1 aggregation. In addition, the morphology of aggregates in Thy1-SOD1/
wtSOD-mice is similar to those in other SOD1-ALS mice.
 In most SOD1-ALS mice, including wtSOD1-mice, protein levels of Copper Chaperone 
for SOD1 (CCS) are increased (5). This enzyme is responsible for copper loading on SOD1. 
Deletion of CCS does not influence disease onset or survival in several lines of mutant SOD1-
mice, suggesting that copper loading is not needed for SOD1-mediated toxicity (table 6.2) (30). 
On the other hand, overexpression of CCS in SOD1-G93A-mice, but not in wtSOD1-mice 
causes a much earlier disease onset, associated with an enhanced localization of SOD1-G93A 
on mitochondria, and a complete lack of ubiquitinated aggregates (31). So there might be two 
different pathologic mechanisms, mitochondrial abnormalities and the formation of ubiquitinated 
aggregates, that both can cause motor neuron death in SOD1-ALS mice. 
 One possible effect of wtSOD1-expression in SOD1-ALS mice could be the further 
upregulation of CCS, that is already upregulated in these mice. This could facilitate mitochondrial 
localization of mutant SOD1 where it could exert its toxic functions. Indeed we observe a high 
level of mitochondrial pathology in Thy1-G93A/wtSOD1-mice, and not in Thy1-SOD1-G93A 
mice. It would be interesting to know if overexpression of CCS can also induce mitochondrial 
pathology in our neuron-specific mutant SOD1-mice. �owever, the implications of these 
discoveries for human ALS are limited, as mitochondrial pathology is not always observed in 
human ALS-patients and aggregates are the common pathological observation. Therefore, low-
level expressing SOD1-ALS mice that develop limited amounts of mitochondrial pathology and 
demonstrate a late onset of disease, are possibly a better model for human ALS. 
Our neuron-specific SOD1-mice unequivocally demonstrate that mutant SOD1-induced 
pathology in glial cells is not necessary for motor neuron death. In sum, the data from chapter 2 
and 3 provide evidence that glial pathology can be secondary to motor neuron pathology. First, 
astrocytic pathology in ubiquitous SOD1-G93A mice occurs relatively late in disease (chapter 
2), and second, degenerative changes in motor neurons induce wild-type SOD1 aggregation in 
oligodendrocytes (chapter 3). So, what then is the role of glia in the pathology of ALS?
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6.1.4 The role of glia: astrocytes
In two in vitro studies using co-cultures of motor neurons from embryonic stem cells or 
primary motor neurons grown on primary astrocytes, mutant SOD1-expressing motor neurons 
were cultured on wild-type astrocytes and vice versa (33, 34). Mutant SOD1-expressing motor 
neurons survived longer when cultured on wild-type astrocytes than on mutant SOD1-astrocytes, 
and mutant SOD1-expressing astrocytes could induce death of wild-type motor neurons. This 
suggested that astrocytic pathology could exert deleterious effects on motor neurons in SOD1-
ALS mice. However, transgenic mice with restricted expression of SOD1-G86R in astrocytes 
develop reactive astrocytosis but no motor neuron pathology or disease (table 6.1) (21). In line 
with the relatively late occurrence of reactive astrocytosis in SOD1-ALS mice, this indicates that 
pathology in astrocytes alone is not sufficient to cause motor neuron death in transgenic mice. 
 In vivo, astrocytes can influence motor neuron health via the regulation of extracellular 
glutamate levels, by uptake of glutamate via specific glutamate transporters (GLT-1/EEAT2). 
High levels of extracellular glutamate can overstimulate glutamate receptors on motor neurons, 
the most important glutamate receptors in this respect being the AMPA-receptors. Overstimulated 
glutamate receptors facilitate Ca2+-influx, which triggers a variety of intracellular cascades and 
can induce motor neuron death. This process is called glutamate excitotoxicity, and is activated 
after acute neuronal injury such as trauma or ischemia. AMPA-receptors consist of GluR subunits 
1-4, the presence of subunit GluR2 determines their Ca2+-permeability. Motor neurons might 
be especially vulnerable to excitotoxicity due to their relatively high level of Ca2+-permeable 
AMPA-receptors and low expression of proteins that can buffer an increased Ca2+-influx (e.g. 
parvalbumin and calbindin) (35, 36). A range of studies suggest that glutamate excitotoxicity 
is associated with motor neuron death in ALS, although the evidence is not very strong. First, 
glutamate receptors are shown to be lost in the spinal cord of ALS-patients and SOD1-ALS mice 
(37). Second, EEAT2-polymorphisms that lead to low EEAT2-expression have been associated 
Table 6.3 
Mouse models for excitotoxicity and effects on SOD1-ALS mice
Mouse model Effect Phenotype Effect on SOD1-ALS mice (G1) Ref.
GluR2-N
Increased Ca-
permeability of AMPA-
receptors
Late onset motor neuron 
disease
earlier onset, 
shorter survival
(39)
(42)
GluR2 tg Decrease in Ca-permeability no disease
delayed onset and 
survival (40)
GluR2-knockout Increase in Ca-permeability
no severe disease, some 
neurological problems
earlier onset, 
shorter survival
(46) 
(41)
EEAT2 tg More glutamate transporters no disease
delayed disease, 
same survival (43)
EEAT2 (GLT-1) 
knockout
<5% glutamate 
uptake in brain
no motor neuron 
disease; seizures and 
hippocampal pathology
same onset, shorter 
survival
(44)
(45)
Parvalbumin-
transgenic
Increased Ca-
buffering no disease
delayed onset and 
survival (47)
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with disease in ALS-patients (38), but this is still controversial. Third, the only drug approved 
for ALS-patients, riluzole, has anti-glutamatergic properties. However, other anti-glutamatergic 
treatments have not been beneficial for ALS-patients (36). 
 Studies with genetically modified mice with altered (levels of) glutamate-receptors 
demonstrate that chronically increased Ca2+-permeability of AMPA-receptors can induce a late-
onset motor neuron disease in mice (39), and that increasing or decreasing Ca2+-permeability in 
SOD1-G93A mice modifies disease onset and survival (table 6.3) (40-42). Also, mutant SOD1 
mice with extra EEAT2-receptors show delayed disease onset, possibly by increased glutamate 
uptake (43). On the contrary, mice with a knockout of astrocytic glutamate receptors (GLT-1), 
that only retain 5% of glutamate uptake in the brain, do not develop motor neuron disease (44) 
and loss of glutamate receptors in SOD1-G93A mice had a very modest impact on survival (45). 
These studies indicate that astrocytes, possibly via regulating glutamate levels, might have a 
modulating role on motor neuron disease, but that reduced glutamate uptake by astrocytes cannot 
induce motor neuron death by itself.
6.1.5 The role of glia: microglia
Microglial cells are the macrophages of the nervous system, and become activated in response 
to acute injury like ischemia and traumatic brain injury and to chronic neuronal injury as in 
neurodegenerative diseases. Reactive microglia are observed in spinal cord tissue from ALS-
patients and SOD1-ALS mice, and can trigger the induction of inflammatory, proliferative, 
oxidative, and excitatory pathways that can have both neuroprotective and neurotoxic effects. 
CSF from ALS-patients contains higher levels of inflammatory molecules in comparison to 
controls, indicating that reactive microglia can have a role in ALS pathogenesis (48, 49). In 
favor of this hypothesis, experimental stimulation of microglial activation via administration of 
lipopolysaccharide (LPS) aggravated disease in the SOD1-G93A mouse (50). However, mutant 
SOD1-expression in microglia only was not sufficient to induce disease (51), whereas selective 
Table 6.4 Effects of glial intervention on SOD1-ALS mice
Mouse Intervention Effect on disease Ref.
SOD1-G93A/ PU.1 ko
SOD1-G93A microglia in 
wild-type mice No disease (51)
Wild-type microglia in 
SOD1-G93A-mice Delays disease progression
Cre/Lox SOD1-G37R Deletion of SOD1-G37R in microglia Delays disease progression (11)
SOD1-G93A/ TNFα ko
SOD1-G37R/ TNFα ko
Deletion of microglial 
activator No effect (52)
SOD1-G93A /MMP-9 ko Inflammatory factor
Enhanced disease (53)
Delayed disease (54)
SOD1-G37R –
LPS treatment
Chronic stimulation of 
microglia
Enhanced disease 
progression (50)
SOD1-G93A/ NOX2 ko
Lower generation of ROS 
from activated microglia
Increased life span (55)
SOD1-G93A/ NOX1/2 ko Very large increase in life span, eye infections (56)
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ablation of mutant SOD1 in microglia extended survival by specifically slowing down the 
progression of disease (11, 51) (table 6.4). So as motor neurons are the initiators of disease as 
shown before, microglia are important regulators of disease progression, and are therefore being 
considered as important targets for pharmacological interventions. 
 Many studies show microglial inflammatory proteins to be upregulated in ALS-patients 
and SOD1-ALS-mice (57). Inhibitors of these proteins have been used for pre-clinical trials in 
SOD1-ALS mice, and some pharmacological interventions have shown to delay the progression 
of disease in these mice, even when administered at or past disease onset (58). However, genetic 
intervention studies deleting inflammatory factors in SOD1-ALS mice have lead to mixed results 
(see table 6.4). Deletion of matrix metalloproteinase 9 (MMP-9) has lead to an acceleration of 
disease in one study (53), and a delayed disease onset in another study (54). Deletion of pro-
inflammatory molecule TNF-α in SOD1-ALS-mice did not change disease onset or pathology 
(52). Deletion of NADPH-oxidases 1 and/or 2 (NOX), microglial ROS generating enzymes, in 
SOD1-ALS mice dramatically increased survival in SOD1-ALS mice in one study (56), and had 
a more modest effect in another study (55). However, in the former study, mice developed severe 
eye infections that were treated with antibiotics, that could have contributed to the observed effect 
on survival of these mice. So the exact role of microglia in the pathogenesis of ALS is complex 
and not completely clear.
 Because promising results with SOD1-ALS mice had been obtained with anti-
inflammatory treatments, many clinical trials for ALS-patients have commenced. So far, none 
of these drugs has been successful in delaying disease in ALS-patients, and a recent clinical trial 
with minocycline has even shown to cause an adverse effect (59). Although many studies suggest 
that microglia do contribute to disease progression, this recent failure of a clinical trial should 
make researchers more careful in designing treatments based on conflicting data.
6.1.6 model for pathological interplay between neurons and glia
Figure 6.1 Model for motor neuron death induced by 
ALS-mutant SOD1 and the role of astrocytes and 
microglia in this process
In conclusion, we propose a model (figure 
6.1) where mutant SOD1-expression 
in neurons induces the formation of 
ubiquitinated aggregates in dendrites 
that initiate neuronal degeneration. 
This degeneration triggers pathology 
in surrounding cells like astrocytes and 
microglia, which in turn contribute 
to the cascade of pathologic events, 
mediating further neuronal degeneration 
and completing a vicious circle of motor 
neuron death. There is a threshold for the 
amount of mutant SOD1-expression that 
can initiate this process in the life-time 
of a mouse. 
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In this model, neurons are considered to be the primary disease initiators and glial cells (microglia 
and astrocytes) the accelerators and modifiers of disease. As ALS-patients are on average 
diagnosed a year or more after disease onset, glial cells have been given most attention in designing 
therapeutic targets to slow down disease progression after onset, although attempts have so far 
been unsuccessful. As motor neurons are already affected in earlier, pre-clinical stages, inhibiting 
disease acceleration might be too late to reverse disease. For the understanding of molecular 
mechanisms underlying ALS pathogenesis, motor neurons should remain the primary subject of 
investigation, as pathology starts in the motor neuron.  
Environmental factors suggested to be risk factors for ALS, as dietary factors and exposure to 
toxins, could cause dysfunction of modifying cells, thereby accelerating disease, or initiating 
disease at sub-threshold mutant SOD1-levels. A similar interplay between genetic and 
environmental factors could occur in SOD1-linked fALS-cases, as the most common SOD1-
mutation in human ALS (A4V) can only induce motor neuron disease in transgenic mice when 
expressed homozygously or by co-expressing wtSOD1 (13). It is possible that this mutation in 
humans does not always cause ALS, and that the disease only manifests when other deleterious 
factors accumulate in motor neurons. 
Because of the low, almost sub-threshold, expression of mutant SOD1 and subsequent very late 
onset of disease, our neuron-specific SOD1-mice could serve as an excellent model to study 
subtle changes in disease and thereby determine important disease modifiers in human ALS. A 
similar suggestion has been made by Dal Canto et al. (8) when they generated the low-expressing 
G5/G5 mouse in 1997 (table 6.1). This mouse does not develop motor neuron disease but shows 
some pathological similarities with human ALS-cases. However, although more than a decade 
ago, researchers have continued to study high-expressing SOD1-ALS mice that show possible 
pathological artifacts like mitochondrial vacuolation. So far, therapeutic attempts with these mice 
have mainly lead to failures of clinical trials in humans (58). This could be caused by fundamental 
differences between mice and men, or to differences between SOD1-ALS and non-SOD1-ALS. 
However, one could also consider studying the low-expressing SOD1-ALS mice, that more 
resemble human disease. This would ask a little more patience from researchers, but, in the end 
might lead to drugs that actually are useful for the treatment of this devastating disorder. 
In conclusion, in both chapter 2 and 3 we have shown that dendritic ubiquitinated SOD1-
aggregates are the dominant pathological structures in SOD1-ALS mice. These aggregates could 
lead to a disruption of organelle trafficking and the structure of the cytoskeleton in dendrites, 
impairing the normal functioning of the cell and eventually leading to motor neuron death.
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Table 6.5  NF-accumulations delay disease in 
SOD1-ALS mice
Crossing (SOD1-
mutant) Effect on disease Ref.
BICD2-N/G1del delayed disease onset Ch. 4
NF-H-b-gal/ G37R no change (69)
NF-L mutant/ G85R delayed disease onset (70)
NF-H tg/ G37R delayed disease onset (71)
NF-L or NF-H/ G93A delayed disease onset (72)
peripherin/ G37R no change (73)
6.2 DiSruPTeD Dynein/DynACTin funCTion DoeS noT LeAD To  
 moTor neuron DiSeASe
As described in the previous paragraph, our data from chapter 2 and 3 show that dendritic 
ubiquitinated aggregates could lead to disturbed intracellular trafficking in motor neurons. To 
study the role of intracellular transport on motor neuron viability in vivo, we developed transgenic 
mice with chronic disruption of cytoplasmic dynein in neurons in vivo via overexpression of a 
truncated form of adaptor protein BICD2 (chapter 4). This leads to disrupted retrograde axonal 
transport and additional pathological changes in neurons resembling those found in ALS-motor 
neurons. No motor neuron death or disease was induced, and crossing these mice with SOD1-
G93A mice led to a delayed onset of disease. The possible mechanisms behind these observations 
are discussed in this paragraph.
 
6.2.1 neurofilament accumulations do not cause motor neuron death
BICD2-N transgenic mice, as described in chapter 4, develop massive accumulations of 
neurofilaments (NFs) in proximal axons, yet are viable and healthy up to two years of age. Similar 
NF abnormalities (axonal spheroids) containing large amounts of NF and peripherin are found in 
the axons of sporadic ALS patients and SOD1-ALS mice, and are early indicators of disease (60-
63). Several studies have shown variations, polymorphisms or mutations in NF-genes associated 
with a high occurrence of ALS (64, 65) (although contradicted by others (66)), suggesting a role 
for NFs in the development of ALS. However, BICD2-N mice, unlike SOD1-ALS mice, do not 
develop motor neuron death or paralysis, indicating that NF accumulations are not necessarily 
toxic to motor neurons. 
 Before the development of SOD1-ALS mice, several lines of genetically engineered 
mice with alterations in NF-subunits or peripherin were generated. These include overexpression 
or deletion of the individual NF-subunits, and combinations of expression of one NF-subunit in 
the absence of others. The detailed description of these mice is beyond the scope of this thesis, 
an overview is given in several reviews (63, 67, 68). In general, many of these mice (referred to 
as ‘NF-mice’) develop NF accumulations in perinuclear and axonal regions of motor neurons, 
but only some develop neuronal death, motor abnormalities and muscle atrophy. The lack of a 
pathological phenotype in some NF-mice and in BICD2-N mice, indicates that NF-accumulations 
are not the primary cause of motor neuron death in SOD1-ALS mice. 
 By crossing these ‘NF-mice’ 
with mutant SOD1-ALS mice, it was 
shown that NF accumulations rather 
have a protective effect on motor 
neuron survival, as many of these 
double transgenic mice show a delay in 
disease onset and a longer survival (see 
table 6.5) (70-72, 74). When crossing 
BICD2-N mice with SOD1-G93A 
mice (chapter 4), we also observed a 
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delay in disease onset. In NF-mice, it has been demonstrated that perikaryal NF accumulations 
cause a reduction of axonal NF content, subsequently leading to smaller axonal diameters. In 
SOD1-ALS mice, smaller axons are less vulnerable to degeneration than larger axons, this could 
explain the observed delay in disease onset in NF/SOD1-ALS mice (74, 75). The protective effect 
of BICD2-N-expression on SOD1-ALS mice could take place via decreasing axonal diameter 
and thereby making motor neurons less vulnerable to degeneration.
6.2.2 Disrupted retrograde axonal transport does not cause motor neuron disease
BICD2-N mice with impaired dynein function in neurons in vivo manifest delayed axonal 
retrograde transport, but no motor neuron death or motor abnormalities (chapter 4). As described 
in chapter 1.4, mutations in microtubule motors, microtubule-related proteins and cytoskeletal 
proteins have been documented to cause motor neuron disease in a number of mouse models. In 
table 6.6 an overview of the pathology in these mouse models is shown. In what respect are these 
mice, that do develop motor abnormalities, different from our BICD2-N mice?
 LaMonte et al generated transgenic mice with a disruption of dynactin in neurons in vivo, 
by overexpression of the dynamitin/p50-subunit of dynactin. p50-mice show late-onset motor 
abnormalities, accompanied by a modest decrease in retrograde axonal transport. In addition, 
NF-accumulations in axonal spheroids are observed, as well as a decrease in large-caliber axons. 
However, only a limited number of motor neurons degenerated, and transgenic mice have a normal 
life span (76). In chapter 4, we compared the mechanisms of dynein disruption via BICD2-N and 
p50 in cultured cells and primary hippocampal neurons. Whereas BICD2-N binds to and recruits 
dynein and dynactin, p50-overexpression rather disrupts the dynactin complex. It is possible that 
in p50-mice, motor neuron abnormalities arise via a toxic mechanism of dynactin disruption and 
not via a decrease in retrograde axonal transport.
 In human motor neuron disease, mutations in p150 were found, that have been hypothesized 
to cause dysfunction of dynein and subsequent disruption of retrograde axonal transport (77-79). 
However, one of the mutations causes aggregation of the mutant protein (79), and large inclusions 
containing dynein and dynactin were found in spinal motor neurons. This suggests that these 
aggregates could cause motor neuron death rather than a disruption of axonal transport. A mouse 
with a heterozygous p150-G59S knock-in develops a late-onset slow progressive motor neuron 
disease with subtle motor abnormalities and motor neuron death, indicating that indeed this 
mutation can be deleterious to motor neurons (80). Homozygously expressing this mutant p150-
protein, as well as homozygous p150-knockout are embryonically lethal, whereas a heterozygous 
p150-knockout mouse does not have any phenotype, suggesting that this mutations has some 
toxic gain-of-function. Recently, a transgenic mouse overexpressing p150-G59S in neurons was 
generated, that developed a late-onset motor neuron disease, characterized by motor neuron death, 
defects in vesicular trafficking, muscle denervation and accumulation of intracellular vesicles. In 
motor neurons of these mice, mutant p150 accumulated in large inclusions over time, suggesting 
that indeed these aggregates are the toxic species in these mice (172).
 Loa and Cra1-mice carry heterozygous mutations in the gene for Dynein Heavy Chain 
(DHC), which leads to late-onset motor abnormalities. When homozygous, both mutations are 
lethal at postnatal day 1 due to defects in neuronal migration. Homozygous DHC knockout is 
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embryonically lethal, whereas heterozygous DHC-knockouts are normal (81), demonstrating that 
these mutations, as the p150-G59S mutations, possess a toxic gain-of-function. At least in Loa-
mice, a reduced branching pattern of the hind-limb nerves is observed, indicative of a developmental 
defect that could lead to paralysis later in life. As these mice manifest no pathological changes 
accompanying motor neuron degeneration, as astrocytosis and microgliosis, it is likely that a 
reduced number of motor neurons is a congenital defect rather than caused by cell death. This also 
might explain why Loa and Cra1-mice have a normal life span. The defect in axonal transport is 
only observed in motor neurons with homozygous mutations, heterozygous Loa and Cra1-mice 
only show a very modest reduction in axonal transport (82). In these mice, motor abnormalities 
are probably caused by a developmental defect and not via decreased axonal transport. 
 A mouse with another mutation in the gene for DHC (Sprawling, Swl) is also 
embryonically lethal when homozygous. When heterozygous this mouse develops an early-
onset sensory neuropathy with muscle spindle involvement (83). This shows that mutations in 
different regions in the DHC gene can affect different neuronal populations and lead to different 
phenotypes.
Table 6.6 Pathology in mouse models with disruptions in motor/
microtubular/ cytoskeletal proteins
Disease/mouse Gene/mutations Pathology Effect on SOD1-ALS mice (G1) Ref
BICD2-N mice Dominant-negative adaptor protein AT,NFa,G,E  
Delayed disease 
onset (G1del)
Chap-
ter 4
Dynactin knockouts, transgenics and mutations
p50-mice Overexpression of p50/dynamitin AT,NFa,MN, P; No change
(76) 
(84)
p150-knockout Knockout of p150/dynactin1
Hom: EL 
Het: no phenotype No change (80)
p150-G59S mice Knockin of mutant p150/dynactin 1
Hom: EL (E8)
Het: MN, Nfa No change (80)
p150-G59S mice Overexpression of mutant p150 NF, E, MN, P, † ND (172)
Dynein knockouts and mutations
DHC knockout DHC knockout Het: no phenotype Hom: EL (E8) ND (81)
Leggs at odd 
angles (Loa)
DHC mutation
(F580Y)
Het: AT,MN, P; not: G, �   †
Hom: Lethal (P1)
Delayed disease 
onset
(82) 
(85)
Cramping1 (Cra1) DHC mutation(Y1055C)
Het: AT,MN, P; not: G, �   †
Hom: Lethal (P1) 
Delayed disease 
onset
(82) 
(86)
Sprawling (Swl) DHC mutation(9bp deletion)
Het: Sensory 
neuropathy, Hom: EL No change (83)
Other mutations
Progressive motor 
neuropathy (pmn)
Tubulin chaperone 
E mutation MN, nmj, P ND (87)
Dystonia 
musculorum (dt)
Mutant adaptor 
protein (BPAG1n) NFab,MN, P, †  ND (88)
Legend: Het=heterozygous, Hom=homozygous, EL=embryonic lethal, AT=decreased axonal 
transport, NF=NF accumulations, (s)=soma, (a)=axon, G=golgi fragmentation, E=endosomal 
alterations, MN= motor neuron death, nmj= denervation of NMJ, P= paralysis or motor abnormalities, 
†= reduced life span. ND= not determined
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 Two spontaneous mouse models with motor abnormalities are pmn (progressive motor 
neuropathy) mice and dystonia musculorum (dt)-mice. pmn-mice develop progressive distal motor 
weakness, accompanied by decreased axonal transport, caused by a mutation in Tubulin Chaperone 
E (87, 89). TbcE is required for microtubule folding and delivery into the axon and controls this 
process from the Golgi apparatus. Lack of TbcE leads to a decrease in axonal microtubules (90). 
The phenotype of the pmn-mouse can be partially rescued by protection of axonal degeneration, 
but not by preventing apoptosis, suggesting that this disorder is an axonopathy rather than a 
neuropathy. The delay of axonal transport is possibly attributable to a loss of microtubules 
rather than to a disruption of transport motors (91). A degeneration of sensory neurons causes a 
movement disorder in dt mice, accompanied by axonal swellings accumulating lysosomes (92). 
In the dt-mouse the neuronal isoform of BPAG1, BPAG1n, is deleted, that is a linker protein for 
MTs and NFs (93). Recently, another neuronal isoform (BPAG1n4) was identified that could bind 
to a specific protein (retrolinkin) on endosomes and to dynactin-subunit p150, thereby serving 
as an adaptor molecule linking this type of vesicles to the dynein motor (table 1.4) (94). The 
observed axonal lysosomal accumulations in sensory axons could be caused by a disruption of 
endosomal trafficking and be responsible for sensory neuron degeneration in these mice. Whether 
axonal transport is disrupted in these mice has not been studied. 
 In sum, these data from mouse models and human motor neuron disease do not provide 
conclusive evidence that a disruption of axonal transport leads to motor neuron disease. Therefore 
it is not so surprising that our BICD2-N mice do not develop motor neuron abnormalities. 
6.2.3 Disruption of retrograde transport is beneficial for SoD1-ALS mice
That disrupted retrograde axonal transport is not a straightforward cause of ALS is further 
demonstrated in chapter 4, where we show that crossing our BICD2-N mice with SOD1-G93A 
mice leads to a delayed disease onset and a longer survival. Crossing the Loa and Cra1-mice 
with SOD1-G93A mice had similar results (85, 86). It seems that a disruption of dynein and/or 
disturbed retrograde transport can delay degeneration of motor neurons in SOD1-G93A mice (see 
table 6.6). However, crossing p50 or p150-G59S-mice with SOD1-G93A mice had no effect on 
disease onset and survival. 
Several mechanisms could explain the delay in disease onset in double transgenic mice:
○ A very early observation in SOD1-ALS mice is a delay of anterograde transport (95). A delay 
in retrograde transport, like in our BICD2-N mice and in the Loa/Cra1-mice, might restore the 
overall transport balance in axons and thereby delay disease onset. 
○ In chapter 2, we show that perikaryal and dendritic aggregates represent the earliest pathological 
changes in SOD1-G93A mice. Protein and organelle trafficking in dendrites is also mediated via 
microtubule motors, and a disruption of dynein/dynactin function in BICD2-N/SOD1-mice could 
contribute to delayed delivery of these aggregates into the regions where they exert their toxic 
properties, thereby delaying disease onset.
○ It has been suggested that mutant SOD1 can interact with dynein and thereby disrupt the dynein 
complex (96, 97). It is possible that this toxic gain-of-interaction of SOD1 and dynein is disrupted 
in the BICD2-N/SOD1 and Loa/Cra1/SOD1 mice, thereby decreasing the formation of toxic 
aggregates and delaying disease onset. 
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○ Transport of misfolded proteins towards the autophagosome is dependent on dynein/dynactin 
(98). A mouse model for Huntington’s disease that develops aggregates, shows an enhanced 
disease phenotype when crossed with the Loa mouse, possibly caused by delayed delivery of 
mutant Huntingtin to the autophagosome (see box 1.2). Mutant SOD1 is mainly degraded by the 
proteasome, explaining why crossing SOD1-ALS mice with the Loa-mice had the opposite effect 
(99), so probably autophagic clearance of mutant SOD1 does not play a major role in disease in 
SOD1-ALS mice. 
○ Delayed retrograde transport slows retrograde injury signaling that could lead to a decreased 
injury/stress response in BICD2-N/SOD1 motor neurons (discussed below).
6.2.4 retrograde signaling is important for motor neuron survival after injury
Stress-injury factors, neurotrophins and their receptors are retrogradely transported from the 
injury site to the nucleus via dynein/dynactin dependent microtubule transport (100). This 
transport is mediated via endosome-like structures (signaling endosomes) that can be packed 
into multivesicular bodies (MVBs) (101). Disruption of dynein/dynactin-transport attenuates 
retrograde neurotrophin signaling, and aberrant retrograde neurotrophin signaling is involved in 
neurodegenerative diseases (102). Stress factors, like the activated form of C-Jun N-terminal kinase 
(p-JNK) and its substrates ATF-2 and ATF-3, are transported to the nucleus shortly after injury 
(103). Following axotomy in BICD2-N-mice we observed retarded delivery of injury response-
factors to the nucleus (chapter 4), BICD2-N neurons showing almost no ATF-3-expression as 
compared to control neurons. This indicates that dynein/dynactin-dependent transport is required 
for injury responses. ATF-3 is also expressed in motor neurons in SOD1-G93A mice prior to 
their death (chapter 2) and is suggested to participate in the initiation of apoptotic cascades. In 
BICD2-N/SOD1 mice retarded delivery of these stress factors to the nucleus due to the disruption 
of retrograde transport could delay motor neuron apoptosis.
 On the longer term after neuronal injury, neurotrophins like Nerve Growth Factors (NGF) 
are transported from the injury site towards the cell body, and bind to neurotrophin-receptors like 
TrkA, B, C and p75NTR to generate injury and survival responses (104). Preliminary data from 
our BICD2-N mice show that three weeks after axotomy, there is a small increase in loss of motor 
neurons as compared to control mice. This suggests that a disruption of retrograde transport could 
lead to diminished neurotrophin signaling that is deleterious for motor neuron survival (104). The 
p75NTR-neurotrophin-receptor is normally not expressed in adult motor neurons, but is activated 
in the spinal cord of ALS-patients and SOD1-G93A-mice (105). Via p75NTR, NGF can activate 
several downstream pathways resulting in apoptosis. For BICD2-N/SOD1 mice, this implies 
that decreased neurotrophin signaling might result in a lower activation of p75NTR-receptors, 
delaying the initiation of motor neuron apoptosis. 
Both pathways, delayed stress response and lower activation of p75NTR, could contribute to the 
delayed disease onset in BICD2-N/SOD1 mice. To be able to separate these two processes, one 
could perform axotomy-experiments with BICD2-N/SOD1 mice and monitor the effect of injury 
on expression of nuclear stress factors, retrograde neurotrophin signaling, motor neuron survival 
and disease. 
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6.2.5 Dynein/dynactin dysfunction perturbs endosomal trafficking in vivo
A number of endosomal abnormalities, primarily in the early endosomal pathway, are observed 
in BICD2-N mice (chapter 4). As already mentioned in chapter 1.4, microtubule transport and 
the secretory/endosomal pathways are closely linked, as almost all vesicular budding, transport 
and tethering steps in these pathways rely on motor proteins (106). The dynein/dynactin motor 
is required for proper localization and morphology of the Golgi apparatus. Fragmentation of 
the Golgi apparatus occurs in many conditions, e.g. following experimental disruption of 
dynein/dynactin or microtubule depolymerization, and preceding apoptosis in motor neurons 
in neurodegenerative diseases (107). In BICD2-N motor neurons, the Golgi apparatus is also 
disrupted, consistent with disruptions in dynein/dynactin function. 
 A lower number of early endosomal vesicles and a smaller size of remaining vesicles 
were observed in motor neurons of BICD2-N mice. In neurons derived from Alsin-knockout 
mice, similar endosomal abnormalities are seen (paragraph 1.4). When Alsin-knockout mice were 
crossed with the (high-copy) SOD1-G93A mice, a trend towards a delayed disease onset was 
observed (table 6.6) (108), or no change (109). BICD2-N-mice were crossed with the low-copy 
SOD1-mice, that could explain the (larger) difference in disease delay. These studies suggest that 
a disruption in endosomal trafficking could decrease early pathological changes in motor neurons 
of SOD1-ALS mice, but not prevent motor neuron death. It is possible that SOD1-aggregates are 
delivered via endosomes towards the intracellular location where they exert their toxic function, 
and that this pathway is delayed in BICD2-N/SOD1-mice, however, this remains speculative. 
Currently we are studying this hypothesis by monitoring endosomal dynamics in SOD1-mice. It 
would be interesting to know if disruption of membrane trafficking in other stages of the pathway 
could also delay disease onset in SOD1-ALS mice. The role of endosomes in SOD1-ALS is 
an intriguing new research topic, as this cellular change in BICD2-N mice could provide the 
explanation why BICD2-N/SOD1-mice have a delayed disease onset. In addition, manipulating 
endosomal dynamics via pharmacological interventions could lead to potential new therapeutic 
approaches.
In conclusion, disruption of retrograde transport is not sufficient to induce motor neuron disease 
by itself, but in combination with axonal injury leads to an increase in motor neuron death. 
Furthermore, it is not completely clear why and how disruption of retrograde transport delays 
disease onset and survival in SOD1-G93A mice, and the observation that endosomal trafficking 
is disrupted in these mice needs to be studied in more detail. BICD2 is an adaptor protein between 
the dynein/dynactin motor and Rab6-cargo vesicles and no specific cell-types have been attributed 
to this interaction. The growing number of adaptor proteins that have been found to link dynein 
to specific types of cargo (table 1.4) could help understand the cell-type specificity of certain 
mutations. For example, the sensory-axon specific vulnerability of the dt-mutation indicates that 
this adaptor molecule determines cargo specificity only in these neurons. It would be interesting 
to know whether other adaptor molecules as shown in table 1.4 could serve similar cell-type 
specific roles and if certain cell-types are especially vulnerable to deletion or mutation of these 
subunits. 
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box 6.1: membranes, lipids and phospholipids
The plasma membrane and membranes of intracellular organelles are dynamic, fluid structures 
composed of a lipid bilayer, that mainly consists of phospholipids, but in smaller amounts also contains 
glycolipids and cholesterol. The major phospholipids in the plasma membrane are sphingomyelin 
(SM), phosphatidylcholine (PC), phosphatidylserine (PS) and phosphatidylethonoloamine (PE), minor 
components are phosphatidylinositols (PtdIns) and its residues, phosphoinositides (PIPs). By subsequent 
phosphorylation and dephosporylation steps, PtdIns can generate 6 different PIPs that have important 
functions as second messengers in intracellular signalling (figure 6.2) (reviewed in (110, 111)). 
On the surface of most plasma membranes, glycolipids are present, that mediate contact of the cell with 
its surroundings; they are especially abundant in neurons (112). In eukaryotic cells, small microdomains 
containing high levels of cholesterol and sphingolipids are present that are called lipid rafts. These 
structures contain a high concentration of signalling molecules, can interact with the cytoskeleton and 
have been implicated in a wide variety of cellular functions, as cell polarity, cell migration and, in neurons, 
the maintenance of synapses and dendritic spines (113, 114). 
Sphingomyelin (SM), the most abundant phospholipid, is synthesized in the Golgi apparatus by the 
conversion of ceramide by SM synthase, the reverse, ceramide can also be generated from SM via the 
action of sphingomyelinase. Ceramide is newly synthesized in the ER and is transported to the Golgi 
apparatus for further metabolism. This is mainly mediated by non-vesicular transport, that has also been 
described for other sterols as oxysterols and PS (115). Non-vesicular transport involves the action of Lipid 
Transfer Proteins (LTPs) that have specific domains for lipid recognition and a pleckstrin homology (P�) 
domain that binds to specific PIPs in the membranes of intracellular organelles. Several of these LTPs 
are targeted to the ER via interaction with VAPA and VAPB trough their FFAT-domain. Through these 
dual-interaction sites, LTPs can move between the membranes of different intracellular compartments, 
thereby transporting lipids from the site of  synthesis to their next location of metabolism. VAPA and 
VAPB mediate the targeting of the LTPs to the ER and are therefore important regulators of intracellular 
lipid homeostasis (figure 6.3) (116, 117).
6.3 VAPb AnD The inVoLVemenT of LiPiD meTAboLiSm in   
 neuroDeGenerATion 
The endosomal and secretory pathways are frequently referred to as ‘membrane trafficking’, 
because they include the subsequent budding, transport and fusion of membraneous organelles. 
For these pathways to function properly, the structure and integrity of membranes, that consist of 
lipids (see box 6.1), is of high importance. In this paragraph, it will be discussed how disruption 
of lipid homeostasis could lead to neurodegeneration. In chapter 5, we show that the ALS-linked        
mutation in VAPB (P56S) has a dominant-negative action, recruiting endogenous VAPB and 
VAPA into insoluble, non-functional cytosolic clusters. Mutant VAPB could exert its toxic function 
on neurons by its inability to bind FFAT (diphenyl-analine in an acidic tract)-domain-proteins, 
thereby mislocalizing Lipid Transfer Proteins (LTPs) and causing defects in lipid metabolism. 
This is a plausible hypothesis, given the many (neurodegenerative) diseases that are linked to 
subtle defects in this pathway.
6.3.1 Defects in phosphoinositide-metabolism can lead to neurodegeneration
One of the FFAT-domain proteins targeted to the ER by proteins of the VAP-family is Nir2, that 
is also known as membrane-bound Phosphatidyl-Inositol Transfer Protein (PITPnm) or retinal 
degeneration-homologue B (rdgB) (118, 119). The family of PITPs comprises two classes in 
mammals, the soluble PITP’s α and β, and the membrane-bound PITPnm-proteins (Nir 1, 2, 
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Figure 6.2. Phosphoinositides and disease. Major phospholipids are depicted in bold, phospholipids 
binding to yeast VAP-homologue Scs2p are underlined. Proteins in this pathway implicated in human or mouse 
(neurological) diseases are shown, the disorders are indicated with arrowheads. The binding of  FFAT-domain-
proteins (*) to PIPs is also shown. See text for explanation and references. 
and 3) (120). Nir2 is homologous to the Drosophila retinal degeneration protein B (DrdgB), 
that when mutated can lead to light-induced degeneration of retinal neurons (121). A soluble 
member of the mammalian PITP-family, PITPα, is mutated in the vibrator-mouse (122). Vibrator 
is a spontaneously arisen, recessive mouse mutant that develops tremors and juvenile death, 
accompanied by degeneration of neurons in the spinal cord, brain stem and cerebellum (see table 
6.7) (123). PITPs function in the transfer of phosho-inositides (PIPs) to their correct intracellular 
locations (figure 6.2). Both DrdgB and Nir2 regulate intracellular PIP-levels, suggesting a 
conserved pathway for the vibrator phenotype and the function of this protein in Drosophila 
(124, 125). Several other proteins important for the strictly regulated turnover of PIPs are found 
to be mutated in certain human (neurodegenerative) disorders and/or spontaneous mouse models 
(table 6.7). The myotubularin-proteins are phosphatases catalysing the conversion of PI(3,5)P2 to 
PI(5)P (figure 6.2). Mutations in myotubularin (MTM) cause myotubular myopathy, a congenital 
muscular disease characterized by the impaired development of muscle fibers (126). Mutations in 
two other members of this family, MTMR2B and MTMR13, cause two subtypes of CMT (127). 
Furthermore, mutations in Dynamin, a GTPase, involved in vesicle-formation and containing a 
PH-domain that binds to PI(4,5)P2, was also found to be mutated in CMT (128). 
 A few recent discoveries have further strengthened the notion that phosphoinositide-
metabolism could be important for neuronal viability. The pale tremor mouse develops tremor 
and abnormal gait, degeneration of neurons preceded by vacuole accumulation, loss of axons and 
juvenile death, the pathology resembling that of Charcot-Marie-Tooth disease. The mutation in 
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these mice was mapped to the gene for Fig4, a PI(3,5)P2-phosphatase involved in both synthesis 
and turnover of PI(3,5)P2 (figure 6.2) (129), also mutations in Fig4 were detected in four unrelated 
CMT-patients. Moreover, mutations in Sac14, a protein that acts in a complex with the protein 
Fig4, caused a sensory neurodegeneration in knockout mice (130) (see table 6.7). 
 PI(4,5)P2, one of the major PIPs, serves as a precursor for the important second 
messengers diacylglycerol (DAG) and inositol-1,4,5-triphosphate (InsP3), that are generated via 
phospholipase-C (PLC) (figure 6.2). InsP3 mediates Ca2+-release from intracellular calcium-
stores via interaction with one of the three InsP3-receptors (ITPRs), resulting in the activation of 
a broad range of Ca2+-mediated processes (131). ITPR1-knockout mice develop seizures, ataxia 
and subtle motor abnormalities, but no motor neuron degeneration (132). In a genome-wide 
association study, an association of variants in ITPR2 was identified in ALS-patients, resulting 
in higher ITPR2-levels, that was suggested to lead to altered intracellular calcium levels (133). 
Together, these data suggest an increased vulnerability of (motor) neurons to small variations in 
phospholipid metabolism, as all proteins described are ubiquitously expressed, however, only 
Table 6.7 Human (neurological) diseases/ mouse models caused by defects in         
the phosphoinositide-pathway or lipid metabolism
Disease/mouse Gene Function Ref 
Vibrator  mouse PITPα PI transfer, required for InsP3 and PIP3 production (122)
Myotubular myopathy Myotubularin (MTM)
Production of PI5P by dephosporylating 
PI(3,5)P2
(126)
CMT4B MTM-related 2 (MTMR2B) (136)
CMT4C MTMR13/SBF2 Interacts with MTMR2B (137)
DI-CMT Dynamin Binds to PI(4,5)P2 (128)
Pale tremor mouse/ 
CMT type J
Fig4: PI(3,5)P2-
phosphatase Generation and turnover of PI(3,5)P2 (129)
Mouse with neurode-
generation
Vac14: PI(3,5)P2-
phosphatase Generation and turnover of PI(3,5)P2 (130)
ALS (susceptibility 
factor) ITPR2 Inositol-1,4,5 receptor-2 (133)
Alzheimer/ ALS (sus-
ceptibility) ApoE Neuronal uptake of cholesterol (138)
Niemann-Pick Dis-
ease type C NPC1 or NPC2 Cholesterol sensors (139)
Niemann-Pick Dis-
ease type A/B Sphingomyelinase Generation of ceramide (140)
Liver X receptor mu-
tant mice LXR 
Central role in fatty acid/ cholesterol 
metabolism (141)
Hereditary Spastic 
Paraplegia 5 CYP7B1 Cholesterol metabolism (142)
ALS8 VAPB Targeting of LTPs to the ER- general role in lipid metabolism?
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affect (motor) neurons when mutated. 
 The yeast homologue of VAPs, Scs2p, required for inositol metabolism in yeast (134), 
can bind to a number of PIPs in vitro via a region in the highly conserved MSP (motile sperm)-
domain, these PIPs are underlined in figure 6.2. This binding is inhibited by mutations in the 
FFAT-binding domain (135), and it is possible that mammalian VAPs can serve a similar role, and 
that the P56S-mutation can disrupt these interactions, however, this has not been proven. 
6.3.2 Abnormalities in cholesterol and ceramide can lead to neurodegeneration
Other LTPs that bind to VAPA and VAPB via their FFAT-domain are Oxysterol Binding Protein 
(OBSP) and the OSBP-Related Proteins (ORP1-4, 6, 7 and 9). OSBP and ORPs mediate the 
non-vesicular transport of oxysterols between the ER and other membranes. Via their FFAT-
domain, ORPs bind to VAPs in the ER, and via a PH-domain they can bind to different PIPs 
in other membranes, thereby acting as anchors at membrane contact sites, and mediating the 
translocation of lipids from one membrane to the other (see figure 6.3). Oxysterols are derivatives 
of cholesterol and can serve as sensors for intracellular cholesterol levels, thereby serving as 
important regulators of cholesterol metabolism. Increased levels of 25-hydroxy-cholesterol can 
induce the translocation of OSBP and ORPs from their cytosolic location to the Golgi apparatus. 
Several abnormalities in cholesterol-metabolism are implicated in neurological diseases (table 
6.7) (143, 144). 
 As a component of mammalian membranes, cholesterol has a particularly high abundance 
in myelin; therefore the brain is highly enriched in cholesterol as compared to other organs. 
Cholesterol is not able to cross the blood-brain-barrier, separating cholesterol metabolism in the 
brain from other tissues (145). The exchange of cholesterol between neurons and other cell-types 
is mediated via ApoE lipoproteins that are secreted by astrocytes. These lipoproteins have three 
alleles in humans (ApoE2,3,4), the ApoE4-allele is a well-known risk factor for Alzheimer’s 
disease, and was also found to be associated with bulbar-onset ALS (138). Furthermore increased 
ApoE-expression correlates with onset of neuronal degeneration in SOD1-mice (146), indicating 
that cholesterol transport is important for the neuronal health in general.
 Another disease that presents with cholesterol abnormalities is Niemann-Pick disease, 
characterized by progressive ataxia, seizures and death in early childhood. Niemann-Pick’s disease 
type C is caused by mutations in either the NPC1- or NPC2-gene (respectively 95% and 5% of 
cases) (145). Both proteins, NPC1 and -2, have a cholesterol-sensing domain and are involved in 
transport of cholesterol out of endosomes/lysosomes to the plasma membrane and the ER. When 
these proteins are lost, as is the case in NPC-neurons, cholesterol, normally present in the plasma 
membrane, accumulates in these late-endosomal and lysosomal peri-nuclear vesicles, making 
the membrane devoid of cholesterol. NPC-mutations cause intracellular trafficking defects of 
cholesterol, but possibly also of other proteins (139). The cholesterol-accumulating endosomes 
also contain glycolipids (gangliosides). Recently, a successful clinical trial with an inhibitor of 
glycosphingolipid synthesis was completed, that resulted in decreased ganglioside accumulation 
and thereby improved clinical health of the patients (147). 
 The last FFAT-domain protein identified until now is ceramide transporter CERT, that 
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mediates the non-vesicular transport of ceramide between the ER and the Golgi trough interaction 
with respectively VAPs and PIPs (see figure 6.3) (148). Ceramide is directly implicated in 
neuronal survival, as it can either promote survival or trigger apoptosis in neurons in culture, 
dependent on its concentration (149). In the lower spinal cord of SOD1-ALS mice and ALS 
patients, levels of sphingomyelin, cholesterol esters and ceramide were found to be significantly 
increased as compared to upper spinal cords or control subjects. An increase in ceramide also 
occurs after oxidative stress, via a mechanism that requires de novo sphingolipid synthesis (150). 
Unfortunately, it is not clear in which cell-types (i.e. neurons or glial cells) this increase occurs, 
or in which subcellular compartments the accumulated lipids reside. Ceramide can be generated 
from sphingomyelin (SM) by acidic spingomyelinase (ASM), that is mutated in Nieman-Pick 
Disease type A and B (140). Under conditions of stress, ASM translocates to the plasma membrane 
Figure 6.3. Model for mutant VAPB-induced abnormalities in lipid homeostasis. Normally, VAPB is 
present in the ER and can bind LTPs via their FFAT-domain. In the mutant situation, this binding is impaired, 
leading to an inability to recruit LTPs to the ER, followed by lipid abnormalities in all membrane-containing 
structures in the cell. An enlarged MCS between the ER and golgi is shown, these contact sites also exist 
between other membraneous structures in the cell 
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where it degrades SM into ceramide, reorganizes membrane rafts and induces apoptosis or 
survival pathways. In Niemann-Pick Disease type A and B, possibly ceramide-mediated signal 
transduction pathways are altered that can lead to cell death (151).
 General gatekeepers of lipid homeostasis are the so-called Liver X Receptors (LXRs) 
that can be activated by oxysterols and in turn regulate expression of many genes, for example 
ApoE and cholesterol. Mice with targeted knockout of LXRα and β show neurodegeneration, 
and LXR-β knockout mice show subtle motor abnormalities (141, 152). This indicates that 
subtle alterations in central lipid pathways can already lead to neurodegeneration and locomotion 
defects, suggesting that (motor) neurons especially rely on correct lipid homeostasis.
6.3.3 model of VAPb-P56S-induced neurodegeneration via lipid abnormalities
As described, VAPA and VAPB can bind to a number of LTPs via their FFAT-domain and target 
these proteins to the ER; nine mammalian proteins with a FFAT-domain have been described so 
far: Nir2, Nir3, CERT, OBSP and ORPs 1-4,6,7 and 9 (119, 143, 148). Dominant-negative VAPB 
might impair the ER-targeting of these LTPs, that can lead to a disruption of lipid transport to and 
from several intracellular membrane compartments as the ER, Golgi apparatus and endosomal/
secretory vesicles (see figure 6.3). Subtle abnormalities in lipid homeostasis, as have been 
described above, can already lead to neurodegeneration. We suggest that VAPB-P56S leads to the 
mislocalization of LTPs and subsequent neurodegeneration in ALS-8-patients (153).
 The next step is to find out whether these proteins are indeed mislocalized in VAP-
linked ALS. For that purpose, we are currently generating VAPB-transgenic mice. Furthermore it 
would be interesting to be able to study tissue material from ALS8-patients, although this will be 
difficult to obtain due to the rarity of this mutation. Also, it is currently not known if mammalian 
VAPs, like yeast Scs2p can also directly bind these phospholipids and whether this binding is 
altered by the P56S-mutation.
 Epidemiological data also point to a role of lipids and fat as determining factor for the 
development of ALS. For example, bacterial and plant sterol derivates, implicated in Guam-
linked ALS, have shown to be neurotoxic (154). Next, although hard to prove, it is observed that 
ALS-patients are in general more lean and athletic than the average population (155) and that 
low fat intake is a risk factor for the development of ALS (156). There is also a relatively high 
occurrence of ALS among men who served in the military that might be attributable to a long 
period of high physical activity (157). All ALS-patients lose a lot of weight prior to death, due to 
disease-induced swallowing problems, but some studies suggest a general hypermetabolic state 
in ALS-patients (158-160). These suggestions were further confirmed in ALS-SOD1 mice, that in 
general have a lower body mass than litter mates and an increased metabolic rate (161, 162). 
Caloric restriction is believed to prolong life in mammals due to decreased oxidative damage, a 
process that has been suggested to play a role in motor neuron death in ALS. However, caloric 
restriction does not seem to be beneficial for ALS-patients, as a leading advocate of caloric 
restriction, Roy Walford, died of ALS at the age of 74. Also, caloric restriction causes earlier 
disease onset in SOD1-ALS mice, the contrary, fast-food diets containing high levels of fat and 
sugar increase the life span of SOD1-ALS mice (163, 164).
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In conclusion, data ranging from genetics, biochemistry and epidemiology, support a hypothesis 
for the involvement of lipids in ALS. That the data originate from a broad range of medical 
disciplines contributes to the understanding that ALS is a multi-factorial disease. Further studies 
are needed to dissect the underlying molecular and physiological mechanisms of lipid homeostasis 
and ALS, and for possible therapeutic interventions in these pathways. 
6.4 fuTure DireCTionS for ALS-reSeArCh
As described in this thesis, our studies resolve parts of the puzzle of motor neuron death in ALS, 
but also create many new questions about the role of newly identified molecular pathways. A 
central question, and so far still unresolved, is: Why are motor neurons especially vulnerable to 
genetic alterations in ubiquitously expressed proteins? 
A few obvious morphological aspects of motor neurons could contribute to this selective 
vulnerability. These include the extremely large size of motor neurons compared to other cell-
types, especially the axon that can reach to over 1 meter in length in humans, resulting in 2000 
times greater contents than the corresponding cell body. In line with this, (motor) neurons have a 
high metabolic activity compared to other cell-types, leading to an increased vulnerability to small 
defects in DNA transcription/ mRNA processing (see box 1.1). Also, motor neurons rely on long 
distance axonal transport of trophic factors, organelles, proteins and retrograde signaling factors 
(see 1.4). The complex morphology of motor neurons, including the many asymmetric processes 
as dendrites, axons, and spines, demonstrates the need of carefully designed transport, membrane 
trafficking and metabolic processes to mediate their proper functioning in entire organisms. 
As suggested in paragraph 6.2, in different cell-types, specialized motor-cargo interactions could 
mediate the active transport of particular vesicles along the microtubule cytoskeleton. Differential 
expression of adaptor proteins, linking the microtubule motors to specific cargo vesicles, might 
explain part of the selective vulnerability of motor or sensory neurons to defects in proteins 
important for intracellular trafficking/ transport. 
A research direction that has not been frequently studied in relation to ALS and other neuron 
diseases, is the role of small RNA species in the regulation of transcription in motor neurons. An 
increasing number of small interference RNA-species are being demonstrated that regulate many 
important processes in mammalian development. Recently, brain-specific miRNA’s that can 
regulate dendritic spine development have been identified (165). As the loss of a dopaminergic 
neuron-specific miRNA has been implicated in the pathogenesis of Parkinson’s disease (166), 
it is possible that miRNA’s could have a more general role in neurodegeneration. Although 
speculative, motor neuron-specific miRNA’s could exist that regulate genes important for the 
complex physiological requirements of these specialized cells. 
An interesting new topic in sporadic ALS is the discovery of TDP-43 as the major disease 
protein in ubiquitinated aggregates (167). The physiological relevance for the translocation of 
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TDP-43 from the nucleus towards these inclusions is still unresolved, although recently the 
progranulin-mediated cleavage of TDP-43 was shown to facilitate this translocation (168). It 
would be interesting to develop mouse models for abnormal TDP-43-localization that would help 
discover the underlying molecular mechanisms of this pathological observation. A somewhat 
disturbing discovery is that TDP-43 is completely absent from ubiquitinated SOD1-inclusions 
in SOD1-ALS mice and SOD1-linked fALS (our observation, (169, 170)). Some researchers 
have openly criticized these new discoveries by either stating that all research performed with 
SOD1-ALS mice is useless for human non-SOD1-linked ALS patients, or by stating that due to 
the lack of TDP-43 in SOD1-ALS mice, TDP-43 pathology is an artifact (171). It might indeed be 
true that there are distinct pathological mechanisms separating SOD1-linked ALS from all other 
sporadic and familial ALS-cases, however the common observation, e.g. dendritic ubiquitinated 
aggregates, shows that there might be a common pathway leading to motor neuron death. 
After more than a decade of drug failures, it might be time to reconsider the methodology of pre-
clinical drug trials for ALS. So far, 80% of all drug and treatment-studies are performed with high-
expressing SOD1-ALS mice, and as mentioned in chapter 6.1 there are reasons to assume that 
this is probably not an appropriate model. Also, most pre-clinical drug trials are initiated before 
symptom onset in these mice, that is not applicable to human ALS-patients, that are on average 
diagnosed with ALS a year or more after disease onset. These methodological shortcomings of 
drug discovery and testing might explain why of the many drugs and treatments investigated so 
far, only one has made it into clinical use, however also with limited survival benefits for patients 
(58). Maybe it is time to start studying other SOD1-ALS mouse models more resembling human 
disease, that would ask a little more patience from researchers, but, in the end might lead to drugs 
that actually are useful for the treatment of this devastating disorder. 
At the moment of finishing this thesis, the results of a new large-scale mutation screen were 
published, revealing mutations in TDP-43 in both familial and sporadic ALS-patients. This study 
suggests that there is a pathophysiological link between TDP-43 and ALS, that could provide 
new insight into the disease mechanisms (173). By future studies, new mutations in sporadic and 
familial ALS patients could be discovered, that could open new doors towards novel mechanisms 
contributing to the death of motor neurons. 
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Amyotrophic Lateral Sclerosis (ALS) is an adult-onset neurodegenerative disorder characterized 
by weakness of voluntary muscles. This is caused by degeneration of the lower motor neurons 
in the spinal cord and the upper motor neurons in the motor cortex. ALS is a rapidly progressing 
disease that ultimately leads to paralysis of respiratory muscles and death, on average within 5 
years after diagnosis. The disease has an incidence of 2-3 per 100.000 persons, making it the 3rd 
cause of death of neurodegenerative diseases after Alzheimer’s and Parkinson’s disease. Currently 
there is no effective treatment available. �ow motor neurons die in ALS is not clear; the large 
majority of ALS-cases (90%) is sporadic, only 10% of patients have a clear familial history of 
disease. Several mutations in ALS-patients have been described, of which mutations in the gene 
for Superoxide Dismutase 1 (SOD1) were the first to be discovered in 1993 and account for 25% 
of familial ALS-cases. Transgenic mice that express human mutant SOD1 develop an ALS-like 
disease and have been a valuable tool to model the human disease. Mutant SOD1 is possibly toxic 
to motor neurons through misfolding and subsequent aggregation of the mutant protein. Sick 
motor neurons in sporadic and familial ALS-patients are characterized by aggregates labeled with 
ubiquitin, a small protein that targets misfolded proteins to cellular defense systems. Recently, a 
new protein, TDP-43, has been detected in inclusions in motor neurons of ALS-patients, which 
could provide new clues towards the etiology of motor neuron death. 
Motor neurons are the largest cell-types in the body and their axons can be up to 1 meter long in 
humans. Therefore they rely on proper distribution of proteins, RNA and trophic factors within 
the cell; this is mediated by active transport via microtubule-dependent motor proteins. Protein 
aggregates could interfere with the transport of macromolecules through the motor neuron, 
and genetic evidence has arisen that defects in motor proteins can indeed lead to dysfunction 
and subsequent death of motor neurons in ALS and other motor neuron disorders. Aberrant 
anterograde transport (from the cell-body towards the end of the axon) can lead to axonopathies, 
and mutations in retrograde motor proteins (that mediate transport from the synapse towards the 
cell-body) cause motor neuron death in some mouse models and human motor neuron disorders. 
Transport of proteins via the secretory and endosomal/ lysosomal pathways depends upon these 
motor proteins, and also abnormalities in this pathway have been observed in different motor 
neuron disorders. In this thesis, we study two pathways that are observed to be affected in 
neurodegenerative disorders��� protein aggregation and the role of intracellular trafficking. 
To elucidate the molecular mechanisms underlying motor neuron death in SOD1-ALS mice, 
we performed a detailed characterization of molecular and pathological changes in spinal cord 
motor neurons of these mice at all disease stages. We showed that the appearance of ubiquinated 
aggregates in dendrites is a very early pathological phenomenon. Often, these motor neurons also 
show a fragmented Golgi apparatus consisting of small vesicles, which is a common hallmark of 
ALS motor neurons and indicates a disruption in intracellular transport. Ultrastructural analysis 
of these motor neurons shows the accumulation of vesicles and organelles in proximal dendrites, 
suggestive of a traffic jam. 
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Mutant SOD1 in supporting cell-types, such as astrocytes and microglia, can cause dysfunction 
of these cells, thereby depriving motor neurons of important survival factors. It is widely debated 
whether pathology in glial cells is actually needed for the death of motor neurons, i.e. whether 
or not ALS is a cell-autonomous disease. To answer this question, we developed transgenic 
mice with a restricted expression of mutant SOD1 in neurons and show that these mice develop 
motor neuron disease at one year of age with pathology resembling that in common SOD1-
ALS mice. Moreover, we show that expression of wild-type human SOD1 can accelerate the 
disease by facilitating mutant SOD1-aggregation in motor neurons, and by self-aggregation 
in oligodendrocytes. We conclude that motor neurons are the primary site where degenerating 
changes take place, only later followed by pathological processes in other cells that can accelerate 
motor neuron death. Since it has been extensively discussed in many reviews that pathology in 
glial cells is needed to initiate motor neuron death we provide a different view on the current 
belief that ALS is a non-cell-autonomous disease.
As defects in intracellular transport have been shown to be a possible cause for motor neuron 
death, we generated transgenic mice with a chronic disruption of the retrograde motor complex, 
dynein/dynactin, in neurons. These mice develop cellular phenotypes that resemble pathology 
found in ALS motor neurons. However, the mice are healthy and viable up to two years of age and 
do not develop any motor abnormalities. Crossing these mice with SOD1-ALS mice results in a 
delay in the onset of motor neuron disease and an extension of survival, suggesting that disrupted 
retrograde transport can be beneficial for SOD1-linked ALS. We conclude that disruption of 
retrograde axonal transport is not a primary cause of motor neuron death and that the role of 
retrograde transport in SOD1-ALS mice remains incompletely understood.
The latest mutation discovered in a family with ALS, in the gene for VAPB, leads to aberrant 
aggregation of mutant VAPB. This relatively unknown protein was implied to function in a 
diverse range of cellular processes, including intracellular transport and membrane trafficking. 
We showed that motor neurons express high levels of VAPB, suggesting a physiological function 
for this protein in motor neurons. Furthermore, we show that mutant VAPB exerts a dominant-
negative function over wild-type VAPB and its homologue VAPA. As VAPB is involved in 
targeting of lipid-transport proteins to their desired intracellular locations, mutations in VAPB 
could lead to aberrant localization of these proteins and a disruption in lipid homeostasis. Genetic 
and environmental data have suggested a possible role for lipids and fat metabolism in ALS. Our 
study suggests that lipid homeostasis might indeed play a role in the etiology of sporadic and 
familial ALS. In line with the recent literature, we believe that this pathway may provide new 
openings to elucidate the complex mechanism of motor neuron death in ALS.
In sum, this thesis provides an overview of the current knowledge on the role of aggregates and 
trafficking in ALS, and a new view on the role of glia, retrograde transport and lipids in this 
disease. 
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ALS staat voor Amyotrofe Laterale Sclerose, een ziekte waarbij de zenuwen die de spieren 
aansturen worden aangetast. Deze zenuwen, die van het ruggemerg naar alle spieren lopen, 
heten de motorneuronen. Door de aantasting van de zenuwen vallen spierfuncties uit, dit begint 
meestal in spiergroepen die zich ‘ver’ van het ruggemerg bevinden, zoals handen en voeten. 
De ziekte leidt tot verlamming van alle spieren in het lichaam (ook de ademhalingsspieren), 
en uiteindelijk tot de dood. Meestal zijn verstand en de zintuigen niet aangetast. Bij de meeste 
mensen begint ALS op late leeftijd (50-60 jaar), en verloopt zeer progressief: de overleving na 
diagnose is gemiddeld minder dan 5 jaar. De diagnose ‘ALS’ wordt gesteld op basis van klachten 
als vermoeidheid en spierslapte, en met EMG-onderzoek bevestigd. Per jaar wordt bij zo’n 300-
450 mensen in Nederland de diagnose ‘ALS’ gesteld. Hiermee is het na Alzheimer en Parkinson 
de 3e doodsoorzaak van ziektes waarbij bepaalde typen zenuwen doodgaan (neurodegeneratieve 
ziektes). Momenteel is er geen goede behandeling of medicijn voor ALS. 
Hoe motorneuronen doodgaan bij ALS-patiënten is nog onduidelijk. Bij de meeste patiënten 
(zo’n 90%) is de ziekte sporadisch, dat houdt in dat er geen familie-geschiedenis van de ziekte 
bekend is. De rest van de gevallen is erfelijk; tot nu toe zijn mutaties in zo’n 6 genen gevonden in 
verschillende families met ALS. Door het bestuderen van de functie van de gemuteerde eiwitten, 
kan duidelijk worden welke mechanismen kunnen leiden tot de dood van motorneuronen. Dit zou 
uiteindelijk eventueel kunnen leiden tot het ontwikkelen van behandelingen en medicijnen. 
De eerste mutaties in ALS-patiënten zijn gevonden in 1993. Dit waren mutaties in het gen voor 
Superoxide Dismutase (SOD1), die bij 25% van de familiare ALS-patiënten voorkomen. Als 
mutant SOD1-eiwit tot expressie wordt gebracht in transgene muizen ontwikkelen deze muizen 
symptomen die lijken op humane ALS, zoals verlammingen. Deze zogenaamde SOD1-ALS-
muizen zijn de afgelopen jaren een bruikbaar model geweest voor de ziekte en hebben geleid 
tot meer duidelijkheid over hoe motorneuronen doodgaan. Waarschijnlijk is het mutante SOD1-
eiwit abnormaal gevouwen, waardoor het op de langere termijn aggregeert (samenklontert) en 
toxisch is voor de motorneuronen. Wanneer het ruggemerg van ALS-patiënten en SOD1-ALS 
muizen onder de microscoop bekeken wordt, zijn er duidelijk aggregaten en eiwit-inclusies in de 
motorneuronen zichtbaar. Door het gedetailleerd bestuderen van deze aggregaten kan men meer 
te weten komen over allerlei processen die betrokken zijn bij de dood van motorneuronen.  
De motorneuronen zijn de grootste cellen van het lichaam; hun uitlopers, de axonen, lopen van 
het cellichaam in het ruggemerg naar de spieren in bijvoorbeeld armen en benen. In mensen 
kunnen deze axonen wel 1 meter lang worden. Hierdoor zijn motorneuronen zeer afhankelijk van 
transport van moleculen en organellen van het cellichaam naar het eind van het axon, en andersom. 
Dit transport wordt verzorgd langs het celskelet, de microtubuli, door microtubuli-afhankelijke 
motor-eiwitten. Grote eiwitaggregaten of inclusies kunnen dit transport in de weg staan, waarbij 
‘verkeersopstoppingen’ kunnen ontstaan. Ook hebben genetische studies laten zien dat mutaties 
in zulke motor-eiwitten voorkomen bij verschillende motorneuron-ziektes in mensen en muizen; 
169
SUMMARY
deze mutaties kunnen via verstoord transport leiden tot de dood van de motorneuronen. 
In dit proefschrift bestuderen we twee processen die hierbij betrokken kunnen zijn: het ontstaan 
van eiwitaggregaten en verstoord intracellulair transport. 
Als eerste gebruiken we SOD1-ALS muizen om te bestuderen welke veranderingen zich op 
celniveau afspelen in motorneuronen, voordat deze dood gaan. We laten zien dat het optreden 
van eiwitaggregaten een van de eerste abnormaliteiten in deze cellen is. Verder hebben ‘zieke’ 
motorneuronen vaak een gefragmenteerd Golgi apparaat; dit is een aanwijzing voor verstoord 
intracellulair transport. Ook zijn structuren te zien die op een verkeersopstopping lijken. 
Pas later in het ziekteproces zijn abnormaliteiten in andere cellen, glia-cellen en astrocyten, te 
zien. Deze cellen zijn belangrijk voor de overleving van motorneuronen maar het is niet bekend 
of abnormaliteiten in deze cellen ook betrokken zijn bij het doodgaan van de motorneuronen. 
Om dit te kunnen onderzoeken hebben we muizen gemaakt die het mutante SOD1-eiwit alleen 
in neuronen hebben. Deze muizen ontwikkelen op hele late leeftijd ook verlammingen. Hiermee 
geven we het bewijs dat mutant SOD1 in motorneuronen abnormaliteiten in glia-cellen kan 
veroorzaken. Dit kan vervolgens het afstervingsproces van neuronen versnellen. 
Om te kunnen onderzoeken of verstoringen van axonaal transport in motorneuronen leidt tot de 
dood van deze cellen, hebben we een transgene muis gemaakt die een verstoring heeft van het 
motor-eiwitcomplex dyneine/dynactine. Dit complex, dat cellulair transport van het eind van het 
axon naar het cellichaam verzorgt (retrograad transport), verstoren we door expressie van een 
linker-eiwit BICD2-N. Motorneuronen in deze muizen hebben allerlei abnormaliteiten die ook 
in ALS-patiënten en SOD1-ALS muizen te zien zijn. De BICD2-N-muizen zijn echter gezond 
en ontwikkelen geen verlammingen tot 2-jarige leeftijd. Als we deze muizen kruisen met SOD1-
ALS muizen, ontwikkelen deze muizen op een latere leeftijd verlammingen en leven ze langer. 
Deze studie laat dus zien dat een verstoring van retrograad transport in motorneuronen niet leidt 
tot de dood van deze cellen, en zelfs beschermend is voor SOD1-ALS muizen.
De nieuwste mutatie die in ALS-patiënten ontdekt is, in 2005, leidt tot aggregatie van het 
mutante eiwit, VAPB. Dit eiwit speelt waarschijnlijk een rol bij intracellulair transport en bij 
het transporteren van lipide-bindende eiwitten. Wij laten zien dat motorneuronen veel VAPB 
bevatten, en dat dit eiwit dus waarschijnlijk een functie heeft in deze cellen. Mutant VAPB 
kan geen lipide-bindende eiwitten meer binden en veroorzaakt de dood van neuronale cellen 
in kweek. Epidemiologische en genetische studies hebben laten zien dat verstoringen van het 
vetmetabolisme bij zouden kunnen dragen aan het doodgaan van de motorneuronen. Onze studie 
bevestigt deze theorie, en we denken dat het bestuderen van het lipide-metabolisme een nieuwe 
opening kan zijn om ALS en andere motorneuron ziektes beter te kunnen begrijpen, en eventueel 
tot nieuwe therapieën kan leiden. 
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Ik hoop dat ik je niet teveel cultuur-shocks heb bezorgd de afgelopen jaren, maar ik denk dat 
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je de Nederlandse cultuur al aardig begint te begrijpen. Bedankt voor alle etentjes, avondjes 
en weekendjes uit en goede gesprekken. Doortje, doordat ik in de buurt was heb ik je twee 
keer bezocht in München, nu ben je (soms) weer terug in Rotterdam. Ook bedankt voor alle 
gezelligheid en steun de afgelopen tijd, en succes met je verdere carrière als arts. 
Aleksandra, jij ook bedankt voor alle avondjes uit, succes met je promotie en alvast bedankt 
voor het zorgen voor Suus. Eric, thank you for all the good conversations, coffees, wines and 
beers during the year that we were colleagues. Good luck with your career and future life in 
Bordeaux. Anderen die zeker hebben bijgedragen aan mijn goede tijd op de afdeling, Hikke, 
Marcel, Martijn, Freek, Alexander, Bart, Corina, Henk-Jan, Laurens, Joel, Paul, Aram, Nils, 
Lianne, Petra, Gao, Boeke, Gen en …. (vul je naam in als je vindt dat die hier had moeten staan): 
bedankt voor de leuke tijd tijdens en buiten het werk. Ik kan onmogelijk iedereen op de afdeling 
Neurowetenschappen persoonlijk noemen, maar dat ik het de afgelopen jaren zo goed naar mijn 
zin heb gehad op de afdeling, komt ook door de aanwezigheid van iedereen die bijgedragen heeft 
aan de goede sfeer, zowel professioneel als tijdens de vele borrels, kerstdiners, labuitjes etc. 
Bedankt aan al mijn collega’s en ex-collega’s. 
Ik wil dit dankwoord ook gebruiken om mijn vrienden en familie bedanken, dat ze er altijd voor 
me waren en, ondanks dat ze me niet altijd begrepen (wat moet je op het lab op zondag) me altijd 
hebben gesteund in mijn complexe bezigheden. Tessa, mijn oudste vriendin, ik vind het leuk dat 
ik al 20 jaar ken en geloof dat we op elkaars 50e verjaardagen gaan komen! Linda, jij hebt mijn 
promotie van heel dichtbij gevolgd. Bedankt voor alle leuke dingen die we samen gedaan hebben 
en hopelijk nog gaan doen, ik kijk al uit naar onze reis! Bas, Erik, Tim en Andrea, binnenkort is 
het tijd onze 5-jaren plannen te onthullen... wat is er over van onze ideeen uit 2003? Annemarie, 
Anouk, Corine en Wendy: van vriendinnen op het VWO naar 3 doctors, 3 huizenbezitters, 1 
huwelijk, we hebben het toch niet slecht gedaan zover. Al mijn zwem-vrienden van Ragnar, 
bedankt voor de gezellige tijd in Rotterdam de afgelopen 4 jaar. 
Natuurlijk ben ik ook mijn ouders en hun aanhang enorm dankbaar voor de onvoorwaardelijke 
steun die ik altijd bij al mijn beslissingen heb gekregen en in de toekomst zal krijgen. Lya, Paul, 
Gerard, Ank, 4 ouders is veel maar jullie hebben allemaal een bijdrage geleverd aan wie ik nu ben. 
Ik weet dat ik altijd bij jullie kan aankloppen voor etentjes, gezelligheid en advies over alles. 
Ike, ik hoop dat onze carrieres elkaar niet zullen gaan tegenwerken in de toekomst, maar zolang 
jij niet van onderwerp wisselt hoef ik niet bang te zijn voor een zus(je) bij Greenpeace. Succes 
met al je bezigheden!
De rest van de familie die ik niet allemaal persoonlijk kan bedanken: ik ben blij dat ik zo’n leuke 
familie heb. Ik ga altijd met plezier naar familie-feestjes en kerstdiners, hopelijk kunnen jullie er 
allemaal bij zijn op mijn promotie.
En als laatste, maar niet als minste, wil ik mijn opa en oma bedanken, aan wie ik dit proefschrift 
heb opgedragen. Ik ben blij dat ik op ‘mijn leeftijd’ nog zulke gezonde  en lieve grootouders heb. 
Ik ben dan wel de eerste in de familie die promoveert, maar vast niet de laatste, jullie nageslacht 
heeft nog veel in petto!

